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Abstract
In a deeply interconnected world of people and goods, infectious diseases constitute
a serious threat. For a prompt and effective response, it is crucial to have accurate and
timely information. These two characteristics are related with two main lines of research:
data quality assessment and improvement and modelling of the reporting delay process.
Every case-reporting system has some degree of under-ascertainment. Timeliness is
a widely acknowledged key indicator for surveillance data quality, in particular the time
between diagnosis and report to the national surveillance system – the reporting delay. A
particular case of a surveillance system is the HIV–AIDS surveillance system. It differs from
others due to the special transmission modes of the disease, charged with heavy social
stigma, long asymptomatic or with mild symptoms latency period of the infection, lack of
affordable treatment and cure, and high fatality rates.
In this thesis we explore many of the breakthrough new ideas in statistical analysis for
modelling the complex reality of reporting delays in a surveillance system, emphasizing the
statistical methods and their conceptual underpinnings.
It is presented a holistic description of epidemics by infectious diseases and how they
are surveyed and reported. The quality of the data is assessed by a new reproducible
methodology . The methodology is based on statistical data pre-processing of surveillance
systems data, and the data quality definition used is an extension of the ISO / IEC 25012,
including statistical dimensions.
Also, the application of a statistical model for estimation of the under-reporting phe-
nomenon in the Portuguese epidemic is assessed as well as the changes on the reporting
delay over time, identifying the main factors influencing the reporting delay and considering
the individual, administrative, organizational and historical contexts.
The classical joint modelling with Poisson counts does not fully capture the reporting
process of the Portuguese HIV -AIDS system. These results are consistent with a previous
publication using data from the same system. Fluctuations in reporting delay patterns over
time were found which can be attributed to changes in the distributions of the covariates, or
to temporary periods of slower reporting in specific geographical areas.
The reporting delay was divided into quarters and in a 2-class division with a cut-off at
the 3-months delay and several supervised learning techniques were applied in order to
identify the main factors influencing these classes. Also, reporting delays were modelled in
continuous time and with a fully multilevel parametric approach, allowing for inferences on
covariate effects to be mainly driven by the shorter delays, which are appropriate when the
goal is to rapidly detect changes in epidemic patterns. This model found a positive effect of
the risk group and of the reporting entity work load and a negative effect of stage and age.
We hope the present study may be useful for the definition and implementation of future
surveillance systems, highlighting the need to empower the data quality alongside with new
statistical tools and techniques to better survey our diseases.
Keywords: Infectious Diseases, HIV-AIDS, Surveillance System, Surveillance Data,
Statistical Pre-Processing, Multilevel Modelling, GLMs, DataMining, Reporting Delay, Under-
Reporting
vii
Resumo
Num mundo profundamente interligado de pessoas e bens, as doenças infeciosas con-
stituem uma séria ameaça. Para garantir uma resposta rápida e eficaz, é crucial ter infor-
mações precisas e oportunas. Essas duas características podem estar na base de duas
linhas principais de investigação: a avaliação de qualidade do dados, assim como a mel-
horia dos mesmos, e análise dos processos de atraso na notificação de casos.
Cada sistema de vigilância tem algum grau de sub-averiguação sendo a prontidão um
indicador chave amplamente reconhecido para a qualidade dos dados, em particular o
atraso na notificação de um caso diagnosticado para o sistema de vigilância nacional - o
atraso na notificação. Um caso particular de um sistema de vigilância nacional é o VIH
- SIDA. Este difere de outros sistemas de vigilância devido a fatores como o modo de
transmissão da doença, carregados de forte estigma social, longo período de latência ass-
intomático ou com sintomas leves, a falta de tratamento e de cura acessíveis e as altas
taxas de mortalidade.
Nesta tese exploram-se várias metodologias recentes de análise estatística de atrasos
de notificação num sistema de vigilância de uma doença infeciosa. Neste enquadramento
são enfatizados os métodos estatísticos úteis no contexto particular do VIH - SIDA e os
seus fundamentos conceituais. É apresentada uma descrição holística das epidemias por
doenças infecciosas e como elas são vigiadas e notificadas. É também proposta e im-
plementada uma metodologia reprodutível para a avaliação e melhoria da qualidade dos
dados estatísticos provenientes de sistemas de vigilância, usando como definição de qual-
idade de dados uma extensão da ISO / IEC 25012, que inclui dimensões estatísticas. É
efetuada a avaliação da aplicação de modelos estatísticos para estimação do fenómeno de
subnotificação da epidemia em Portugal e as alterações no atraso na notificação ao longo
do tempo. Finalmente são identificados os principais fatores que influenciam o atraso do
relatório, tendo em consideração o contexto individual, administrativo, organizacional e
histórico.
A modelação clássica baseada em contagens com distribuição de Poisson não de-
screve completamente o processo de notificação no sistema Português de vigilância do
VIH - SIDA. Estes resultados são consistentes com publicações anteriores para o mesmo
sistema. Foram encontradas flutuações ao longo do tempo nos padrões de atraso na
notificação que podem ser atribuídos a mudanças nas distribuições das covariáveis ou a
períodos temporários de notificação mais lentos e em áreas geográficas específicas. O
atraso na notificação foi dividido em trimestres e foi considerada uma divisão em 2 classes
com um ponto de corte de 3 meses. Várias técnicas de data mining foram aplicadas para
identificar os principais fatores que influenciam estas classes. Além disso, os atrasos na
notificação foram modelados em tempo contínuo e com uma abordagem paramétrica hi-
erárquica, permitindo que as inferências sobre efeitos de covariáveis sejam impulsionadas
principalmente pelos atrasos mais curtos, que são apropriados quando o objetivo é detetar
rapidamente mudanças nos padrões epidémicos. Este modelo identificou um efeito posi-
tivo do grupo de risco e da carga de trabalho da entidade notificadora e um efeito negativo
do estado da doença e da idade.
Esperamos que o presente estudo possa ser útil para a definição e implementação de
futuros sistemas de vigilância, destacando a necessidade de avaliar e melhorar a qualidade
dos dados juntamente com novas ferramentas e técnicas estatísticas.
Palavras-Chave: Doenças infeciosas, HIV-SIDA, Sistema de Vigilância, Dados de Vig-
ilância, Pré-processamento Estatístico, Modelagem multinível, GLMs, Mineração de Da-
dos, Atraso na Notificação, Subnotificação
viii
Contents
1 Introduction 1
1.1 Context . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.3 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.4 Contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.5 Thesis Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2 Infectious Diseases and Surveillance Systems 6
2.1 Human Immunodeficiency Virus - Acquired Immunodeficiency Syndrome . . 7
2.2 Tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.3 HIV-AIDS / TB Co-Infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.4 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.5 HIV / AIDS Socio - Ecological Framework . . . . . . . . . . . . . . . . . . . . 14
2.6 Public Health Surveillance Systems . . . . . . . . . . . . . . . . . . . . . . . 18
2.6.1 Surveillance Data Representativeness . . . . . . . . . . . . . . . . . . 20
2.6.2 Reporting Delay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.6.3 Form Completion or Data Entry Errors . . . . . . . . . . . . . . . . . . 22
2.7 European Surveillance of HIV/AIDS . . . . . . . . . . . . . . . . . . . . . . . 23
2.7.1 Reporting Delay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.7.2 Duplication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.7.3 Completeness and Consistency of Risk Factors’ Details . . . . . . . . 26
2.7.4 TESSy - The European Surveillance System . . . . . . . . . . . . . . 27
2.7.5 The Portuguese HIV/AIDS Reporting System and The Public Health
System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.8 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3 Statistical Data Pre - Processing 35
3.1 Data quality dimensions and issues . . . . . . . . . . . . . . . . . . . . . . . 36
3.2 Procedure for improving data quality . . . . . . . . . . . . . . . . . . . . . . . 38
3.2.1 Data Validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.2.2 Error Localization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.2.3 Repair and Improve . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.3 Surveillance Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.4 ECDC dataset structure: HIV / AIDS case-based record type . . . . . . . . . 48
3.5 Data from the Portuguese Surveillance System . . . . . . . . . . . . . . . . . 50
3.5.1 Evaluation of the HIV-AIDS Portuguese Surveillance Data . . . . . . . 53
3.6 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
ix
4 Mathematical models for Reporting Delay Estimation 69
4.1 Concepts and Fundamentals . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.1.1 Statistical and Data Mining Models . . . . . . . . . . . . . . . . . . . . 71
4.1.2 Model Validation and Selection - Some General Considerations . . . . 92
4.2 Modelling the Reporting - Delay Distribution and Incidence . . . . . . . . . . 95
4.2.1 Joint Modelling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
4.2.2 Separate / Partial Modelling . . . . . . . . . . . . . . . . . . . . . . . . 98
4.2.3 Data - structure and notations . . . . . . . . . . . . . . . . . . . . . . . 99
4.2.4 Likelihood for the Joint Model . . . . . . . . . . . . . . . . . . . . . . . 102
4.3 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
5 Methodology and Results 106
5.1 The HIV - AIDS Portuguese Epidemic . . . . . . . . . . . . . . . . . . . . . . 106
5.1.1 Incidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
5.1.2 Reporting Delay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
5.2 Discrete Outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
5.2.1 Joint Modelling - Count Regression Models . . . . . . . . . . . . . . . 113
5.2.2 Separate Modelling - Accounting for a Non Stationary Process . . . . 123
5.2.3 Non-Parametric Estimates . . . . . . . . . . . . . . . . . . . . . . . . 128
5.3 Continuous Outcome - Multilevel Regression . . . . . . . . . . . . . . . . . . 130
5.3.1 The specification of the reporting delay model . . . . . . . . . . . . . . 131
5.3.2 Reporting delay with a Multilevel Structure . . . . . . . . . . . . . . . 136
5.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
6 Conclusions 149
6.1 Synthesis and Main Contributions . . . . . . . . . . . . . . . . . . . . . . . . 149
6.2 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
6.3 Recommendations for Future Work . . . . . . . . . . . . . . . . . . . . . . . . 151
References 152
A HIV-AIDS European Case Definition 165
B European AIDS case definition 167
C Codes of AIDS Indicator Disease 177
D Portuguese Regulation 179
E Portuguese Notification Form 183
F Literature Review 185
G French Notification Form 189
H Italian Notification Form 192
I Polish Notification Form 195
J The Netherlands Patient Data Collection 198
K TESSy - The HIV/AIDS metadata set 205
x
List of Tables
2.1 Elements included in the HIV testing practice (n=23). Source: European
Centre of Disease Control and Prevention (ECDC) in [104] . . . . . . . . . . 26
2.2 HIV-AIDS surveillance system overview [66, 106, 103] . . . . . . . . . . . . . 28
3.1 Extended version of problems and data issues [128, 125] . . . . . . . . . . . 37
3.2 Overview of the available revised set of variables for case-based HIV-AIDS
surveillance. Source [105] . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.3 Values and validation rules of the revised set of variables for case-based
HIV-AIDS surveillance. Source [105] . . . . . . . . . . . . . . . . . . . . . . 49
3.4 Variables collected by the HIV-AIDS Portuguese notification form. . . . . . . 50
3.5 Values and validation rules of the revised set of variables for case-based
Portuguese HIV-AIDS surveillance . . . . . . . . . . . . . . . . . . . . . . . . 51
3.6 Central Administration of the Health System List of Health Providers . . . . . 52
3.7 Summary highlights of Health Provider Interviews. Adapted from Mauch in
[93] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.8 Some issues for variable “Nationality” and “Hospital” . . . . . . . . . . . . . . 56
3.9 Percentage of Valid, Invalid, Missing and Outliers . . . . . . . . . . . . . . . 56
3.10 Validation rules applied to HIV-AIDS Portuguese data set . . . . . . . . . . . 59
3.11 Examples of inconsistencies on T4_T8 records . . . . . . . . . . . . . . . . . 61
3.12 Summary of Error Location Algorithm per Record . . . . . . . . . . . . . . . . 62
3.13 Summary of Error Location Algorithm per Variable . . . . . . . . . . . . . . . 62
3.14 Examples of matched pairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.1 Common canonical link functions [167] . . . . . . . . . . . . . . . . . . . . . . 73
4.2 Characteristics of some common univariate distributions in the exponential
family. Based in [167]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.3 Density, Survival and Hazard functions for the distributions commonly used
in the parametric methods in survival analysis . . . . . . . . . . . . . . . . . . 83
4.4 Comparison of reporting delay estimation models . . . . . . . . . . . . . . . 99
5.1 Overview the two classes of reporting delay per demographic variables . . . 113
5.2 Number of cases per notification and diagnosis year . . . . . . . . . . . . . . 114
5.3 Count regression models using as predictors the delays quarter and diagno-
sis quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
5.4 Estimated reporting delay probabilities for each quarter . . . . . . . . . . . . 120
5.5 Description of analysed clusters . . . . . . . . . . . . . . . . . . . . . . . . . 127
5.6 Estimates from the regression model for the relative AIDS incidence (within
the HIV population) cross-classified by year of diagnosis and reporting delay
quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
5.7 Individual models for the annual AIDS percentage cross-classified by diag-
nosis year and reporting delay quarter . . . . . . . . . . . . . . . . . . . . . . 128
xi
5.8 MLP, KNN, NAIVE and SVM performance . . . . . . . . . . . . . . . . . . . . 130
5.9 The estimates and standard error of a full model for the normal, log-normal,
Weibull and gamma distribution . . . . . . . . . . . . . . . . . . . . . . . . . . 133
5.10 The estimates of the log-normal model . . . . . . . . . . . . . . . . . . . . . . 134
5.11 Null Multilevel Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
5.12 Null Models I.C.C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
5.13 Models Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141
5.14 Model with a random intercept and population level covariates . . . . . . . . 142
5.15 Estimates from the model with a random intercept and a random slope . . . . 144
5.16 Multilevel Models comparison . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
5.17 Full model and with random intercept and random intercept and slop . . . . . 146
F.1 Reporting Delays and HIV-AIDS Incidence - Modelling Approaches . . . . . 185
xii
List of Figures
2.1 Healthy T cell (left) and HIV infected T cell (right) . . . . . . . . . . . . . . . . 7
2.2 Typical progression of HIV infection without intervention (reprinted with per-
mission from Fauci A.S. Pathogenesis of HIV Disease: Opportunities for
New Prevention Interventions. Clinical Infectious Diseases, Oxford Univer-
sity Press, 2007, 45, S206-S212 ) . . . . . . . . . . . . . . . . . . . . . . . . 8
2.3 Mycobacterium tuberculosis bacteria (left) and Healthy and TB infected pa-
tient x-ray (right) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.4 Estimated tuberculosis (TB) incidence in relation to human immunodeficiency
virus (HIV) prevalence for 42 countries in the World Health Organization
African Region [59]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.5 New HIV diagnoses per 100000 population, 2015 [66] . . . . . . . . . . . . . 12
2.6 Percentage of AIDS diagnoses with tuberculosis reported as AIDS - deﬁning
illness, by country, European Union and European Economic Area, 2014 [62] 14
2.7 Percentage of HIV-positive cases among tuberculosis cases with known HIV
status, by country, European Union and European Economic Area, 2014 [62] 14
2.8 Factors influencing HIV-related behaviour and / or behaviour change at each
level of the socio-ecological model [70] (reprinted with permission fromMichelle
Kaufman) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.9 Simplified flowchart of a generic surveillance system based on [3] and [88] . 19
2.10 Typical morbidity surveillance system [90]. UR - underreporting, UA-under-
ascertainment, UE - Underestimation . . . . . . . . . . . . . . . . . . . . . . . 21
2.11 Case reporting main issues from a surveillance system . . . . . . . . . . . . 24
2.12 Simplification of key elements for the description of Portuguese Surveillance
System based on information’s reported by Mauch in [93] . . . . . . . . . . . 29
2.13 Major changes in Portuguese Surveillance System . . . . . . . . . . . . . . . 30
2.14 Portuguese Health Regions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.15 Organizational chart of the Ministry of Health from [109] . . . . . . . . . . . . 31
3.1 Validation Process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.2 Repair and Improve Process . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.3 Missing values per variable . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.4 Distribution of age by notification year . . . . . . . . . . . . . . . . . . . . . . 55
3.5 Distribution of age of babies by clinical Stage . . . . . . . . . . . . . . . . . . 55
3.6 Distribution of the HIV stage reported by the clinician. . . . . . . . . . . . . . 55
3.7 Distribution of reporting delay per notification year . . . . . . . . . . . . . . . 55
3.8 Distribution of time between reception and notification of the form at CVDET
per notification year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.9 Percentage of Valid, Invalid, Missing and Outliers . . . . . . . . . . . . . . . 57
3.10 Functional dependencies among Portuguese HIV-AIDS surveillance system
variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.11 Validation rules applied to HIV-AIDS Portuguese data set . . . . . . . . . . . 60
xiii
3.12 Evaluation of validation rules applied to HIV-AIDS Portuguese data set per
record . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.13 Patterns of missing values per notification year . . . . . . . . . . . . . . . . . 65
3.14 Missing values patterns . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.15 Missing values patterns against notification year. The top panel represents
the number of observed cases per notification year in each variable while the
lower panel represent the number of missing observations per notification year. 66
3.16 Number of AIDS cases per notification year and length of the reporting delay. 67
4.1 Diagram of types of censoring for survival times [171]. . . . . . . . . . . . . . 80
4.2 Relationship among different entities f(t), F (t) and S(t) [171]. . . . . . . . . 81
4.3 An example of the architecture of a feed - forward network having two layers
of adaptive weighs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
4.4 Maximum-margin hyperplane and margins for an SVM trained with samples
from two classes. Samples on the margin are called the support vectors. [18] 91
4.5 Schematic picture of the behaviour of bias and variance [18]. . . . . . . . . . 94
4.6 Behaviour of test sample and training sample error as the model complexity
varies [18]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
4.7 Truncation mechanism in reporting cases based on [211] . . . . . . . . . . . 100
5.1 Number of cases by notification year . . . . . . . . . . . . . . . . . . . . . . . 107
5.2 Number of cases by diagnosis year . . . . . . . . . . . . . . . . . . . . . . . . 107
5.3 Number of AIDS cases per year of notification for each disease stage . . . . 107
5.4 Number of AIDS cases per year of diagnosis for each disease stage . . . . . 107
5.5 Number of notified cases per year for each sex . . . . . . . . . . . . . . . . . 108
5.6 Number of diagnosed cases per year for each sex . . . . . . . . . . . . . . . 108
5.7 Number of notified cases per year for each risk group . . . . . . . . . . . . . 108
5.8 Number of diagnosed cases per year for each risk group . . . . . . . . . . . . 108
5.9 Age distribution per notification year . . . . . . . . . . . . . . . . . . . . . . . 108
5.10 Age distribution per diagnosis year . . . . . . . . . . . . . . . . . . . . . . . . 108
5.11 Number of HIV - AIDS cases per RHA and per notification year . . . . . . . . 108
5.12 Number of HIV - AIDS cases per RHA and per diagnosis year . . . . . . . . . 108
5.13 Number of AIDS diagnosed per year and epidemiological events . . . . . . . 109
5.14 Mortality by INE and CVEDT . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
5.15 Difference from INE and CVEDT . . . . . . . . . . . . . . . . . . . . . . . . . 109
5.16 Mortality difference percentage INE and CVEDT . . . . . . . . . . . . . . . . 109
5.17 Number of cases of AIDS per Notification year and reporting delay by trimester
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
5.18 Number of cases of AIDS per Diagnosis year and reporting delay by trimester110
5.19 Percentage of AIDS cases per diagnosis year and reporting delay year . . . 110
5.20 Percentage of HIV-AIDS cases per diagnosis and delay quarters. The lighted
region identifies those (recent) years that have to be corrected. . . . . . . . . 110
5.21 Separate delay curves for percentage of HIV-AIDS cases per diagnosis and
delay quarters. The lighted region identifies those (recent) years that have
to be corrected. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
5.22 Number of HIV-AIDS infections by year of diagnosis (x-axis), reporting delay
quarter (y-axis) and gender (right vertical boxes) . . . . . . . . . . . . . . . . 112
5.23 Number of HIV-AIDS infections by year of diagnosis (x-axis), reporting delay
quarter (y-axis) and patients nationality (right vertical boxes) . . . . . . . . . . 112
5.24 Number of HIV-AIDS infections by year of diagnosis (x-axis), reporting delay
quarter (y-axis) and disease status (right vertical boxes). . . . . . . . . . . . 112
xiv
5.25 Number of HIV-AIDS infections by year of diagnosis (x-axis), reporting delay
quarter (y-axis) and risk group (right vertical boxes) . . . . . . . . . . . . . . . 112
5.26 Number of HIV-AIDS infections by year of diagnosis (x-axis), reporting delay
quarter (y-axis) and health care institution (right vertical boxes) . . . . . . . . 112
5.27 Number of HIV-AIDS infections by year of diagnosis (x-axis), reporting delay
quarter (y-axis) and regional administration (right vertical boxes) . . . . . . . 112
5.28 Number of cases per notification year and reporting delay with marginal dis-
tributions of reporting delay and number of cases per notification year . . . . 114
5.29 Number of cases per diagnosis year and reporting delay with marginal distri-
butions for the reporting delay and incidence . . . . . . . . . . . . . . . . . . 114
5.30 Half-normal plot of the residuals of the Poisson model . . . . . . . . . . . . . 119
5.31 Relationship between mean and variance . . . . . . . . . . . . . . . . . . . . 119
5.32 Number of observed AIDS cases against the predicted number of AIDS by
the Poisson model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
5.33 Optimization Performance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
5.34 Number of AIDS cases observed against number of AIDS cases estimated
by the BB/NBD model. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
5.35 Expected probability of an AIDS case being notified for a given number of
notified AIDS cases. The estimations were obtained with the BB/NBD model 125
5.36 Number of AIDS cases diagnosed and reported to CVDET per year (with-
out adjustment) and number of AIDS cases adjusted for reporting delay and
underreporting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
5.37 Percentage of AIDS cases per diagnosis and delay quarters. The shaded
region identifies those (recent) years that have to be corrected. . . . . . . . . 126
5.38 Percentage of AIDS cases per quarter of diagnosis and delay quarter longer
than 3 months . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
5.39 Quality Criteria for longitudinal clustering. 0 - Calinsky and Harabatz; 1 -
Calinsky and Harabatz2; 3 - Calinsky and Harabatz3; 4 -Ray and Turi; 5 -
Davies and Bouldin; 6 - Bayesian Information Criterion (BIC); 7 - BIC with
correction for finite sample size; 8- Akaike Information Criterion (AIC); 9- AIC
with correction for finite sample size . . . . . . . . . . . . . . . . . . . . . . . 127
5.40 The estimates and profile confidence intervals from the normal distribution . . 134
5.41 The estimates and profile confidence intervals from the log normal distribution134
5.42 The estimates and profile confidence intervals from the Weibul distribution . 134
5.43 The estimates and profile confidence intervals from the gamma distribution . 134
5.44 Residuals from normal distribution . . . . . . . . . . . . . . . . . . . . . . . . 136
5.45 Residuals from log normal distribution . . . . . . . . . . . . . . . . . . . . . . 136
5.46 Residuals from log gamma distribution . . . . . . . . . . . . . . . . . . . . . . 137
5.47 Conceptual representation of the nested structure . . . . . . . . . . . . . . . 137
5.48 Profile zeta plot of the parameters in full null hierarchical model. . . . . . . . 139
5.49 Profile zeta plot of the parameters in the minimal multilevel model . . . . . . 141
5.50 Profile zeta plot of the parameters of the random intercept model. . . . . . . . 143
5.51 95% prediction intervals for the random effect Entity . . . . . . . . . . . . . . 144
5.52 95% prediction intervals for the random effect Administration . . . . . . . . . 144
5.53 Profile zeta plot of the parameters from the model with a random intercept
and a random slope. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
5.54 95% prediction intervals on the random effect Entity . . . . . . . . . . . . . . 145
5.55 95% prediction intervals on the random effect Administration . . . . . . . . . 145
xv
Abreviations
ACSS Central Administration of the Health System.
AFT Accelerated Failure Time Models.
AIC Akaike Information Criterion.
AIDS Acquired Immunodeficiency Syndrome.
ART Anti-Retroviral Therapy.
BCG Bacillus Calmette-Guérin.
BIC Bayesian Information Criterion.
CART Classification and Regression Trees.
CDC Centers for Disease Control and Prevention.
CDisF Cumulative Distribution Function.
CNLCS Comissão Nacional de Luta Contra a SIDA.
CNSida Coordenação Nacional para a Infecção VIH - SIDA.
CVEDT Centro de Vigilância Epidemiológica das Doenças Transmissíveis.
ECDC European Centre of Disease Control and Prevention.
EEA European Economic Area.
EM Expectation Maximization.
ESS QAF The Quality Assurance Framework of the European Statistical System.
EU European Union.
FSWs Female Sex Workers.
GLMs Generalized Linear Models.
HA Hungarian Algorithm.
HAART Highly Active Anti-Retroviral Therapy.
HIV Human Immunodeficiency Virus.
IDU Injecting Drug User.
xvi
IDUs Injecting Drug Users.
INE Instituto Nacional de Estatística.
KS Kaposi’s Sarcoma.
LVT Lisbon and Tagus Valley.
MCMC Markov Chain Monte Carlo.
MDR-TB Multidrug-Resistant Tuberculosis.
MSMs Men who have Sex with Men.
MTB Mycobacterium tuberculosis.
r.t.h. Reverse Time Hazard Function.
RHA Regional Health Administration.
SA Sampling Algorithm.
SC Supervised Clustering.
SEM Socio-Ecological Model.
SSPRM Semi-Supervised Probabilistic Relational Models.
SVM Support Vector Machines.
SWs Sex Workers.
TB Tuberculosis.
TESSy The European Surveillance System.
UNAIDS Joint United Nations Programme on HIV/AIDS.
WHO World Health Organization.
WHOE World Health Organization - Regional Office for Europe.
xvii
xviii
Chapter 1
Introduction
No man is an island,
Entire of itself,
Every man is a piece of the continent,
A part of the main. John Donne
1.1 Context
In a deeply interconnected world of people and goods, infectious diseases constitute a
serious threat. So, an active vigilance “for signs of an outbreak, rapid recognition of its
presence, diagnosis of its microbial cause” is required [1]. It is also necessary to identify
modes of transmission and at-risk population groups, and to define public measures for
target prevention [2, 3]. The collection of adequate data is vital to evaluate the burden of
the disease and the impact of prevention and control programmes, aiming at effective and
efficient responses.
Typically, this implies a complex system that relies on processes and individuals and
thereby can be found to differ substantially according to the disease, health condition and
country. Also, traditional public health surveillance approaches use pre-specified case defi-
nitions and employ manual data collection, human decision making, and manual data entry
[4, 3, 5, 6].
Every case-reporting system has some degree of under-ascertainment. This can be
due to failure of patients to present for diagnosis, failure of physicians to diagnose or report
the disease, and failures in the health department itself to count cases owing to misclas-
sification or other reasons [7]. Timeliness is another widely - acknowledged key indicator
for surveillance data quality. It should be periodically evaluated because it can reflect the
reporting time delay between any number of response steps in a surveillance process [3].
Reporting delays may depend on a number of factors such as the patient’s recognition
of symptoms; the patient’s acquisition of medical care; the use of confirmatory laboratory
testing; reporting by the health care provider or the laboratory to the local, region, or state
public health authority; the volume of cases identified in the state; case follow-up investiga-
tions to verify the case report or to collect additional case information; periods of decreased
surveillance system activity due to variable employment levels; computer system down-time
for maintenance, upgrades, or new application development; and data processing routines,
such as data validation or error checking [5, 8].
A particular case of a surveillance system is that for the Human Immunodeficiency Virus
(HIV) - Acquired Immunodeficiency Syndrome (AIDS). It differs from other surveillance sys-
tems in many ways, namely by reflecting the special transmission patterns charged with
heavy social stigma, the long asymptomatic or with mild symptoms latency period of the
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infection, the lack of affordable treatment and cure, and its high fatality rates [9].
1.2 Motivation
Infectious diseases have been an ever-present threat to mankind and plait the history. From
the Biblical Plagues and the Plague of Athens in ancient times, to the Black Death of the
Middle Ages, the 1918 “Spanish Flu” pandemic, Tuberculosis, and more recently, the HIV -
AIDS pandemic, Cholera, Dengue and Zika, infectious diseases have continued to emerge
and re-emerge in a manner that defies accurate predictions [10, 11].
Infectious diseases are the second leading cause of death and disability - adjusted life
years worldwide (1 disability - adjusted life year is 1 lost year of healthy life). Over time
many microbes, such as Mycobacterium tuberculosis, have continued to develop re-
sistance to drugs defying conventional therapies and posing a threat to public health [11].
Another example arises from the epidemiological history of the HIV - AIDS that led to a
clear understanding that reducing its incidence is a complex battle whose scope goes way
beyond the shaping of the individuals disease related risk-behaviour. A holistic intervention,
considering all the main factors, is essential.
Humans are hard to model and in the context of this thesis several layers of complex-
ity are added and need to be addressed. The HIV - AIDS is a complex disease in terms
of biology and social context. It is characterized by long and variable asymptomatic or
with middle symptoms phases and transmission modes grounded in highly controversial
behaviours. These behaviours may cause discrimination and stigma leading the individu-
als to avoid testing, treatment and / or provide all the necessary information for treatment
and surveillance. On the other hand, patients are emerged in large and complex health
and surveillance systems composed by bureaucratic processes and, of course individuals.
Among these individuals, the health care providers play a crucial role and their main focus
is on saving lives not bureaucratic paper work. So, when public health systems report the
numbers of new infected individuals they are reporting the disease history but also reflecting
the processes of detecting and registering of the cases.
Focusing only on the reporting systems, it is widely recognized that these systems are
accommodated by several problems that imprint on data several data quality issues. Most
common sampling and non-sampling errors are caused by problems such as [12, 13, 3, 14,
15, 16]:
• unrepresentativeness or selection bias of the patients;
• system implementation, that suffered alterations throughout times, due to governmen-
tal rules and regulations;
• case definitions used inconsistently by the main diagnosis stakeholders;
• data processing errors;
• reporting delays.
For a rapid reaction to an emerging infectious disease, it is crucial to have accurate and
timely information. These two characteristics can create two main lines of research: data
quality assessment and improvement of the raw data, and modelling of the reporting delays
process.
Statistical modelling in science remains, partly at least, an art [17]. In practice, there
are some principals to guide the analyst and a multidisciplinary approach is often useful.
Although a simplification of the reality, statistical models try to mimic the structure of the
data and guide the investigation lighting the main relationships among variables.
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The field of Statistics is constantly challenged by the problems brought by the real world.
With the advent of technology, statistical problems have exploded both in size and complex-
ity [18]. Challenges arise in terms of storage, organization, quality of information and even
in relevance of the interpretation of traditional p-values.
A large amount of data is being generated in many fields, and the statistician’s job is
to make sense of it all: extract relevant information, extract important patterns and trends,
and understand ”what the data says” [18].
These challenges led to an explosion of methods in the statistical sciences along with
new technologies, information systems, decision support systems and clinical parameters
prediction algorithm, in particular, in many Health related areas [19].
There are essentially two goals in statistical analysis: prediction of an outcomemeasure
based on a number of input measures and/or description of the associations and patterns
among a set of input measures.
This thesis is an attempt to bring many of the breakthrough new ideas in statistical
analysis for modelling the complex reality of reporting delays in a surveillance system, em-
phasizing the statistical methods and their conceptual underpinnings [18].
1.3 Objectives
The aim of the thesis is to study the phenomenon of reporting delay of a surveillance data
using all possible information. The main hypothesis addressed in this thesis is:
It is possible to describe the phenomenon of reporting delay, in a surveillance system,
modelling the individual factors, as well as the health care and surveillance systems.
In order to accomplish this goal, the following specific objectives were defined:
• to review the relevant related work in the field of modelling reporting delay distribu-
tions;
• to survey of the relevant statistical models used within the framework of this thesis;
• to propose and implement a reproducible methodology for assessment and improve-
ment of data quality through statistical data pre-processing for surveillance systems
data;
• to evaluate the application of traditional methodologies developed for large epidemics
in the Portuguese epidemic, which is small and concentrated;
• to assess the application of a statistical model for estimation of the under-reporting
phenomenon in the Portuguese epidemic;
• to assess the changes on the reporting delay throughout time ( study the possibility of
non-stationarity of the reporting delay process) taking into consideration the nested
individual, health care and organizational contexts.;
• to identify the main factors influencing reporting delays of HIV - AIDS cases within the
Portuguese surveillance system;
• to compare the models’ achieved results and evaluate their performance.
1.4 Contributions
This thesis makes the following contributions to the field:
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• It presents a holistic description of HIV -AIDS epidemic and how they are surveyed
and reported.
• Unification of the definitions of data quality based on the classical ISO / IEC 25012
and the quality assurance framework of the European Statistical System, to be used
by others in related works. Also, it updated the map between the main data set issues
affecting each data quality dimension. This work is being prepared for publication in
a scientific journal [20].
• Proposal of a systematic process for performing statistical data pre - processing based
on the following processes: perform an imprinting of the main characteristics of a
data set and review the main strategies for data cleaning and improvement. The
methodology was applied to the Portuguese Surveillance system. This work is being
prepared for publication in a scientific journal [21].
• The statistical models applied to large data sets do not fully capture the reporting
process of the Portuguese data set. In particular, the conclusion that the fully marginal
Poisson process does not capture the underlying phenomena of under - reporting.
This work led to a publication presented in [22].
• The study of the time patterns of Portuguese of reporting delay. It was shown that
the reporting patterns can be fairly divided into two groups. There are some fluctua-
tions indicating that the reporting is done in batches. This work led to a publication
presented in [23].
• The thesis identifies the main factors influencing reporting delays in the HIV - AIDS
cases within the Portuguese Surveillance System. This work led to a publication pre-
sented in [24].
• It also describes the reporting delay distribution in continuous time taking into consid-
eration the individual, administrative, organizational and historical context. This work
is being prepared for publication in a scientific journal [25].
Besides these contributions, the work presented in this thesis establishes work relations
with national and international organizations for disease control such as Commissão da
Luta Contra a SIDA, European Centre of Disease Control and Prevention and the Public
Health of Poland. Contacts with the elements of Statistics Netherlands helped to bring the
expertise of the UNECE on statistical business methodology to the scientific field.
In the course of this PhD two contributions on close fields were also developed: one
modelling of the incidence of the Portuguese Tuberculosis epidemics and the understand-
ing of the Perceived Quality of Life among first-year health students engaged in problem
based learning and traditional teaching model: First-year students of health sciences. The
first consisted in modelling the incidence through time clustered by regions with similar
patterns of incidence [26]. It is well known that tuberculosis and HIV share several social
determinants and this work helped to rise this awareness. The second was the first explo-
ration of the multilevel modelling in the context of perceived quality of life among first-year
health students [27].
1.5 Thesis Structure
The remainder of this thesis is organized as follows:
Chapter 2 - Infection Diseases and Surveillance Systems. The chapter overviews
the main concepts related to the life cycle of HIV, its geographical distribution and also who
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is diagnosed and treated. It also presents a description of how public health surveillance
systems are organized, how the data is collected and what is the data flow throughout the
system. We list the main possible sources of errors that bias the results that arise from it.
Chapter 3 - Statistical Data Pre – Processing. This chapter proposes a data quality
methodology for detecting and correcting the main errors. We describe the data sources
used in the thesis according to the variables, types and validation rules.
Chapter 4 - Mathematical Models for Reporting Delay Estimation. This chapter
explores the mathematical methods used to solve our main objectives. Also, it presents a
literature review regarding the modelling, direct or indirect, of the reporting delay pointing
the strengths and weaknesses of each method.
Chapter 5 – Methodology and Results. The chapter describes the methodology and
the results, showing the mathematical models with increasing layers of complexity for cap-
turing the underlying phenomenon of reporting delay in a surveillance system. It also
presents and analyses the results achieved by the methods proposed.
Chapter 6 - Conclusions. The final chapter summarizes the main conclusions and
contributions of this thesis and, in addition, some of its limitations and future perspectives.
Software used: The results presented on this thesis were preformed on the following
software R, Python, Java and RapidMiner.
Ethical commission: This work was submitted and approved by the ethical commission
of Oporto University.
Chapter 2
Infectious Diseases and Surveillance Sys-
tems
Among the many challenges to health, infectious diseases stand out for their
ability to have a profound impact on the human species. Great pandemics and
local epidemics alike have influenced the course of wars, determined the fates of
nations and empires, and affected the progress of civilization, making infections
compelling actors in the drama of human history.
The Perpetual Challenge of Infectious Diseases, Fauci 2012
Infectious diseases are a result of the penetration of foreign pathogenicmicro-organisms
into human tissues or organs, followed by their deleterious proliferation in the host [28]. The
pathogenic process is generally due to virus or bacteria, fewer times it can also be fungi
or parasites. The illness can be spread, directly from one person to another or indirectly
from one person to the environment and then to another person, throughout inoculation,
airborne or water-borne.
Once the infectious agent enter the body, host’s immune system reacts with a response
to neutralize the pathogens [29]. This resistance (by prevention or eradication) is mediated
by a collection of cells, tissues, organs and molecules. Examples of these mechanisms are
the epithelial barriers, lymphoid cells, lymphocytes cells (B and T) and their products such
as antibodies [30]. The two major subpopulations of T lymphocytes are the CD4+ and the
CD8+ cells. The first regulates immune response upon recognising antigen and the second
also have the recognizing ability but also gives rise to cytotoxic T cells [31]. If a harmful
pathogen overcomes these defences mechanisms, an inflammatory process is initialized.
This process is characterized by a redness, warmth, swelling, pain, loss of appetite, fatigue,
and loss of the tissue function [32]. Abnormal immune responses cause many inflammatory
diseases with serious morbidity and mortality [30].
Some immunological system cells have the ability to respond more rapidly and effec-
tively to pathogens that have been encountered previously - immune memory, and the
vaccines uplift this capacity.
Presently, the top three single agent/disease killers are HIV / AIDS, Tuberculosis (TB)
and Malaria, and while the number of deaths due to nearly every disease have decreased,
the ones due to HIV/ AIDS have increased fourfold [33].
In our deeply interconnected world of people and goods, infectious diseases constitute
a serious threat. An active vigilance for signs of an outbreak, rapid recognition of its pres-
ence, diagnosis of its microbial cause is required [1]. It is also necessary to identify modes
of transmission and at-risk population groups, and to define public measures for target pre-
vention [2, 3]. The collection of adequate surveillance data is vital to evaluate the disease
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Figure 2.1: Healthy T cell (left) and HIV infected T cell (right)
burden and the impact of prevention and control programmes, aiming for effective and effi-
cient responses.
This chapter provides, in section 2.1, an overview of the HIV life cycle, transmission
modes, infection diagnosis and treatment; section 2.2 overviews these same topics about
tuberculosis. In section 2.3 described the HIV and TB co-infection dynamics. The epidemi-
ology of the diseases is presented in 2.4. A holistic framework of the epidemic is presented
in 2.5. Section 2.6 focus on the data collection process and its main issues are reporting de-
lay, data duplication, completeness and consistency. Section 2.7 discusses these issues
for the European reporting processes and overviews the European and the Portuguese
Surveillance Systems.
2.1 Human Immunodeficiency Virus - Acquired Immunodeficiency
Syndrome
HIV is a biological agent that infects several types of human body cells with affinity for the
cells of the immune system, particularly the T cells, that bear the CD4 receptor (CD4+)
(Figure 2.1). It is a very complex virus with a rapid replication, high mutation rate and with
the ability to escape immune-mediates clearance. Hence, once infection is established, it
is never eliminated completely from the body [34, 35]. There are two types of virus: HIV-1
and HIV-2. The first is the predominant worldwide and the last is commonly found in West
Africa, and occasionally in East Africa, Europe, Asia and Latin America [36].
Once HIV enters the body, and without any intervention (prophylactic treatment), there
is a short term acute illness phase. In this phase the virus is able to integrate into the
host’s cell’s genes and remain hidden from the host immune response initiated 2-4 weeks
after the primary infection. People may experience a flu-like illness that may include fever,
headache, rash or sore throat. Since they have a large amount of virus in their blood, they
are very contagious. Past this few weeks, the HIV virus load drops and begins to prolifer-
ate steadily over the following years while CD4+ cell progressively decrease. At this stage
there may be an absence of observed disease and this period is the so-called clinical la-
tency or asymptomatic HIV infection because individualsmay not experience any symptoms
[35, 37, 38]. Without treatment, this stage can last approximately 10 years unless individu-
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als are infected with HIV-2; in this case it can be longer. During the viral suppression (when
the virus load is at a very low level), the transmission is less likely but not impossible. Over
time, a person’s viral load increases and the CD4 cell count begins to decrease and so a
spectrum of constitutional symptoms start to emerge. Without treatment, individuals start
to develop a collection of opportunistic diseases such as constitutional diseases, expedient
infections, neurological complications (dementia complex), tuberculosis, lymphomas and
Kaposi’s Sarcoma (KS) neoplasms that seldom occur in persons with intact immune func-
tion [35, 39, 40], and it is said that the person has AIDS. At this stage, the viral load is high
and individuals are again very infectious and without treatment; typically it will take 3 years
until death.
The typical progression of HIV without intervention is represented in figure 2.2 as well
as the decrease of CD4+ cells count. This indicator in normal individuals should range from
500 - 1200 cells / mm3 and late presentations of HIV infection should be below 350 cells
/ mm3 for adults and children with more than 5 years old. Children with AIDS and aged
under 12 months-old should have CD4+ cell count under 30 cells / mm3, from 12 until 35
months-old should have under 25 cells / mm3 and for children from 36 until 59 months-old
should be under 20 cells / mm3 [37] .
The ratio T4/T8 is often recognized as a quantitative outcome that reflects the critical
role of both CD4+ and CD8+ T-cells in HIV-1 pathogenesis or disease progression [41]. The
ratio T4/T8 can be approximated by the CD4/CD8 lymphocyte ratio which is approximated
2:1 in normal human peripheral blood [41, 31]. It declines with age but it may be significantly
altered by HIV infection.
Figure 2.2: Typical progression of HIV infection without intervention (reprinted with permission from
Fauci A.S. Pathogenesis of HIV Disease: Opportunities for New Prevention Interven-
tions. Clinical Infectious Diseases, Oxford University Press, 2007, 45, S206-S212 )
The diagnosis of the infection is done by the detection of presence or absence of anti-
bodies to HIV in the blood.
The clustering of AIDS cases and the occurrence of cases in diverse groups can be
explained by the disease transmission mode. Exchange of body fluids from infected indi-
viduals is necessary but not enough. Only certain body fluids - blood, semen, pre - seminal
fluid, rectal fluids, vaginal fluids, and breast milk - from infected individuals can spread the
virus, both types of virus, although the transmission of HIV-2 is slightly less easy. These
fluids must come in contact with a mucous membrane or damaged tissue or be directly in-
jected into the bloodstream (e.g. with a needle or syringe) [35, 42]. So, certain behaviours,
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practices and conditions put individuals at greater risk of infection such as:
• having frequently unprotected sexual contact;
• having unprotected anal sex (the highest-risk sexual behaviour) with multiple partners;
• injecting drugs with multi-user unsterilised equipment and drug preparations;
• perinatal transmission from mother to newborn infant;
• receiving unsafe injections, blood transfusions, medical procedures that involve un-
sterilised cutting or piercing; and
• experiencing accidental needle stick injuries, including among health workers [39, 43,
44].
Although HIV can affect anyone, certain groups are more vulnerable because have one
or more of the conditions and behaviour described above:
• Female Sex Workers (FSWs), who have numerous partners, often within a very short
period and often can’t negotiate the use of condom;
• clients of Sex Workers (SWs), often acting as a bridge to low-risk populations;
• Injecting Drug Users (IDUs), often share injecting equipment with non self blood;
• Men who have Sex with Men (MSMs), because unprotected anal sex has much higher
transferability [43, 44].
There is no safe and effective cure for HIV/AIDS but the infection can be controlled.
The proper treatment is called Anti-Retroviral Therapy (ART) and it can dramatically in-
crease longevity among infected individuals, reduce the viral load and, therefore, reducing
the probability of transmitting to others [?, 35]. Although not fully restored, with ART the
virus replication rate diminishes and the immune system is capable to protect the individual
against some opportunist diseases. So, the proper care may lead to a near-normal, produc-
tive life and with a life expectancy that may approach the observed in uninfected population.
So, HIV is now considered as a chronic disease [45].
While ART treatment reduces the risk of transmitting, death and complications from
the disease, these medications are expensive and have several and serious side effects.
Treatment is recommended as soon as the diagnosis is made regardless of the stage [46].
Not only HIV enables opportunistic pathogens that otherwise rarely infect human beings
to cause illness, it also substantially worsen the manifestations of other pathogens [47]. TB
and Viral Hepatitis are two common co-infections in HIV patients. If individuals have latent
TB, with co-infection aremore likely to develop active disease and if they have Viral Hepatitis
they may rapidly develop liver damage.
2.2 Tuberculosis
TB is the oldest infectious disease known (since pre-historical times) and it is the second
most common cause of death from single infectious agent [48]. It is caused by the My-
cobacterium tuberculosis (MTB), also known as “Koch’s bacillus”, and the World Health
Organization (WHO) estimates that as much as one-third of the world’s population is or
was infected by it [49].
Once the micro-organism enters, the host’s immune system tries to combat the disease
and it is believed that much of the tissue damage encountered has its origin from this re-
sponse. In the process, CD4 cells are thought to have a central role in the regulation of the
immune response to MTB controlling the bacteria growth [49, 50].
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Figure 2.3: Mycobacterium tuberculosis bacteria (left) and Healthy and TB infected patient x-ray
(right)
In immuno - competent individuals, a relatively small proportion (5 - 15%) of the esti-
mated 2 - 3 billion people infected with MTB will develop TB disease during their lifetime
[51]. Commonly, TB occurs in the lungs (90% of the cases) but the bacteria can migrate
to other body parts. However, just the pulmonary presentation is infectious (pulmonary tu-
berculosis) [52]. Therefore, the transmission is done mainly through air from individuals
with active pulmonary and/or throat tuberculosis when they cough, sneeze, speak or sing
[53]. These infectious droplets can be inhaled by an individual that can become infected or
re-infected. With a proper environment, frequent and prolonged interactions, a person with
untreated active TB can infect 10 to 15 people each year [40].
It may take many months from the time of exposure to the bacteria until physical symp-
toms of the infection develop. It has a variety of general symptom such as fatigue, fever,
loss of appetite, etc. In particular, on pulmonary form, individuals can experience cough
for more than three weeks, cough up sputum, cough up blood, shortness of breath and
chest pain. In extra-pulmonary form, the symptoms will depend on what part of the body is
involved [54].
The most common method for diagnosing TB worldwide remains on century-old sputum
smear microscopy, in which bacteria may be observed under a microscope. In the last few
years it is increasing the use of rapid molecular tests to diagnose TB and drug-resistant TB.
In countries with more developed laboratory capacity, cases of TB are also diagnosed via
culture methods (the current reference standard) [55].
The currently recommended treatment for new cases of drug-susceptible TB is a six-
month regimen of four first-line drugs: isoniazid, rifampicin, ethambutol and pyrazinamide,
with treatment success rates of 85% or more for new cases. Treatment for Multidrug-
Resistant Tuberculosis (MDR-TB), defined as resistance to isoniazid and rifampicin (the
two most powerful anti-TB drugs) is longer, and requires more expensive and toxic drugs.
The current regimens recommended by WHO, proposes a 20 months’ regimen with much
lower success rate [55].
Although curable, TB is still a serious threat, having high morbidity and mortality death
rate due to the complex treatment regime and to the increasing emerge of drug resistance
strains.
The only available vaccine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), is
delivered mainly on infants and confers highly variable efficacy against pulmonary disease
[56]. In developed countries, and following a continued decline in TB rates, the immunisa-
tion is given to children at most risk of exposure.
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2.3 HIV-AIDS / TB Co-Infection
HIV and TB have been closely linked since the emergence of AIDS, and both have pro-
found effects on the immune system, as they are capable of disarming the host’s immune
responses through mechanisms that are not fully understood [57, 58].
HIV increases susceptibility to MTB: not only does the HIV increase the risk of reac-
tivating latent MTB infection, it also increases the risk of rapid TB progression soon after
infection or reinfection with MTB [59, 36]. People living with HIV are 29 times (26 - 31) more
likely to develop TB disease as people without HIV and living in the same country (exposed
to the same risk of TB) [60]. The increased of HIV-associated TB also increases MTB trans-
mission rates at the community level [59]. More over, most of the risk factors associated
to one infection predispose the individuals to the other and, therefore, the two infections
are concentrated in the same sub-populations [61]. Also, the incidence of TB among HIV
infected individuals depends on the number of cases of TB in the country.
TB is the most common opportunistic infection and is a leading cause of death among
people living with HIV, accounting for 1 in 5 HIV-related deaths globally. As a corollary, in
2013, 1 in 4 TB deaths were associated with HIV.
In 2014, an estimated 2.0 million persons were newly infected with HIV at a global level
and an estimated 9.0 million people developed TB worldwide. Of these, 1.1 million (12%)
had both HIV and TB, and 360 000 died from HIV-associated TB [62].
In Portugal, in 2014 and for the first time, the numbers of TB cases were lower than
20 new infections per 100 000 residents. However, the number of HIV infected individuals
among TB cases are twice higher than in the European Union [26, 63]. It was shown that
the HIV notification rate had a positive and significant effect on TB notification rate. If the
rate of notification of HIV increases, it is expected an increase in the TB notification rate.
More precisely, an increase of 10 HIV notifications cases per 100,000 population leads to a
rise of 2.5 TB notifications per 100,000 population (p <0.05), for a fixed year, geographical
location and population density value [26]. So, the Portuguese Direcção - Geral da Saúde
started to preventively treat for TB risk groups, such as individuals with HIV - AIDS [63].
There is a strong spatio-temporal association between the two epidemics - Figure 2.4.
Evidences show that HIV prevalence is exacerbating the TB epidemic even in regions with
low incidence [26] . The WHO has recommended the package of interventions collectively
called collaborative TB - HIV activities since 2004 [57, 60].
2.4 Epidemiology
HIV continues to be a major global public health issue, having claimed more than 36 million
lives so far and with no clear signs of overall decrease [39, 64]. Seven out of ten people
living with HIV are in sub-Saharan Africa, where this infection is a leading cause of death
among adults, women of child-bearing age and children [64].
In 2015, Joint United Nations Programme on HIV/AIDS (UNAIDS) / WHO estimated that
a total of 31.8 million adults and 3.2 million of children (< 15 years old) were living with HIV
worldwide. Although the numbers decreased since 2014, there were still 1.9 million adults
and 240 000 children newly diagnosed and AIDS had claimed 1.1 million lives [65].
The epidemic trends and patterns vary widely across European countries. In 50 of
the 53 countries of the WHO European Region, there was a rate of 17.6 newly diagnosed
infections per 100 000 population which corresponds to 153 407 new HIV / AIDS cases,
with the highest prevalence presented in the East of the Region and lowest in the Centre
1(Figure 2.5).
1WHO European Region and Lichtenstein: West: Andorra, Austria, Belgium, Denmark, Finland, France,
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Figure 2.4: Estimated tuberculosis (TB) incidence in relation to human immunodeficiency virus (HIV)
prevalence for 42 countries in the World Health Organization African Region [59].
Figure 2.5: New HIV diagnoses per 100000 population, 2015 [66]
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The rate of new HIV diagnoses was higher among men being the overall male-to-female
ratio of 3.3 and the highest crude age-specific rate was observed among subjects aged 25-
to-29 years old.
An excessively high number of people (48%) were diagnosed in advanced stage (CD4
count < 350cells/mm3). The highest proportion was observed among IDUs (58%) and
those acquiring HIV through heterosexual contact (57%), and the lowest in people who
acquired HIV through sex between men (37%). The proportion of late diagnoses increased
with age, being this characteristic present in 63% of persons aged 50 or older. Beingmigrant
from sub-Saharan Africa and south-east Asia placed people at-higher risk of late diagnoses
(both 56%).
Although the number of AIDS cases has consistently declined since the mid-1990s, in
2015 this stage was diagnosed in 3 754 people of 29 European Union (EU)/European Eco-
nomic Area (EEA) countries, corresponding to a rate of 0.8 cases per 100 000 individuals.
The highest rates were reported by Latvia (6.6) and Portugal (2.3). The most common AIDS
- defining illness reported by 19 countries was TB (pulmonary and/or extra-pulmonary) [66].
The reported main transmission mode in EU / EEA was sexual contact between men,
but in East of the Region heterosexual contact and injecting drug use prevailed [66, 67].
The HIV epidemics of the European Regions in key populations at high risk are intersect-
ing epidemics, in which sexual risks intersect with those related to injecting drug use [68].
SWs involved in injecting drug use have higher HIV prevalence than SWs who do not inject
drugs. The first are also more vulnerable to violence, reduced condom use, increased men-
tal health problems and unwanted pregnancies. Studies on risk factor showed a strong and
consistent association between an increased number of people imprisoned and increased
HIV prevalence among IDUs and FSWs. Prison, an effect of criminalisation of drug use
and sex work, is a risk environment for the transmission of HIV [68].
Comparing a 5-year averages of HIV cases according to the reported probable trans-
mission mode and considering that:
1. the exposure group ‘heterosexual’ includes sex work-related transmission
2. risk practices overlap such as some sex workers injecting drugs and
3. exists variation in frequencies of reported HIV cases within each sub-region
data suggest that the epidemic is concentrated among MSMs, IDUs in the West which
counts also with the contribution of the heterosexual transmission; although with lower num-
bers, the Centre epidemic is still concentrated among MSMs, the higher transmission in
European Regions occur in the East and it is concentrated among IDUs and with strong
contribution of heterosexual transmission [68, 69].
For better understanding the epidemiology of TB/HIV co-infection in the EU / EEA, Euro-
pean Centre of Disease Control and Prevention (ECDC) performed a comparative descrip-
tive analysis of the TB (both HIV-positive and HIV-negative) and AIDS (both with TB-positive
and TB-Negative) case-based surveillances data.
The TB perspective In 2014, 21 243 (64.6%) of 32 892 TB cases were reported to have
undergone HIV testing, and 1051 (4.9%) of those with known HIV status were reported as
HIV-positive [62]. These data were reported by 21 of the 31 EU / EEA countries.
Germany, Greece, Iceland, Ireland, Israel, Italy, Liechtenstein, Luxembourg, Malta, Monaco, The Netherlands,
Norway, Portugal, San Marino, Spain, Sweden, Switzerland, United Kingdom Centre: Albania, Bosnia and
Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Hungary, Montenegro, Poland, Romania, Serbia,
Slovakia, Slovenia, the former Yugoslav Republic of Macedonia, Turkey East: Armenia, Azerbaijan, Belarus,
Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of Moldova, Russian Federation, Tajik-
istan, Turkmenistan, Ukraine, Uzbekistan
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Figure 2.6: Percentage of AIDS diagnoses with
tuberculosis reported as AIDS - deﬁn-
ing illness, by country, European
Union and European Economic Area,
2014 [62]
Figure 2.7: Percentage of HIV-positive cases
among tuberculosis cases with
known HIV status, by country, Euro-
pean Union and European Economic
Area, 2014 [62]
Four countries had HIV testing coverage less than 50%: Czech Republic (28.4%),Den-
mark (1.9%), Hungary (3.5%) and Ireland (26.6%). Among the 17 countries with at least
50% reporting completeness, the proportion of co-infected cases was highest in Latvia
(19.5%) followed by Malta (17.1%), Portugal (14.7%) and Estonia (10.1%) 2.6 [62].
The AIDS perspective In 2014, 3863 cases of AIDS were reported by 29 countries in
the EU/EEA. TB was the second most common AIDS-deﬁning illness with 691 (17.9%)
(the first more common was Pneumocystis pneumonia). Among these co-infected cases,
497 (71.9%) were reported as pulmonary TB and 194 (28.1%) as extra-pulmonary TB. The
highest proportions of TB as an AIDS-deﬁning illness were reported by Malta ( 75% of AIDS
diagnoses), Romania ( 43.9%), Latvia (41.5%) and Lithuania ( 37.8%), whereas in Cyprus,
Greece, Slovenia and Slovakia no AIDS cases were reported as presenting with TB as
AIDS-deﬁning illness 2.7 [62] .
2.5 HIV / AIDS Socio - Ecological Framework
Thirty-five years of HIV / AIDS history led to a clear understanding that reducing its
incidence is not simply a battle for using condoms and keeping individuals engaged with
medication [70]. The unsuccessful individualistic or single-issue focussed interventions led
to a clear recognition that “HIV risk behaviour can only be significantly and sustainably
changed by considering all the up-stream factors which shape those patterns of behaviour”
[71, 72].
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Practices are socially produced behaviours that are organised and patterned by culture
[73]. So, HIV / AIDS epidemic is shaped by social and structural drivers as well as by indi-
viduals characteristics [74, 72, 68]. These multifaceted factors and their relationships can
be explained by a Socio-Ecological Model (SEM) which is based on the premise that while
individual levels risks are necessary for the disease spread, they are insufficient to explain
population level epidemic dynamics [72] . This model typically contains five hierarchical
levels highly interactive throughout mechanisms of critical importance:
1. individual,
2. interpersonal / network,
3. community,
4. organizational / institutional / health system, and
5. structural / policy / environment.
The individual level corresponds to biological or behavioural characteristics associated
with vulnerability to acquire or transmit illness or infection [72]. It includes factors such as
perceptions, beliefs, emotions, knowledge, attitudes, self-efficacy, developmental history,
gender, age, religious and racial/ethnic identity, sexual orientation, economic status, finan-
cial resources, values, goals, expectations, personal stigma, fear of others stigma among
others [70, 71, 73, 72, 75].
The interpersonal /network level consists of interpersonal relationships including family,
friends, peers, co-workers and other that directly influence health and health behaviours in
multiple ways [72]. Includes factors such as relationship satisfaction, social support sys-
tems, customs or traditions and networks, which are not bounded by geography, socio-
economic status, or cultural and racial [70, 71, 73, 72, 75].
The definition of what is a community is not consensual but generally includes: network
ties, relationships between organizations and groups, and geographical / political regions
[72]. This level includes influences such as gender norms, stigma, mobility of the local pop-
ulation, social capital, community norms, informational networks within defined boundaries,
the built environment (e.g., parks), village associations, community leaders, businesses,
and transportation.
The organizational / institutional level focus on factors within the health system with
rules and regulations for operations that affect how, or how well services are provided. Ex-
amples of these factors are quality of services, confidentiality, sufficient resources, support
tools, convenient and responsive services.
At last, the structural can be described as a level of local, state, national and global
laws, legal rights or regulations and polices, including polices regarding the allocation of
resources[75]. This last macro-level contains factors that are out of individuals control,
acting as barriers or facilitators, mediating lower order risks such as those at the individ-
ual or interpersonal / network levels [72]. It includes factors affecting behaviour, such as
economy, political climate, enforcement of policies and laws, or funding dynamics, poverty,
educational curriculum and gender equality [70, 71, 73, 72, 40].
Figure 2.8 represents several factors at each level of the SEM for HIV-related behaviour
and /or behaviour change; although over simplified it is consistent with the majority of the
ecological literature [70]. Note that factors can span levels and therefore the boundaries
between themmay be understood as permeable, also the relative importance of each factor
varies with population and local context [72]. For example, the behaviour - condom use -
has varied social and cultural meanings depending whether it concerns a ’marriage bed’, a
brothel or casual sexual encounter [73].
Individual characteristics such as knowledge and skills may influence the perception
about what may be a HIV risk behaviours but may also affects the capability of taking the
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Figure 2.8: Factors influencing HIV-related behaviour and / or behaviour change at each level of the
socio-ecological model [70] (reprinted with permission from Michelle Kaufman)
necessary actions to self - preservation [74]. For example, individuals that have low health
literacy concerning HIV-prevention methods are more vulnerable, thus being at a higher
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risk of becoming ill. Another example is low self-esteem that may lead individuals to seek
multiple sexual encounters in an attempt to self-validation, or lead individuals taking refuge
in the use of alcohol or drugs — substances that impair judgement and may interfere with
the risk perception and with the person’s ability to negotiate and practice safer sex — to
enable sexual encounters [76]. Individuals in both high and low-risk contexts can reduce
their sexual risk of contracting HIV- by being abstinent, selecting HIV-uninfected partners,
being monogamous with an HIV-uninfected partner, engaging in safer sex practices (e.g.,
always using a condom), and/or adhering to a pharmaceutical pre-exposure prophylaxis
regimen [77].
Individuals cannot exist without social networks which directly influence behaviours,
even when the individual may wish to act differently [70]. A well-known protective factor
is the social support and trust throughout family and social networks, reinforcing social
norms and behaviour. On the contrary, sexual and social networks with high infection rates
and high prevalence of risk behaviour such as multiple sexual contacts and share of used
injection drugs paraphernalia exponentiates HIV transmission between the members of the
network [72]. Other barrier is an unfriendly social and cultural environment that can create
stress and thus interfere with the individuals’ ability to self - health promotion.
History provides an unfortunate abundance of examples of community prejudice, dis-
crediting, discrimination, discounting and mistrust directed toward particular groups of indi-
viduals [76, 78, 74]. It is widely recognized that these phenomenons are a persistent and
pernicious barrier to prevention, uptake of HIV test and treatment creating health risk and
worsening health care [70, 79, 80, 81]. They may also be an obstacle to the proper com-
munication of the transmission modes, and may induce individuals to deny their serological
status and neglect their specific needs [78].
Two out of three countries in Europe and Central Asia acknowledge that stigma and
discrimination within key HIV affected populations are a barrier to epidemic control and
contributes to late diagnosis. These negative attitudes among health professionals, partic-
ularly with respect to sex workers, men who have sex with men and people who inject drugs,
reportedly persists across the region and plays a role in preventing these key populations
from accessing HIV prevention, testing and treatment [81].
Other important driver factors are the interpretation of community norms and public HIV-
positioning of influential members of the community affecting the provision and/or uptake
of HIV prevention, testing, treatment and access to care services [76, 72].
The deprivation of convenient, competent and responsive health resources is a clear bar-
rier to epidemic control. Among these resources, health providers are essential given that
they are the first contact with patients who need counselling, support and proper treatment.
So, effective and supportive providers are determinant to patients trust in their counselling
and following their recommendations. Confidentiality and privacy of health institutions are
other key elements due to stigma and illegality of some HIV-related behaviours.
People living with HIV and AIDS need a variety of healthcare and social support, be-
cause of their vulnerability to opportunistic infections and their progressive disease [82]. A
special and essential role of counselling, prevent, monitor the evolution, support and com-
fort are provided by the Physicians’ which have a privileged point of global attention. The
global shortage of health workers is estimated at over 4 million, with 57 countries experi-
encing severe shortage; defined as fewer than 0.23 doctors, nurses, or midwives per ten
thousand people. This translates into nearly a billion people who have no access to a health
worker of any kind of the one- seventh of the world’s population. The majority of identified
HIV-positive people are in contact with health care providers. [82]
Laws criminalizing injecting drugs, same-sex behaviour or commercial sex may cause
an individual feel fear of discrimination or even of being arrested when seeking a health
care institution for diagnostic and treatment. Also, may have an impact on stigma and mis-
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conceptions at the community and interpersonal levels affecting the adoption of prevention
and treatment behaviours [70]. Another example is the economic inequalities at the macro-
social scale that can divide communities, encourage transactional sex and introduce vast
interpersonal power inequalities in the negotiation of safer sex, affect the access to forms
of prevention such as buying condoms and prophylactic treatment [70, 83]. Countries econ-
omy affect the quality of health care, quality of intervention programmes and the individuals’
acceptability of the services which “is a concept that is embodied in individuals and is thus
affected by perceptions of the accessibility of the healthcare, health system responsiveness,
and individuals psychological status, experiences and expectations” [83]. This ultimately im-
pacts satisfaction, adherence to prescriptions and treatment outcomes which increases the
risk of poor health conditions, onward HIV transmission and ultimately death [83]. Policies
determine allocation of economic resources to education, health care, job training, financial
assistance and HIV prevention services and therefore play a substantial role in shaping
structural contexts of HIV risk [72].
More than one in three countries in Europe and Central Asia report that unfavourable
laws and policies are a barrier to provision of HIV prevention services for people who inject
drugs and sex workers. In two out of five countries, such laws and policies reportedly limit
the provision of HIV prevention services, including harm reduction intervention, in prisons
and in half of the countries, laws and policies are reported to limit access to treatment for
undocumented migrants [84].
Knowledge about disease incidence is vital to its control so a proper case register sys-
tem must be implemented in each country.
2.6 Public Health Surveillance Systems
Surveillance has been defined as the continual scrutiny of all aspects in emerging and
spread of a disease that are pertinent to effective control, involving a systematic collection,
analysis, interpretation, and dissemination of health data [1, 12, 2]. Surveillance systems
rely on processes and individuals, thereby can be found to differ substantially according to
the disease, health condition and country. Nevertheless, all traditional public health surveil-
lance approaches use pre-specified case definitions, employ manual data collection and
human decision-making [4, 3, 5, 6].
For surveillance purposes, before counting cases it is necessary to decide what a “case”
is. Case definitions are a set of standard clinical and laboratory criteria that unequivocally
classify whether a person has a particular disease, syndrome or other health condition
developed by epidemiologists [85, 3]. These case definitions remove the potential bias and
make the comparison between populations possible in different geographical locations and
times. So, they are a fundamental cornerstone for standardising the collection of data [3].
Typically, epidemiologists in national public health authorities collect confirmed cases
from laboratories, general practitioners and hospitals which are common detection and pri-
mary infection diagnosis data sources [3]. Each case is record, processed and compiled in a
national database.Then the information is analysed and made available to public health pro-
fessionals, the general public and public health authorities for supporting decision-making
in public health practices [15, 3].
In Europe and in accordancewith the ECDC founding regulation (Regulation (EC) 851/2004),
all EUMember States (28) have to provide to this centre in a timely manner, the available sci-
entific and technical data on 52 communicable diseases and related special health [86, 87],
using The European Surveillance System (TESSy) which is hosted and validated by ECDC.
In the case of HIV, TB and Influenza, the surveillance is conducted with the collaboration
of the World Health Organization - Regional Office for Europe (WHOE) (Figure 2.9).
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Figure 2.9: Simplified flowchart of a generic surveillance system based on [3] and [88]
Considering the attributes of the disease and objectives for which they were imple-
mented, surveillance systems may be classified as passive or active, as compulsory or
voluntary and as comprehensive or sentinel. In a passive system, the data providers take
the initiative to report the case to the public health agency which do not stimulate the re-
porting nor give feedback. By the contrary, an active surveillance relies on the initiative of
public health official that contact relevant sources of data, stimulating them to report, send
agencies alert or remind and give feedback of the results [3, 89]. Some systems make data
submission mandatory by law, professional edict, policy or guidance. Comprehensive sys-
tems include reports of cases that occur within the whole population of a geographical area
covered by surveillance system while sentinel rely on notifications from a selected group of
reporting sources [3, 89]. Active and mandatory systems typically generates high-quality
data (defined as high levels of completeness, validity and timeliness).
The information reported can be aggregated or case-based. The latter occur when indi-
vidual anonymized data is reported while in aggregate-based systems only the information
related to a group of people classified under the same category for a disease or health-
related event (for example the number of people reported by age and / or risk group) is
registered [3].
The format in which data is collected may be paper or electronic through an information
system. The paper format has the advantage of requiring no special technical skill and
it entirely circumvents the difficulties of interfacing between information systems and the
disadvantage of needing to undergo a transcription step increasing the risks of introducing
additional errors and do not enforce the completion of mandatory fields or other validation
checks [3].
Moreover, given the typical fragmentation of surveillance systems and the demands of
health care systems, several problems inherent to data must be recognized. This issues
may occur in each and every step of the data collecting process, data management and
analysis, affecting negatively the aim for which the data was collected [12, 13, 3, 14, 15, 16].
The most common problems are unrepresentative or selection bias , changes in the system
implementation through time, inconsistent case definitions, availability of cases, reporting
delay, and processing errors such as errors during completion of the reporting form or data
entry.
The first problem causes sampling errors on data obtained from the surveillance reg-
20 Chapter 2. Infectious Diseases and Surveillance Systems
istries while the others may introduce bias on statistical estimates commonly designated by
non-sampling errors. Changes in the system implementation through time are inevitable.
As epidemiologists’ knowledge about the natural history of the disease being surveyed and
diagnosis techniques evolve its natural that the case definition change. Likewise, the evolu-
tion and adopting of different information technologies used for reporting a case may affect
the behaviour of system main stakeholders. Other important factors affecting data quality
are changes in government funding, legislation or reporting sources. It must be recognized
that any change in the reporting system may interfere with the number of cases recorded
and thus with the statistical analysis, especially in time trend monitoring. Moreover, time
changes in surveillance infrastructure, clinical practices and reimbursement policies may
smite representativeness [3].
2.6.1 Surveillance Data Representativeness
Generally, health conditions are not reported randomly. Diseases handled in a public health
facility are reported disproportionately more frequently than those diagnosed by private
practitioners; conditions that lead to hospitalization, are more likely to be reported than
problems dealt with on an outpatient basis; diseases with testing practices implemented
by the central government are more likely to be diagnosed and reported [12, 3, 85]. So,
the information collected may not be representative of the affected population and thus
the occurrence of the health-related event over time and its distribution in the population
by place and person may not be accurately described [3]. Collecting data from multiple
sources may help to provide ways to improve the representativeness of the information.
The unregistered cases may occur at a community level, when patients do not seek
professional care, in a surveillance system level when the system fails/misses or delays
the reporting of diagnosed case or / and in the health department itself when, for example,
cases are lost due tomisclassification [90, 3, 7]. A general morbidity surveillance pyramid, is
often used to illustrate the availability of disease data at each surveillance level. “With each
ascending level (from the community, to healthcare institutions, to regional and national
public health agencies) data availability shrinks and only a fraction of cases from the level
below is captured. In contrast to the narrow tip of the pyramid which represents data held by
national public health agencies, the base is wide as it holds all infections in the community.
The difference between the numbers at the top and at the base can be considered cases lost
to underestimation” which is the sum of cases lost to under-ascertainment and cases lost to
underreporting. The typical morbidity pyramid is presented in Figure 2.10 [90]. Depending
on the disease, 5% to 80% of the cases that actually occur will be reported [12, 3].
Under-ascertainment or under-diagnose of cases correspond to patients that are not
diagnosed and hence not identified by the healthcare systems and it may occur when:
• patients do not visit the healthcare services because they do not feel symptoms or
feel only mild symptoms
• a patient have low health literacy and do not recognize symptoms nor perceive the
need to seek healthcare;
• unequal geographical distribution of healthcare services exists;
• diagnostic tools are unavailable;
• routine surveillance does not capture marginalised high-risk groups (e.g. commercial
sex workers, IDUs, MSMs);
• physicians and the general population are unaware of the disease [3].
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Figure 2.10: Typical morbidity surveillance system [90].
UR - underreporting, UA-under-ascertainment, UE - Underestimation
Underreporting of cases occurs when patients visit physicians or healthcare facilities,
but once diagnosed, they are not properly reported to the local public health unit [3, 12]. As
ECDC points, it may occur when:
• patients during visiting the doctor do not show symptoms of the notifiable disease;
• a patient has more than one reportable condition and only one is reported (e.g. AIDS
with TB as opportunistic disease);
• the surveillance system (e.g. communication system or software) does not fully sup-
port the actions initiated by the healthcare provider (or reporter) so he/she cannot file
the formal report;
• an attempt to a report was made but the communication or the software system failed;
• the patient is presenting a serious clinical condition and the physician focuses on the
patient, simply forgetting to notify the case;
• the registered case is present and registered in the public health surveillance database,
but has been misdiagnosed, misclassified, or miscoded [3].
Assessing the non-visible cases (under-reported or under-diagnosed) is a difficult task
[3]. When the disease is on a symptomatic stage other sources of information may be
useful, such as:
• monitoring sales of specific drugs over time through electronic systems;
• investigating the symptomatic cases social networks for identification of non-visible
cases;
• screening of risk groups or samples of the general population (e.g. pregnant women,
refugees, prisoners, sex workers, blood donors, pre-surgical patients). [3]
When the disease is on an asymptomatic stage the only way to find the patients would
be through specific sero-surveys (e.g. serological surveys). This could be relevant for
diseases such as hepatitis B/C and HIV [3].
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2.6.2 Reporting Delay
Reporting delay can be defined as the time between the diagnosis of a case (by the physi-
cian and/or the laboratory) and its report to the national surveillance system. Timely report
may enable public health authorities to take fast and effective actions to prevent outbreaks
by reducing disease transmission in a population [91, 92, 93]. Reporting delays may de-
pend on a number of factors such as:
• the use of confirmatory laboratory testing;
• the volume of cases identified in the reporting source;
• the reporting process by the health care provider or the laboratory to the local, region,
or state public health authority;
• the case follow-up investigations to verify the case report or to collect additional case
information;
• periods of decreased surveillance system activity due to reduction of financial re-
sources;
• computer system down-time for maintenance, upgrades, or new application develop-
ment;
• data processing routines, such as data validation or error checking;
• physicians workload;
• different geographical location [5, 8];
• reporting format.
2.6.3 Form Completion or Data Entry Errors
During completion of the reporting form or data entry, different types of errors may occur:
• Errors in interpretation or coding, for example:
– Unclear case definitions or that are not widely known may lead to variation on
the criteria use. The greater complexity of the diagnosis, “the greater the diffi-
culty in reaching consensus on a case definition” and properly register the case.
For example, pediatricians sometimes report diagnosed cases of childhood dis-
eases such as measles as verified, even though the EU case definition requires
laboratory confirmation;
– frequently adjustments to the disease case definition due to evolution of disease-
related knowledge, may introduce a confounding effect;
– emerging of new diseases or definition of parameters that the surveillance sys-
tem has not taken into account cannot be reported. When S. enterica serovar
was first recognised, some systems reported related cases either as unknown
or as S. typhimurium because this new monophasic Salmonella serovar was not
included in the pre-populated list of values [12, 3, 94].
• Errors of intention, for example:
– selecting only cases with good outcomes to report (“cherry-picking”). Avoidance
or detection of intentional error can be challenging. Some approaches include
checking for consistency of data between sites, assessing screening log infor-
mation against other sources (e.g., billing data), and performing onsite audits
(including monitoring of source records) either at random or on purpose.
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– when some of the information of the reporting form is self-reported; for example,
in diseases like HIV, individuals may not report embarrassing conditions, socially
discriminated or criminalizing activities [95];
– stakeholders perceive negative consequences to their interests by reporting high
infection rates, so intentionally report lower ones [96].
• Errors when data is entered into the registry inaccurately, such as incompletion of the
reporting form, data entry, transfer, or transformation accuracy. These errors are due
to insertion, deletion or substitution of characters or writing wrong dates, such as:
– a laboratory value of 2.0 entered as 20;
– it has been documented that data entry operators show a systematic digit pref-
erence when filling in numeric fields for age (ages ending in 0 and 5 are overrep-
resented) or date (01, 10, 15 and 20 are overrepresented);
– digit preference may be also combined with the tendency to avoid certain ’un-
pleasant’ numbers, such as 13 [3].
The most common errors are random ones, during completion of the reporting form or
during data entry, namely insertion of characters, missclassification of the disease, chang-
ing code of observations, writing wrong dates and do on [3]
Avoidance or detection of interpretive error can be achieved by adequately training main
providers on definitions and testing against standard charts. Avoidance or detection of
accuracy errors can be achieved through upfront data quality checks (such as ranges and
data validation checks), re-entering samples of data to assess for accuracy (with the percent
of data to be sampled depending on the study purpose), and rigorous attention to data
cleaning [94].
From Population under Surveillance or Coverage until Central Government, it must be
recognized that the surveillance data collection process is composed by several critical
levels with unique mechanisms. It has a strong human decision-making component firmly
imprinted in data which may affect the information quality registered on the system. From
representativeness until simple data entry errors several issuesmay occur. Themain issues
described in the previous sections are summarized in Figure 2.11 and grouped by the key
levels of the system.
A particular case of a surveillance system is that for the HIV/ AIDS. It differs from other
surveillance systems in many ways, namely by reflecting the special transmission patterns,
the long asymptomatic or with mild symptoms latency period of the infection, the lack of
affordable treatment and cure, high case fatality rates, and the social stigma associated
with it [9].
2.7 European Surveillance of HIV/AIDS
Surveillance for HIV/AIDS is among the most complex surveillance systems [13]. Its main
purposes are to determine the extent of the epidemic and to track the changes or trends in
the epidemic overtime [97].
HIV - AIDS surveillance collects, analyses, and disseminates information about new
and existing cases of HIV infection (in all stages of development). Given the long asymp-
tomatic (or with mild symptoms) incubation period between infection and the development
of AIDS, a surveillance system that relies solely on AIDS case reporting is not effective
since these data are usually used to reconstruct the past prevalence of HIV infection and
are not appropriate for tracking current infections [9]. In addition, the definition of AIDS be-
comes increasingly meaningless with the provision of Highly Active Anti-Retroviral Therapy
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Figure 2.11: Case reporting main issues from a surveillance system
(HAART) [97, 9, 68] since this stage is becoming rarely observed (when patients undergo
proper treatment) .
Since 1982, many definitions have been used for national and international reporting. In
2012, the European Parliament and the Council established case definitions for AIDS and
HIV on the Commission Decision of 27/09/2012 to the community network under Decision
No 2119/98/EC [98]. This definition of AIDS includes all HIV - infected individuals with
CD4 counts less than 200 cells /µL as well as those with certain HIV - related conditions
and symptoms. Although the fine points of the classification system are rarely used in the
routine clinical management of HIV infected patients, a working knowledge of the staging
criteria is useful in patient care [99, 100]. The details of the definition are presented in
Appendixes A and B.
HIV/AIDS surveillance also poses a number of special ethical problems arising mainly
from the stigma and discrimination attached to AIDS. Finally, HIV/AIDS surveillance in-
cludes behavioural surveillance, in order to understand trends in behavioural risk factors
for HIV [9].
All European countries have developed systems to monitor the evolution of AIDS [68].
Since the identification of the first case in the early 1980s, the focus of surveillance was on
AIDS reporting. With the development of HIV laboratory technologies and the introduction
of HAART the number of AIDS diagnoses no longer reflects the underlying trends in the HIV
epidemic satisfactorily [101]. The collection of these cases remains important for providing
insights into the extent of late diagnosis and the impact of HIV treatment [68, 101].
All countries in theWHOE, except Monaco and Liechtenstein, have established systems
for monitoring the number of new HIV diagnoses [68]. These systems have been replacing
the AIDS surveillance to overcome their major limitations: when used to monitoring the HIV
epidemic they do not represent the true HIV - incidence, reported cases may include infec-
tions that occurred several years previously and are dependent on uptake of HIV testing
practices in the population [102, 68].
In some countries, systems have undergone significant revision in the way that they
operate; as a result, data from different time periods are not always comparable and some
have no national coverage [68].
2.7. European Surveillance of HIV/AIDS 25
Surveillance systems are not identical across Europe. In addition to the surveillance
data common quality issues discussed in previous sections (in particular, reporting delay,
case duplication,completeness,...) , one must recognize that countries vary in data collec-
tion methods and testing policies that may have an impact on the the results and introduce
bias in comparisons between countries[68, 103, 66].
Due to these variations, national data need to be compared carefully since countries
with the largest number of diagnosed cases may reflect not the true scale of the epidemic
but the efficacy in case finding.
2.7.1 Reporting Delay
It is widely recognized that reporting delay is an ever present issue that downward biases
the HIV trend estimates. This bias is greater in most recent years and, to a lesser extent,
in the 2 to 3 years prior to the reporting period [66].
In 2006, a European-wide survey of HIV surveillance systems in 44 countries found that
among the 16 countries that had examined reporting delay, the majority stated that 90% of
the HIV diagnoses were reported within 6 months and only 3 countries stated that 75% of
cases were reported in the same time period [68, 102]. In present days, it was estimated
that the longest delays occurred in 9 countries: Greece, France, Italy, Luxembourg, the
Netherlands, Poland, Portugal, Sweden, and the UK [103].
The key challenge related to the reporting delay are specific one-off actions in surveil-
lance aiming to capture previously unreported cases.These cases are subsequently re-
ported with excessively long delays. The analysis of the trends in reporting delays exhibits
peaks related to control activities in surveillance (“cleaning events”) in Portugal (2013 –
2014), the Netherlands (2010 – 2011) and Poland (2010) [103].
Underreporting The exact extent of underreporting is unknown. Fewer than 40% of Eu-
ropean countries have evaluated their surveillance systems for this limitation and only two
have published the results. Previous estimates states that it ranges from 0% to 25% for
AIDS cases, while for HIV it can range from 10% (Iceland and Italy) to around 40% (Ger-
many and the UK) [68, 102, 66].
In many cases, underreporting is viewed as a special case of reporting delay; it is con-
sidered a reporting delay with infinity length.
2.7.2 Duplication
The duplication of HIV/AIDS reported cases occurs in several European surveillance sys-
tems [66, 103] and may be originated by the following settings:
1. an individual may have more than one positive HIV test as a result of receiving health
care in different settings or using both anonymous and named testing services;
2. a single positive test could be reported more than once, for example, by both the
laboratory undertaking the testing and the clinician [68];
3. a single case reported by two physicians in two different settings; for example, a
positive test on an Injecting Drug User (IDU) that is engaged in a drug treatment
program may be reported, simultaneously by the clinic when the treatment occurs
and by the general practitioner.
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2.7.3 Completeness and Consistency of Risk Factors’ Details
Missing data are also a well-recognised problem within surveillance systems that may lead
to biased and potentially less precise estimates. In principle, whenever reporting delays or
missing data occur, the accuracy of epidemiological distributions and trends is questionable
[103].
The completeness of key epidemiological variables such as age, sex, transmission cat-
egory, CD4 count at diagnosis and migration status (either of the following: country of birth,
region of origin, country of nationality) vary over time and between countries [103, 68, 66].
In 2015, ECDC and WHOE reported the lowest completeness rate being observed on CD4
count [66]. This rate increased from 25.9% in the pre-2000 period to 56.8% during 2012-
2014, corresponding to the improvement in CD4 availability, which increased from 31.5%
among those diagnosed before 2000 to 63.1% for the 2012-2014 period. Some countries
did not provide any CD4 counts and others included this variable in surveillance with de-
lay. In countries who included the CD4 counts in the form, the information is systematically
missing either at all or for the earlier years. Migration status could be determined for 88%
of the cases diagnosed during all analysed time periods after 2000 compared with 66% for
those diagnosed pre-2000. On the other hand, the proportion of individuals with known
transmission category decreased slightly from 89.2% among those diagnosed pre-2000 to
81.7% for those diagnosed in the period 2012-2014. Age and gender were consistently
reported in proportions greater than 98% during all periods [103].
HIV Testing Practices
HIV testing practices have a direct effect on the extent to which HIV infections are diagnosed
and reported an hence also on the representativeness (this is called a non-sampling error).
Approaches to HIV testing vary widely in the European region, but most countries have a
policy or strategy to offer HIV testing and counselling to most-at-risk groups and pregnant
women [68, 104]. In 2015, ECDC commissioned an evaluation of the HIV testing practices
through a distribution of a survey [104] to a Primary Target Group Member States. The sur-
vey showed that, considering their national guidelines, 78% of the countries had post-test
access to treatment, care and prevention services, 70% of the countries had voluntary, con-
fidential testing with informed consent and post-test counselling, and 57% reported having
a pre-test counselling or pre-test discussion. Dedicated HIV testing centres (e.g., for people
at a high risk such as IDUs) are present in 65% of the countries. Testing of all pregnant
women for HIV is recommended in 70% of the countries and this practice is offered to all
most-at-risk population groups in 57% of the countries [104]. Table 2.1 describes the testing
practices and their distribution throughout the countries according to the target sub-groups,
its goals and principles and setting.
Table 2.1: Elements included in the HIV testing practice (n=23). Source: ECDC in [104]
Elements % (n) Member States
Sub-groups
Testing of all pregnant women for HIV
(opt-out)
70% (16) Austria, Belgium, Czech Republic, Estonia, Finland, France,
Greece, Ireland, Italy, Lithuania, Malta, Netherlands, Norway,
Portugal, Romania, Slovakia
Testing of all most-at-risk population
groups
57% (13) Belgium, Croatia, Czech Republic, Estonia, Finland, France,
Greece, Italy, Lithuania, Netherlands, Norway, Portugal, Roma-
nia
Testing of sero-discordant couples (rou-
tine testing of HIV negative partner)
52% (12) Croatia, Czech Republic, Estonia, Finland, France, Greece,
Lithuania, Malta, Netherlands, Norway, Portugal, Romania
Testing of people with an indica-
tor condition, e.g. pneumonia,
mononucleosis-like illness
48% (11) Belgium, Croatia, Estonia, Finland, France, Greece, Italy,
Lithuania, Netherlands, Portugal, Romania
Table continues...
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Table 2.1: Elements included in the HIV testing practice (n=23). Source: ECDC in [104] - continue
Elements % (n) Member States
Testing frequency 30% (7) Estonia, France, Greece, Malta, Norway, Portugal, Romania
Tandem Hep C or B/C and HIV testing 22% (5) Estonia, Finland, Greece, Malta, Romania
Goals and principles
Post-test access to treatment, care and
prevention services
78% (17) Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland,
France, Greece, Ireland, Italy, Lithuania, Malta, Netherlands,
Norway, Portugal, Romania, Slovakia
Voluntary, confidential testing with in-
formed consent
70% (16) Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland,
France, Greece, Italy, Lithuania, Malta, Netherlands, Norway,
Portugal, Romania, Slovakia
Post-test counselling 70% (16) Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland,
France, Greece, Italy, Lithuania, Malta, Netherlands, Norway,
Portugal, Romania, Slovakia
A defined target audience 65% (15) Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland,
Greece, Ireland, Italy, Lithuania, Netherlands, Norway, Portugal,
Romania, Slovakia
Pre-test counselling or pre-test discus-
sion
57% (13) Belgium, Croatia, Czech Republic, Estonia, Finland, Greece,
Italy, Lithuania, Malta, the Netherlands, Norway, Portugal, Ro-
mania
Desirability or requirement to remove
legal or financial barriers
43% (10) Belgium, Czech Republic, Croatia, Denmark, France, Greece,
Italy, Norway, Portugal, Slovakia
Raise professional awareness and
train the workforce
43% (10) Croatia, Czech Republic, Denmark, France, Greece, Italy,
Lithuania, Malta, Portugal, Romania
Monitoring and evaluation programme 39% (9) Croatia, Czech Republic, Denmark, Finland, France, Greece,
Netherlands, Portugal, Romania
Partner notification 35% (8) Czech Republic, Denmark, Estonia, Greece, Lithuania, Malta,
Netherlands, Norway
Testing conducted by lay providers 22% (5) Czech Republic, Denmark, France, Greece, Portugal
Streamlining of counselling process
(less demanding)
17% (4) Croatia, Denmark, Finland, Greece
Written informed consent 9% (2) Lithuania, Romania
Settings
Dedicated HIV testing centres (e.g. for
people at high risk, IDUs services)
65% (15) Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland,
France, Greece, Italy, Malta, Netherlands, Norway, Portugal,
Romania, Slovakia
Outreach services 43% (10) Belgium, Croatia, Denmark, Finland, Greece, Lithuania, Nether-
lands, Portugal, Romania, Slovakia
Routine offering in general practice 35% (8) Belgium, Estonia, France, Malta, Norway, Portugal, Romania,
Slovakia
Non-medical, non-traditional alterna-
tive settings (saunas, field visits, etc.)
30% (7) Belgium, Denmark, Finland, France, Netherlands, Norway, Por-
tugal
Routine offering in emergency depart-
ments
17% (4) Belgium, Malta, Norway, Romania
2.7.4 TESSy - The European Surveillance System
In Europe, surveillance data on HIV/AIDS is collected annually from countries of the WHOE
region following the guidelines published onReporting Protocol which was a joint ECDC/WHO
coordinate group since 2008. This group, along with European disease networks, ensure
standardised reporting and data comparability across Member States through use of com-
mon (externally quality-assured) diagnostic and typing methods, European case definitions
(in appendix A), metadata and reporting protocols [87, 105]. These data are predominantly
case-based and comprise demographic, clinical, epidemiological and laboratory informa-
tion.
Despite the agreed protocol, the collected data is originated in each country national
surveillance systems and bears with all the heterogeneity of the national implementations.
The different data collection systems take its toll on TESSy data quality.
In this work we focus on reported data from France, Italy, the Netherlands, Portugal and
Poland and so it is necessary to overview their surveillance systems which is presented on
Table 2.2. This sum-up focus on characteristics that, directly or indirectly may affect the
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data quality of the surveillance system in terms of representativeness namely: legal cover-
age of the reporting; identification of the reporting entity and a summary of major historical
changes in the surveillance systems. All countries described their surveillance system as
case-based, comprehensive and passive [106, 103, 66]. Only in one country the reporting
was voluntary whereas in the remaining countries it was mandatory. All these countries
reported changes in their surveillance system. Full national coverage was achieved with
delay in Italy and France started surveillance in 2003 [103].
Table 2.2: HIV-AIDS surveillance system overview [66, 106, 103]
Reported ByCountry Data Source Legal Lab Physicians Hospital Other Comments
France FR-AIDS Cp N Y Y N Case-based data reported through TESSy are
not exhaustive due to reporting delays and un-
derreporting. The most recent estimates of the
latter are 41% in 2007–2009 for AIDS and 30%
in 2014 for HIV.
France FR-MNOID-
HIV
Cp Y Y Y N
Italy IT-COA-ISS Cp Y N Y N From 2004 until 2006, only 10 of the 22 Italian
reported new HIV cases, in 2007 reported 11 re-
gions, in 2008 reported 12 regions, 18 regions in
2009, and regions since 2012. AIDS deaths for
years 2011, 2012, 2013, 2014 are not reported
due to lack of updated data from the national
mortality register.
Nether-
lands
NL-HIV/AIDS V N Y Y N NewHIV reporting system started in 2002 includ-
ing many cases diagnosed in previous years.
Data prior to 2002 are from a national cohort of
HIV-positive adults receiving antiretroviral ther-
apy; 1999 data include many cases diagnosed
in previous years. Control activity in 2010-2011.
Poland PL-AIDS Cp Y Y Y N Control activity in 2010.
Portugal PT-HIV/AIDS Cp N Y N N The database is fully case-based containing de-
tails of cases diagnosed from 1983. In 2013 and
2014, it was implemented a strategy to address
underreporting and reporting delay, resulting in
significant increases in the number of reported
cases diagnosed between 1983 and 2012.
Y: Yes; N: No; Cp: compulsory reporting; V: voluntary
2.7.5 The Portuguese HIV/AIDS Reporting System and The Public Health
System
The Portuguese HIV/ AIDS confidential case-based reporting system was performed vol-
untarily by physicians since the identification of the infection until 2005. Since then, it is
mandatory to report all cases in any of the stages of the infection (asymptomatic, AIDS re-
lated complex and AIDS) and all the progressions including death (presented in appendix
D), using case definition of WHO and the ECDC HIV / AIDS (which have minor difference
but are fully compatible), identifying the probable source of transmission (Heterosexual,
MSMs and IDUs) and always assuring patient’s confidentiality by introducing a Soundex
code. Until 2011, the forms were then sent by mail to Centro de Vigilância Epidemiológica
das Doenças Transmissíveis (CVEDT), who collected, manually updated the data set, main-
tained, stored, analysed, produced and disseminated bi-annual reports, always keeping the
data set confidential [93]. Figure 2.12 describes a simplification of the key elements of the
Portuguese Surveillance System. It represents the data flow from the population under
surveillance until the data recipients. This system has the general Portuguese population
as target population but some key populations are more strictly looked at: HIV testing is
mandatory for military and strongly recommended for pregnant women and IDUs entering
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a treatment programme. Detection and primary diagnosis of infection are made by clin-
icians working in several settings such as: hospitals, Local Health Units, Health Centres
and Grouped Health Centres. Once the case is confirmed throughout clinical and laboratory
diagnosis, the form is filled in and sent. CVEDT provides data to Coordenação Nacional
para a Infecção VIH - SIDA (CNSida), Portuguese working groups of the Ministry of Health,
ECDC and the general public of research purpose.
Figure 2.12: Simplification of key elements for the description of Portuguese Surveillance System
based on information’s reported by Mauch in [93]
In 2009, the Portuguese HIV / AIDS reporting system situation was assessed and the
results were published in [93]. The study had the aim to examine the Portuguesemandatory
notification system for HIV and AIDS infections as determined by the timeliness of reporting,
completeness of information, acceptability by relevant stakeholders, as well as simplicity,
stability and flexibility of the surveillance system.
Current national directives compel the reporting of all stages of HIV / AIDS along with its
progressions and death to the Portuguese Centre for the Transmissible Diseases (CVEDT),
within 48 hours after the event. Although this statutory requirement, the interviewed clini-
cians did not report being accountable to any time constraints. A proper notification form
(appendix E) should be filled in by the patient’s medical doctor. However, this procedure has
only been mandatory since 2005 [107]. In 2009 Mauch study, all interviewed clinicians re-
ported that they complete the notification form after the patient has left the office, sometimes
several days or weeks later which may contribute to inaccuracies in reporting for some data
variables, such as associated risk group, due to recall errors [93]. Also, according to these
key stakeholders, reporting death and changes in disease status are particular problematic.
After the individual paper case reports are sent to the national surveillance office, they are
processed by a team of administrative staff. The form is reviewed to ascertain whether it
has the minimum data variables necessary to check for a duplicate record or create a new
entry. For duplicate record identification it is required at least the soundex code, date of
birth and gender and for creating a new entry, additional variables are needed such as virus
type, risk group, and in case of an AIDS case notification, an AIDS indicator disease from
the 1993 case definition [93].
Over the years, the surveillance procedure has suffered some changes that may have
altered the quality of the reports. We point out the following:
1. in 1985, the creation of HIV/AIDS surveillance system;
2. in 1988, the reporting form was altered and more variables were included;
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3. in 1990, the Comissão Nacional de Luta Contra a SIDA (CNLCS) was created;
4. in 1993, tuberculosis was included as an AIDS defining disease;
5. in 1996, HAART was introduced;
6. in 2005, the notification forms were re-structured;
7. in 2009, CVEDT was re-structured (Figure 2.13)[93].
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Figure 2.13: Major changes in Portuguese Surveillance System
It is also important to notice that prior to 1988, the notification form did not include impor-
tant variables such as CD4 cells count, because the natural history of the infection was not
fully known. And prior to 2001 the system did not record modifications to case entries, mak-
ing impossible to track changes to records regarding disease progression. The entry was
simply modified without tracking the date of updated diagnosis, date of updated notification
or updated disease classification [93].
Similarly to other European Countries, the Portuguese Surveillance system suffers from
under-reporting, under-diagnosed and reporting delay affecting timeliness and data quality.
Mauch found that the average delay for all diagnosed cases was approximately 1.5 years.
The under-diagnosis is less likely in late-stage infections (AIDS) as the need for medical
care is much stronger and in HIV stage it depends heavily on the testing patterns of the
individuals. In Portugal testing is mandatory for military and strongly recommended for
pregnant women and IDUs entering treatment programs [93].
In 2013, a policy of case re-notification to improve HIV information quality was imple-
mented, and no additional resources to assist with processing due to widespread public
sector austerity in Portugal. All existing HIV positive patients in Portugal were notified irre-
spective of previous notification during that year resulting in tremendously increase of the
number of case reports received to the national officer (from 2500 notifications per year to 23
000 notifications). The National Officer implemented a process to improve processing time
but recognized that further work would be valuable to address the reporting delay between
diagnosis and notification and thereby improve the overall timeliness [108]. The average
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reporting delays trends display evident peaks related to this policy [103]. Two records were
defined as being duplicates if it had the same soundex code. These records were verified
and corrected where necessary. To prevent future duplicates a check code of EpiInfo was
introduced. This function automatically searched for matching soundex codes during data
entry and alerted transcribers to the potential duplicate entry of cases [108].
All data collected by the CVEDT falls under the Data Protection Act and legal action can
be taken if there is misuse of the data [93].
Portuguese health care providers play an important role in care and support for HIV -
AIDS patients but are also one of the principal components of the notification system; they
are the primary source of health information. They work in a variety of settings of the health
care system: hospitals, local health units and grouped health centres. Grouped health
centres provides primary health care to the local communities, hospitals provide specialize
secondary health care services and local health units’ groups together the health centres
and hospitals located in the same city or region in a single administrative unit, providing
both primary and secondary health care.
These health providers’ system is managed by the Central Administration of the Health
System (ACSS) and by the five Regional Health Administration (RHA) boards implemented
in mainland North, Centre, Lisbon and Tagus Valley (LVT), Alentejo and the Algarve regions
2.14.
The RHAs are responsible for the regional implementation of national health policy ob-
jectives and for coordinating all levels of health care. They work in accordance with princi-
ples and directives issued in regional plans and by the ACSS. In the autonomous regions
of Azores and Madeira, health policy followed the same general constitutional principles
of the National Health Service, but are implemented locally by regional governments who
retained full administrative flexibility [109] (Figure 2.15).
Figure 2.14: Portuguese Health Regions Figure 2.15: Organizational chart of the Ministry
of Health from [109]
The hospital network (the number of hospitals, their location and typology) should be
understood as an integrated system of health care, thought and organized in a coherent
way, based on principles of rationality and efficiency [110]. The organization of the network
respects national geographic diversity, equity in distribution and access to health services,
different levels of intervention, primary health care, hospital care and continued care.
Portugal has adopted a “gate-keeping” system; this means that, in general, when seek-
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ing for health evaluation, a patient must first go to a general practitioner (called a family
doctor) and, if necessary, the primary care unit will send the patient to other levels of care,
e.g. a hospital, where the specific care will be provided [111]. So, when a patient is diag-
nosed with HIV by a primary health care centre, usually it is referenced to see a specialist
in the hospital. These special visits may also be required directly in the hospital.
Reporting HIV - AIDS cases is an administrative act that may be influenced by the fac-
tors described in the previous sections and so it is important to understand how health care
providers are organized. Moreover, there are considerable inequalities in the distribution of
hospital resources in Portugal [112] thus turning access and usage of health care, testing
and prevention services also geographically unequal. In addition, the Health System has
cost containment problems such as: accountability problems, inadequacies in the use of
operational reforming tools (such as resource allocation mechanisms) and a lack of mech-
anisms to promote efficient behaviour [113]. Analogous results were found in primary care
services [114].
Barros, in 2011, pointed out that the striking lack of nursing personnel, the scarcity of
doctors in some regions and specialities (e.g. general practitioner), and the imbalance in
numbers of primary care clinicians versus hospital specialists are some of the visible signs
of the weakness of public health policy in the field of human resources. Moreover, the
retirement in the near future of many physicians will create a shortage, as the numerus
clausus policy applied in the past did not ensure a sufficient intake to replace them [109].
2.8 Summary
The immune system is a complex defence system that protects the host from foreign pathogenic
micro-organisms. It is composed by several biological structures, such as lymphocytes T
cells, and processes that react with a response to neutralize the alien and prevent the ill-
ness.
Immunodeficiency occurs when the ability of the immune system to properly respond to a
threat is compromised or even absent. This state may be due to several reasons but most
of the cases are acquired due to extrinsic factors such as advanced age, environmental
factors and HIV infection [115].
Once the patient is infected with HIV, the immune system reacts and this process causes
a short term acute illness with very few specific symptoms where, without any intervention,
the virus is able to integrate into the host’s cell genes. Past few weeks, the initial high
virus load drastically decreases but soon starts to proliferate steadily whereas the CD4+
cells (also known as CD4+ T cell) progressively decrease over the following years. Without
a strong immune system, the body becomes very susceptible to opportunistic diseases.
Generally, soon after the initial HIV infection and the acute illness, the patient enters in an
Asymptomatic (A) phase that may last for several years. When diseases start to appear it
is said that the individual is in a Symptomatic Condition (SC) and, when severe symptoms
associated to serious life threatening diseases emerge, it is said that the individual has
Acquired Immunodeficiency Syndrome (AIDS).
Although HIV can affect anyone, there are key populations whose behaviours and con-
ditions put them at greater risk of HIV exposure: injection-drug users, men who have sex
with men, female sex workers and clients of sex workers [43, 44]. For the transmission of
the HIV, although not sufficient, it is necessary to have exchange of certain body fluids from
infected individuals. These fluids must be in contact with a mucous membrane or damaged
tissue or be directly injected into the bloodstream [35, 42].
In spite of the great progresses on medication and prevention over the last years, HIV
infection continues to be a major global public health issue, having claimed more than 36
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million lives over the last 35 years since the recognition of the disease [39, 64]. Geograph-
ically, the burden of the disease is not equally distributed. For instance in 2015, Latvia
experienced a 6.6 new AIDS diagnoses per 100,000 individuals, Portugal had a rate of 2.3
per 100,000 while the rate in the EU/EEA was of 0.8 cases per 100,000. Injecting drug
use and sexual contact between men were the most reported transmission modes, so the
European epidemic may be classified as concentrated in key populations.
These statistics show that while individual characteristics are necessary to the spread of
the disease, they are not sufficient to explain the population level incidence. So, to reduce
the burden of the infection, an endeavour and multi-factorial strategy for shaping individuals
behaviours must be considered. These factors may be organized into five level hierarchical
structure: individual, interpersonal, community, organizational and structural level.
Monitoring of HIV-AIDS cases, through registries, is vital to assess general health care
needs and to support long-term health-policy control planning [116]. Surveillance systems
have thus been established to accomplish this critical mission [117]. Typically, it depends
on several processes and stakeholders, such as the population under surveillance, health
care providers, laboratories and the Public Health Services, which challenges an efficient
and effective detection and reporting of the diagnosed cases. This compartmentalized sys-
tem may imprint several problems in the data which in turns may affect negatively the aim
for which the data were collected. The most common problems are unrepresentativeness
or selection bias of the population, changes in the system implementation through time,
inconsistent case definitions, miss diagnoses, miss or fail to report a case, reporting delay,
and errors during completion of the reporting form or data entry.
The HIV - AIDS surveillance system is a specific case of a surveillance systems due to
the infection characteristics and its social repercussions. It must reflect the special trans-
mission patterns, the long asymptomatic or with mild symptoms’ latency period, the lack
of affordable treatment and cure, high case fatality rates, and the social stigma associated
with it [9]. More over, because of the long asymptomatic latency period and the effect of
treatment, current HIV (asymptomatic) cases are hard to track and the reported AIDS cases
reflect past infections that have occurred many years ago.
National surveillance systems are not identical across Europe. In addition to the com-
mon surveillance data quality issues, there are variations in data collection methods and
testing policies which can introduce bias introduce bias in comparisons between countries.
Such as, the comparison of HIV-AIDS case numbers between countries must be done care-
fully.
Portuguese HIV - AIDS confidential case-based reporting was performed voluntarily by
physicians since the identification of the infection until 2005. Since then, it is mandatory
to report all cases in any of the stages of the infection (asymptomatic, AIDS related com-
plex and AIDS) and all the progressions including death, using the case definition of the
World Health Organization (WHO) and the European Centre for Disease Control (ECDC)
HIV - AIDS, identifying the probable source of transmission (Heterosexual, Men who have
sex with Men (MSM) or Injecting Drug Users (IDUs)), always assuring patient’s confiden-
tiality by introducing a Soundex code. Until 2011, the forms were then sent by mail to
Centro de Vigilância Epidemiológica das Doenças Transmissíveis (CVEDT), that collected,
manually updated the data set, maintained, stored, analysed, produced and disseminated
bi-annual reports, always keeping the data set confidential. Indeed, the Portuguese health
care providers are one of the principal components of the notification system as they are
the primary source of health information. They work in a variety of settings of the health
care system: hospitals, local health units and grouped health centres but the geographical
distributions of this resource is not equal.
One of the most widely recognized issue of surveillance data is the administrative re-
porting delay [69, 67, 66]. It can be defined as the time mediating from the identification
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of the HIV-AIDS related event to its national reporting [69]. It has been mentioned that
this problem depends on a number of factors such as the geographical region of the di-
agnosis, the calendar year, the patient’s age at diagnosis and the HIV infection mode
[116, 118, 119, 120, 121, 122]... Although 35 years have already passed since the identifi-
cation of the disease, an accurate estimation of the reporting delay remains a challenging
problem; in this thesis, we address the issue considering its multifaceted nature.”
Chapter 3
Statistical Data Pre - Processing
We are living in a world of information abundance, surplus, and access. We have tech-
nologies to acquire any type of information but we still face the challenge of extracting the
underlying valuable knowledge. Data analyses and mining processes may be severely
impaired whenever data are corrupted by noise, ambiguity and distortions [123]. Data de-
pends largely on its quality which is build upon the way the collection process is imple-
mented and managed [94, 124]. Most of data analyses and mining processes focus on
extracting knowledge from data; whenever the latter is of poor quality, the objective may be
severely impaired and can even be beyond the scope of statistical analysis [16, 125, 126].
Data quality is an ever gradually developing concept, with roots in measurement error
and survey uncertainty, that encompasses multiple disciplinary fields such as commerce,
engineering, medicine, public health and policy making. This complex concept spotlights a
rich set of scientific, technological and process control challenges [16, 127, 128].
There are several definitions of data quality, almost asmuch as the study fields. It can be
defined as: the capability of data to be used effectively, economically and rapidly to inform
and evaluate decisions (with roots in decision theory field) [16] or as the degree to which
a set of characteristics of data fulfils requirements (ISO/IEC 25012 standard, with roots in
engineering and computer science) [128] or even as accurate, reliable, valid, timely and
trusted data (with roots in integrated public health informatics network ) [94].
Despite the diversity, many definitions became aligned with the engineering, computer
science and decision theory definitions. This was the situation in health information and
survey research [127]. Statistics provides valuable contributions such as outliers detec-
tion, statistical data editing, probabilistic record linkage and the measurement error and
survey methodology. Total quality measurement uses concepts such as multi-dimensional
data quality, data quality metrics, evaluation of the user’s assessment of data quality and
data production maps [16].Computer science is exposed to data quality issues since orga-
nizations started collecting and storing their data electronically. So, it has well-developed
technologies to address issues such as data standardization and duplicate detection and
elimination, and data parsing, among others.
It is recognized that data quality is a concept with multi-dimensions (characteristics or
attributes) and depends on a sustainable work-flowmodel integrated withminimal disruption
into the day-to-day life of all the relevant stakeholders [16, 94, 128]. These characteristics
are fundamental drivers that can be corrupted by specific problems with genesis on each of
the steps of the work-flow. As such, the best practice process for improving and ensuring
high data quality follows the so-called data quality cycle. The cycle is made up of an iterative
process of analysing, cleansing and monitoring data quality [129, 130, 131].
It is very rare to find the raw data in the correct format, without errors, complete and
with all the correct labels and codes that are needed for the analysis [132]. In single data
collections, such as files and databases, several problems commonly arise due to mis-
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spellings during data entry, missing information, lack standardization and / or validation of
self-reported information, the existence of duplicate or redundant information, or the exis-
tence of anomalous events [133, 127, 94].
Data quality mining deals with detecting and removing errors and inconsistencies from
data [133, 134]. Preparing and cleaning data is often more time-consuming than the sta-
tistical analysis itself [132, 125]. Moreover, developing a data cleaning procedure guided
by the dimensions that characterize the quality of data is not only essential but also a quite
difficult task [128]. In this chapter, it is thus presented an approach to extend, improve
and systematize some state of the art methods, aiming to obtain an unified data quality
methodology. The procedure applies to single file data sources without schema that may
be corrupted by the most common data problems. The methodology is guided by the di-
mensions of data quality standards, focuses on the goal of performing reasonable posterior
statistical analyses and finally formalized into an algorithm.
We will consider datasets defined according to Codd’s 3rd normal form but with the
constraints framed within a statistical language [125].
In section 3.1, we present an overview of the most common data quality dimensions
and specific issues; in section 3.2 we provide a summary of some advanced statistical
methods for data anomalies detection and data editing; in section 3.5 we preform a data
quality assessment and improvement methods on the HIV-AIDS Portuguese surveillance
data; the last section 3.6 contains the concluding remarks.
3.1 Data quality dimensions and issues
At a database level, data quality has a large set of dimensions but most of the researchers in
informatics and official statistics have consensus on: accessibility, accuracy, completeness,
consistency and timeliness [128, 135, 136]. A precise definition of each dimension can
be found in ISO / IEC 25012 catalogues, in Laranjeiro et al or in The Quality Assurance
Framework of the European Statistical System (ESS QAF) [128, 16, 136]. Briefly, we have
the following:
Accuracy: The degree to which data attributes or variables correctly represent the true
value of the intended object or population.
Completeness: The degree to which an entities’ values correspond to all instances of
the attributes.
Timeliness: Time-related dimension, reflecting if data is up to date.
Consistency: The degree to which an information object is presented in the same
format, being compatible with other similar information objects or populations.
Accessibility: The degree to which data can be accessed in a specific context of use,
which includes suitability of representation.
At a statistical level, we add the relevance dimension defined by the Eurostat as:
Relevance: The degree to which statistics meet the needs of current and potential
research objective [136].
Data validation confronts a data set with a group of desired properties. It provides
awareness for the major issues in the dataset, commonly classified as being at a structure
(schema) level or at an instance-level. The latter type reflect sampling and non-sampling
errors such as data processing errors (includes collection, coding and entry) or inconsis-
tencies while the former are associated with lack of integrity constraints or poor structure
design. For data sources without schema, such as single files, there are few restrictions on
how data can be entered and stored, turning errors and inconsistencies more probable[133].
The most common data problems and issues as well as the corresponding affected data
quality dimensions are described in table 3.1 [128, 137, 133]. We notice that if data are
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inconsistent then they are also inaccurate; indeed, if values are represented in different for-
mats and/or structures, then it is difficult to determine their true representation. So, it was
extended the correspondences surveyed by Laranjeiro. Moreover, we added the dimension
’relevance’ and the most commonly encountered file and statistical problems: proprietary
file format, wrong variables type, tabular design, missing variables, lack of information di-
versity, outliers and coverage errors.
A proprietary format may contain data that is ordered and stored according to a particular
encoding-scheme and so the decoding and interpretation of the stored information may only
be accomplished with the use of a particular software or hardware. If the specification of the
data encoding format is not released, the accessibility of the information is compromised.
Also, if a variable is assigned to a wrong type, the information may be difficult to access.
Tabular design occurs when variables form both the rows and the columns and/or col-
umn’ headers are values, not variables names. These questions violate the dimensions ac-
cessibility (i.e. data needs to be manually inspected and reasoning about the problem) and
accuracy (i.e., the variables do not correctly represent the true population value). The issue
of missing variables occurs when important variables were not included in the dataset. This
compromises the dimensions completeness and accuracy, once the true object is not repre-
sented. Lack of information diversity occurs when a variable has few and under-represented
unique values. This affects accessibility since the variable is not suitably represented and
accuracy because the true value of the intended object may be missing. Finally, we point
out the existence of outliers, corresponding to extreme values of, at least, one variable that
are far apart from the remaining values. It may or may not be an incorrect value (although
very suspicious) and by definition affects the accuracy.
Relevance may be affected by issues such as incorrect values, coverage, missing vari-
ables and lack of information diversity since the objective of the statistical methods may not
be accomplished due to the lack of the necessary information. Also, illegal values, violation
of logical dependencies, wrong data type or syntax violation, missing data, incorrect data,
misspellings, ambiguous data, extraneous data, misfield values may impair statistical infer-
ences and therefore affect relevance. This dimension may be affected by the presence of
duplicates because they may impair representativeness of the data.
Table 3.1: Extended version of problems and data issues [128, 125]
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a. Proprietary File
Format
Occurs when a file is designed for a
specific application / system.
X
b. Wrong Variables
Type
Occurs when a variable is assumed
to be of a wrong type.
X
c. Tabular data de-
sign
Occurs when variables form both
rows and columns and/or column
headers are values, not variable
names
X X
d. Illegal values Occurs when variables have a value
that is out of range
Diagnosis date = 30/02/2006 X X
e. Violation of values
logical dependen-
cies
Occurs when some logical depen-
dency between values is broken
Patient( age = 35, sex = female,
HIV risk group = ’MSM’)
X X
f. Wrong data type or
syntax violation
Occurs when a value does not re-
spect the data type constraints
Hospital = ’42’ X X X
g. Missing data Occurs when data is not present or
coded with a dummy value
Probable year of infection = 9999,
’Not mentioned’
X X X
(Table continues...)
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Table 3.1: Extended version of problems and data issues [128, 125]
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h. Incorrect data Occurs when data contain valid val-
ues that do not correspond to real
values
HIV risk group = ’Heteressexual’
instead of ’IDUs’
X X X
i. Misspelled Occurs when data are misspelled Nationality = ’Portgal’ instead of
’Portugal’
X X
j. Ambiguous data Occurs when data values can have
different interpretations. It can be
due to abbreviations or an incom-
plete context
Hospital = ’Maria’, it can be ’Hos-
pital Santa Maria’ or ’Hospital
Santa Maria Maior’ or even ’Hos-
pital Santa Maria Pia’ (Hospitals
in Portugal)
X X X
k. Extraneous data Occurs when additional data is rep-
resented
Name = ’Mrs. Maria’ X X X X
l. Outdated temporal
data
May be valid for a time point or inter-
val
Hospital = ’Desterro’ (this hospital
was closed in 2007)
X X
m. Misfielded values Occurs when the data values are
stored in the wrong column
CD4 count in the variable of
T4/T8 ratio
X X X X X
n. Duplicates Occurs when the same data appear
more than once but with a different
identifier and may have contradict-
ing information
Patient1(ID = ’AERER’, age = 31,
sex = ’male’, risk group = ’MSM’
) and Patient2(ID= ’AERER’, age
= 31, sex = ’male’, risk group =
’IDU’ )
X X X
o. Outliers Occurs when a variable has an out-
lier. It may or may not be an incor-
rect or dummy value (although they
are very suspicious)
Age=88,age=99 X
p. Missing Variables Occurs when an important variable
is missing.
Individual records of HIV patients
without clinical variables.
X X X
q. Lack of informa-
tion diversity
Occurs when a variable has few and
under-represented unique values.
All observations of variable HIV
type equal to HIV1.
X X X
r. Coverage errors Occurs when a unit in the sample is
incorrectly excluded or included, or
is duplicated in the sample.
X X* X
* Just in case of ex-
cluding a sample.
It is important to point that data validation adds value to the dataset by rising awareness
about the presence of issues that may impair its usefulness for the intended purposes [138].
3.2 Procedure for improving data quality
Data Quality Mining (DQM) can be defined as the deliberate application of data mining tech-
niques for the purpose of data quality improvement [134]. Themain goals in any data quality
improvement process are: the detection, the explanation of the source and correction of de-
ficiencies such that the ’improved’ dataset is close as possible to the original collected data.
Other important goal is to confidently allow for posterior statistical analysis.
In this chapter we follow Wickham and Jogen definitions of dataset [125, 132]: it is a
collection of values (qualitative or quantitative), each belonging simultaneously to a variable
and an observation. A variable contains all values that measure the same underlying at-
tribute across units. An observation contains all values measured on the same unit across
attributes. This is Codd’s 3rd normal form but with the constraints stated within a statistical
framework [125].
The central problem for data improvement is how to make data consistent, accurate,
accessible, timeliness, complete and relevant while keeping the edits to as few as possible,
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respecting the constraints and context [132, 139, 140].
A common approach to address the problem of dirty data is to apply a set of data quality
rules or constraints over a target database, to ’detect’ and to eventually ’repair’ data issues
[139], but first one must be able to read and understand the data. After that, four stages
can be identified: data structuring, data validation, error localization and repair.
3.2.1 Data Validation
The credibility of the data may be assessed by data validation activities whose negative
outcome guarantees the data have quality issues, mainly accuracy and consistency dimen-
sions. Data validation can be defined as follows:
Definition 1 Data validation is an activity verifying whether or not a combination of values
is a member of a set of acceptable combinations [138, 141] .
The set of ’acceptable combinations’ may be a set of possible values for a single variable
or a set of valid combinations of values for an observation, variable, or larger collection of
data [138]. It is an iterative procedure based on the tuning of validation or edit rules that will
converge to a minimal set that must be necessarily satisfied [141]. Moreover this set must
be complete, concise and consistent [142].
Completeness may be defined as
Definition 2 Completeness is the extent to which prior knowledge about the data set has
been expressed in terms of a set of validation rules or the extent the variables in a data set
are covered by the rules in a set.
The prior knowledge includes rules that arise from physical or logic facts and from do-
main experts. When the influence on the data values are due to facts or events that can
only be stated imprecisely it is difficult to state it on validation rules.
This property is hard to quantify but may be assessed by knowledgeable peers review
or by checking whether at least one of the explicitly defined rules is valid (assuming that the
set of rules is on a standard and minimal form) [142].
A concise set of validation rules can be defined as
Definition 3 A concise set of validation rules is a irreducible set that contains the minimal
set of rules that must be satisfied.
A set of validation rules divides the space of all possible records into a valid, or acceptance
region, and an unacceptable region. A rule is redundant in the set if removing it from the
set does not alter the acceptance region [142]. Linear programming is a common approach
for redundancy removal.
Finally, a consistent set of validation rules is a set with a non-empty acceptance region.
Inconsistency occurs when a rule set contains a rule that is contradictory in itself [142].
Common strategies for finding inconsistencies in a set of rules are the Fourier-Motzkin
elimination variables for rules involving numerical variables, and multivalent resolution for
rules involving categorical variables.
Statistical data editing is the automated process of stepping through the data observa-
tions and correcting them whenever they violate the validation rules [16]. The validation
activities may be grouped, from a research perspective, in six ordered levels starting with
simple single value checks and moves to more complex checking involving more observa-
tions, variables and data sets [143, 144]:
Level 0: Validation of the Information Technology structural requirements. At this level the
data set is checked format and file structure and variables types (issues a,b and c
from Table 3.1).
40 Chapter 3. Statistical Data Pre - Processing
Level 1: Validation for consistency of single data points. For example comparing a single
data point with constants. At this level the data set is confronted with rules for checking
the presence of issues as described in d, f, g, i, j, k and m on Table 3.1.
Level 2: Validation for consistency of multiple variables of the same statistical object. At
this level the data set is confronted with rules for checking the presence of issues as
in e above.
Level 3: Validation for consistency of multiple statistical objects of the same variable. At
this level the data set is confronted with rules for checking the presence of issues
such as o and q.
Level 4: Validation for consistency of repeated measures of the same variable and same
statistical object. At this level the data set is confronted with rules for checking the
presence of issues such as l.
Level 5: Validation for consistency of multiple variables and multiple statistical objects. At
this level the data set is confronted with rules for checking the presence of issues
such as n.
Level 6: Validation for consistency based on the comparison of the file content with the
content of other files. By other files we mean other versions of exactly the same file,
same data set but referring to a different time period, different data set but collected
from the same domains or even from correlated domains. At this level the data set
may be confronted with rules for checking the presence of issues such as h, p and r.
These proposed steps for the validation process are represented in Figure 3.1.
In these chapter we followed the definition of validation rules given by Jonge et all in
[145].
Denote by vi (i = 1, . . . ,m) a categorical variable and by xj (j = 1, . . . , n) a numerical
variable. The finite set of observed categories of the ith categorical variable is represented
by Di, where
Di = 1, 2, . . . , ni.
In a general form, a statistical object r may be written in the form
r = (v1, . . . , vm, x1, . . . , xn) = (v,x) (3.1)
taking values in D1 ×D2 × . . .×Dm × Rn = D × Rn [145].
Usually rules for categorical variables are defined negatively by stating a subregion
of D with the disallowed values, while linear validations define allowed regions in Rn. It
is possible to use a complementary approach in which rules are expressed in ”negative
form”, then validation is done by verifying that a pre-defined non - acceptable combination
of values do not occur [141]. So, for a single edit the region G with rules in a negative form
can be defined as:
G = {r ∈ D × Rn : v ∈ F ∧ x ∈ P} (3.2)
with F ⊂ D representing the values that are considered as invalid. Note that F = F1×F2×
. . . × Fm such that Fi ⊂ Di. And P is a convex subset of Rn defined by a set of k linear
restrictions (k = 1, . . . , n) of the form Ax > b.
The positive reformulation of 3.2 is:
¬ (v ∈ F ∧ x ∈ P )
¬
(
v ∈ F ∧ aT1 x1 > b1 ∧ aT2 x2 > b2 ∧ . . . ∧ aTnxn > bn
)
v ∈ F ∨ aT1 x1 ≤ b1 ∨ aT2 x2 ≤ b2 ∨ . . . ∨ aTnxn ≤ bn (3.3)
3.2. Procedure for improving data quality 41
Figure 3.1: Validation Process
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where ai ∈ R, (i = 1, . . . , n).
In this formulation, it is said that r is valid if and only if
r ∈ G⇔ ∨mi=1vi ∈ Fi ∨ ∨kj=1aTj x ≤ bj
As Jonge pointed out in [145], the rule defined in equation 3.3 can be formulated as
a ’conditional validation’ by using the implication replacement rule from propositional logic
which states that ¬p ∨ p may be replaced by p ⇒ q. If we limit equation 3.3 to a single
condition,
v ∈ F ⇒ aTx ≤ b (3.4)
Validation checking, then, involves evaluating v ∈ F ⇒ aTx ≤ b and comparing the
result with the valid-values set G¯. If the rule cannot be evaluated then the checking returns
NA. So validation checking is a surjective function of a generic statistical object r:
V : D × Rn → {0, 1, NA} (3.5)
where 0 is interpreted as invalid, 1 as valid andNA when the rule cannot be evaluated. The
valid region of D × Rn is defined as the preimage
G¯ = V −1 (1) = {r ∈ D × Rn : V (r) = 1} (3.6)
3.2.2 Error Localization
Data editing is a complex process that often involves cross-variable and interrelated con-
tingency rules. Fellegi and Holt formulated a theoretical model for this process with the
following goals [146]:
1. in each record or observation, data should satisfy all validation rules by changing the
fewest possible items (variables or fields);
2. imputation rules should be derived automatically from validation rules;
3. when imputation is necessary, it is desirable to maintain the marginal and joint fre-
quency distributions of variables.
The problem of finding the variable(s) violating the validation rules and needs to be
corrected can be stated as following:
Problem 1 Given a statistical object r with n variables, subject to a number of possibly
multivariate validation or consistency rules, find the smallest (weighted) subset of variables,
such that after replacement of their values, r violates no rules [145].
DeWaal in [147] presents the mathematical formulation of the above problem as follows:
Minimize
m∑
i=1
wiIi +
n∑
i=1
wm+iIm+i; (3.7)
subject to v ∈ F ⇒ aTx ≤ b. (3.8)
where
Ii =
{
1 if field i is to be changed
0 otherwise and wi is a reliability of variable i given by field
experts. A small value of wi indicates that the variable is more likely to have an error. So,
this is an optimization problem over m + n binary decision variables that indicate which
variables in a record should be changed [145]. As Jonge pointed, this problem is NP -
complete where “the search space related to the minimization problem grows exponentially
with the number of fields”. Moreover, the problem is complicated by the existence of implicit
rules (rules that are logically or arithmetically derived from explicit rules).
There are several algorithms for solving this problem, the two most popular being the
branch-and-bound and mixed-integer programming, described in [148].
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3.2.3 Repair and Improve
In this subsection, methods for repairing the main issues presented on Table 3.1, guided by
the validation steps given on page 40, will be over-viewed. Note that the correction steps
are not in the exactly same order as the checking steps; more precisely, all the imputation
methods are done after all the errors have been addressed.
It is recommended that data is in a text-based format because this has several favourable
properties over other formats, including being human readable, the possibility to represent
any type of value, and avoiding underlying stored data issues.
More than 80% of all data is unstructured [124]. For statistical analysis it is desirable
that the values are organized in a rectangular table with rows and columns such that:
1. each column corresponds to a single variable, with a proper label,
2. each row has just one observed case, and
3. each type of observational unit forms a table.
A bad table design can be due to: column headers representing values and not variable
names, one column containing multiple variables, variables being stored in both rows and
columns, same table storing different observational units or single observational unit being
stored in multiple tables [125].
These issues are out of the scope of the current work but often requiremanual inspection
of the data(s) file(s), reasoning about the problem representation on the dataset and the
identification of what needs to be re-structured keeping the focus on the aim of the analysis
and domain expertise.
Once the file is in a type agnostic text format, like csv or tsv, and after being properly
structured, variables’ parsing has to be performed; this means converting each variable
from the text string representation to memory typed values, ready to be manipulated with
statistical tools like R or SPSS.
Since data improvement is a resource consuming process, it is important to chose wisely
which variables need to be cleaned taking into consideration the context relevance. For the
selected variables we should proceed with a uniformization of the values. A simple scan for
unique values and its corresponding distribution in data can detect several problems such
as: misspellings, extraneous data, misfield values, wrong data type or syntax violation,
ambiguous data and illegal values.
The first two issues may be addressed by simply editing the value to the corrected form.
The misfield values should be placed in the correct variable leaving the original cell empty.
In the case of syntax error, one must follow the same procedure as that of misspelling
errors, but if the error is of wrong data type that data editing is more difficult. The first
solving approach should be consulting the metadata for guidance and consult the data
domain experts. If this does not solve the problem, then one must find support among other
variables and look for logical dependencies with other variables (this issue will be addressed
later in this chapter). If this still does not prove to be helpful then one should simple delete
the value. A wrong value is worse than no value at all because it may introduce unwanted
bias. The procedures for ambiguous and illegal values should be the same as those for the
wrong data type.
An observation (or set of observations) which appears to be inconsistent with that set of
data is called an outlier [132]. For detection of outliers, several approaches have been de-
veloped, such as error bounds, tolerance limits and control charts; model-based regression
depth and residual analysis, distributional representations and time-series analysis.
Outliers can appear from several different mechanisms or causes: they can be simply
an error or arise from the inherent variability of the data. When an observation is clearly an
error, simply delete the value but, if it is legitimate or of unclear source, then the problem
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becomes difficult. One way for keeping an outlier is to transform the variable either by
applying a function or by truncation to the closest extreme. If none of these transformations
turn out to be helpful, then one may need to use “robust” parameters estimate methods for
data mining[149].
Violations of logical dependencies between variables are easily detected with data vi-
sualization tools and with cross tabulations. Each dependence between variables, also
known as editing rule, require the definition of a proper pre-specification of specify domain-
knowledge-based constraints.
As a violation may be resolved in more than one way, an immediate question is which
one to choose? Solutions may include repairing values that require the least number of
operations, or repairing values according to a pre-specified cost model. Many cost models
have been proposed but they rely on the same idea: to associate weights according to the
user’s confidence on the accuracy of the values [140] . For ”expensive“ editing, the rule is
to delete the case.
After the cleaning process, one should turn his/her attention to missing values. Since
attempts to recover missing values may impair inferences (the main goal of a statistical
procedure), a missing value treatment cannot be properly evaluated apart from the mod-
elling, estimation, or testing procedure in which it is embedded [150]. Several methods for
data imputation have been proposed and they can be divided into two categories: single
variable or considering relationships among variables [126]. For single variable methods
it is assumed that the distribution of the missing values is the same as the non-missing
values and so the missing values are replaced by the non-missing values mean, median
or other point estimates. The methods that consider relationships among variables use
regression (parametric) or propensity scores (nonparametric). These techniques assume
that the explanatory variables are non-missing. If the proportion of observations having any
variable missing is less than or equal to 5% then missing values imputation does not have
high impact and a single imputation method can be used [151]. Otherwise, when the rate
of missing values is high, the chosen imputation method ’will exert a high degree of influ-
ence over the results’ [150]. To guide the choice of the imputation method the researcher
must firstly identify the pattern of missing values and use a method that considers the re-
lations between the variables. After any imputation procedure it is necessary to perform a
sensitivity analysis, comparing the pre-imputation with the post-imputation scenarios.
Methods for adjusting / repair outdated temporal data will be discussed in Chapter 4.
Duplicated records may be introduced in a data set through several different mecha-
nisms. Typically, by typographical and data entry errors. An individual’s information may
change over time with some life events like moving or deliberately reporting false informa-
tions [152]. Due to these idiosyncrasies, the previous data cleaning and standardization
steps are critical.
The duplicate detection is typically performed by applying similarity functions to pairs
of observations. If the values of two records are sufficiently similar, they are assumed to
be duplicates’ [153]. This task starts with the definition of a search string key composed
by, at least, one variable. Records that share a key are, without a doubt, duplicates. But
some times, the variables in the genesis of the key are corrupted by different formatting
conventions, abbreviations, typos ... In that case it is recommended to use algorithms of
approximate string comparison. These algorithms allow for character deletion, insertion,
substitutions and transpositions, common sources of differences when comparing strings.
The identification of these suspected duplicate records is a difficult task but once they are
flagged they can be processed manually or in a semi-automated manner [154, 16].
Some common and successfully similarity measures that handle typographical errors
well are: edit-based distances (Hamming, generalized Levenshtein, the longest common
sub-string, optimal string alignment, and generalizedDamerau - Levenshtein), q-gram based
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distances (q-gram, Jaccard, and cosine) and the heuristic Jaro and Jaro-Winkler distances.
The edit-based distances are determined by counting the number of fundamental opera-
tions necessary to transform one string to another. Operations may include substitution,
deletion, insertion of a character or transposition of characters. When more than a single
operation is needed, it may be useful to assign weights to the different operations, ’for exam-
ple to make a transposition contribute less to the distance than character substitution’ [155].
’Distances based on q-grams are obtained by comparing the occurrence of q-character se-
quences between strings. Heuristic measures have no strong mathematical underpinning
but have been developed as a practical tool with a particular application in mind’ [155]. One
example is the Jaro distance that was originally developed for the purpose of linking records
based on inaccurate text fields, by the U.S. Bureau of the Census, and it is very efficient on
statistical matching problems involving relatively short string [155].
Methods for detecting duplicates consisting of multiple variables can be divided into two
categories:
1. Approaches that rely on training data to “learn” how to match the records; these in-
clude probabilistic approaches and supervised or semi-supervised machine learning
techniques.
2. Approaches that rely on domain knowledge or on generic distance metrics to match
records; these include deterministic linkage methods using distance metrics appropri-
ate for the duplicate detection task [154].
Successful probabilistic approaches in duplicate detection comprise technique such as
Bayes decision rule for minimum error, for minimum cost or with reject region. Supervised or
semi-supervised methods include: Classification and Regression Trees (CART) algorithms,
Support Vector Machines (SVM), Supervised Clustering (SC) techniques, Semi-Supervised
Probabilistic Relational Models (SSPRM), Markov Chain Monte Carlo (MCMC), Sampling
Algorithm (SA) among many others. Approaches using distance metrics include the Hun-
garian Algorithm (HA) Hungarian Algorithm, Successive Shortest Paths algorithm, experts
rule-based bootstrapping, techniques based on clustering, hierarchical or graphical models
for learning to match record pairs, just to cite a few [154, 156].
This task is highly data-dependent and therefore choosing a detection technique is sim-
ilar to model selection and performance prediction for data mining tasks [154, 156]. How-
ever, it has been demonstrated that deterministic approaches have high validity and relia-
bility and has been employed successfully in multiple updates of the SEER (Surveillance,
Epidemiology and End Results)-Medicare linked dataset. “The algorithm consists of a se-
quence of deterministic matches using different match criteria in each successive round”
[152].
If the records detected as suspicious duplicates match in every variable, then just delete
one of those records. But if duplicated records have contradicting information the task is
much more difficult requiring a manual clerical review to decide their final match status
[156]. If they are to be considered as duplicates the next task is to decide what to do with
them: delete both, one or merge the records. If the decision is to keep just one, the natural
question is which one. The decision of the record that must be deleted can be based on
a cost model ranking the records from the most to the least reliable. This cost model can
take into consideration the number of data quality issues contained in each record and a
domain expert weight about the reliability of each variable.
For correcting ambiguous data and missing variables it is useful to check different ver-
sions of the same data set, or to match the data with correlated data sets from the same or
different sources or even different domains.
Incorrect data rising from random intentional errors may be treated as outliers but if
these errors are systematic, it is very hard to detect and correct them.
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Figure 3.2: Repair and Improve Process
Coverage errors can be minimized by capture - re-captures techniques, matching the
data set with a correlated data set from a different domain.
A relevant audit is if any important variable is missing in the dataset. If so, the main goal
for which the data was collected may be irreparably compromised.
In this section, it is proposed a macro sequence across the levels of validation, which
follows from level 0 until 6 but the contained errors checking may be of any order. The
repair process, however, must follow a more strict order, the last addressed errors being the
ones for which the correction involves imputation and outliers handling due to the obvious
influence over the results of a subsequent statistical analyses. The steps proposed for data
repairmen and improvement are presented in are present in Figure 3.2.
Once the repair and improve process is ended, data is then ready for statistical analysis
and model selection. The above procedure is formalized up in algorithm 3.1 below.
3.3 Surveillance Data
ECDC and WHO jointly collect HIV - AIDS surveillance data covering the full WHO Euro-
pean Regions, i.e. the 31 European Union / European Economic Area (EU / EEA) countries
and 23 countries outside the EU / EEA, through TESSy - a web-based data submission,
data storage and dissemination platform. This data collection is guided by a Reporting
Protocol designed to improve user-friendliness by introducing a uniform structure, standard
variables, data formats and codes [105].
The stored anonymized data may be accessed for research purposes / tasks in the
public interest upon request which should be placed to the competent national authority.
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Algorithm 3.1 Data quality improvement
1: procedure Issue detection and repair
2: Input: A dataset A
3: Output: An improved dataset
4: alpha← Data Explore(A) {
5: if A satisfies all necessary specifica-
tions then
6: alpha =True
7: else
8: alpha =False
9: end if}
10: if alpha=True then
11: B← Data Structure(){
Ensure: Each variable in a column, each
observation in a row, each observational
unit in a table.
12: B = arranged A }
13: C← Data Parsing(B){
14: for all Variables in B do
15: Convert variable type to the proper
one
16: end for
17: Store variable in C }
18: D← Select Important Variables(C){
19: Select the variable to be clean accord-
ing to the context
20: Store variable in D }
21: if D not empty then
22: E← Uniformization(D){
23: for all Observations of text variables
do
24: if value is affected by an issue of
type d., f., i., k. or m. then
25: Edit value to correct form
26: end if
27: Store values in E
28: end for}
29: F← Missing Values Imputation(E){
30: for all Variables in E do
31: Apply techniques for missing values
imputation
32: Perform sensitivity of the results to
departures from assumptions analysis
33: end for
34: Store results in F }
35: G ← Identification and Correction of
Outliers(F){
36: for all Numerical variables in F do
37: Apply techniques of outlier detection
38: Apply techniques to minimize the ef-
fect
39: end for
40: Store the results in G }
41: H ← Validate Logical Relation-
ships(G){
42: Apply validation rules to G
43: Determine the minimal set of vari-
ables to be changed
44: Correct any violation
45: Store the results in H }
46: I← Missing Values Correction(H){
47: for all Variables in H do
48: Determine missing values pattern
49: Impute missing values
50: end for
51: Store the results in I }
52: J← Outdated Data Correction(I){
53: for all Variables in I do
54: Determine if data is outdated
55: Correct any violation
56: end for
57: Store the results in J }
58: K← Duplicate Detection and Correc-
tion(J){
59: Apply similarity measures between
observation
60: Apply algorithms to find matches in
datasets
61: Correct the duplicates
62: Store results in K }
63: L← Ambiguous, Incorrect or Missing
Variables(K){
64: Determine if there exists missing vari-
ables, incorrect or ambiguous data
65: Match the file with correlated informa-
tion
66: Store the data in L }
67: M← Data Transformation(L){
68: Compute important variables
69: Store variables in M }
70: else
71: Collect new data
72: end if
73: else
74: Collect new data
75: end if
76: end procedure
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In the particular case of the Portuguese surveillance system, the data is collected through
a standardized notification form for HIV infections that was revised several times since the
identification of the disease. The most recent version, currently in use, was introduced in
2005 and can be found in appendix E). “A single notification form is used for reporting both
HIV and AIDS infections, as well as any change in disease status, including death, for both
adult and paediatric cases. The notification form consists of 13 categories, with approx-
imately 100 potential data field” [93]. Also, data is accessed upon request for research
purposes / tasks in the public interest.
3.4 ECDC dataset structure: HIV / AIDS case-based record type
The dataset for case-based combined HIV / AIDS surveillance consists of a set of 33 vari-
ables, 17 of which are mandatory and the remaining 16, optional. The mandatory variables
represent a minimum standard designed to provide an overview of the ECDC epidemic and
to improve data completeness and accuracy across Europe”. The optional variables are
aimed at countries that are able to complete them and are aspirational to other countries
for using this as guide to design and enhance national surveillance systems [105].
To accomplish the main objectives of this research, and under the ECDC guidance, we
restricted our attention to the variables presented in Table 3.2. Variables’ values and used
validation rules are described in Table 3.3. With this respect, we have used the following
notation:
• Errors - indicates that the structure of the file should be corrected. The file is rejected,
should be reformatted and then uploaded again;
• Warning- is always combined with a course of action to improve data quality;
• Remark - informs the user that steps should be taken to improve data quality [3].
Table 3.2: Overview of the available revised set of variables for case-based HIV-AIDS surveillance.
Source [105]
Variable Report
Type
Description
TESSy System Related Variables
1. RecordType M Structure and format of the data (case based reporting and aggregate reporting). It
specifies what data values TESSy expects to receive.
2. RecordTypeVersion O The version of the record type defines the current structure of the data reported. If
the original dataset for any particular disease is changed, the versioning will change
according to increasing numbering.
3. Subject M The subject describes the disease associated to the reported case(s).
4. DataSource M The data source (surveillance system) from where the record originated.
5. ReportingCountry M The country reporting the case.
6. DateUsedForStatis-
tics
M This is the date used by the national surveillance institute or organisation in the na-
tional HIV/AIDS case reports and other official statistics.
Diagnosis Information
7. DateOfDiagnosis M The date of first HIV diagnosis; clinical or laboratory diagnosis.
8. DateOfNotification M This is the date on which the HIV case was notified for the first time to the the surveil-
lance system in the reporting country.
9. HIVType M Describes the type of HIV infection
10. HIVStatus O Information on previous positive test results, prior to the first time of reporting. This
variable allows cases that are “newly diagnosed” to be distinguished from cases who
had a positive HIV test in the past but are tested and/or reported for the first time in
the country (i.e. transfer of care).
11.Stage O This variable specifies the clinical stage at the time of HIV diagnosis.
12. Transmission M Most probable route of HIV transmission.
M: Mandatory; O: Optional (Table continues...)
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Table 3.2: Overview of the available revised set of variables for case-based HIV-AIDS surveillance.
Source [105] - continue
Variable Report
Type
Description
13. FirstCD4Date M Date of first available CD4 cell count.
14. AcuteInfection O Evidence of recent infection, aside from the recent infection assay result. An infection
can be considered to be recent if a patient presents with seroconversion illness, has
a negative HIV test within 6 months of diagnosis or has evidence from p24 antigen
or Western Blot assays.
Demographics
15. Age M This is the age at diagnosis of the person in years as reported in the national system
of the Member State.
16. Gender M Gender of the infected person.
17. RegionOfOrigin O Region from which the case originates.
Clinical Information
18. ART O Was the patient receiving antiretroviral therapy at the date last seen for care?
19. CD4cells O CD4 cell count at time of diagnosis.
20. DateOfAIDSDiag-
nosis
O The date of first AIDS diagnosis; clinical or laboratory diagnosis.
21. AIDSIndicatorDis-
ease
O AIDS indicator disease at the time of AIDS diagnosis occurring within two consecutive
months from the date of AIDS diagnosis.
Death
22. Outcome O The vital status of the patient: ‘Alive’ or ‘Died’.
23. DateOfDeath M Date of death due to any cause.
24. DeathCause M Information on whether the case is alive or deceased (due to AIDS-related and non-
AIDS related causes).
Table 3.3: Values and validation rules of the revised set of variables for case-based HIV-AIDS surveil-
lance. Source [105]
Variable Codes, Allowed Formats and Validation Rules
TESSy System Related Variables
1.RecordType HIV
2.RecordType-
Version
3.Subject HIVAIDS = HIV diagnoses case-based, including AIDS.
4.DataSource FR-HIVAIDS = France Surveillance; IT-COA-ISS = Italy Surveillance; PT-HIVAIDS = Portugal Surveillance
NL-HIV/AIDS = Netherlands Surveillance; PL-HIV = Poland Surveillance
5.ReportingCountry FR = France; IT = Italy; NL = Netherlands; PL = Poland; PT = Portugal
6.DateUsedStatistics yyyy, yyyy-Qq, yyyy-mm, yyyy-ww, yyyy-mm-dd
Diagnosis Information
7. Date of yyyy, yyyy-Qq, yyyy-mm, yyyy-ww, yyyy-mm-dd
Diagnosis (Error) Date of diagnosis must be after 1970.
8.DateOfNotification yyyy, yyyy-Qq, yyyy-mm, yyyy-ww, yyyy-mm-dd
9.HIV Type HIV1 = HIV1 only; HIV2 = HIV2 only; HIV12 = HIV 1 and HIV 2 (co-infection); Unk =Unknown
10.HIVStatus PREVPOS = Previous HIV positive; NEG = Negative; UNK = Unknown
11.Stage ACUTE =Acute HIV infection; AIDS = AIDS; SYMPNONAIDS = Symptomatic non - AIDS; ASYMP NONAIDS = Asymptomatic Non -
AIDS, not further specified; UNK = Unknown
(Remark) In each patient register, Stage should be reported.
(Warning) If Stage is reported as acute infection, then DateOfDiagnosis should be reported.
(Warning) If Stage is reported as AIDS, then DateOfAIDSDiagnosis should be reported.
(Warning) If Stage is not reported as AIDS, then DateOfDiagnosis should not be later than DateOfAIDSDiagnosis
12.Transmission HETERO = Heterossexual contact; TRANSFU = Transfusion recipient; MSM = MSM/homo or bisexual male; HAEMO = Haemophil-
iac patient; MTCT = Mother-to-child-transmission; IDU = Ever injected drugs; UNK = Unknown or undetermined including case of
occupational exposure
(Error) If transmission category is men how have sex with men, then gender shouldn’t be female
(Remark) If transmission category is reported as transfusion of blood or its component due to
haemophilia, then gender is not very often female
(Warning) If the person is younger than 13 years old, transmission is often mother to child
(Error) If transmission category is reported as MTCT, stage cannot be acute HIV infection
13.FirstCD4Date yyyy, yyyy-Qq, yyyy-mm, yyyy-Www, yyyy-mm-dd, UNK, NA
14.AcuteInfection EV24ANT = Evidence from p24 antigen; EVWBLOT = Evidence from Western Blot; NEGTEST=Last negative test within 6 months of
HIV diagnosis; SEROILL = Seroconversion illness; NA = Not applicable (not acute infection); UNK = Unknown
Demographics
15.Age (Warning) If the person is younger than 13 years old, transmission is often mother to child
(Remark) It is unlikely that the age is more than 80 (Age <=80).
16.Gender F = Female; M = Male; O = Other (e.g., transsexual); Unk = Unknown
(Error) If transmission category is men who have sex with men, then gender should not be female.
(Remark) If transmission category is reported as transfusion of blood or its component due to haemophilia, then gender is not very often
female
(Table continues...)
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Table 3.3: Overview of the revised set of variables for case-based HIV-AIDS surveillance. Source
[105] - continue
Variable Codes, Allowed Formats and Validation Rules
17.RegionOfOrigin ABROAD = Abroad, sub continent unknown; AUSTNZ =Australia and New Zealand; CAR=Caribbean; CENTEUR = Central Eu-
rope; EASTASIAPAC = East Asia and Pacific; EASTEUR = East Europe; LATAM=Latin America; NORTHAFRMIDEAST=North Africa
and Middle East; WESTEUR=West Europe; EUROPE = If not in West, central or Eastern Europe, should be reported in Europe;
NORTHAM = North America; REPCOUNTRY = Same as reported country; SOUTHASIA=South East Asia; SUBAFR = Sub Sahara
Africa; NORTHAFRMIDEAST = North Africa and Middle East; Unk=Unknown
Clinical Information
18.ART Y = Yes; N = No; UNK = Unknown
(Remark) If ART is Y, last attendance date should be reported.
19.CD4cells A numerical values of the CD4 from 0 to 6000 or unknown (UNK)
(Remark) Usually CD4 cell count varies in a range from 0 to 1500 and due to rare extremely values upper high limit is set to 6000 per
cubic millimetre.
20.DateOfAIDSDi- yyyy, yyyy-Qq, yyyy-mm, yyyy-ww, yyyy-mm-dd
agnosis (Error) Date of AIDS diagnosis must be after 1970.
(Remark) If death due to AIDS is reported, patient should also have a DateOfAIDSDiagnosis.
21. AIDSIndicator 31 codes of the AIDS diseases defined in Appendix C
Disease (Warning) If AIDS indicator disease is reported, DateOfAIDSDiagnosis should be reported.
Death
22.Outcome A = Alive; D = Died; UNK = Unknown
(Warning) If it is known that a person died, it is usually expected that the Date Of Death is reported.
23.DateOfDeath yyyy, yyyy-Qq, yyyy-mm, yyyy-ww, yyyy-mm-dd
(Warning) If it is known that a person died, it is usually expected that the DateOfDeath is reported.
24.DeathCause DAIDS = Death due to AIDS; DNOAIDS = Non AIDS-related death; DUNK = Died of unknown cause
(Remark) If death due to AIDS is reported, patient should also have a DateOfAIDSDiagnosis.
(Warning) If DateOfDeath is known, DeathCause should be coded as DAIDS or DNOAIDS or DUNK.
(Warning) If it is known that a person died, it is usually expected that the DateOfDeath is reported.
3.5 Data from the Portuguese Surveillance System
Among all the potential fields of Portuguese notification form, only 31 were made available.
The variables collected until 2011 are described in Table 3.4. Since this data collection sys-
tem is paper based, we were unable to classify the variables as “Mandatory” or “Optional”,
so we chose to classify them as “Most likely to be complete” (C) or “Most likely to be missing”
(F) based on the completeness level of each variable published by Mauch 2009 report [93]
and on the requirements of the ECDC. Cases were considered ”most likely to be complete”
whenever the percentage of ”blank” and ”unknown” responses was at least 25%.
Mauch refers that after data is manually entered, logical errors and inaccuracies are
assessed and corrections made as needed. Validation rules are not routinely implemented
by the system and inaccuracies are assessed by cross-tabulations. The identified format
and values are represented in Table 3.5.
Table 3.4: Variables collected by the HIV-AIDS Portuguese notification form.
Variable Report
Type
Description
System Related Variables
1. NO - Case Number C Number of the record in CVEDT
2. Soundex code C Encrypted small string patient identifier
3. Reception Date C Date of Reception at CVEDT
4. Clinical Stage C This variable specifies the clinical stage of the last notification
Diagnosis Information
5. Notification Date C Date on which the case was notified for the last time.
6. Diagnosis Date C Date on which the case was diagnosed or progressed.
7. Notification HIV Date C Date on which the case was first notified.
8. Diagnosis HIV Date C Date on which the case was first diagnosed.
9. Stage Clinician C Clinical stage at the time of HIV diagnosis [93].
10. First symptoms F Date on which patient experienced the first symptoms
11. VIH 1 C Was the patient infected with HIV 1 type of virus?
12. VIH 2 C Was the patient infected with HIV 2 type of virus?
13. Risk Group C Most probable route of HIV transmission.
C: Most likely to be complete ; F: Most likely not to be filled (Table continues...)
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Table 3.4: Variables collected by the HIV-AIDS portuguese notification form. - continue
Variable Report
Type
Description
Demographics
14. Sex C Gender of the infected patient
15. Birth Date C Birth date of the patient
16. Age C Age at diagnosis of the person in years
17. Months C Age at diagnosis of the person in months
18. Nationality C Nationality.
19. Region of birth F Region of birth.
20. Residency C Region where the patient lives
21. Pregnant woman F In case of a female patient, whether or not she is pregnant
Clinical Information
22. Year of Probable Infection F Probable year of infection
23. AIDS indicator disease 1 C AIDS Indicator Disease
24. AIDS indicator disease 2 C AIDS Indicator Disease
25. CD4 F CD4 cell count at time of diagnosis.
26. CD8 F CD8 cell count at time of diagnosis.
27. T4/T8 F T4/T8 cell ratio at time of diagnosis (also called CD4 / CD8 cell ratio).
28. Treatment F Was the patient receiving antiretroviral therapy at the date last seen for
care?
29. Hospital C Reporting Health Provider name
Death
30. Death Date F Date of death due to any cause.
C: Most likely to be complete ; F: Most likely not to be filled
Table 3.5: Values and validation rules of the revised set of variables for case-based Portuguese
HIV-AIDS surveillance
Variable Codes, Allowed Formats and Validation Rules
System Related Variables
1.NO
2. Code Until five capital letters and ’-’ characters
3. Reception dd/mm/yyyy
Date Reception date should always be filled
(R25) Reception date must be after 1985
(R36) Reception date should be after Diagnosis date (5.)
(R37) Reception date should be after Notification date (4.)
(R39) Reception date should be after Diagnosis of HIV date (7.)
(R38) Reception date should be after Notification of HIV date (6.)
(R40) Reception date should be after Death date (30.)
4.Clinical Stage PA = Asymptomatic Non-AIDS; SIDA = AIDS ; CRS = Symptomatic Non-AIDS
(R31) If clinical stage of the last notification is reported as AIDS, then at least one AIDS indicator disease should be reported.
(R57) If clinical stage of the last notification is reported as AIDS and patient has more than 5 years old, then CD4 should be less than
350 cells /mm3. If AIDS patient has age less then 12 months then CD4 should be less than 30 cells /mm3, if the age is between 1
and 2 years old should be less than 25 cells /mm3 and with age between 3 and 4 should be less than 20 cells /mm3 .
Diagnosis Information
5.Notification ddd/mm/yyyyy
Date (R26) The last notification date should be after 1985.
(R41) The last notification date should be after diagnosis date.
(R37) The last notification date should be before reception date.
(R42) The last notification date should be after the notification of HIV date.
(R43) The last notification date should be after the diagnosis of HIV date.
6. Diagnosis dd/mm/yyyy
Date (R27) The last diagnosis date should be after 1983.
(R41) The last diagnosis date should be before last notification date.
(R36) The last diagnosis date should be before reception date.
(R44) The last diagnosis date should be after the diagnosis of HIV date.
7. Notification dd/mm/yyyy, NA
HIV Date (R28) The first notification date should be after 1985.
The first notification date should be after first diagnosis date.
(R38) The first notification date should be before reception date.
(R42) The first notification date should be before last notification date.
The first notification date should be before last diagnosis date.
8.Diagnosis dd-mm-yyyy
VIH date (R29) The first diagnosis date should be after 1983.
The first diagnosis date should be before first notification date.
(R39) The first diagnosis date should be before reception date.
9. Stage PA = Asymptomatic Non-AIDS; SIDA = AIDS ; CR = Symptomatic non-AIDS
clinician The first clinical stage should be at least as severe as the last clinical stage.
10. First dd-mm-yyyy; NA
symptoms (R45) The date of first symptoms should be before diagnosis date.
(R46)The date of first symptoms should be before notification date.
(Table continues...)
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Table 3.5: Overview of the revised set of variables for case-based HIV-AIDS surveillance - continue
Variable Codes, Allowed Formats and Validation Rules
(R47)The date of first symptoms should be before reception date.
(R49) The date of first symptoms should be before first diagnosis date.
(R48)The date of first symptoms should be before first notification date.
11.VIH 1 P = Positive; N = Negative; D = Unknown
12.VIH 2 P = Positive; N = Negative; D = Unknown
13.Risk Group DADOR = Donor; DESCONHECIDO = Unknown; HEMOFILICO = Haemophiliac patient; HETEROSSEXUAL = Heterosexual contact;
HOMO OU BISSEXUAL = MSM / homo or bisexual male; HOMO/TOXICODEPENDENT = Homo or bisexual male / Injected drugs;
MAE/FILHO = mother-to-child-transmission; NOSOCOMIAL = Nosocomial patient; TOXICODEPENDENTE = Injected drugs; TRANS-
FUSIONADOS = Transfusion recipient; OUTRO/INDETERMINADO = Other or mined unknown.
(R32) If risk group category is men who have sex with men, then sex should not be female.
(R32) If risk group category is reported as transfusion of blood or its component due to haemophilia, then sex is not very often female.
(R34) If risk group category mother to child transmission, then age is usually less than 13 years.
Demographics
14.Sex D = Unknown; F = Female; M = Male
15.Birth Date dd/mm/yyyy and 11-11-1111
16.Age Number from 0 to 99
17.Month Number from 0 to 11
18.Nationality Country name or nationality
19.Region of Birth Districts, islands, autonomous regions (the Azores and Madeira), municipalities (concelhos), countries and continents
20.Residency Districts, autonomous regions, countries, continents, NA
21. Pregnant N = No ; S = Yes
Woman (R33) If pregnant women is ’Yes’, then sex must be female.
Clinical Information
22.Year of Pro- Four digit number, the number 9999 is also present meaning Unknown
bable Infection (R50) The year of probable infection should be before the year of last diagnosis.
(R51) The year of probable infection should be before the year of last notification.
(R52) The year of probable infection should be before the year of first symptoms.
(R53) The year of probable infection should be before the year of first diagnosis.
(R54) The year of probable infection should be before the year of first notification.
23. AIDS Indica 31 codes of AIDS indicator disease described in Appendix C.
tor Disease 1 If AIDS indicator disease is filled then last clinical stage should be AIDS.
24. AIDS Indica 31 codes of AIDS indicator disease described in Appendix C.
tor Disease 2 If AIDS indicator disease is filled then last clinical stage should be AIDS.
25.CD4 Numerical value
(R15 and R16) Usually CD4 cell count varies in a range from 0 to 1,500 and due to rare extremely high values upper limit is set to 6,000
per cubic millimetre.
26.CD8 Numerical value
(R17 and R18) Usually CD8 cell count varies in a range from 0 to 1,500 and due to rare extremely high values upper limit is set to 6,000
per cubic millimetre.
27.T4/T8 Numerical value
(R35) Should be equal to the ratio between CD4 and CD8.
(R19 and 20) Should be between 0.54 and 1.01 for middle-aged HIV-infected population on long term ART and with good immunoviro-
logical status [157].
28.Treatment 1 = Yes ; 2 = No; 9 = Unknown
29.Hospital Name of Regional health administrations (RHAs); Hospital Name; Institutes of Ministry of Health; Ministry of Health Services; Primary
Care Services Names; Addictive behaviour treatment centres; Private Practices; Districts ; Prisons; Others
Death
30. Death Date dd/mm/yyyy
(R56) The death date should be before reception date.
(R55) The death date should be before notification date
The Portuguese health care system has a very complex structure that suffered several
reforms throughout time. In order to give a common understanding to the variable “Hospital”
from the Portuguese surveillance system, this variable was cross-checked with the official
list of Health Providers made available by the Portuguese Ministry of Health in Website of
Central Administration of the Health System (ACSS). The description of these variables is
presented in Table 3.6.
Table 3.6: Central Administration of the Health System List of Health Providers
Variable Description Values
ARS Health Administration Region ARS Alentejo; ARS Algarve; ARS Cen-
tro; ARS LVT; ARS Norte
COD LOCAL PRESCR Code of Health Provider Numerical value
NOME LOCAL PRESCR Name of Health Provider A character
TIPO LOCAL Type of Health Provider Primary Care; Personalized Care; Diag-
nosis Centre; Private Care; Hospitals;
Shared Services; Counseling Centre; ...
RESP FINANCEIRA Name of Financial Manager ARS Alentejo; ARS Algarve; ARS Cen-
tro; ARS LVT; ARS Norte; Personalized
Health Care Unit
DATA INICIO RESP FINAN-
CEIRA
Beginning date of Financial Manager
(Table continues...)
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Table 3.6: Central Administration of the Health System List of Health Providers - continue
Variable Description Values
DATA FIM RESP FINANCEIRA Late date OF Financial Manager
CONCELHO Region Portuguese Region
ACTIVO If it is active
DATA INICIO ARS Beginning date of administrative responsibil-
ity
DATA FIM ARS Last date of administrative responsibility
As previouslymentioned, the PortugueseHIV-AIDS reporting system is confidential, and
case- and paper-based. It was performed voluntarily by physicians since the identification
of the infection in 1983 and until 2005. Since then, it is mandatory to report all cases in
any of the stages of the infection (asymptomatic, AIDS related complex and AIDS) and all
the progressions including death. The stages of the infection are determined according to
case definition of WHO and the ECDC since 1993. The registry also includes information
on the most probable source of transmission (Heterosexual, Men who have Sex with Men
and Injecting Drug Users), as well as demographic and clinical variables. The demographic
variables include age, sex, birth date, nationality and region of birth. The diagnosis infor-
mation includes notification date, diagnosis date, notification of HIV date, diagnosis of HIV
date, year of the first symptoms and type of HIV virus. Clinical Information includes prob-
able year of infection, codes of AIDS Indicator Disease, CD4 and CD8 cells count, T4/T8
cell ratio at the time of diagnosis, the status of the treatment and the name of the reporting
Health Provider. The death information includes date of death due to any cause. Patients
confidentiality is assured through the use of a Soundex code filled in by the clinicians and
data is processed manually.
It is important to notice that the entire Portuguese population is virtually under surveil-
lance but the testing practices are mandatory for military and strongly recommended for
pregnant women and IDUs entering treatment programs.
3.5.1 Evaluation of the HIV-AIDS Portuguese Surveillance Data
In 2009, the Portuguese HIV-AIDS reporting system situation was assessed and the results
were published in [93]. By then, it was acknowledged, like in most similar surveillance
systems, that the Portuguese surveillance suffers from under-reporting, under-diagnosing
and reporting delay, clearly affecting timeliness and therefore the data quality. The study
aimed to examine the quality of the data collected by the portuguese mandatory notification
system for HIV - AIDS infection as determined by the timeliness of reporting, completeness
of information, acceptability by relevant stakeholders, as well as simplicity, stability and
flexibility of the surveillance system.
Mauch found that the acceptability, as measured through qualitative interviews with key
stakeholders, is relatively low. These interviews were conducted on a selection of health
providers that play a key role in HIV - AIDS care and treatment in seven different hospitals
in Lisbon and Porto. These seven hospitals have been responsible for reporting 41% of all
cases notified. All clinicians interviewed were either the Director of the Infectious Disease
Service or a practising physician on the service and so are important in the notification
process. Five clinicians regularly see 12 to 20 patients per day while the other follow only a
handful of patients on a regular basis. The hospitals varied on the number of HIV+ patients
being followed in their Infectious Disease Service but ranged from 1300 to 2500 patients [93].
Also, she found that no standard operating procedures, such as description of objectives
and responsibilities of an institution operating within the system, were implemented until
the time of the study [93].
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All clinicians agree that the system is useful, confirmed knowing that the notification
is mandatory and under what conditions regarding clinical stage, confirmed that the sub-
mission was preformed on a regular basis for initial diagnosis. The main reasons for not
submitting a notification form are related with paperwork not representing a priority, forget,
consider that the infra- structure of the process is difficult to deal with, overwork and the
necessity of large backlog of patient records to review. Clinicians did not report being ac-
countable to any time constraints. This leaves a considerable amount of leeway for health
providers as to how quickly they should be submitting a notification form. They reported
that the filling in of the notification form was occurring after the medical appointment, some-
times several days or weeks later, also referred that there were some personal judgement
about the importance of filling some variables, that do not have “proprietary” ownership of
the data and that some patients had problems recalling some events. This fact can con-
tribute to missing values and inaccuracies in some variables such as the associated risk
group[93]. According to these key stakeholders, reporting death and changes in disease
status are particular problematic.
This informations are summarized in Table 3.7.
Table 3.7: Summary highlights of Health Provider Interviews. Adapted from Mauch in [93]
Hospital A Hospital B Hospital C Hospital D Hospital E Hospital F Hospital G
View the Notification System
as useful
Agree Agree Agree Agree Agree Agree Agree
Received training or support
regarding data submitted via
notification
Disagree Disagree Agree Disagree Disagree Disagree Disagree
Receive regular reports from
the CVEDT
Disagree Disagree Agree Agree Disagree Agree Agree
Regularly receives confirma-
tion from CVEDT that notifica-
tions were received
Agree Agree but
coded so diffi-
cult to compare
to internal
records
Disagree Agree Agree but
coded so diffi-
cult to compare
to internal
records
Disagree Disagree
Case definition being used to
classify disease status of pa-
tient
1993 CDC 1993 CDC, mi-
nus CD4 cell
count criteria
1993 CDC Unsure 1993 CDC ECDC 1993 CDC, mi-
nus CD4 cell
count criteria
Clinicians individually respon-
sible for submitting notifica-
tion forms
Agree Agree Agree Disagree - Cen-
tralized to 2
doctors
Agree Agree Disagree - Cen-
tralized to 1
doctor
Aware that notification is
mandatory at first diagnosis
and any change in disease
status, including death
Agree Agree Agree Agree Agree Agree Agree
Regularly submits notification
for initial diagnosis
Agree Agree Agree Agree Agree Agree Agree
Regularly submits notification
for disease progression in pa-
tient (PA to CRS, CRS to
AIDS)
Disagree Disagree Disagree Disagree Disagree Reports
change to
AIDS status,
not to CRS
Disagree
Regularly submits notification
for death of patient
Disagree Disagree Disagree Disagree Disagree Disagree Disagree
Reason for not submitting a
notification form
Paperwork not
a priority
Paperwork not
a priority, For-
get
Infra- structure
of the process
makes it diffi-
cult
Large back-
log of patient
records to
review
No reason
given
Overwork, For-
get
No reason
given
Time required to complete no-
tification form
2 minutes for
regular patient,
up to 10 min for
new patients
10 minutes 10 minutes for
regular patient,
up to 30 min for
new patients
10 minutes for
own patient, up
to 1 hour for
patient of other
doctor
2 minutes for
regular patient,
up to 10 min for
new patients
3 to 4 minutes 5 to 10 minutes
Variables most likely to not be
completed
Motive to test,
Disease classi-
fication
Risk group,
concelho,
Country of
probable infec-
tion, Date for
first HIV+ test
No specific vari-
ables
Foreign travel,
Date for first
HIV+ test
Motive to test,
Foreign travel
Motive to test,
Military service
Risk group
Reasons for not completing a
variable
Not relevant to
CVEDT needs
Information not
requested, Pa-
tient recall
Lab results
not available,
Patient recall
Information not
requested, Too
time- consum-
ing
Not relevant to
CVEDT needs
Information not
requested, Pa-
tient recall
Patient recall
Support implementation of
electronic notification system
Disagree Agree Agree Agree Agree Agree Agree
Feasible to add variables al-
ready in use for clinical pur-
poses (i.e. CD4, treatment)
Agree Agree Agree Agree Agree Agree Agree
Over the years, the surveillance procedure has suffered some changes that may have
altered the quality of the reports. One important change was the inclusion of relevant new
variables in 1988 due to the evolution of knowledge about the natural history of the infection
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Figure 3.3: Missing values per variable
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Figure 3.6: Distribution of the HIV stage reported
by the clinician.
Figure 3.7: Distribution of reporting delay per no-
tification year
Figure 3.8: Distribution of time between recep-
tion and notification of the form at
CVDET per notification year
and the elimination of others in 2005 [93].
One of the first tasks consisted of determining the number of missing cases on each vari-
able. Figure 3.3 elucidates about the global picture happening in the dataset with respect
to the number of missing cases in each variable and the identification of the cases mostly
affected by missing information. Twelve variables presented more than 20% of missing val-
ues. However, in the variables Pregnant-women, AIDS indicator disease 1, AIDS indicator
disease 2 andMonths, most of the missing values were structural and, although the variable
Region of Birth appears to be non - missing, most of the observations are Not Mentioned
(about 11958 cases).
The text fieldsNationality, Region-of-birth andHospital have issues such as misspelling,
illegal values, ambiguities and syntax violations (Table 3.8).
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Table 3.8: Some issues for variable “Nationality” and “Hospital”
Error Type Frequency
PORTGUESA Misspelled by deletion of character 1
PORTUGUESAA Misspelled by insertion of a character 1
PORTUGAL Illegal Value 13
BRASILEIRO Misspelled by substitution of a character 2
Univ Coimbra Syntaxe violation and ambiguous
The most common ambiguities are values representing names of Administrative Health
Regions, names of Districts and short names of Health Care Institutions as the one men-
tioned in Table 3.1.
When the distribution of age according to the year of notification was looked at (Figure
3.4), it became clear that the very suspicious value “99” did not correspond to years of age
but to a code form for a missing value instead.
The interpretation of positive HIV antibody testing is complicated in children less then
9−12 months due to the fact that maternal HIV antibody can persist for 18 months and
so, the standard HIV testing cannot be reliable. The distribution of age of babies under 9
months - old by clinical stage was assessed and it is present in Figure 3.5.
We defined missing values in any variable as the entries with blank fields and coded
as missing values such as, “9”, “99”, “9999”, “Not Mentioned”, “Unknown”,“D” (first letter of
Unknown in Portuguese), “Other/Undetermined” or “—–”, “—(any two letters)”, “(any three
letters)–” or “AAAAA”. The entries with illegal values, wrong data or misspellings were con-
sidered as invalid values.
The results of HIV-AIDS data audit are presented in Table 3.9 and graphically in Figure
3.9. From the analysis of these elements it is clear that almost 50% of the variables have
potential for significant data quality problems since they are severely affected by missing
values. The lack of information is sharp on variables like “Months”, “CD4”, “CD8”,“T4/T8”,
“Region of Birth”, “Treatment”, “AIDS indicator disease 1”, “AIDS indicator disease 2”, “First
symptoms” , “Death date” and “Year of probable infection”. It is also of note that the variable
“Hospital” has a moderate amount of invalid values.
In Table 3.9, the number it is also available the the number of distinct observation each
may influence the representativeness of some groups, this is especially problematic in the
variable “Hospital”.
Table 3.9: Percentage of Valid, Invalid, Missing and Outliers
Name Valid Invalid Missing Outliers Distinct
ID Variable — 2 Variables 40690 Observations
NO- Case Number 100% 0% 0%
Numerical Variables — 5 Variables 40690 Observations
Age 95% 0% 1% 4% 89
Months 0% 0% 100% 12
CD4 40% 0% 59% 1% 1355
CD8 29% 0% 70% 1% 2390
T4/T8 14% 0% 85% 1% 232
Factor Variables — 14 Variables 40690 Observations
Clinical stage 100% 0% 0% 3
Sex 100% 0% 0% 2
Pregnant women 64% 0% 36% 2
Stage clinician 79% 0% 21% 3
Region of birth 36% 3% 61% 445
Residency 98% 0 2% 24
Nationality 94% 1% 5% 101
Risk group 98% 0% 2% 9
(Table continues...)
3.5. Data from the Portuguese Surveillance System 57
Table 3.9: Percentage of Valid, Invalid, Missing and Outliers
Name Valid Invalid Missing Outliers Distinct
Treatment 8% 0% 92% 2
AIDS indicator disease 1 41% 0% 59% 30
AIDS indicator disease 2 11% 0% 89% 27
VIH 1 99% 0% 1% 2
VIH 2 99% 0% 1% 2
Hospital 86% 14% 0% 521
Dates Variables — 9 Variables 40690 Observations
Reception date 100% 0% 0% 4510
Birth date 99% 0% 1% 15301
Notification date 100% 0% 0% 6065
Diagnosis date 100% 0% 0% 7073
Notification HIV date 79% 0% 21% 4961
Diagnosis HIV date 79% 0% 21% 6052
First symptoms 26% 0% 74% 2426
Death date 23% 0% 77% 5256
Year probable infection 16% 0% 84% 41
Figure 3.9: Percentage of Valid, Invalid, Missing and Outliers
Throughout the years, the surveillance system suffered changes that are imprinted in
the data. One example includes the variable “HIV clinical stage reported by the clinician”,
as seen in Figure 3.6.
The presence of reporting delay and longitudinal outliers is represented in Figure 3.7.
It can also be seen that there are reporting delays longer than 25 years and that this data
has a visible right truncation mechanism.
In any process of data editing it is necessary to take into consideration all the relation-
ships between the variables in the data set. The constraints describing the relationships
are called functional dependencies. Given the biology of the HIV-AIDS disease it is natural
to define the dependency between the “CD4” and “CD8” cell counts and as a consequence
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of the ratio between them, which is commonly represented by the “T4_T8” ratio. Moreover,
the variable “Sex” is related to “Risk group” due to the transmission patterns of the disease
and linked to the variable“Pregnant woman”. Another natural relationship occurs between
“Age” and “Birth date” variables. Moreover, given the natural history of the disease and
the chronology of each event, all variables concerning dates are related. Since the “Clini-
cal Stage” is defined by clinical and laboratory criteria it is natural that these variables are
related to “CD4”, “CD8”, “T4_T8”, “AIDS_indicator_disease1”, “AIDS_indicator_disease2”
and “Age”. The functional dependencies among all variables are represented in Figure
3.10.
Figure 3.10: Functional dependencies among Portuguese HIV-AIDS surveillance system variables
Considering these relationships and applying the business rules defined in Table 3.5
more inconsistencies appeared.
Violation of logical dependencies are also presented in time related variables. For ex-
ample, when considering the relation between the reception of form in CVEDT date (filled
by CVEDT) and notification date (filled by clinician), recent dates can be found in the latter
(Figure 3.8).
The validation rules in Table 3.10 were deducted based on the rules implemented on
TESSy for the HIV - AIDS Surveillance System and extended for accommodating some
logical or mathematical relationships and are present in Table 3.5. So, the completeness
property is satisfied. The initial set was pruned in order to eliminate redundancies and
inconsistencies.
The final set of validation rules is described in terms of material conditions and eva-
luated in Table 3.10 and Figure 3.11. Theses rules were applied to Portuguese HIV data
set. All rules involving “Death date”, “Year Probable Infection”, “Treatment”, both “AIDS
Indicator disease”, “Months”, “CD4”, “CD8” and the ratio ”T4_T8” are severally affected by
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missing values. Themissing values of variable “Months” are due to the nature of the disease
which affects mainly young adults and due to HAART vertical transmission is almost null
in Portugal. Some lack of information on “Treatment”,“CD4”, “CD8” and the ratio ”T4_T8”
is due to the 2005 revision: these variables were excluded from the notification form ([93]).
“Nationality” and “Hospital” were the variables counting with more invalid or ambiguous
values, due to typo’s or values representing other statistical objects. It is important to notice
that the rule number R57 takes into consideration the laboratory and clinical criteria to AIDS
stage definition.
Table 3.10: Validation rules applied to HIV-AIDS Portuguese data set
Rule Expression %
Con-
firmed
%
Failed
%
Miss-
ing
R1 Risk group ∈ {”Dador” , ”Desconhecido” , ”Hemofilico” , ”Heterossexual” , ”Homo ou Bissexual”
, ”Homo/Toxicodependent” , ”Mae/Filho” , ”Nosocomial” , ”Outro/Indeterminado” , ”Toxicode-
pendente” , ”Transfusionado”}
98% 0% 2%
R2 Sex ∈ {”F”,”M”} 100% 0% 0%
R3 Pregnant women ∈ {”Y es”, ”No”} 64% 0% 36%
R4 Clinical stage ∈ {”PA”, ”SIDA”, ”CRS”} 100% 0% 0%
R5 Stage Clinician ∈ {”PA”, ”SIDA”, ”CRS”} 79% 0% 21%
R6 Region of birth 36% 36% 32%
R7 Residency 98% 0% 2%
R8 Nationality 94% 1% 5%
R9 Treatment 8% 0% 92%
R10 AIDS indicator disease 1 41% 0% 59%
R11 AIDS indicator disease 2 11% 0% 89%
R12 V IH1 ∈ {P,N} 99% 0% 1%
R13 V IH2 ∈ {P,N} 99% 0% 1%
R14 Hospital 86% 14% 0%
R15 CD4 >0 41% 0% 59%
R16 CD4 <6000 41% 0% 59%
R17 CD8 >0 30% 0% 70%
R18 CD8 <6000 30% 0% 70%
R19 (T4_T8 - 0.54) >= -1e-08 4% 11% 85%
R20 (T4_T8 - 1.01) <= 1e-08 14% 1% 85%
R21 (Age - 0) >= -1e-08 99% 0% 1%
R22 Age <98 99% 0% 1%
R23 (Months - 0) >= -1e-08 0% 0% 100%
R24 Months <12 0% 0% 100%
R25 Reception date >= ”1/1/1985” 100% 0% 0%
R26 Notification date >= ”1/1/1985” 100% 0% 0%
R27 Diagnosis date >= ”1/1/1983” 100% 0% 0%
R28 Notification HIV date >= ”1/1/1985” 79% 0% 21%
R29 Diagnosis HIV date >= ”1/1/1983” 79% 0% 21%
R30 Death date >= ”1/1/1983” 23% 0% 77%
R31 !(Clinical stage == ”SIDA”) | ((is.na(AIDS_indicator_disase_1) == FALSE |
is.na(AIDS_indicator_disase_2) == FALSE))
100% 0% 0%
R32 !(Risk_group %in% c(”Homo/Bissexual”, ”Homo/Toxicodependent”, ”Hemofilico”)) | (Sex ==
”M”)
100% 0% 0%
R33 !(Pregnant_women == ”S”) | (Sex == ”F”) 72% 0% 28%
R34 !(Risk_group == ”Mae/Filho” & Clinical_stage =“PA”) | (Age_first_diagnosis <= 13) 100% 0% 0%
R35 round(CD4/CD8, digits =2 ) == T4_T8 7% 6% 87%
R36 Reception_date >= Diagnosis_date 100% 0% 0%
R37 Reception_date >= Notification_date 100% 0% 0%
R38 Reception_date >= Notification_HIV_date 79% 0% 21%
R39 Reception_date >= Diagnosis_HIV_date 79% 0% 21%
R40 Reception_date >= Death_date 11% 11% 77%
R41 Notification_date >= Diagnosis_date 100% 0% 0%
R42 Notification_date >= Notification_HIV_date 79% 0% 21%
R43 Notification_date >= Diagnosis_HIV_date 79% 0% 21%
R44 Diagnosis_date >= Diagnosis_HIV_date 79% 0% 21%
R45 !(Clinical_stage != ”PA”) | (First_symptoms_year <= Diagnosis_date) 72% 0% 28%
R46 !(Clinical_stage != ”PA”) | (First_symptoms_year <= Notification_date) 72% 0% 28%
R47 !(Clinical_stage != ”PA”) | (First_symptoms_year <= Reception_date) 72% 0% 28%
R48 !(Clinical_stage != ”PA”) | (First_symptoms_year <= Notification_HIV_date) 63% 0% 36%
R49 !(Clinical_stage != ”PA”) | (First_symptoms_year <= Diagnosis_HIV_date) 63% 1% 36%
R50 Year_prob_infection <= Diagnosis_Year) 16% 0% 84%
(Table continues...)
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Table 3.10: Validation rules applied to HIV-AIDS Portuguese data set
Rule Expression %
Con-
firmed
%
Failed
%
Miss-
ing
R51 Year_prob_infection <= Notification_Year 16% 0% 84%
R52 Year_prob_infection <= First_symptoms_Year 3% 0% 97%
R53 Year_prob_infection <= Diagnosis_HIV_Year 16% 0% 84%
R54 Year_prob_infection <= Notification_HIV_Year 16% 0% 84%
R55 Death_date <= Notification_date 11% 12% 77%
R56 Death_date <= Reception_date 11% 11% 77%
R57 (!((Age >= 5 & CD4 < 350) | is.na(AIDS_indicator_disase_1) == FALSE) | (Clinical_stage ==
”SIDA”)) & (((Age >= 5 & CD4 < 350) | is.na(AIDS_indicator_disase_1) == FALSE) | ((!((Age
< 1 & CD4 < 30) | is.na(AIDS_indicator_disase_1) == FALSE) | (Clinical_stage == ”SIDA”)) &
(((Age < 1 & CD4 < 30) | is.na(AIDS_indicator_disase_1) == FALSE) | ((!((Age > 0 & Age < 3 &
CD4 < 25) | is.na(AIDS_indicator_disase_1) == FALSE) | (Clinical_stage == ”SIDA”)) & (((Age
> 0 & Age < 3 & CD4 < 25) | is.na(AIDS_indicator_disase_1) == FALSE) | (!((Age > 2 & Age <
5 & CD4 < 20) | is.na(AIDS_indicator_disase_1) == FALSE) | (Clinical_stage == ”SIDA”)))))))
54% 8% 38%
R58 lubridate::year(Birth_date) <= Year_prob_infection 0% 16% 84%
R59 Birth_date <= First_symptoms_year 25% 0% 75%
R60 Birth_date <= Death_date 23% 0% 77%
R61 Birth_date <= Diagnosis_HIV_date 79% 0% 21%
R62 Birth_date <= Diagnosis_date 99% 0% 1%
R63 Birth_date <= Notification_HIV_date 79% 0% 21%
R64 Birth_date <= Notification_date 99% 0% 1%
R65 Birth_date <= Reception_date 99% 0% 1%
It is important to notice that R35 is severally impaired due to missing values in at least
one of the 3 variables that composes this relationship and due to violation of the functional
relationship (Figure 3.11). Indeed, variable “T4_T8” have a lot of inconsistencies, some of
which are presented in Table 3.11.
Figure 3.11: Validation rules applied to HIV-AIDS Portuguese data set
Other important remark is that the AIDS case definition changed along the studied
surveillance years and in this study the data were confronted with the 2012 European AIDS
case definition and so the failures reported by rule 57 may be roots on the evolution of the
system.
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Table 3.11: Examples of inconsistencies on T4_T8 records
CD4 CD8 CD4/CD8 T4_T8
102 318 0.32 3.20
286 638 0.45 4.50
19 236 0.08 8.00
36 24 1.5 1.50
952 418 2.30 2.30
389 525 0.74 1.90
57 314 0.18 6.00
42 449 0.09 0.01
When this methodology is applied from the record perspective it can be seen that all the
records have some percentage of rules that can not be evaluated due to missing values in
variables involved on the rule definition. The majority of the records have at least 25% and
a maximum of 62% of rules that can not be evaluated. It can be found at least a record
with a maximum of 25% of failed rules and a record with just 25% of the rules confirmed
3.12. After correcting the trivial typo’s in the data set and given the set of validation rules
which takes into consideration the web of dependent variables given in Figure 3.10 so that
the correction of a record in order to repair a rule does not make it invalid for other rule, a
record based error detection framework was implement. This framework implements the
Felligi Holt algorithm minimizing a weighted number of values that need to be adjusted
to remove the invalidation. It was used the errolocate R package which translates the
validation and error localization problem into a mixed integer problem and uses - a Mixed
Integer Programme solver to find a solution [145, 158]. Taking into consideration the total
percentage of failed or missing values and given that some variable have some degree of
uncertainty due to recall errors and stigma.
Figure 3.12: Evaluation of validation rules applied to HIV-AIDS Portuguese data set per record
It was also considered that the “Diagnosis date” has some uncertainty in it. The variables
were ordered and weights were given accordingly, with a low weight corresponding to a
higher uncertainty [159, 145]:
W1 T4_T8;
W2 Death_date;
W3 Year_prob_infection, First_symptoms_year, Treatment, CD8 ;
62 Chapter 3. Statistical Data Pre - Processing
W4 Region_of_birth, CD4;
W5 Diagnosis_HIV_date ;
W6 Notification_HIV_date, Pregnant_women, Stage_clinician, Nationality, Residency;
W7 Diagnosis_date; Risk_group ;
W8 Notification_date, AIDS_indicator_disease_1 , AIDS_indicator_disease_2, VIH_1, VIH_2,
Hospital
W9 Sex, Birth_date, Age, Months ;
W10 Clinical_stage, Reception_date
This statistical cleaning step revealed that almost 99% of the records did not violate the
logical dependencies between the variables variables, 5123 records needed a change in
one variable and 17 records needed a change in two variables (Table 3.12).
Table 3.12: Summary of Error Location Algo-
rithm per Record
Number of Errors Number of Records
0 35550
1 5123
2 17
Table 3.13: Summary of Error Location Algo-
rithm per Variable
Variable Number of issues Missing
T4_T8 5088 34544
CD4 36 23994
CD8 28 28357
Risk_group 1 0
It is clear that the percentage of missing values in each variable is an important issue
and it was found that problems in laboratory variables must also be taken into consideration.
The framework determined that the minimal set of variables needing an adjustment consists
of the variables “T4_T8”, “CD4”, “CD8”, “Risk_group” and “Age at the first diagnosis” with
errors and missing values represented in Table 3.13.
The detected issues on the variable “Risk_group” were not corrected since the rule
represents only a soft edit.
Table 3.11 suggested that some of the values were records with some typographical
errors. The records with valid values of “CD4” and “CD8” were used for proxy impute the
“T4_T8” variable.
The duplicates or record linkages arised, most probably, by one of the following mech-
anisms: a patient seeked care on a primary care centre and, after confirmation of the in-
fection, the patient is transferred to a specialized unit; a hospitalized patient developed a
disease that needs special treatment offered in a specific unit; patient moved to a different
region and, once there, seeked for a new health centre; health care; patients that were
in prisons and had their HIV positive status confirmed need to be followed by an hospital;
changes in disease stage and possible errors on key identifier and changes on the system
dataset structuring. For duplicate detection, it would be necessary to have a meaningful
observation identifier but the original Soundex Code could not be provided.
Given the high proportion of missing values in several variables, the presence of ty-
pographical errors and invalid values, we adopted an iterative deterministic technique for
detecting record linkage. First we considered the variables “Encrypted Code”, “Sex” and
“Birth_date”. For the generation of the comparison patterns it was established that the
records should exactly match on the variables “Sex” and “Birth_date” and have, at least, a
similarity of 0.9 with ‘Encrypted Code”. We used the Jaro similarity measure, taking values
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in [0, 1], where 0 denotes maximal dissimilarity and 1 stands for equality. This allows for
’fuzzy’ comparison patterns and is useful for dealing with typographical errors and with small
length strings. We allowed misspell errors in identifiers adjusting the distance in order to
accommodate one character deletion, one insertion, one substitution and one transposition.
Given two strings s = a1 . . . aK and t = b1 . . . bL, a character ai in s is said to be common
with t if there exists a j such that ai = bj and |j − i| < min(|s|,|t|)2 , where |s| (resp. |t|) is the
number of characters forming the corresponding string [160, 155, 161].
Let s′ = a′1 . . . a′K be the characters in s that are common to t (exactly in this order) and
let t′ = b′1 . . . b′L be an analogous string. A transposition for s′, t′ can be defined as a position
i such that a′i ̸= b′i. Let T be half the number of transpositions necessary to turn s′ into t′
[161] . The Jaro similarity measure for s and t is
djaro (s, t) =
1
3
( |s′|
|s| +
|t′|
|t| +
|s′| − T
|s′|
)
(3.9)
A variation of this measure is the Jaro-Winkler measure that uses the length P of the
longest common prefix of s and t. This measure incorporates a penalty for characters
mismatches in the first four characters and so, it favourables pairs of strings containing
identical prefixes. Letting P ′ = max (P, 4), the Jaro-Winkler measure is defined as [161]
djaro−winkler (s, t) = djaro (s, t) +
P ′
10 (1− djaro (s, t)) (3.10)
A record pair is classified as a match if the two records agree, character by character,
on all identifiers and the record pair is uniquely identified (no other record pair matched the
same set of values). A record pair is classified as a non match if the two records disagree
on any of the identifiers, if the record pair is not uniquely identified or if there is reasonable
doubt on the match status (this dataset undergoes a revision when a new case is entered by
a trained CVEDT employee so if there is a doubt about the matching status of two records,
then we decide by a non match status ) [152].
In the studied dataset, the approach generated 352299493 comparison pairs from which
280 pairs were classified as possible matches. A second step, with deterministic approach
with clerical review was performed considering all the available information. Given that the
variables have a considerable amount of missing values, it can be defined the following
rules:
R1 For each pair, does one element come from a primary care health provider or associa-
tion and the other come from a specialized health care provider? If so, the pair can
represent the same patient
R2 For each pair with different death dates, is the difference larger than one month? If so,
the pair can correspond to different patients.
R2.1 If just one has a death date, does the other the other have a later date of diag-
nosis? If so, the pair may correspond to different patients.
R3 Comparing the diagnosis dates, does the most recent corresponds to a latter stage of
the disease? Then it can be different patients.
R4 Is the case from aminority group (ex: Cabo-Verde, Angola, Açores andHomo-Bissexual,
Female and IDUs, ... )? Then probably is the same case.
R5 Given that the two notifications came from different hospitals, if the region of residency
is on the second Hospital region, then it can be the same case.
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R6 Given two AIDS cases, does the AIDS indicator diseases the same? If they have the
same AIDS indicator disease then it is probably the same patient.
R7 Given that the two AIDS case, does the AIDS indicator disease(s) need a special care?
Verify if the health provider is compatible with the special need.
R8 Given that the cases are a women, compare if the cases are pregnant. If yes, then is
very likely that is the same case.
The risk group was not considered as a possible match field due to the existence of
overlapping risk groups and the widely recognized uncertainty in the classification of the
patients. Examples of the resulting matched pairs are presented in Table 3.14.
Table 3.14: Examples of matched pairs
Clini-
cal
stage
Sex Birth
date
Notifi-
cation
date
Diagno-
sis
date
Noti-
fica-
tion
HIV
date
Diagnosis
HIV
date
Stage
clini-
cian
First
symp-
toms
year
Year
prob
in-
fec-
tion
Region
of
birth
Resi-
dency
Preg-
nant
wo-
men
AIDS
indicator
disease
1
Risk
group
Hospital
A F 04/
05/
1974
02/
02/
1996
25/
02/
1995
NA NA NA NA NA NA Lisboa NA NA Toxico-
depen-
dente
C.S.
Lapa
A F 04/
05/
1974
03/
02/
2011
29/
10/
1997
03/
02/
2011
29/
10/
1997
PA NA 1997 Lisboa Lisboa N NA Hetero
-
ssexual
Santa
Maria
AIDS F 01/
03/
1955
01/
03/
2002
30/
11/
2001
01/
03/
2002
30/
11/
2001
AIDS 15/
11/
2001
NA NA Lisboa N Candi-
diasis,
oesopha-
geal
Hetero-
ssexual
Desterro
AIDS F 01/
03/
1955
15/
02/
2002
20/
11/
2001
15/
02/
2002
20/
11/
2001
AIDS NA NA NA Lisboa N Candi-
diasis,
oesopha-
geal
Hetero-
ssexual
Capuchos
A F 31/
07/
1951
26/
03/
2008
25/
03/
2008
26/
03/
2008
25/
03/
2008
A NA NA Porto Porto N NA Hetero-
ssexual
Sao
Joao
A F 31/
07/
1951
28/
03/
2008
24/
03/
2008
28/
03/
2008
24/
03/
2008
A NA NA NA Porto N NA Hetero-
ssexual
Sao
Joao
From the 280 pairs identified previously, only 132 were considered as record linkage in
the second approach. It is important to notice that the coding variable have missing values
indicated by the codes “—–” and “AAAAA”. These records were classified as non matches.
For the analysis of the missing values patterns, the observations were ordered per no-
tification year Figure 3.13. It can be seen that the variables “Stage_clinician”, “Diagno-
sis_HIV_date” and “Diagnosis_HIV_date” were most frequently missing in the early years
while the variables “CD4”, “CD8” and “T4_T8” presented a higher concentration of missing
values in the most recent years. It is important to notice that these variables were dropped
in the 2005 revision. Most of the missing values present in the variables ”Pregnant_women”,
“AIDS_indicator_disease_1” and “AIDS_indicator_disease_2” are structural because “Male”
is the prevalent sex and all cases classified as “AIDS” have at least one indicator disease.
Considering only the variables with missing values and given that the trivial missing
cases on “pregnant_women” and “T4_T8” were corrected, it can be seen that when one
variable has a missing value than all the variables are missing (Figure 3.14).
As already said, over the years, the portuguese HIV/AIDS surveillance system has suf-
fered several modifications. This changes are highlighted when missing pattern are anal-
ysed through the notification year. It can be seen that the variables “Clinical_Stage”, “Di-
agnosis_HIV”, “Notification_HIV” and “Pregnant_women” have a clear dependence on the
notification year, being the information present on the most recent years. The missing rates
of the demographical variables “Nationality” and “Residency” is fairly resolvable through-
out the years. The missing patterns associated with the variables “Year_Prob_Infection”,
“Death_date” and “First_symptoms” have consistent missing values throughout all the noti-
fication years. Although the variables “CD4”, “CD8” and “T4_T8” have high rates of missing
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Figure 3.13: Patterns of missing values per notification year
Figure 3.14: Missing values patterns
values throughout the years, that incidence is higher over the last years, since in the 2005
revision these variables were dropped from the notification forms (Figure 3.15.
The number of cases with missing data in some variables are very high (> 5%); never-
theless, it is not reflected on the key variables for the study. Because the rate of missing
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(a) Nationality (b) Residency (c) Stage Clinician (d) Year Prob. Infec-
tion
(e) CD4 (f) CD8 (g) T4_T8 (h) Death_date
(i) Diagnosis HIV (j) Notification HIV (k) Pregnant (l) First Symptoms
Figure 3.15: Missing values patterns against notification year. The top panel represents the number
of observed cases per notification year in each variable while the lower panel represent
the number of missing observations per notification year.
values is high, the chosen imputation method will exert a high degree of influence over the
results, and differences among competing methods will be magnified. Effects will also be
large because of the unusually strong nature of the missingness mechanism [150]. More-
over, there is a clear multilevel nature of this dataset. The observations are nested within
health providers which in turn are nested in ARS with administrative autonomy.
Due to the high percentage of missing values and the nested nature of the data, we
consider that there is not enough support for uniquely identifying the population each case
is originated from, and so we are unable to perform multiple imputations on the variables
mentioned above.
At last the timeliness of the data; in these settings, it can be defined as the time between
the diagnosis of a case and its proper reporting to the surveillance system. Similarly to all
the surveillance systems, reporting delay is an issue present since the beginning (Figure
3.16). This issue will be addressed in chapters 4 and 5.
For augmenting the information of this data set, the names of the Health Providers were
matched against the official list of Health Care Providers provided by the ACSS. This list
cross-classified each entity with the Health Region Location and type of provided services,
such as, hospital care and primary care services.
A crucial feature of a public health surveillance system is the data representativeness
and thus if the results are generalizable to the population under surveillance, i.e. have high
external validity [162]. When a disease or other outcome of interest is highly prevalent in
the general population, and a large proportion of the population comes into at least periodic
contact with health services, routine reporting by health clinics and other service-providing
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Figure 3.16: Number of AIDS cases per notification year and length of the reporting delay.
institutions suffices as a surveillance mechanism [162].
The entire Portuguese is under HIV - AIDS surveillance but representativeness is un-
clear. The epidemic is small, concentrated in smouldered high-risk subpopulations whose
members are often reluctant to get tested, care or, once diagnosed, often omit important
informations. The mapping of these groups relies on easily identifiable of its elements and
in some cases it is not possible such in cases of IDU’s who have drugs delivered and inject
at home, some MSM, clandestine sex workers and their clients... Testing is mandatory for
military and strongly recommended for pregnant women, all most-at-risk population such
as IDU’s and prisoners and HIV status discordant couples. But the high percentage of late
diagnosis is an indicator that, individuals do not recognize the transmission modes, symp-
toms, fear of the result or stigma and discrimination and so just when the severe symp-
toms emerge the case enters the system. In these settings it is unlikely that the system
is capable of producing representative surveillance data. Moreover, under-reporting is a
well-recognized problem of the system. It is important to notice that the Portuguese system
although classified as comprehensive ’theoretically’ covering the all population, it was also
classified as passive so the public health agency do not stimulate the reporting nor give
feedback about the process.
3.6 Summary
Data cleaning refers to the correction or amelioration of data problems, including missing
values, incorrect or out-of-range values, responses that are logically inconsistent with other
responses in the database, and duplicate observations. Though we dream with perfection,
in reality, ’clean data’ is a relative term. Metadata documents are of crucial importance
and documents explaining which data elements should be cleaned, with the “description
of data validation rules or logical checks for out-of-range values, how missing values and
values that are logically inconsistent can be handled, and discussing how duplicate patient
observations can be identified and managed” are of great importance. [94].
Data pre-processing and knowledge retrieving, is a multidisciplinary discipline involving
topics from statistics, computer science and domain knowledge experts, it is always on data
pre-processing and analysis [16].
This chapter describes methods for identifying the main issues in dataset that influence
the common dimensions of data quality and provides some correction methods. It proposes
two processes: one process for detection of data issues and the another for repairment and
improvement of the information in the dataset.
In the case of the Portuguese HIV - AIDS surveillance system, detected barriers were:
68 Chapter 3. Statistical Data Pre - Processing
illegal values, misspellings, missing data, inconsistencies in disease stage case definition,
ambiguous data, outliers, duplicated records and timeliness issues. Most of these barriers
were solved with the exception of timeliness, which will be discussed on chapter 4 and on
chapter 5.
Chapter 4
Mathematical models for Reporting De-
lay Estimation
Modelling in science remains, partly at least, an art. Some principles do
exist, however, to guide the modeller. A first, though at first sight, not a very
helpful principle, is that all models are wrong; some, though, are more useful
than others and we should seek those. A second principle is not to fall in love
with one model to the exclusion of alternatives. Data will often point with
almost equal emphasis at several possible models and it is important that the
statistician recognise and accept this.
McCullagh and Nelder [17]
One major component for the control of infectious epidemics is the timely identifica-
tion of HIV patients and the definition of adequate public health strategies. The number
of cases is determined by the collection of diagnosed cases within a health care system.
However, typically, a Surveillance System depends on several stakeholders, such as health
care providers, the general population and laboratories, which challenges an efficient and
effective reporting of diagnosed cases [24]. Delays may be intrinsic of the disease natural
history and / or external processes such as time taken to reach a diagnosis or to get the
case reported. One issue of particular interest and that often arises is the administrative
delay regarding the time mediating from the identification of the HIV-AIDS related event
to its national reporting [24]. So, the use of surveillance data requires adjustments of the
under-reported case load caused by the delay in reporting within an observation time frame
[163].
In this chapter we overview the statistical concepts and fundamentals in section 4.1.
This section is divided into two subsections: 4.1.1 where the main statistical and data min-
ing models used for solving the central research questions are presented and discussed,
and 4.1.2 discusses some general considerations on model selection and validation. The
first presents a brief introduction to: the generalized linear models, the multilevel models,
survival analysis, the k-nearest neighbour algorithm, the longitudinal k-means algorithm,
naive-bayesian classifier, the multilayer perceptron and support vector machines are briefly
described. Section 4.2 reviews the literature, describing strengths and limitations of the
main works. Essentially, the traditional approaches can be grouped into two groups: the
joint modelling discussed in section 4.2.1 and the separate or partial modelling discussed
in section 4.2.2. In section 4.2.3 the data structure is described and section 4.2.4 computes
the likelihood for joint models.
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4.1 Concepts and Fundamentals
Although simplifying the reality, statistical models investigate the effect of some explanatory
variables on some response variables, mimicking the data structure. A well - fitted model
has several benefits:
• the structural form of the model describes the patterns of association and interaction;
• estimates of the model parameters determines the strength and importance of the
effects;
• inferences about the parameters evaluate which explanatory variables affect the re-
sponse variable Y, while controlling for possible confounding variables ;
• model’s predicted values may smooth the data by providing improved estimates of
the mean of Y at possible explanatory variables values [164].
Modelling in science remains, partly at least, an art [17]. But some principles do exist.
Some important steps to be followed include:
1. the understanding of the problem.
2. an adequate experimental planning and data collection.
3. a complete exploratory data analysis, if necessary with data cleaning.
4. model fitting through the following stages:
(a) Postulate the model.
(b) Estimate parameters.
(c) Select and validate the model.
(d) Return to 4a if model does not satisfy the criterion defined in 4c.
(e) Use model to investigate the effects of some explanatory variables on response
variable(s).
Understanding the full scope of the problem is essential to the model purpose and goals,
identification of the important variables, and definition of their scale and relationships.
Data is a critical element in any modelling process. The way it is collected may deter-
mine the significant power and conclusions of posterior statistical inferences, thus turning
data cleaning into a crucial initial process. Also, it may highlight data quality issues (for
example, the values plausibility, as discussed in Chapter 3) [165].
Steps 4b to 4e are commonly named Model Fitting and are the kernel of any modelling-
building process. The goal is to develop a functional relationship between random variables
that accurately describes the intrinsic variability structure with low bias. The observed data
are supposed to be a realization of these random variables or, of a measurable function of
these random variables [166].
In step 4a, one must specify a model class and select a model structure, namely the set
of covariates or explanatory variables, the equation linking the response to the explanatory
variables and the reasonable probability distribution of the error structure in the parametric
models.
Parameter estimation varies according to the model at hand but maximum likelihood
and least squares methods are among the most used methods in parametric modelling. If
conditions for parameter estimation are imposed, then validation of those conditions has to
be performed. The model validation is usually the next step, evaluating the ”closeness” be-
tween the predicted and the true values of the response for given values of the explanatory
variables. [165].
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In this section are presented some models ranging from the generalized linear models
to some data mining approaches.
When postulating a model we must take into consideration the distribution of the re-
sponse, the selection of relevant co-variable and the choice of the functional relationship be-
tween the expected value and the linear predictor. The Generalized Linear Models (GLMs)
form a unified approach of regression models that extend the linear regression model to a
large set of non-Gaussian responses and to non-identity relationships between the mean
response and the linear predictor [167, 168, 169]. The postulation of the model will be
focused in section 4.1.1.
Random-effect models, and more generally multilevel models, are essentially an expan-
sion of the generalized linear models to correlated and nested data. The modelling of the
inter-individual variation makes use of the so-called random-effects, which are parameters
with a structure of random variables. They are particularly appropriate for research designs
where data for participants are organized at more than one level [170].
Survival analysis is a sub-field of statistics that analyses and models data where the
outcome is time until the occurrence of an event of interest [171]. This framework presents
many challenges, including the incorporation of information from individuals not experienc-
ing any event during the monitoring period - censored observations. Due to censoring, the
commonly used statistical methods do not apply straightforwardly. Statistical approaches
have been widely developed in the literature to overcome that threat also, many machine
learning algorithms were adapted to effectively address this characteristic [171].
The term “data mining” refers to a collection of techniques that provide the necessary
actions to retrieve and gather knowledge from an exhaustive assemblage of data and facts
[172]. In particular, they can uncover new biomedical and health care knowledge for clinical
and administrative decision-making as well as generate scientific hypotheses from large
experimental data, clinical databases, and / or biomedical literature [173]. Data mining
models can be classified into two categories: descriptive (or unsupervised learning) and
predictive (or supervised learning) [174]. Descriptive data mining consists of a collection of
techniques aiming to discover unknown patterns or relationships in data. This exploratory
analysis includes clustering, association, and sequence discovery [174]. Predictive data
mining infers prediction rules from data. It includes tasks such as classification, regression,
time series analysis, and prediction [173]. Classification is the most frequently used data
mining method with a predominance of the implementation of k-Nearest Neighbour (k-NN)
algorithm, k-means algorithm, Bayesian classifiers, Neural Networks, and SVMs [175].
Having selected the class of the model, it is necessary to choose from the set of all
possible parameters values the ones that make the fitted values closer to the observed
ones. So, a measure of goodness-of-fit must be defined. The optimal parameters will be
those minimizing a certain ”closeness” criterion. One may use information criteria, such
as Akaike Information Criterion (AIC) or Bayesian Information Criterion (BIC), for model
selection among a finite set of models, once the likelihood function is defined for those
models; or evaluate the fitting by efficiently data reuse through cross-validation or bootstrap.
A good model for a specific problem must achieve the equilibrium of three characteristics:
must be adequate, be minimal and easily interpreted [167].
4.1.1 Statistical and Data Mining Models
Generalized Linear Model
Terminology A data set will be represented by a matrix, a two-dimensional array in which
the rows are indexed by experimental or survey units and the columns correspond to the
variables such as measurements.
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The variables regarded as responses or dependent variables are the variables whose
values are believed to be affected by the covariates variables [17].
All variables may be quantitative or qualitative. The first type of variables take on numer-
ical values while qualitative, some times referred to as factors, take non-numerical values
or levels from a finite set of values or labels.
LetY = [Y1, . . . Yn]T be a random variable. The set of covariates, which it is believed to
explain some of the variability of Y, is arranged as an n× p matrix X = [X1, . . . , Xp]; here,
each row of X refers to a different observation, and each column to a different covariate,
which may be deterministic or random variables. Associated with each covariate is a co-
efficient or parameter, usually unknown. Each Xi, i = 1, . . . , p and Y may be continuous,
discrete, polytomous or even binary. When the Xi is qualitative with k categories, they
must be coded into k − 1 dummy variables.
In a linear regression context, the relation between Y and X can be written as
Y = Z + " (4.1)
where Z is a matrix of dimension n × (p+ 1), with first column consisting of 1’s and the
rest given by X,  = [β0, . . . , βp]T of dimension p+ 1 and ε is a vector of random errors of
dimension n× 1. In matrix form, equation 4.1 become:
Y1
Y2
...
Yn
 =

1 x11 x12 . . . x1p
1 x21 x22 . . . x2p
...
...
...
...
1 xn1 xn2 . . . xnp
×

β0
β1
...
βp
+

ϵ1
ϵ2
...
ϵn
 (4.2)
which is equivalent to
Y|X ∼ N (X,Σ) (4.3)
in particular, E(Y|X) = X.
TheGLMs are composed by three parts: a random component, a systematic component
and a link function relating the two components [176]:
• The random component, response distribution or ’error structure’:
Given X = [X1, . . . , Xp], the Yi (i = 1, . . . , n) are (conditionally) independent random
variables with means E (Yi|Xi) = µi and all following the same distribution belonging
to the exponential family (to be defined below) .
• The systematic or structural component :
Consists of a specification of the vectori in terms of unknown parameters β0, β1, . . . , βp.
Most of the times, a linear predictor  = Z is used.
• The link function between the random and systematic component: If a linear
predictor i = Zii is used, the conditional expected value i is related to the linear
predictor by a monotonic differentiable function h such that:
i = h (i) = h (Zii) .
This is the component that describes how the location of the response distribution
changes with the exploratory variables.
The function g = h−1 is called the link function. So
g (i) = i = Zii = β0i + β1iX1i + . . .+ βpiXpi,
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describes the relationship between the mean of the response and the linear predictor.
The choice of this link function depends on the problem and on the distribution of Y .
For clarity, the index i will be omitted whenever the comprehension is not compromised.
Classical regression models assume a normal distribution on the random component
and the identity function such that the linear predictor  is equal to .
GLMs use a special family of distribution functions enjoying nice statistical properties,
the exponential family [176]. A brief overview of this family is described below .
Exponential family distributions
Definition 4 A random sample Y has a distribution function belonging to the exponential
family if its density function can be written in the form
fY (y; θ, ϕ) = exp
{
yθ − b (θ)
a (ϕ) + c (y, ϕ)
}
, (4.4)
for some specific real functions a (.), b (.) and c (., .) and real values ϕ and θ.
The parameters, θ is the canonical form of the location parameter, while ϕ is the disper-
sion parameter which, in general is known [167, 17, 176]. Different specifications for the
functions a (.) and b (.) lead to different distributions. For some distributions (e.g. binomial),
ϕ is equal to 1 thus not requiring any estimation. The cumulative function is b (θ) and b′′ (θ)
is the variance function.
It can be shown ([17]) that the mean and variance of a random variable Y following a
distribution from the exponential family are given by, respectively:
E (Y ) = µ = b′ (θ)
V (Y ) = b′′ (θ) a (ϕ)
The most important distributions of the exponential family are the Binomial distribution,
used when Y takes on dichotomous values; the Poisson for count data, the Normal distri-
bution and the Gamma and Inverse Gaussian distributions when the response consists of
non-negative continuous values.
Link function The simplest link function is the identity link used in the linear regression
model.
Other link functions allow  to be non-linearly related to the linear predictor being the
most popular the ones described in Table 4.1. The choice of the link function should be com-
patible with the distribution of the response and must take into consideration the problem,
the observed data and the interpretation of the results.
The canonical link function connects µ, η and θ such that η ≡ θ, then this link is called
canonical.
Table 4.1: Common canonical link functions [167]
Family Canonical Link Variance Function
Normal η = µ 1
Poisson η = logµ µ
Binomial η = log
(
µ
1−µ
)
µ (1− µ)
Gamma η = µ−1 µ2
Inverse Guassian η = µ−2 µ3
Some characteristics, such as support (range of Y ), parameters, cumulative functions
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and variances functions of these distributions are summarized in Table 4.2.
Table 4.2: Characteristics of some common univariate distributions in the exponential family. Based
in [167].
Normal Binomial Poisson Gamma Inverse Gaussian
Notation N
(
µ, σ2
)
B (m,pi) /m P (µ) G
(
υ, υ
µ
)
IG
(
µ, σ2
)
Support (−∞,∞)
{
0, 1
m
, . . . , 1
}
{0, 1, . . .} (0,∞) (0,∞)
θ µ ln
(
pi
1−pi
)
ln (λ) − 1
µ
− 1
2µ2
a (ϕ) σ2 1
m
1 1
υ
σ2
ϕ σ2 1 1 1
υ
σ2
c (y, ϕ) − 12
(
y2
ϕ
+ ln (2piϕ)
)
ln
(
m
my
)
− ln y! υ ln υ − ln Γ (υ) +
(υ − 1) ln y
− 12
(
ln
(
2piϕy3
)
+ 1
yϕ
)
b (θ) θ
2
2 ln (1 + exp(θ)) exp(θ) − ln (−θ) − (−2θ)
1/2
b′ (θ) =
E (Y |θ) = µ (θ)
θ pi = exp(θ)1+exp(θ) λ = exp (θ) µ = −
1
θ
µ = (−2θ)1/2
b′′ (θ) = V (µ) 1 pi (1− pi) λ µ2 µ3
var (Y ) σ2 pi(1−pi)
m
λ
µ2
υ
µ3σ2
MaximumLikelihoodEstimation Although, in some special cases, explicit mathematical
expressions for the maximum likelihood estimator can be obtained, numerical methods are
usually needed. Typically these methods are a form of iteratively re-weighted least squares
and are based on the Newton-Raphson algorithm [165].
Consider independent and identically distributed random variables Y1, . . . , Yn. In a GLM,
one wishes to estimate the parameters , usually denoted by regression coefficients or pa-
rameters. The standard way of doing so is by maximum likelihood. In a GLM context, the
likelihood function is given by
L(θ, ϕ; y, x) =
n∏
i=1
fY (yi; θi, ϕ) . (4.5)
For maximization purposes, it is better to consider the logarithm of the likelihood function,
thus for independent observation it is considered maximizing
l(θ, ϕ; y, x) = logL(θ, ϕ; y, x) =
n∑
i=1
yiθi − b (θi)
a (ϕ) + c (yi;ϕ) . (4.6)
Since µ = b′ (θ), g (µ) = η and η = β0 + β1X1 + . . . + βpXp, the likelihood in (4.5) can
be represented by L(; y, x) and the log-likelihood (4.6) by l(; y, x).
Inference The two main tools of statistical inference are confidence intervals and hypoth-
esis tests [165]. Confidence intervals are increasingly regarded as more useful than hypoth-
esis tests because their width provides a measure of the precision with which inferences
can be made [165].
The hypothesis tests are performed by comparing nested models where the parameters
of the model with the fewest parameters (M0) is a subset of the parameters of the other
model (M1). In the case of generalized linear models, these two models must have the
same response distribution and the same link function [165].
The two common approaches for model comparison are the log-likelihood ratio test and
the Wald test (usually applied to test for the significance of a regression parameter).
In general, let M1 denote the p parameters of the modelM1 and βˆM1 be the maximum
likelihood estimator of M1 . In the same way, let M0 denote the r (with p > r > 0) pa-
rameters of the model M0 and βˆM0 be the maximum likelihood estimator of M0 Let the
log-likelihood function for the M1 model evaluated at βˆM1 be l(βˆM1 ; y, x) and l(βˆM0 ; y, x)
denote the maximum value of the log-likelihood function for the model M0. Then the log
likelihood-ratio statistics is
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G = −2 log
(
L(βˆM0 ; y, x)
L(βˆM1 ; y, x)
)
= −2
(
l(βˆM0 ; y, x)− l(βˆM1 ; y, x)
)
. (4.7)
Large values of G suggest that the model M0 is a poor descriptor of the data relative
to M1. The critical region of G is determined throughout its sampling distribution. Large
sample theory states that the asymptotic distribution of likelihood ratio statics under the
usual regularity conditions and under H0 is χ2p−r:
G
a∼ χ2(p−r). (4.8)
The Wald test is a quadratic approximation of G. It is a simple test that uses the sam-
pling distribution of the parameter maximum likelihood estimate. If the response variable is
Normally distributed, the sampling distribution used for inference can often be determined
exactly. For other distributions the large-sample asymptotic results based on the Central
Limit Theorem can be used. Under the null hypothesis
H0 : β = 0 (4.9)
H1 : β ̸= 0
W =
 βˆ
sˆe
(
βˆ
)
2 a∼ χ2(1) (4.10)
or, equivalently
W = βˆ
sˆe
(
βˆ
) a∼ N (0, 1) . (4.11)
Again, high values of W suggest that the variable associated to the the parameter β is
significant.
The goodness-of-fit test is a model comparison test whereM0 is identified as the model
of interest and the M1 is the full or saturated model were the data is explained exactly,
typically needing n parameters for n data points [168]. Also, the full model gives a measure
of how well any model could possibly fit and so we might consider the difference between
the log-likelihood for the full model, l
(
θ˜, ϕ; y, x
)
and that for the model under consideration,
l
(
θˆ, ϕ; y, x
)
,expressed as a likelihood ratio statistic:
2
(
l
(
θ˜, ϕ; y, x
)
− l
(
θˆ, ϕ; y, x
))
. (4.12)
Provided that the observations are independent and for an exponential family distribution,
when ai (ϕ) = ϕwi with wi this a known weight simplifies to:
∑
i
2wi
(
yi
(
θ˜i − θˆi
)
− b
(
θ˜i
)
+ b
(
θˆi
))
ϕ
(4.13)
which can simply bewritten as d
(
θˆ; y
)
/ϕwhere d
(
θˆ; y
)
is called the deviance and d
(
θˆ; y
)
/ϕ
is called the scaled deviance.
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Model Checking As with standard linear models, it is important to check the adequacy
of the assumptions supporting GLMs. The diagnostic methods for GLMs mirror those used
for the Gaussian linear models but some adaptations are necessary and, depending on the
type of the response, not all diagnostic methods will be applicable [168].
The choice of the response distribution is done by scientific insight about the data or
by comparing the model fit for a variety of different distributions selected based on prior
assumptions [177].
The diagnostic methods can be divided into two groups: methods to detect single cases
or small groups of cases that do not fit the pattern of the rest of the data and methods to
check the assumptions of the model. The latter, which is the focus here, can be divided into
those that check the structural form of the model, such as the choice and transformation of
the predictors, and those that check the random component of the model[168].
The following is based on the book of Faraway on GLMs. He suggests that the diagnos-
tic methods should be performed as follows ([168]) :
• checks of the random component of the model: plot of Pearson residuals versus fitted
values and versus the linear predictor ηˆ. Where Pearson residuals are defined as:
rP =
y − µˆ√
V (µˆ)
(4.14)
where V (µ) = b′′ (θ).
– Check for the presence of nonlinear relationships between the predicted values
and the residuals. If so, this would indicate a lack of fit and that a change in the
model is needed. It is recommended to make changes only on the predictors
since that involves the least disruption to the GLMs.
– Check the variance of the residuals with respect to the fitted values. The GLMs
assumptions require constant variance in that plot and a violation of such condi-
tion implies a change in the model. For all GLMs but Gaussian, the variance func-
tion is non-constant; however, if the deviance residuals are used, the variation
is scaled out and a constant variance is expected in such a plot. The deviance
residuals can be defined as:
rD = sign (y − µˆ)
√
di (4.15)
where di is the individual deviance contribution.
Note that, in some cases, plots of the residuals may not be particularly helpful. In the
case of discrete responses, such as binomial responses with small group sizes and
Poisson responses with small values, the residuals can only take few distinct values.
Moreover, the plots tend to show curved lines consisting of points corresponding to
the limited number of observed values. Such artefacts can obscure the main purpose
of the plot. More difficulties arise if the covariates are measured in a very different
scales.
• checks for the structural component of the model - plots of the response versus each
covariate. These plots allow the investigation of the nature of the relationship between
the predictors and the response. The interpretationmust be done carefully since these
simple representations do not take into account the effect of other predictors.
• check the nature of the relationship between the predictors and the response plotting
the response against the predictors.
• In any scientific context, predicted and observed values should also be confronted
[169].
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Multilevel Models
Many common statistical models can be expressed as linear models that incorporate both
fixed effects, which are parameters associated with an entire population or with certain
repeatable levels of experimental factors, and random effects, which are associated with
individual experimental units drawn at random from a population [178]. A model with both
fixed effects and random effects is called a mixed-effects model, hierarchical model or even
a multilevel model.
The primary goal of the multilevel model is to describe relationships between a response
variable and some covariates in data that are grouped according to one or more classifica-
tion factors [178].
Definition 5 A fixed effect is an unknown constant that we try to estimate from the data. A
random effect is a random variable hence it requires the estimation of the parameters of its
distribution.
As extensions of GLMs, the linear predictor in multilevel models is linear in the fixed and
random-effects.
In this section we follow Pinheiro and Bates formulation of multilevel models described
in [178] and [179].
Lets consider a single level of random-effects. The linear mixed-effects model with
response Yi ∈ Rni for the ith group is:
Yi = Xi + Zibi + i, i = 1, . . . ,M, (4.16)
bi ∼ N (0,Σθ) , i ∼ N
(
0, σ2I
)
,
where  is the p - dimensional vector of fixed effects, bi is the q-dimensional vector of
random effects,Xi (of size ni× p) and Zi (of size ni× q, q < p) are known fixed-effects and
random-effects regressor matrices, and i is the ni-dimensional within-group error vector
with a Gaussian distribution. The random effects bi and the within-group errors i are
assumed to be independent for different groups and to be independent of each other for
the same group [178].
The distribution of the random effects vectors bi is completely characterized by its
variance–covariancematrixΣθ whichmust be symmetric and positive - definite. The variance-
covariance matrix can be written in a more convenient form in terms of a relative covariance
factor, ∆θ, which is a q × q matrix, depending on a variance-component parameter, θ such
as:
Σθ = σ2∆θ∆Tθ . (4.17)
If Σθ is positive-definite then ∆θ exists although it is not unique. Given this decomposi-
tion, b can be written in terms of a spherical random variable U ∼ N (0, σ2Iq) such as
b = ∆θU. (4.18)
For this model, the penalized residual sum of squares is the sum of the residual sum
of squares, measuring fidelity of the model to the data, and a penalty on the size of U,
measuring the complexity of the model [179]:
r2 (θ,,U) =∥ y−X − Z∆θU ∥2 + ∥ U ∥2 (4.19)
For minimizing r2 with respect to U, that is
r2,θ = minU
{
∥ y−X − Z∆θU ∥2 + ∥ U ∥2
}
(4.20)
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it is necessary to determine the sparse Cholesky factor, Lθ, which is a lower triangular
q × q matrix satisfying
LθLTθ = ∆Tθ ZTZ∆θ + Iq (4.21)
where Iq is the q × q identity matrix.
The estimate of  is given by the minimum of the function
r2θ = minu,β
{
∥ y−X − Z∆θU ∥2 + ∥ U ∥2
}
(4.22)
and is called the conditional estimate of  given θ and represented as ˆθ.
The deviance of the model, given the data, y, is [179]
d (θ,, σ;y) = n log
(
2piσ2
)
+ log
(
|Lθ|2
)
+
r2β,θ
σ2
(4.23)
where |Lθ| denotes the determinant of Lθ .
Minimizing r2 in terms of  and u gives the so called conditional mode of the spherical
random effects and the conditional estimate, βˆθ, of the fixed effects. At the conditional
estimate of the fixed effects ˆθ the deviance, can be written as
d (θ,, σ;y) = n log
(
2piσ2
)
+ log
(
|Lθ|2
)
+ r
2
θ
σ2
(4.24)
whose minimum with respect to σ2 is the conditional estimate
σˆ2θ =
r2θ
n
(4.25)
which provides the profile deviance:
d˜ (θ;y) = d˜
(
θ, ˆθ, σˆθ;y
)
= log
(
|Lθ|2
)
+ n
[
1 + log
(
2pir2θ
n
)]
, (4.26)
a function of just θ.
The maximum likelihood estimate of θ is the value that minimizes the profiled deviance
in equation (4.26) [179]. The minimum of this deviance is obtained throughout numerical
optimization, such as the EM algorithm or Newton - Raphson algorithms.
The elements of the conditional mode of b, also called the best linear unbiased predic-
tors of the random effects, evaluated at the parameter estimates are
b˜θˆ = ∆θˆu˜θˆ. (4.27)
The restricted or residual maximum likelihood estimates (REML) of the variance compo-
nents are often preferred over the maximum likelihood estimates since they have a lower
bias than the latter. [179]. This approach is a particular form of maximum likelihood es-
timation that uses a likelihood function calculated from a transformed set of data so that
nuisance parameters have no effect [180].
Using REML, the deviance can be can be expressed as
dR (θ, σ;y) = −2 log
∫
Rp
L (θ, β, σ;y) dβ. (4.28)
In this setting the penalized residual sum of squares is
r2θ,β = r2θ+ ∥ RX
(
β − βˆθ
)
∥2 . (4.29)
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where RX is an upper triangular p× p matrix satisfying
LθRZX = P∆Tθ ZX (4.30)
and
RTXRX = XTX−RTZXRZX (4.31)
with P representing a q × q permutation matrix consisting of permuted columns of the
identity matrix, Iq. This matrix aids the reduction of the number of non-zeros in the factor,
Lq .
So, the deviance can be re-written as
dR (θ, σ;y) = (n− p) log
(
2piσ2
)
+ 2 log (| Lθ || RX |) + r
2
θ
σ2
. (4.32)
and the profile deviance is
d˜R (θ;y) = 2 log (| Lθ || RX |) + (n− p)
[
1 + log
(
2pir2θ
n− p
)]
. (4.33)
The REML estimates are
θˆR = argminθd˜R (θ;Y) (4.34)
and
σˆ2R =
r2
θˆR
n− p. (4.35)
The estimate of  is commonly taken to be βˆR = βˆR (θ).
The models are compared according to the change in the deviance, which is the like-
lihood ratio test statistic [179]. Bates et all applied a signed square root transformation to
this statistic and plotted the resulting function, called the profile zeta plot and represented
by ζ , versus the parameter value [179]. A ζ value can be compared to the quantiles of the
standard normal distribution, ζ ∼ N(0, 1) and when the plot exhibits linearity for a given pa-
rameter it implies that the likelihood profile is quadratic and thus that Wald approximations
would be reasonably accurate [179].
The single-level multilevel model can be extended to accommodate multiple, nested
levels of random effects in a similar way.
Survival Analysis
Terminology An important type of data is the time from a well-defined starting point until
some event occurs . Data on times until the event, or more commonly, ’duration of survival’
or ’survival times’, have two important features:
• the times are non-negative and typically have skewed distributions with long tails;
• some of the subjects may survive beyond the study periods so that their actual survival
times may not be known; in this case, and other cases where the failure times are not
known completely, the data are said to be censored [165].
Random censoring can be broadly categorized into three groups based on when the
record of time stops:
• right-censoring, occurs when a subject leaves the study before an event occurs, or
the study ends before the event has occurred. So, the observed survival time is less
than or equal to the true survival time;
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Figure 4.1: Diagram of types of censoring for survival times [171].
• left-censoring, occurs when the event of interest has already occurred before enrol-
ment. For which the observed survival time is greater than or equal to the true survival
time;
• interval censoring, the combination of the previous two, for which we only know that
the event occurs during a given time interval [171].
It should be noted that the true event occurrence time is unknown in all the three cases.
Other important mechanism of missing information is truncation which is deliberate and
due to systematic selection process inherent to the study design. Similar to censoring, it
can be right, left or interval.
Note that censoring is a problem different from truncation, because with censored data
the researcher has at least some partial information on the censored lifetimes. Right trunca-
tion happens when the selection process of the study stops at some point. For example, if
a study deals with people who got infected within a specific time period, there is a lack of ob-
servation for infections past this specific time period. This lack of observation is considered
to be right-truncated.
In Figure 4.1, an illustrative example is given for a better understanding of the definition
of censoring and the structure of survival data. Five instances were observed in this study
that occurred between TO and TC which are the beginning and end of the study period,
respectively. E denotes ’event’ and A denotes ’alive at the end of the study’; L indicates
that the subject was known to be alive at the time shown but then became lost to the study
and so the subsequent life course is unknown [165].
For subjects 1 and 2, the entire survival period occurred within the study period. For
subject 3, 4 and 5 the survival times were censored and so, are partially observed. More
specifically, subject 3 is censored since there was no event occurred during the study period,
4 is censored due to the withdraw or being lost to follow-up within the study time period and
5 since the survival time started before the initial of observation study.
The censoring problem can be stated as:
For a given instance i, represented by a triplet (Xi, yi, δi), where Xi ∈ R1×P is a covari-
ate (feature) vector; δi is the binary event indicator, i.e., δi = 1 for an uncensored instance
and δi = 0 for a censored instance; and yi denotes the observed time and is equal to the
survival time Ti for an uncensored instance and Ci for a censored instance i.e.,
yi =
{
Ti if δi = 1
Ci if δi = 0.
(4.36)
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Figure 4.2: Relationship among different entities f(t), F (t) and S(t) [171].
It should be noted that Ti is a partly observed survival time.
The goal of survival analysis is to estimate the time to event of interest Tj for a new
instance j with covariates denoted by Xj .
The Survival and Hazard Functions - S (t) and λ (t) Let the random variable T denote
the survival time and let f(t) denote its probability density functions (also denoted through-
out by death function). Then the probability of an individual surviving until at least time t
is
S (t) = Pr (T ≥ t) (4.37)
where t is a time of interest. This function S is denoted by survival function.
The survival function monotonically decreases with t, and at t = 0 is equal to 1, repre-
senting the fact that, at the beginning of the study period, 100% of the subjects ’survive’; or
in other words, none of the events of interest has occurred [171].
On the contrary, the cumulative death distribution function, or proportion of death,
F (t) = Pr (T ≤ t) =
∫ t
0
f (x) dx = 1− S (t) (4.38)
represents the probability of event occurring earlier that t. The death density function f (t)
can be obtained by f (t) = ddtF (t) in the continuous case and by f (t) =
F (t+△t)−F (t)
△t , where
△t represents a small variation in time interval, in the discrete case. Figure 4.2 represents
the relationship between these functions.
The hazard function λ (t), also called the force of mortality, the instantaneous death
rate or the conditional failure rate is defined as instantaneous rate of occurrence of the
event at time t given that no event has occurred before time t [171]. Mathematically, the
hazard function is defined as:
h (t) = lim
∆t→0
Pr (t ≤ T ≤ t+∆t | T ≥ t)
∆t =
f (t)
S (t) (4.39)
which can also be written as
h (t) = f (t)
S (t) = −
d
dt
[lnS (t)] . (4.40)
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So, the survival function (4.37) can be written as
S (t) = exp (−H (t)) (4.41)
where H (t) =
∫ t
0
h (u) du denotes the cumulative hazard function.
The ’average’ survival time is usually estimated by the median of the distribution. This
is preferable to the expected value because of the skewness of the distribution and is given
by solving the equation F (t) = 1/2.
The analysis of survival time data is largely studied. Statistical methods for estimation
of the survival / hazard functions can be of three different types: non-parameteric, semi-
parametric and parametric.
In this section, only parametric models and a continuous scale for survival time data will
be considered; that is, models that require a specification of a probability distribution for the
survival times. In particular, this means that one of the best known forms of survival analy-
sis, the Cox proportional hazards model, is not considered because it is a semi-parametric
model in which dependence on the explanatory variables is modelled explicitly but no spe-
cific probability distribution is assumed for the survival [165]. An advantage of parametric
models, compared to the Cox proportional hazards model, is that it is easy to interpret,
more efficient, accurate and there is a wider range of models with which to describe the
data, including accelerated failure time models [171, 165].
Parametric Models Parametric models assume that the survival times or their logarithm
of all instances in the data follow a particular theoretical distribution [171]. They can be
rewritten specifying a direct relation between the survival time or its logarithm and the ex-
planatory variables, just as a multiple linear regression model does. They are simple, effi-
cient and effective in predicting the time to the event.
The commonly used distributions in parametric censored regression models are: nor-
mal, exponential, Weibull, logistic, log-logistic and log-normal. If the logarithm of the survival
times of all instances follow these distributions, the problem can be analysed using the Ac-
celerated Failure Time Models (AFT), these models assume that the variable can affect the
time to the event of interest of an instance by some constant factor. It should be noted that
if no suitable theoretical distribution is known, non-parametric methods are more efficient.
[171]
The model parameters can be estimated by maximum likelihood. The likelihood func-
tion contains two components, one involving the uncensored survival times and the other
making as much use as possible of information about the survival times which are censored
[165].
Estimation Let N be the total number of instances such that c are censored and N − c
are uncensored observations, and  = (β1, β2, . . . , βP )T be the set of model parameters.
For the jth subject, the observed data are: tj the survival time; δj the event indicator;
and xj a vector of explanatory variables. Let t1, . . . , tc denote the censored observations
and tc+1, . . . , tN denote the uncensored ones. The contribution of the censored variables
to the likelihood function is
N∏
j=c+1
f (tj , β) . (4.42)
For a censored observation, it is known that the survival time T is at least tj (1 ≤ j ≤ c)
and the probability of this is Pr (T ≥ tj) = S (tj), so the contribution of the censored obser-
vations to the likelihood function is
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c∏
j=1
S (tj ,) . (4.43)
The full likelihood is
N∏
j=1
f (tj ,)δj S (tj ,)1−δj . (4.44)
so, the log-likelihood function is
N∑
j=1
[δj log f (tj , β) + (1− δj)S (tj , β)]
=
N∑
j=1
[δj log h (tj , β) + S (tj , β)] . (4.45)
Note that these functions depend on the parameters of the probability distributions and
on the parameters from the linear component X. For several of the more commonly
used probability distributions the requirements for generalized linear models are not fully
met. Nevertheless, estimation based on the Newton-Raphson method for maximizing the
likelihood provide good estimates [165].
The death density function f(t), its corresponding survival function S(t) and hazard
function h(t) for the most commonly use distributions are presented in Table 4.3.
Table 4.3: Density, Survival and Hazard functions for the distributions commonly used in the para-
metric methods in survival analysis
Distribution PDF f(t) Survival S(t) Hazard h(t)
Exponential λ exp(−λt) exp(−λt) λ
Weibull λktk−1 exp(−λtk) exp(−λtk) λktk−1
Normal 1√
2piσ
exp
(
− (t−µ)
2
2σ2
)
1− Φ
(
t−µ
σ
)
1
√
2piσ
(
1−Φ
(
t− µ
σ
)) exp(− (t−µ)2
2σ2
)
Log-Normal 1√
2piσt
exp
(
− (log(t)−µ)
2
2σ2
)
1− Φ
(
log(t)−µ
σ
)
1
√
2piσt
(
1−Φ
(
log(t)− µ
σ
)) exp(− (log(t)−µ)2
2σ2
)
Exponential Distribution: Among the parametric models in survival analysis, the ex-
ponential model is characterized by only one parameter which is a constant hazard rate,
λ. The occurrence of the event is assumed to be a random event independent of time. A
larger value of λ indicates a higher risk and a shorter survival time period [171].
Weibull Distribution: The most common distribution in survival analysis is the Weibull
distribution. It is characterized by two parameters, the scaling and the shape, λ > 0 and k >
0 respectively. The shape of the hazard function is determined using the shape parameter
k, which provides more flexibility compared to the exponential model. If k < 1, the hazard
function will be decreasing over time [171]. Similarly to the exponential model, a larger
value of λ indicates a shorter survival time [171].
Normal and Log-normal Distribution: The normal distribution is characterize by two
parameters, the mean µ and variance σ2. [171].
Accelerated Failure Time Model The AFT models establishes a direct relationship be-
tween the predictors and the survival time, making its interpretation easier and are very
similar to the conventional linear regression models [177]. In general, the AFT model can
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be expressed as:
ln (T ) = Xβ + σϵ (4.46)
where X is the covariate matrix, β represents the coefficients vector, σ (σ > 0) is the
unknown scale parameter, and ϵ is an error term which follows a similar distribution to
ln (T ).
Since the relationship between the logarithm of the survival time T and the covariates
is linear in nature, it can be considered as a generalized linear model [171].
Typically, the parametric assumptions on ϵ can follow any of the distributions given in
Table 4.3. In this case, the survival is dependent on both the covariates and the underlying
distribution. Then, the only distinction of an AFT model compared to regular linear methods
would be the inclusion of censored information in the survival analysis problem.
Model checking The model checking can be performed as in the case of the generalized
linear models [165].
K - Nearest Neighbour
The K-nearest neighbour algorithm is one of the most popular classification algorithm meth-
ods and it can also be used for regression although this is not focused on this section. The
algorithm performs a space partition in a pre-user-defined number of clusters (K) and by
comparing a given test sample with a training sample. Each object is assigned to the class
corresponding to the majority vote from its K nearest neighbours.
Suppose that the state space is
(
Rd, ∥ · ∥
)
where ∥ · ∥ is a reference distance. A com-
mon choice for ∥ · ∥ is the Euclidean distance but others can be used with similar properties.
Lets consider a fixX ∈ Rd. Given an i.i.d sample Sn = {(X1, Y1) , (X2, Y2) , . . . , (Xn, Yn)}
in Rd × {0, 1}, where Yi is the class label of Xi. Given a new incoming observation X, the
goal is to predict its corresponding label Y .
The algorithm starts by re-ordering the Sn with respect to the distances ∥ Xi−X ∥, such
that
∥ X(1) −X ∥≤ · · · ≤∥ X(n) −X ∥. (4.47)
So, X(m) is the m-nearest neighbour of X and Y(m) is the corresponding label [181].
Given any integer k in N, the principle of the nearest neighbour algorithm is to construct
a decision rule based on the k-nearest neighbour of the X: the Sn - measurable classifier
Φn,k of the observation X is
Φn,k =

1 if 1
k
k∑
j=1
Y(j) >
1
2
0 otherwise
(4.48)
So, the decision is based upon a majority vote [181].
Longitudinal k-means algorithm
Consider a longitudinal study, collecting observations at multiple different times for each
individual, thus defining individual trajectories. The longitudinal k-means algorithm is used
to determine sets of homogeneous groups of trajectories.
Formally, let S be a set of the n subjects in the sample. For each subject i, denote by Yik
the outcome of subject i measured at time k. The vector Yi = (Yi1, Yi2, . . . , Yit) is denoted
trajectory.
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K-means is an algorithm belonging to the Expectation Maximization (EM) class. It starts
by randomly select k individuals from the data set and uses these as the initial means. Then
it progresses by assigning each observation to the cluster where its distance to the center
is minimal. The center of each cluster is then updated, from the mean of all observations
within the cluster, and the process is iterated until some convergence criterion is attained.
[182].
For measuring the ’closeness’ the Euclidean distance is typically use which, in this con-
text is defined as, for i, j = 1, . . . , n,
D(Yi, Yj) =
√√√√1
t
t∑
k=1
(Yik − Yjk)2 (4.49)
The Calinski and Harabasz criterion C (g) can be used to determine the optimal number
of clusters [182]. This criterion evaluates the clustering quality by combining the clusters
between- and within variance. Let nm be the number of trajectories in the cluster m; g
the total number of clusters; Y¯m the mean of the trajectory of the cluster m; Y¯ the mean
trajectory of the whole set S. The between-variance matrix is
B =
g∑
m=1
nm
(
Y¯m − Y¯
)T (
Y¯m − Y¯
)
. (4.50)
The within-variance is
W =
g∑
m=1
nm∑
k=1
(
Ymk − Y¯m
)T
(Ymk − Ym) (4.51)
For the optimal partition to have compact and well separated clusters it is desired a
high value of between-variance and a low of within-variance. The Calinski and Harabasz
criterion combines these two variability measurements in a ratio:
C (g) = Trace(B)
Trace(W ) ×
n− g
g − l (4.52)
This is a heuristic measurement and so the proper way to use it is to compare clustering
solutions obtained on the same data. This solutions may differ by the number of clusters or
by the clustering method used.
Some clustering quality criteria commonly used are: some variation of the Calinski and
Harabasz , Ray and Turi, Davies and Bouldin, BIC, BIC with correction for finite sample
size, AIC and AIC with correction for finite sample size [182].
Naive Bayesian Classifier
A naive (or simple) Bayesian (NB) classifier is a probabilistic classifier which assumes that
all features contribute equally and independently to the final decision [173]. It is a computa-
tional simple algorithm that can handle a data set with many attributes and thus widely-used
in medical data mining. It combines a probability model with a decision rule.
The Naive Bayes conditional probability model assigns to each category of outcome
variable Y ( Y ∈ {C1, . . . , CJ}) and n independent features X = (X1, . . . , Xn) (Xi and Xj
are independent for i ̸= j and i, j ∈ {1, . . . , n}), it assigns to each instance the probabilities:
Pr (Y = Ck|X1, . . . , Xn) (4.53)
for each of k ∈ {1, . . . , J} possible outcomes or classes Ck [183].
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If n is large or if any of theXi takesmany values, then basing such amodel on probability
tables is infeasible. Using Bayes’ theorem, the conditional probability can be decomposed
as
Pr(Y = Ck | X) = Pr(Y = Ck) Pr(X | Y = Ck)
Pr(X) =
prior× likelihood
evidence = posterior. (4.54)
Assuming that each feature Xi is conditionally independent of every other feature Xj
for j ̸= i, given the category Ck the joint model (4.54) can be written as:
Pr(Y = Ck | X1, . . . , Xn) _ Pr(Y = Ck) Pr(X | Y = Ck) (4.55)
= Pr(Y = Ck, X1, . . . , Xn)
= Pr(Y = Ck) Pr(X1 | Y = Ck) Pr(X2 | Y = Ck)
Pr(X3 | Y = Ck) · · ·
= Pr(Y = Ck)
n∏
i=1
Pr(Xi | Y = Ck) .
One common decision rule is the maximum a posteriori or MAP decision rule which
assign the observation to the class with the higher probability. The corresponding Bayes
classifier is, therefore, the function that assigns a class label yˆ = Ck for some k with the
following the rule:
yˆ = argmax
k∈{1,...,K}
Pr(Ck)
n∏
i=1
Pr(xi | Ck). (4.56)
The class prior, Pr{Y = Ck} , can be estimated by assuming equiprobable classes, or
by calculating an estimate for the class distribution in a training set.
The individual class-conditional marginal densities, Pr{Xi | Y = Ck}, can be esti-
mated separately [18]. It can be estimated by assuming a distribution or by generating
non-parametric models from the training set [184] .
If a component Xj is continuous, a common assumption is the Gaussian distribution,
otherwise, an appropriate histogram estimate can be used. In the latter cases, multinomial
and Bernoulli distributions are popular choices for the estimation proceeder.
Despite these rather optimistic assumptions, Naive Bayes classifiers often outperform
far more sophisticated alternatives. Although the individual class density estimates may
be biased, this bias might not hurt the posterior probabilities as much, especially near the
decision regions [18].
In the context of survival analysis, the Naive classifier provide the probability of the
event of interests as their outputs. The experimental results of using Bayesian methods
on survival data show that Bayesian methods have good properties of both interpretabil-
ity and uncertainty reasoning [171]. It has been used in several settings such as to make
predictions in clinical medicine by estimating various probabilities from the data and inte-
grating Bayesian methods with an AFT model by extrapolating the prior event probability to
implement early stage prediction on survival data for the future time points [171].
It uses the Bayes theorem, which provides a link between the posterior probability and
the prior probability, so that one can see the changes in probability values before and after
accounting for a certain event [171].
One drawback of Naive Bayes method is that it makes the independence assumption
between all the features, which can not be verified in some survival analysis problems [171].
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Multilayer Perceptron Networks
Artificial Neural Networks were inspired by the biological neural systems. The ’simplest’ ar-
tificial neural networks is composed by a collection of computational units denoted by ’neu-
rons’ that are connected based on weighted links, called edges, forming a network. Each
neuron generates an output based on a certain kind of activation function and transmits
throughout the link to another neuron.
Artificial Neural Networks can be used to define probabilistic models for regression and
classification tasks by using network output to define the conditional distribution for one or
more targets, Y = Ck, given the various possible values of a feature vector, X [185].
These algorithms are a popular alternative to conventional statistical models [186]. In
particular feed - forward single hidden layer networks, with back - propagation training algo-
rithms, are the most widely used and described here. They are effective in the analysis of
complex data with non - linear trends and time - dependent covariates, and even high-order
interactions [187].
A neural network is a two-stage regression or classification model, typically represented
by a network diagram as the one in Figure 4.3 [18]. This diagram represents a network with
p input (also named features or covariates) variables, M neurons in the hidden layer and
K in the output layer.
Figure 4.3: An example of the architecture of a feed - forward network having two layers of adaptive
weighs.
For regression, usually K = 1 and there is only one output Y1, but these networks can
also handle multiple quantitative outputs. For a classification problem withK classes, there
are K units, and the output of the k neuron of the last layer is the probability of the class k.
There are K target measurements Yk, k = 1, . . . ,K, each being coded as 0 or 1 for the kth
class [18].
The features Zm are created from linear combinations of the inputs Xp, and then the
target Yk is modelled as a function of linear combinations of the Zm:
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Zm = hm
(
α0m + αTmX
)
, m = 1, . . . ,M,
Yˆk = gk
(
β0k + βTk Z
)
, k = 1, . . . ,K,
Yˆk = fk (X) = gk ◦ h (X) (4.57)
whereZ = (Z1, Z2, . . . , ZM ),Z = (Z1, . . . , ZK), αm = (α1m, . . . , αpm), βk = (β1k, . . . βMk)
and the terms α0m and β0k are the bias capturing the intercept. The terms αij with i =
0, . . . , p and j = 1, . . . ,M and βlu with l = 0, . . . ,M and u = 1, . . . ,K are called weights.
The activation function h (U) is usually chosen to be sigmoid: h (u) = 11 + e−u , although
other functions may be used.
In regression problems, the output function g (U) is usually the identity function and for
classification problems with K classes the softmax function [18]:
g (Tk) =
exp(Tk)
K∑
l=1
exp (Tl)
. (4.58)
As any model, before finding the best set of parameters, it is necessary to define a
measure of ’closeness’ or ’fit’ between the observed values and the estimate provided by
the model.
So, considering the complete set of weights defined as
θ = {αim, βjk; i = 0, . . . , p,m = 1, . . . ,M and j = 0, . . . ,M, k = 1, . . . ,K} (4.59)
The measurement of ’fit’ depends on the task. If the task is regression, the commonly
used measure is the sum-of-squared (error function):
R (θ) =
K∑
k=1
N∑
i=1
(yik − yˆik)2 (4.60)
where yik; i = 1, . . . , N ; k = 1, . . . ,K is the target or observed data.
If the task is classification it is either used the squared error or cross-entropy (deviance):
R (θ) = −
K∑
k=1
N∑
i=1
(yik log (yˆik))2 (4.61)
where yik; i = 1, . . . , N ; k = 1, . . . ,K is the target or observed data and the classification
rule is G (x) = argmaxkfk (x), with G (x) representing the class of observation x.
If the neuronal network used the softmax activation function and the cross-entropy error
function, the model is exactly a linear logistic regression model in the hidden units, and all
the parameters are estimated by maximum likelihood [18].
For networks having differentiable activation functions h and g, there exists a powerful
and computationally efficient method, called error back-propagation for estimating the un-
known weights. This approach minimize R (θ) by using gradient decent. Because of the
compositional form of the model, the gradient can be easily derived using the chain rule for
differentiation and by keeping track of quantities local to each unit in each a forward and
backward sweep over the network [18].
Let zmi = hm
(
α0m + αTmXi
)
and Zi = (z1i, z2i, . . . , zMi), for the sum - of - squared
(MSE) error function the algorithm is preformed as:
The learning rate γr is usually taken to be a constant, and can also be optimized by a
line search that minimizes the error function at each update [18].
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Algorithm 4.2 Back - Propagation algorithm
Require: Input: A dataset X with dimension
n× p and a vector Y with dimension K.
Output: θˆ
Initialize network weights θ with random
values (often near zero);
Set Epochs r= 0;
Initialize weights θ = αβ with random val-
ues;
Set a minimal value for R (θ): R (θ)mm;
Set temporary value for R (θ) that must be
greater than R (θ)mm;
Set a maximum value for iterations - rmax;
Set iteration counter as r = 1;
while R (θ) > R (θ)mm and r < rmax do;
for each Observation Xi = [x1, . . . , xp]
and target Yi = [y1, . . . , yk] do ;
Feed - Forward
for all Neurons in the network do
Calculate zmi as in Equation (4.57);
Calculate yˆik as in Equation (4.57);
end for
Calculate R (θ)i =
∑K
k=1 (yik − yˆik);
Back - Propagate:
for all Neurons in the network do
Calculate derivatives;
∂Ri
∂βkm
= −2 (yik − fk (Xi)) g′k
(
βTk Zi
)
Zmi;
∂Ri
∂αml
= −2
K∑
k=1
2 (yik − fk (Xi))×
g
′
k
(
βTk Zi
)
βkmh
′
(
αTmXi
)
Xil;
Update Weights;
β
(r+1)
km = β
(r)
km − γr
N∑
i=1
∂Ri
∂β
(r)
km
;
α
(r+1)
ml = α
(r)
ml − γr
N∑
i=1
∂Ri
∂α
(r)
ml
; Where γr
is the learning rate;
end for
end for
Set r = r + 1
Calculate R (θ)i =
∑K
k=1Ri
end whilereturn θ
The contribution of each variables in feed forward neural network can be assessed for
determining the relative importance of independent variables to the final outcome. The
connection weight method is one of the most used for this task. For each input node i, it
calculates the sum of product of raw weights of the link from input node to hidden nodes
(WI−>H ) with the connection from hidden node to output nodes (WH−>O) for all input nodes:
RI =
h∑
H=1
WI−>HWH−>O (4.62)
The larger the sum for a given input node, the more the importance of the corresponding
input variable [188].
Artificial neural network has been widely used in survival analysis with mainly three
proposes:
• for predicting the survival time of a subject directly from the given inputs;
• for extending the Cox proportional hazard model;
• for obtaining a more flexible non-linear model by considering the censored information
in the data using a generalization of both continuous and discrete time models [171].
Support Vector Machines Learning
SVM are the most popular and efficient classification and regression methods currently
available. These algorithms apply simple linear methods in a high-dimensional feature
space that is non-linearly related to the input space. Usually, all attributes are employed
and non-overlapping partitions are generated.
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Consider that our data is composed by N pairs (X1, Y1) , ((X2, Y2) , . . . , (XN , YN ), with
Xi ∈ Rp and Yi ∈ {−1, 1} each indicating the class to which the pointXi belongs. The goal
is to find the ”maximum-margin hyperplane” that divides the group of points Xi for which
Yi = 1 from the group of points for which Yi = −1, which is defined so that the distance
between the hyperplane and the nearest point Xi from either group is maximized.
Any hyperplane can be written as the set of points X satisfying:
L =
{
X : f (X) = XTβ + β0 = 0
}
(4.63)
where β is a unitary vector: ∥ β ∥= 1 [18]. This hyperplane has the following properties:
• For any two points x1 and x2 lying in L, T (X1 −X2) = 0, and hence β∗ = β∥β∥ is the
vector normal to the surface of L.
• For any point X0 in L, TX0 = −0.
• The signed distance of any point X to L is given by
β∗T (X−X0) = 1∥ β ∥
(
TX+ 0
)
(4.64)
= 1∥ f ′ (X) ∥f (X) .
A classification rule induced by f (X) is
G(X) = sign
[
XT + 0
]
. (4.65)
If the data is linearly separable, two parallel hyperplanes that separate the two classes
of data can be selected, so that the distance between them is as large as possible. The
region bounded by these two hyperplanes is called the ”margin”, and the maximum-margin
hyperplane is the hyperplane that lies halfway between them. With a normalized or stan-
dardized dataset, these hyperplanes can be described by the following equations:
XT + 0 = 1 (4.66)
and
XT + 0 = −1. (4.67)
Geometrically, the distance between the two hyperplane is 2∥∥ , so for the distance to
be maximum, ∥  ∥ must be minimum (Figure 4.4a). This optimization problem can be
rephrased as:
Problem 2
min
0
∥ β ∥ subject to yi
(
XTi  + 0
)
≥ 1, i = 1, . . . , N. (4.68)
When the classes have some overlapping, linear separating hyperplanes can still be a
good solution. So, the problem can still be solved by maximizing the margin 2∥∥ allowing
for some controlled cases to be on wrong side of the margin penalizing them.
Let  = (1, 2, . . . , N ) be the slack variables that define the amount by which data
points are on the wrong side of the margin:
• if the point ξ∗i lie on wrong side of the margin and is misclassified then ξi > 1
• if the point ξ∗i is correctly classified but inside of the margin then 0 ≤ ξi ≤ 1 (Figure
4.4b).
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(a) Linearly separable classes with the solid line
as the decision boundary and the dashed
lines bound the maximal margin.
(b) Non-linearly separable classes with the solid
line as the decision boundary and the dashed
lines bound the maximal margin. The points
label ξ∗j are on the wrong side of their margin.
Figure 4.4: Maximum-margin hyperplane and margins for an SVM trained with samples from two
classes. Samples on the margin are called the support vectors. [18]
If the point Xi rightly classified and in the right decision space then ξi = 0.
The optimization problem is a slight modification of the precious problem by introducing
a introducing a penalty term:
Problem 3
min ∥ β ∥ subject to

yi
(
XTi  + 0
)
≥ 1− ξi∀i,
ξi ≥ 0,
N∑
i=1
ξi ≤ constant.
(4.69)
Support Vector Machines are widely used mainly for classification problems even with
survival data. It can be simply used considering only with recorded of patient experiencing
the event in support vector regression or using the censored data with the constraint clas-
sification approach which imposes constraints in the SVM formulation for two comparable
instances. Some authors have proposed a support vector regression for censored data,
that can consider both uncensored and censored data, and takes advantage of the stan-
dard support vector regression and also adapts it for censored cases by using an updated
asymmetric loss function [171].
In supervised methods one of the most common strategy for model validation is re-using
efficiently the sample by preforming cross - validation.
Cross-validation consists of randomly dividing the data set in three independent parts:
train, validation and test. The first dataset is use to fit the model, the validation set is used
to estimate prediction error for model selection; the test set is used for assessment of the
generalization error of the final chosen model [18]. Typical the training set will count 50%
of the data, and the rest will be spit into equal parts for validation and testing.
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4.1.2 Model Validation and Selection - Some General Considerations
The model validation and selection is an important component of model fitting because
model misspecification may cause severe bias and even lead to incorrect inference [189].
Since models are only approximations and a perfect fit may be too much to ask for, the
problem becomes assessing the model’s performance on approximating the true model.
This problem can also be formulated as how to select a model amongst different models
for a given research question which, in practice, is more important that the actual method
for estimating the parameters. The basic idea is that, even if the method is useless for the
intent for which it was specified, the proper model selection will reveal this weak approach
and show that other methods are preferable.
There are two main approaches for model validation: analytically through goodness-of-
fit measures or by efficient sample re-use (cross-validation or bootstrap) [18].
Unfortunately, there are no formal standards for how to evaluate the quantitative goodness-
of-fit of models to data, either visually or numerically resulting in a considerable number of
methods. While there are some subtle and perhaps controversial issues involved in the
evaluation of goodness-of-fit, there are many simple conventions that are quite uncontro-
versial; those will be described in this subsection [190].
The goodness-of-fit test compares the model fit with the data that represents the fit
of the most complex model possible - the saturated model, having a parameter for each
observation [164]. The most common measures are described in [168] and in [190] (some
of the measures only work for specific models):
• Standard χ2 goodness of fit: χ2 = ∑ (O−E)2E - the difference between model predic-
tions and data on each condition mean is squared and divided by themodel prediction;
• Residual sum of squares: ϵˆT ϵˆ - measures howwell the model fits in an absolute sense;
• Coefficient of determination (or percentage of explained variance): R2 - measures
how well the models fits in a relative sense. It measures the proportion of variation
in the outcome that is accounted for by the predictors. Measures the extent to which
the model accounts for the observed data. Only available for the linear model. Some
extensions have been proposed for, at least, logistic regression;
• Mean Squared Error or RootMean Squared Error: MSD =
∑k
i=1(mi−di)
k andRMSD =√
MSD , where mi is the model mean for each point i and di is the data mean for
each point i and k is the number of points i being compared - this measure gives more
emphasis is placed on points that do not fit well than on points that do fit well;
• AIC:AIC = −2 (ln (likelihood)− k)where k is the number of parameters in the model
- The optimal model is the one that minimizes this quantity [164].
• BIC: BIC = ln (n) k − 2 ln (likelihood) where n is the number of points and k the
number of models parameters. The preferred model should be the one the minimizing
this quantity.
For several reasons, goodness-of-fit indexes whose contribution is just fit versus does
not fit, such as the χ2 test, should be avoided for assessing the fit of theoretical models to
data [190]. They provide positive evidence only by accepting the null hypothesis and favour
data sets with low number of cases and with increased noise it is less likely to obtain a ”does
not fit” outcome. Moreover, models have heuristic and summative value even though a
model does not capture all the non-noise variance in the data, it may capturemany important
aspects. If a model is currently the only model of a phenomenon or best model, then one
should not discard it as completely false because one aspect of the data is not yet captured
[190, 191].
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On the contrary, if we have a very large sample, the statistical test will almost certainly
be significant. The low p-values might be an artefact of large-sample sizes and, if this is
the case, we will wrongly reject the model, even if it actually describes the data quite well -
the Cried Wolf effect [191].
A saturated model that specifies all possible paths between all variables always fits the
data perfectly, but it is just as complex as the observed data and a trade-off between the two
must be achieved [191]. The goal is to use a goodness-of-fit index that does not depend
on the sample size or the distribution of the data. In fact, simulations have shown that most
goodness-of-fit indices still depend on sample size and distribution, but the dependency is
much smaller than that of the routine χ2 test [191].
Other perspective of models quality is its generalization performance which relates to
its prediction capability on providing reliable estimates in independent test data [18]. So,
typically, data is divided in training and testing whose behaviour according to the model
complex is represented in Figure 4.6. The training error tends to decrease with the increase
of model complexity. However, the model becomes too proficient in describing the training
data and will not generalize well (i.e., have large test error) - this phenomenon is called
over-fitting. In that case the models predictions will have a large variance. On the contrary,
if the model is not complex enough, it will underfit and may have large bias, again resulting
in a poor generalization [18].
It is well known that models with low bias in parameters estimation have a higher vari-
ance of the parameter estimates across samples, and vice versa. High bias can cause a
model to miss the relevant relations between features and target outputs - underfitting phe-
nomenon. The variance measures the model sensibility to small fluctuations in the data, so
a high variance can cause overfitting describing the random noise in the training data. So,
interplay between bias, variance and model complexity must be carefully analysed.
Let’s consider a response variable Y and X a set of predictors such that Y = f(X) + ϵ
where E(ϵ) = 0 and V ar(ϵ) = σ2ϵ . The expected prediction error of a regression model fit
fˆ(X) at a point X = x0 using squared-error loss, can be written as:
Err(x0) = E[(Y − fˆ(x0))2|X = x0]
(4.70)
For simplicity, the conditional term will be dropped and so the squared-error loss can be
written as:
Err(x0) = E[Y 2]− 2E[fˆ(x0)]E(Y ) + E[fˆ2(x0)]
= V ar(Y ) + f2(x0)− 2E[fˆ(x0)]f(x0) + V ar(fˆ(x0)) + E(fˆ(x0))2
= V ar(Y ) + [E(fˆ(x0))− f(x0)]2 + V ar(fˆ(x0))
= σ2ϵ +Bias2(fˆ(x0)) + V ar(fˆ(x0))
= Irreducible Error+ Bias2 + Variance. (4.71)
The ’Irreducible Error’ is the variance of the response variable around its true mean
f(x0), and cannot be avoided no matter how well we estimate f(x0), unless σ2ϵ = 0. The
second term is the squared bias, the amount by which the average of the estimate differs
from the true mean; the last term is the variance, the expected squared deviation of fˆ(x0)
around its mean. Typically, the more complex the model fˆ , the lower the (squared) bias but
the higher the variance [18].
Figure 4.5 shows the bias–variance trade-off schematically. Considering a linear model
as an example, the model space is the set of all linear predictions from p inputs and the
black dot labelled ”closest fit” is Xβ. The blue-shaded region indicates the error σϵ with
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which the truth in the training sample is represented. Also shown is the variance of the least
squares fit, indicated by the large yellow circle centred at the black dot labelled ’closest fit
in population’. If a model is fit with fewer predictors, or the coefficients are shrinked towards
zero, it would result in a ”shrunken fit”. This fit has an additional estimation bias, due to the
fact that it is not the closest fit in the model space but smaller variance. If the decrease in
variance exceeds the increase in (squared) bias, then this is worthwhile [18].
Figure 4.5: Schematic picture of the behaviour of
bias and variance [18].
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FIGURE 7.1. Behavior of test sample and training sample error as the model
complexity is varied. The light blue curves show the training error err, while the
light red curves show the conditional test error ErrT for 100 training sets of size
50 each, as the model complexity is increased. The solid curves show the expected
test error Err and the expected training error E[err].
Test error, also referred to as generalization error, is the prediction error
over an independent test sample
ErrT = E[L(Y, fˆ(X))|T ] (7.2)
where both X and Y are drawn randomly from their joint distribution
(population). Here the training set T is fixed, and test error refers to the
error for this specific training set. A related quantity is the expected pre-
diction error (or expected test error)
Err = E[L(Y, fˆ(X))] = E[ErrT ]. (7.3)
Note that this expectation averages over everything that is random, includ-
ing the randomness in the training set that produced fˆ .
Figure 7.1 shows the prediction error (light red curves) ErrT for 100
simulated training sets each of size 50. The lasso (Section 3.4.2) was used
to produce the sequence of fits. The solid red curve is the average, and
hence an estimate of Err.
Estimation of ErrT will be our goal, although we will see that Err is
more amenable to statistical analysis, and most methods eﬀectively esti-
mate the expected error. It does not seem possible to estimate conditional
Figure 4 6: Behaviour of test s mple and training
sample error a the model complex-
ity varies [18].
The selection of the explanatory variables in regression models, is a particular case of
model selection but with the same considerations about the bias-variance trade-off.
It must take into consideration that the more complex the model, the more capable it is
to capture the underlying variance but the less able it is to predict the response to new data.
That is, adding variables turns the model specialist in the particular observed data set used
to estimate the parameters. Indeed, by using as many parameters as observations the fit
can be made perfectly [17].
Traditionally, stepwise methods for variables selection focus on iteratively adding or
eliminating variables. These method have been rising some controversy; two of the most
common argument is highlighted:
People sometimes think that if a coefficient estimate is not significant, then it
should be excluded from the model. We disagree. It is fine to have non signifi-
cant coefficients in a model, as long as they make sense [169].
and
Unfocused search throughout many possible models increase the likelihood of
capitalizing on change and thereby finding a model that represents only a spu-
rious relationship. It is our experience and strong belief that better models and
a better understanding of one’s data result from focussed data analysis, guided
by substantive theory [192].
Models identified by stepwise methods have an inflated risk of capitalizing on chance
features of the data. They often fail when applied to new datasets but also, are rarely tested
in this way [192].
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Frank Harrell, in [193] compiled a list of problems with automated stepwise model se-
lection procedures:
1. It yields R2 values that are badly biased to be high.
2. The F and chi-squared tests quoted next to each variable on the printout do not have
the claimed distribution.
3. Themethod yields confidence intervals for effects and predicted values that are falsely
narrow [194];
4. It yields p-values that do not have the proper meaning, and the proper correction for
them is a difficult problem.
5. It gives biased regression coefficients that need shrinkage (the coefficients for remain-
ing variables are too large [195]; ).
6. It has severe problems in the presence of collinearity.
7. It is based on methods (e.g., F tests for nested models) that were intended to be used
to test prespecified hypotheses.
8. Increasing the sample size does not help very much [196];.
9. It allows us not to think about the problem.
10. It uses a lot of paper.
As an alternative, variables selection should be regarded as model selection and should
use the same methods always grounded in solid theory.
4.2 Modelling the Reporting - Delay Distribution and Incidence
The statistical problems involving reporting delay with right-truncated data has a history
stretching back at least 50 years being Sartwell’s, with the study of incubation periods using
log-normal distributions, one of the earliest reference. Most recently, Bayesian methods
have been used to handle situations in which infection times are unobserved and data
mining techniques were also addressed in contexts of survival time of cancer patients, and
reporting delay of HIV-AIDS. Similar problems involving right-truncation data arises from
analysis of AIDS latency where the time of onset of AIDS is truncated since only those HIV
infected individuals who develop AIDS within the truncation interval are observed. [8, 197,
186, 24]. It is precisely the HIV-AIDS context that has been providing a great impulse to
the statistical treatment of right-truncated with focus in obtaining valid estimates of recent
incidence, when case ascertainment or reporting is subject to delays [198].
In this section it will be reviewed the key publications on statistical inferences consisting
of estimating the lag distribution between an identification of an event and its reporting, and
the size of the random sample of the diagnosed cases using the observed (reported) cases
[8]. The full literature review summary table of all key publications in these settings as well
as related work is given in Appendix F.
The most common approaches arise from joint estimation of the reporting delay and
incidence, which can be grouped into two major approaches whose focus is one of the two
distributions. The subsection 4.2.1 overviews key publications of the twomost common joint
modelling approaches in this context focusing of chosen approaches, objectives, estimation
techniques and strengths and limitations; subsection 4.2.2 overviews key publications of
separated modelling approaches and subsection 4.2.3 gives a brief review of the approach
for the underlying statistical problem of the two most common approaches of joint modelling:
to make inferences about a stochastic process (estimating the reporting delay distribution
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as well as the random sample size) for which realizations are right-truncated in an interval
defined by the analysis; if a diagnosis takes place at time x and the analysis at time x∗, only
cases that have reporting delays less than time x∗ − x will be considered.
4.2.1 Joint Modelling
A general formulation involving joint estimation of the incidence distribution as well as the
reporting delay distribution, based on two sub-models linked through specific association
parameters, is the starting point with Harris [198]. Under this approach, several methods
have been developed for analysing right truncated data which can be largely grouped into
two major categories [163]: one is to treat the reporting delay as the time between the
occurrence of the event and its report and use survival analysis methods to estimate the
delay distribution, and the other considers the observed cases as a discrete outcome and
uses models for discrete responses such as the Poisson and Multinomial to model the delay
distribution. The former typically focuses on inference about the reporting delay distribution,
while the latter concentrates on the disease incidence [163].
Under the first approach, consider fitting a regression model based on a discrete reverse
- time proportional hazard function. Brookmeyer and Liao in [199] proposed a convenient
method for the analysis of grouped data that does not involve the incidence function [198].
This popular model is simple when implemented with a complementary log - log link, in-
ducing a relationship between the Cumulative Distribution Function (CDisF) of the delay
distribution of the form:
F (t | X) = F0 (t)exp(β
TX)
whereF (t | X) is the CDisF of delays in a sub-population with characteristicsX andF0 (t) =
F (t | 0) [198]. As Brookmeyer and Liao had noted, this model is not a proportional hazards
model because when βTX > 0, the ratio of hazard functions increases monotonically from
0 to 1, thus converging at long delays [198]. This model, can be implemented as a gen-
eralized linear model, and has been largely used to study the effect of several factors on
the delays in AIDS such as area of residence, exposure category, seasonal variation [119].
It relies on a result for right-censored data under non-informative censoring whose validity
for right-truncated data requires further investigation [8]. Kalbfleisch, in [200], also fitted a
regression model based on a reverse - time hazard function but applied to AIDS latency dis-
tribution. This approach expressed the reverse time hazard for both discrete and continuous
times. For discrete times, he developed a full likelihood while for continuous times, a partial
likelihood that can only be applied to proportional hazards model and accommodates only
right truncated data. Nonetheless, the models may be used to assess the quasi - stationary
of lag distributions and to provide flexible representations of covariate effects for truncated
data. A similar approach was used by Lagakos to obtain non-parametric estimates of AIDS
latency distributions [201].
The reverse - time proportional hazard function approaches generally imply a transfor-
mation of the data and the interpretation of the results is not simple. We notice that the
approach was mainly tested with the Centers for Disease Control and Prevention (CDC)
data who collects data from the U.S. epidemic.
Under the second approach, that of discrete outcome models, Harris described the joint
probability function for reporting delay and incidence under the assumption that the cross
- classified counts are independent and Poisson distributed. He also assumes that the
likelihood function can be written as a product of the conditional and marginal likelihoods
[121]. He described categorical and mixed categorical / continuous - time models for re-
porting delay while for incidence described only categorical and continuous - time. The
incidence of HIV cases was obtained by back-calculation over the incidence of AIDS cases.
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This approach can accommodate both truncated and censored data and the obtained back-
calculated results were consistent with the used serological data. However, the method
imposes constraints on the distributions that may be satisfied only by some type of regres-
sion models. Moreover, the counts of cases are very unlikely to be Poisson and if cases are
reported in batches the independent multinomial assumption does not capture the pattern.
Pagano, in 1994, discussed an extension of a discrete outcome regression model that
can be applied not only to truncated data but also to censored. This approach treats trun-
cation, as well as censoring, as a type of missing data and discussed the application of
missing-data techniques to simplify estimation. They augmented the incomplete data us-
ing the most direct missing - data technique in this setting: the EM algorithm. The algorithm
iterates between the E-step, which augments the observed portion of the sample by an es-
timate of the unobserved portion due to truncation, and the M-step, which maximizes the
log-likelihood of the augmented data, until a convergence criterion is reached [8].
Green, in 1998, described adjustments to be made to the number of AIDS cases consid-
ering delays in reporting, the lack of HIV-exposure information for some cases, and future
diagnoses of AIDS-defining opportunistic illnesses among persons reported with AIDS un-
der severe immune - suppression. The cases were separated into clusters that are small
enough for within-cluster reporting delays to be fairly homogeneous but large enough to
yield precise estimates of their reporting delay distributions. First, he evaluated a set of co-
variates to determine which of their levels are associated with reporting delay. Second, the
reporting delay distribution is estimated separately for each group of cases by the cross-
classification of levels identified during the first stage, and groups with similar estimated
delay distributions are combined. The covariates are selected using binary response re-
gression models. This approach takes the context of the reporting institution into consid-
eration and allow variations in AIDS incidence trends by mode of exposure to HIV, sex,
race/ethnicity and geographic region which are in qualitative agreement with reported vari-
ations in HIV prevalence rates and changes in HIV prevalence over time. This analysis use
a very short period of time and assumed that the reporting delay does not vary over six-year
period within groups for which separate estimates are made. Moreover, a large uncertainty
in the exposure distributions is described [120].
Amaral et al., in 2000 and 2005, applied a back-calculation method for obtaining fore-
casts of the Portuguese incidence data accounting for reporting delay and under-reporting.
Themethod used to estimate the reporting delay distribution is based on Poisson regression
and involves cross-classifying each reported case by calendar time of diagnosis and report-
ing delay, similarly to the Brookmeyer approach in [202]. The adjusted AIDS incidence data
are then used to obtain short-term projections and lower bounds on the size of the AIDS
epidemic using a Weibull incubation period distribution. The EM algorithm is used to obtain
maximum-likelihood estimates when the density of the infection times is parametrized as
a step function. Recent discussions suggest that the back-calculation method is gradually
becoming less appropriate for reliable incidence and prevalence estimates, as it does not
take into account the effect of treatment. Only the lower bound of the epidemic was de-
fined. The authors pointed as limitations, the unknown incubation period distribution and
the inaccuracy in the observed disease incidence over time, the assumptions made relative
to the reporting delay distribution were very unlikely and assumptions on under-reporting
percentage and treatment effect were not taken into consideration [203, 204].
Midthune et al., in 2005, generalized the jointly Harris model to include, along with re-
porting delay, data correction to the cancer registries data . The reporting delay component
of the model which, as its predecessors, is specified for grouped data, parametrizes the
probability of a given delay in terms of the discrete hazard, using a complementary log–log
link function, though the model is not a generalized linear model [198]. They divided the
registries population into sub-populations based on the usual subgroups used for report-
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ing, that is, one for each combination of levels of the following variables: year of diagnosis
(17 years), gender, race (for melanoma, they used only whites, because melanoma is rare
among other racial groups), and 5 - year age groups. All reporting models assumed that
the reporting process was relatively stable. Although the reporting-delay model with a ran-
dom reporting-year effects fitted the data much better than the non-random model, it still
exhibited some lack of fit. For simplicity, it was assumed that the random effects were nor-
mally distributed and independent; alternatively, one could allow the random effects to be
correlated or use non-parametric methods to estimate the distribution of the effects. This
model allows correlation within reporting year and it would be useful to also allow correla-
tion within diagnosis year [205]. Although parametric assumptions allow for the estimation
of the distribution of the reporting delays, the results are extremely imprecise and depend
strongly on the assumptions [117]. Moreover, any effect, no matter how tiny, can produce
a small p-value if the sample size or measurement precision is high enough [206].
As an alternative, non-parametric data mining techniques have been used in cases
where similar patient records and related symptoms were used [172].
4.2.2 Separate / Partial Modelling
Ideally, the reporting delay can be handled by jointly modelling and estimating the incidence
and reporting delay distributions. Unfortunately, this joint estimation process is not trivial
to perform due to missing information in the notification forms [116]. To overcome those
difficulties, separate approaches have also been proposed, one of the first authored by
Barnard in 1999.
Barnard, in [116], reviewed three applications of the well known Rubin’s imputation
method that are directly relevant for medical studies. One of them consists of the esti-
mation of the survival time after AIDS diagnosis in the presence of reporting delay, using
data from the CDC AIDS surveillance system. The emphasis of this review was on the
building of imputation models (i.e. the first step), which is the most fundamental aspect of
the method. This approach allows dealing separately with the reporting delay and with the
survival analysis, thus avoiding the difficulties of joint estimation. One can first concentrate
on the modelling of the survival time without worrying about the reporting delay, and then es-
timate the last distribution using the available information. Then, it is suggested to multiply
impute the delayed cases and proceed with the second and third steps of Rubin’s method to
be able to infer about the survival time. However, if the imputation model is seriously flawed
in terms of capturing the missing-data mechanism, then so will be any analysis based on
such imputations. It is less efficient than joint modelling of the missing-data mechanism and
the substantive analysis, in terms of both statistical efficiency (e.g. avoiding the reliance on
a finite number of imputations) and computational efficiency (e.g. avoiding simulation via
the use of the EM algorithm).
Xia, in 2015 in [163], developed a distribution-free approach to allow separate modelling
of the incidence and reporting delay but with joint inference for both modelling components,
based on functional response models. This separate approach allows the accommodation
of a sub samples of data to model the reporting delay. The model is fitted using a set of
weighted generalized estimating equations adapted to the functional response models ir or-
der to provide consistent parameter estimates and valid inferences. The authors discussed
inferences about projections of future disease incidence to help identify significant shifts
in temporal trends. Simulated data provided good performances, even for relatively small
sample sizes .
In the same year, Noufaily in [198] focus just on the reporting delay and developed a
model for describing the hazard to gain a better understanding of the reporting process
being the recent incidence a possible covariate. They also investigated the effects of tem-
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poral factors such as calendar time, season and recent incidence on the reporting delay.
The authors use a continuous time spline - based model for the hazard of the delay distri-
bution along with an associated proportional hazard model. This approach allows a natu-
ral investigation of covariates effects, with a relative simple hazard interpretation and also
the inclusion of long delays which are often excluded from the analysis. The major disad-
vantage of the approach is that it is more cumbersome than the generalized linear model
method. Noufaily also noticed that the estimates of the hazard at long delays are sensitive
to irregularities in the data.
Table 4.4 presents a brief comparison of the main approaches, described above, for the
estimation of the reporting delay and incidence.
Table 4.4: Comparison of reporting delay estimation models
Joint Modelling
Reverse time hazard Discrete outcomes Separate Modelling
Focus Reporting delay Incidence Reporting delay and / or inci-
dence
Data needed Case base data Aggregated data Case based data / Aggregated
data
Strengths Allows the visualization the haz-
ard in continuous time and study
the effect of covariates in a
natural fashion. Can describe
and characterize the entire delay
distribution, accommodating the
long delays.
This approach accommodates
truncation without transforming
the data. Can be implemented
with standard statistical pack-
ages.
Provides more flexibility for mod-
elling the sub-models, possibly
with different samples, allowing
more complex approaches.
Weaknesses Generally implies data transfor-
mation and interpretation of the
results is not simple.
Need parametric assumptions,
which may yield biased infer-
ences if data fail to meet the
posited distributional assump-
tions [163].
May need parametric assump-
tions on the incidence compo-
nent.
Key publica-
tions
[201], [202], [122], [207], [198] [121], [208], [8], [116], [209],
[120], [203], [204], [210], [205]
[197], [163]
4.2.3 Data - structure and notations
Let t0 represent the earliest time date and tn the latest time date for which an HIV-AIDS
case(s) is known or the end of the observation period is available. Consider that the time
interval [t0, tn] can be divided into n units of equal length of the form [tj−1, tj ] which are
indexed by non-negative integers j = 1, . . . , n. For simplicity, and without loss of generality,
we will consider the time interval [tj−1, tj ] represented only by tj . Let d be the reporting
delay. That is, if an HIV - AIDS case is diagnosed at the time period tj it only gets reported
until d time periods latter; the reporting time is thus tj + d for j = 1, . . . , n. This case will
only be observed if tj + d ≤ tn, or equivalently 0 ≤ d ≤ tn − tj .
Let D be a random variable of reporting delays taking values 0 < d1 < d2 < . . . < di <
. . .. The distribution of Dj conditional to a covariate vector Zj has CDistF:
Fj
(
di|Zj
)
= Pr
{
D ≤ di|Zj
}
(4.72)
We assume that dm is the longest reporting delay that can be reliably estimated and so
Fj
(
dm|Zj
)
= 1. Under this assumption, cases diagnosed prior to tn − dm are all reported
by time tn, while only a proportion of those whose diagnose occurs between tn − dm and
tn (tn − dm < tj < tn), is observed (with reporting delay d < tn − tj) [163].
All HIV-AIDS cases can be cross - classified by their date of diagnosis and the length of
their reporting delay: let Yij be the number of HIV-AIDS cases diagnosed at tj with reporting
delay di. The incidence in time tj is denoted by Y+j and given by:
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Figure 4.7: Truncation mechanism in reporting cases based on [211]
Y+j =

Y C+j =
m∑
i=0
Yij = if t0 ≤ tj ≤ tn − dm
Y Tr+j =
tn−tj∑
i=0
Yij if tn − dm + 1 ≤ tj ≤ tn
(4.73)
Shown in Figure 4.7 is the typical representation of the data structure and the formula-
tion of this problem: making inference about an unobservable random variable with right-
truncated values defined by the observation period.
Joint modelling of the Reporting Delays as a Survival Time
Since D is, by definition, the time that a diagnosed HIV-AIDS case gets reported to the
surveillance system, it can be viewed as a ’survival time’ and survival methodology can be
employed for the estimation of its distribution.
Let D be a discrete random variable taking values 0 ≤ d1 < d2 < . . . < di with probabil-
ities conditional to a covariate vector Zj
fj
(
di | Zj
)
= fij
(
Zj
)
= Pr
{
D = di | Zj
}
(4.74)
Let Fj
(
di | Zj
)
be the cumulative probability function
Fj
(
di | Zj
)
= Fij
(
Zj
)
= Pr
{
D ≤ di | Zj
}
. (4.75)
Moreover, define the probability of a case being reported di units of time after diagnosis
time tj , given that it is reported within di units of time, as
gj
(
di | Zj
)
= gij
(
Zj
)
= fij
(
Zj
)
Fij
(
Zj
) = Pr {D = di | D ≤ di,Zj} . (4.76)
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The function gj is the reverse time hazard function and as Kalbfleisch pointed in [122],
only the reverse time hazards are strictly identifiable with truncated data.
Under the assumption of a maximum delay dm, (4.75) can be written as:
Fij (di | Zj) =
{
Pr
{
Dj ≤ di | Zj
}
if tn − dm + 1 ≤ tj ≤ tn
1 if t0 ≤ tj ≤ tn − dm , 0 ≤ di ≤ dm−1. (4.77)
Note that if a case (diagnosed between tn − dm + 1 ≤ tj ≤ tn ) has a reporting delay
less than di (with 0 ≤ di ≤ dm−1) , it implies not having a reporting delay of d(i+1) given
that it is reported until d(i+1) unit times later, nor d(i+2) given that it is reported until d(i+2)
unit times later, ... Hence (4.77), and as Kalbfleisch in [122] demonstrated and considering
(4.76), can be written as:
Fij (di | Zj) =

dm∏
k=d(i+1)
(1− gkj) if tn − dm + 1 ≤ tj ≤ tn
1 if t0 ≤ tj ≤ tn − dm
, 0 ≤ di ≤ dm−1. (4.78)
To model gij , let Y+kj be the total number of cases diagnosed in tj and reported until dk
and Ykj the total number of cases diagnosed in tj with reporting delay exactly equal to dk
(1 ≤ dk ≤ dm). Then
Ykj | Y+kj ,Zj iid∼ Bi(Y+kj , gkj
(
Zj
)
), with
{
0 < di < dm if 0 < tj < tn − dm
0 < di < tn − tj if tn − dm + 1 < tj < tn
where Bi represents a binomial distribution. A natural class of regression models for (4.76)
is [122]:
ψ (gij) = 0 +XTj x with
{
0 < di < dm if 0 < tj < tn − dm
0 < di < tn − tj if tn − dm + 1 < tj < tn (4.79)
where ψ is a function of [0, 1] onto [−∞,∞],  is a vector of the regression parameters and
0 is the Reverse Time Hazard Function (r.t.h.) baseline [122].
Two natural choices for link functions ψ (·) are the logit function:
ψ (u) = log
(
u
1− u
)
(4.80)
and the complementary log-log, a particular popular choice :
ψ (u) = log {− log (1− u)} (4.81)
For the model in (4.81), Fij
(
di|Xj,
)
can be written as:
Fij
(
di | Xj,
)
= F0 (di | )exp(X
T
j x) with F0 (dij | ) =
dm∏
k=d(i+1)
exp (− exp (0))
where 0 ≤ di ≤ dm−1, tn − dm ≤ tj ≤ tn,  =
(
β01, . . . , β0m,
T
x
)T (4.82)
Joint Number of Reported Cases as Observed Responses of a Multinomial Model
Another popular approach is to consider that the observed responses arise from a Multi-
nomial model, to apply models for such responses and to estimate the model parameters
parameters using methods for missing data.
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Let Yij be the random variable representing the number of HIV-AIDS cases diagnosed
at the time unit tj with reporting delay di. For a given j, the conditional distribution of
Yj = {Y0j , . . . , Ydmj}T at a given Y+j =
dm∑
k=0
Ykj is multinomial with the trials’ probabilities
given by f0j
(
Zj
)
, . . . , fdmj
(
Zj
)
, that is Yj | Y+j ∼MN(Y+j , f0j
(
Zj
)
, . . . , fdmj
(
Zj
)
).
Remember that, for a given tj , only Yij satisfying tj + di ≤ tn are observed. So, Yj can
be re-written as:
Yj =

Y Cj =
{
Y C0j , . . . , Y
C
dmj
}T
if t0 ≤ tj ≤ tn − dm
Y Trj =
{
Y Tr0j , . . . , Y
Tr
dtn−tij
}T
if tn − dm + 1 ≤ tj ≤ tn
(4.83)
Note that, if t0 ≤ tj ≤ tn−dm , Y+j = Y C+j otherwise Y+j > Y Tr+j . However , in each case
the number of reported cases follows a multinomial distribution, with sample sizes Y C+j and
Y Tr+j and probabilities
fj =

fCj =
{
fC0j
(
Zj
)
, . . . , fCdmj
(
Zj
)}T
if t0 ≤ tj ≤ tn − dm
fTrj =
{
fTr0j
(
Zj
)
, . . . , fTrdtn−tij
(
Zj
)}T
if tn − dm + 1 ≤ tj ≤ tn
(4.84)
respectively.
A common model for the reporting delay distribution that arises from a multinomial re-
sponse is:
fij
(
di | Zj
)
= exp
(
ηij
(
Zj
))
dmj∑
di=0
exp
(
ηij
(
Zj
)) (4.85)
where dmj is the longest reporting delay that can be reliably estimated in tj and ηij(Zj) is
the log-linear
ηij
(
Zj
)
=
{
0 if di = 0
αij + ZijTβij if 1 ≤ di ≤ dmj
(4.86)
where αi and βi are parameter vectors. This model implies that the probability that a
case with covariate Zj is reported at time tj is multiplied by a factor exp
(
ZijTβij
)
. Note
that by letting α0j = β0j = 0, (4.86) can be expressed as ηij = αij +ZijTβij ( 0 ≤ dij ≤ dmj
) . For a further simplification, we let θ = (α, β) and denote the dependence of fij
(
dij | Zj
)
on θ by fij
(
dij | Zj, θ
)
[8].
The maximum likelihood functions, which are the basis of the inferences, for these two
approaches are analogous and are based on the multinomial - Poisson transformation de-
scribed in the next sub-section.
4.2.4 Likelihood for the Joint Model
Many count problems lead tomultinomial distributions, either unconditional or conditional[212].
The associated likelihood if often difficult to maximize but it can be transformed into a sim-
pler form associated with a Poisson distribution and with additional parameters, still yielding
identical estimates and asymptotic variances. This method can be applied to complete or
incomplete data.
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Multinomial - Poisson transformation for complete data
Assume that
Y = {Y1, . . . , Yj , . . . , YJ}
follows amultinomial distribution with parameters proportional to exp (βj). Let (y1, . . . , yj , . . . , yJ)
be a realization of Y. The maximum likelihood function is
LM ({βj}) = (y1 + . . .+ yJ)!
y1! . . . yJ !
J∏
j=1
(
exp (βj)∑J
i=1 exp (βi)
)yj
(4.87)
Baker in [212], proved that maximizing equation (4.87) over {βj} provide the same es-
timates as maximizing the augmented model
LP (ϕ, {βj}) = 1
y1! . . . yJ !
J∏
j=1
(exp (ϕ+ βj))yi exp (− exp (ϕ+ βj)) (4.88)
over ϕ and {βj}, which is the maximum likelihood for a vector of independent Poisson
random variables: Yj ∼ P (exp (ϕ+ βj)), for j = 1, . . . , J .
We consider a more general case. Let Yi = {Yi1, . . . , Yij , . . . }, for i = 1, 2, . . . , I, and
j ∈ Ji denote a vector of random variables with realization yi = {yi1, . . . , yij , . . . }. The
subscript i indexes levels of a categorical covariate or a cross-classification of categorical
covariates. Assume that Yi ∼ multinomial with parameters
{
gij(β)
Gi(β) , j ∈ Ji
}
where Gi =∑
j∈Ji gij (β) and β = {β1, . . . , βq}. The maximum likelihood is
LM (β) =
(∑I
i=1
∑Ji
j=1 yij
)
!∏I
i=1
∏Ji
j=1 yij !
I∏
i=1
Ji∏
j=1
(
gij (β)
Gi (β)
)yij
(4.89)
There are four approaches to maximize (4.89):
• Newton-Raphson algorithm without any transformations or reparametrizations;
• modification of the EM algorithm for truncated categorical data;
• especially for discrete time survival data, using a newton-raphson algorithm after a
reparametrization using reverse time hazard functions;
• using a Multinomial-Poisson transformation transformation.
Let ϕ = (ϕ1, . . . , ϕi, . . . ϕI)T . The Multinomial - Poisson transformation of (4.89) is
Lp (ϕ, β) =
I∏
i=1
∏
j∈Ji
{gij (β) expϕi}yij exp {−gij (β) expϕi} (4.90)
The derivative of the logarithm of (4.90) with respect to ϕi is
∑
j yij − Gi (β) expϕi.
Setting this derivative to 0, solving for ϕˆi (β) and substituting into equation (4.90) gives
LP
(
ˆϕ (β), β
)
∝ LM (β) [212]. These two likelihood functions have identical maximum like-
lihood estimates for β and their asymptotic variances (based on the observed information
matrix) and therefore only (4.90) can be used to draw inferences about β.
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4.3 Summary
Generalized linear models (GLM) are methods that allow the investigation of the effects of
explanatory variables on response variables of several types. It is assumed that the distribu-
tion of the response belongs to the exponential family. GLMs consist of three components:
a probability distribution from the exponential family for the response Y ; a linear predictor
η = Xβ; and a link function g such that E (Y ) = µ = g−1 (Xβ). The model parameters can
be estimated by the principle of maximum likelihood. A common choice for checking the
model assumptions is through the graphical inspection of the residuals.
Amultilevel model incorporates fixed-effects parameters and random parameters, which
are unobserved random variables. The data has a grouped, nested or hierarchical structure
such as: repeated measures, longitudinal and/or multilevel or hierarchical. In this model it
is considered that the variance-covariance matrix of the residuals is simply a multiple of the
identity matrix. Parameter estimates can be obtained by maximum likelihood or restricted
maximum likelihood, which minimizes the standard errors of the regression coefficients
estimates.. To asses the precision of the parameter estimates, it is used the profile deviance
with respect to each of the parameters and applying a signed root transformation to the
statistic of the likelihood ratio test. These calculations provide a profile zeta function for
each parameter used to construct likelihood-based confidence intervals for the parameters.
Profile zeta plots allow us to visually assess the precision of individual parameters and
evaluate the models assumptions. Prediction intervals from the conditional distribution of
the random effects, given the observed data, allow us to assess the precision of the random
effects[179].
Survival analysis is a sub-field of statistics concerning the study of times to a particularly
event. Whenever the events do not occur during the study period, the corresponding times
are said to be censored data. Traditional methods have been largely developed and in
addition, many machine learning algorithms have also been adapted to effectively handle
survival [171]. In particular, the parametric method presents an easy to interpret, efficient
and accurate method when the survival times follow a particular distribution. These models
can be built and evaluated similarly to the generalized linear models.
The K-nearest neighbour algorithm is an unsupervised learning algorithm which per-
forms a space partition in a pre-user-defined number of clusters (K). Any new observation
is compared to a training sample. This new case is then assigned to the class correspond-
ing to the majority vote from its K nearest neighbours.
Longitudinal k-means is also an unsupervised learning algorithm. The aim of thismethod
is to determine sets of homogeneous and separated groups of trajectories. A trajectory is a
sequence of observations of an individual measured at different times. This is an algorithm
belonging to the EM class which alternates between the mean estimation and its assigning.
Naive Bayesian Classifier is a supervised learning algorithm and probabilistic classifier
which assumes that all features contribute equally and independently to the final decision
[173]. It combines a probability model based on the Naive Bayes conditional probability
with a decision rule. The decision rule is simply the assignment of the observation to the
class with the highest probability.
Multilayer perceptron networks, in particular the feed-forward single hidden layer net-
works, with back - propagation training algorithms, are the most common networks. They
are supervised learning methods and can be used for classification or regression tasks.
They are effective in the analysis of complex data with non - linear trends and time - depen-
dent covariates, and even high-order interactions [187].
Support vector machines are the most popular and efficient classification and regression
methods currently available. They are supervised learning methods that apply simple linear
methods in a high-dimensional feature space that is non-linearly related to the input space.
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Usually, all attributes are employed and non-overlapping partitions are generated.
In supervised methods, one of the most common strategies for model validation is re-
using efficiently the sample by performing cross - validation.
Over almost 40 years, researchers have been interested in obtaining valid estimates of
recent incidence of reportable diseases which are, inevitable, subject to delays. Accurate
and timely estimates are necessary for research evidence guiding Public Health decision-
makers.
Most of the approaches addressing the reporting delay focus on the joint modelling of
the reporting delay and incidence of HIV-AIDS. In this setting the two major approaches are
the reverse time hazard and the discrete outcome models.
The reverse time hazards approach focus on the reporting delay distribution and allow
the visualization of the hazard function in continuous time. Moreover, the analysis of the
effect of the covariates is done in a natural fashion. The long delay is taken into considera-
tion and so the entire delay distribution is analysed. The main weakness of this approach
is that, in general, it implies data transformation on the time axis and the interpretation of
the results is more difficult.
The discrete outcome models focus on incidence and accommodate right truncation
without transforming the data. They can be implemented with standard statistical pack-
ages. Usually Poisson and Multinomial assumptions are involved, which may yield biased
inferences if data fails to meet the posited distributional assumptions.
Recently, separate approaches are being considered to provide more flexibility and com-
plexity to the reporting delay and incidence sub-models. Each model can even be fitted in
different samples. Like the discrete outcome approach, it may need parametric assump-
tions.
Chapter 5
Methodology and Results
Circumstances do not make the man, they reveal him. - James Allen
In the presence of reporting delays, only a portion of diagnosed patients in the ith time
period are observed within a limited time interval. As a consequence, the number of ob-
served cases generally underestimates the disease true incidence. Given the importance
of an accurate and timely estimate of the HIV-AIDS incidence, several approaches have
been studied.
Traditionally, reporting delays are divided into yearly quarters and considered as a dis-
crete outcome. This approach is convenient when there are considerable uncertainties in
the dates of interest; moreover, in many countries, the cases are reported in batches and
so, grouping the time dates accommodates these fluctuations.
In section 5.1 it is presented a description of the main features of the Portuguese Epi-
demic and how it was surveyed. In section 5.2 the reporting delays are grouped into yearly
quarters and considered as a discrete outcome. An incidence and delay joint model ap-
proach is described in section 5.2.1. In this setting, a stop Poisson model is described
for capturing the underlying phenomena of underreporting which is presented in 5.2.1. A
model adding stationarity is presented in section 5.2.2 and non-parametric approaches are
presented in section 5.2.3, namely: feed-forward, naive bayesian classifier, k-nearest neigh-
bour and support vector machines. In section 5.3 the reporting delay is considered a con-
tinuous outcome and the full context of the complex system is taking into consideration
through a multilevel approach.
5.1 The HIV - AIDS Portuguese Epidemic
Since the beginning of the epidemic, most of the reported cases were from asymptomatic
cases, closely followed by AIDS cases. Following the observed pattern in the European
countries, the majority of diagnosed cases were men. The heterosexual were the most
common risk-group category in the absolute sense. In the relative sense, taking into con-
sideration the size of the risk groups, there were a large amount of cases within injecting
drug users (IDUs). The first case being diagnosed occurred in 1983 and the first notification
was in 1985.
5.1.1 Incidence
Looking at the Portuguese trend of the number of cases by year of diagnosis (Figure 5.2),
the epidemic suffered an increase in the year 2000, then progressively decreased until
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around the year 2005, at which the number of reported and diagnosed cases became ap-
proximately constant until 2008; from then onwards, it started to descend again. It is impor-
tant to bear in mind that the surveillance system is affected by reporting delays and so the
number of cases in the latest years of the epidemic in this study most probably does not
corresponds to the true incidence.
When the cases are analysed by year of notification, it can be seen an increasing ten-
dency on the number of cases until the year 2000, a rapid decrease in the next year and,
from there onwards, the number of notified cases has became roughly constant (Figure
5.1).
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Figure 5.1: Number of cases by notification year
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Figure 5.2: Number of cases by diagnosis year
Late diagnosis, that is AIDS cases, was the most reported stage in the early beginning
of the epidemic and of the surveillance system. Around the year 2000, asymptomatic cases
were reported more frequently being followed closely by the AIDS cases (Figure 5.3). The
same pattern is observed when this characteristic is represented by the notification year
(Figure 5.4).
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Figure 5.3: Number of AIDS cases per year of
notification for each disease stage
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Figure 5.4: Number of AIDS cases per year of di-
agnosis for each disease stage
In the whole epidemic history, male cases have always been more frequently observed
(Figures 5.5 and 5.6). Injection drug users (IDU’s) were the most frequent risk group di-
agnosed and reported until around the year 2002; from that onwards, it gave place to the
heterosexual risk group (Figures 5.7 and 5.8 ). The median age of infected individuals was
around 40 years old, in the whole epidemic history considered in this study (Figures 5.9
and 5.10 ).
Throughout the years there have been several fluctuations on the number of cases per
year of notification and region of health administration RHA’s, (Figure 5.11). Nevertheless,
Lisbon and the Tagus Valley and the North have been the regions with the majority of the
contributions, most probably because they serve the two major Portuguese cities. It is
important to notice a large contribution of cases coming from a non identified region.
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Figure 5.5: Number of notified cases per year for
each sex
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Figure 5.6: Number of diagnosed cases per year
for each sex
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Figure 5.7: Number of notified cases per year for
each risk group
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Figure 5.8: Number of diagnosed cases per year
for each risk group
Figure 5.9: Age distribution per notification year Figure 5.10: Age distribution per diagnosis year
From the perspective of the diagnosis year, the epidemic curves are smoother and nat-
urally, the main contributions arise from the same regions as before (Figure 5.12 ) .
Figure 5.11: Number of HIV - AIDS cases per
RHA and per notification year
Figure 5.12: Number of HIV - AIDS cases per
RHA and per diagnosis year
Considering all stages, the observed number of diagnosed HIV-AIDS cases in Portugal,
from 1983 to 2011, is presented in Figure 5.13. This indicator exhibited an increasing trend
between 1983 and the year 2000, four years after the introduction of HAART. Since then,
the number of diagnosed cases has been steadily decreasing. When the notification be-
came mandatory, a slight growth was observed.In the lower panel of the figure, we have
included information about the historical events that may have introduced bias in the preva-
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lence numbers. It can be seen that the prevalence curve of AIDS changes slightly at those
moments.
Figure 5.13: Number of AIDS diagnosed per year and epidemiological events
Death related to AIDS cases is reported through a notification form to CVEDT and to
Instituto Nacional de Estatística (INE) based on death certificates. The difference between
the two systems is represented in Figures 5.14, 5.15 and 5.16. It is clear that the underre-
porting of death within the HIV -AIDS surveillance system is high; since this is a very special
case, it cannot be used for estimating the underreporting behaviour at other stages.
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Figure 5.14: Mortality by INE
and CVEDT
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Figure 5.15: Difference from
INE and CVEDT
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Figure 5.16: Mortality differ-
ence percentage
INE and CVEDT
5.1.2 Reporting Delay
Considering the importance of the reporting delay on the timely ascertainment of the cases,
we focus our attention on that issue in this section.
Moreover, it is less likely to have underreporting at the last stage of the disease due to
the severe symptoms and the need for care so, in a initial analysis, we will restrict ourselves
to the AIDS cases.
Considering the notification year, most of the cases have been reported between 1994
and 2006 with a reporting delay up to two years. The same pattern has been observed
when considering the diagnosis year. There is a considerable long reporting delay through
all years of notification and diagnosis; for example, in the year 2000 approximately 200
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cases had a reporting delay of 4 years (Figures 5.17 and 5.18). There is an increasing
pattern in the number of cases until the year 2000 and a decreasing pattern afterwards,
which resembles the incidence pattern represented in (Figure 5.13 ).
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Figure 5.17: Number of cases of AIDS per Noti-
fication year and reporting delay by
trimester
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Figure 5.18: Number of cases of AIDS per Diag-
nosis year and reporting delay by
trimester
Taking into consideration the annual incidence, the percentage of AIDS cases (within
all cases) by reporting delay and year of diagnosis is presented in Figure 5.19. From this
representation, it can be seen that the majority of cases are reported within one year.
To get a better description of the patterns of the observed delays, the time intervals
(diagnosis, notification, delay,...) were divided into trimesters discarding the first three years
of the disease, since in the early days there were not enough knowledge and stability of the
surveillance system for the true pattern to be accurately captured.
Figure 5.20 depicts the annual percentage of cases within each diagnosis year and re-
porting delay. The interpretation of the curve in the most recent years (shaded region) must
be done carefully since there are cases that have not been notified yet.
Most of the cases are reported within 3 months after diagnosis but some of them are still
being reported with a delay longer than one year. For the sake of clarity, delays longer than
18 months are omitted from Figure 5.20 (the longer delay occurs with a low frequency).
Figure 5.19: Percentage of AIDS cases per diag-
nosis year and reporting delay year
Figure 5.20: Percentage of HIV-AIDS cases per
diagnosis and delay quarters. The
lighted region identifies those (re-
cent) years that have to be cor-
rected.
Looking closely at the delay curves, the percentage (considering all cases diagnosed
in the trimester) of cases reported within 3 months has been increasing. That means that,
in the most recent years,the system is registering cases with a more reasonable delay
time and the percentage of cases reported within 3 to 6 months has been relatively stable
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between 10% and 20% (Figure 5.21).
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Figure 5.21: Separate delay curves for percentage of HIV-AIDS cases per diagnosis and delay quar-
ters. The lighted region identifies those (recent) years that have to be corrected.
The longitudinal distribution of the reporting delays according to several demographical
and institutional variables are described in Figures 5.22 to 5.27. In these pictures, the delays
are divided into 3 months long intervals and are identified as: 0 representing the quarter
[0, 3]months , 1 the quarter [3, 6]months, 2 the quarter [6, 9]months and 3 the longer delays.
The infection is concentrated at the male gender (Figure 5.22 ) and most of the cases
have, naturally, an European nationality being followed by Africans (Figure 5.23 ). From
these representations, it is clear a large concentration of cases with delay [0, 3] months; in
the case of the European citizens, there is also a considerable amount of cases with other
reporting delay lengths.
Early detections (corresponding to asymptomatic cases) were most of the reported
cases, especially in the most recent years. These cases presented equally distributed
reporting delays through the quarters (Figure 5.24). Large concentrations of AIDS - cases
(late detections and/or disease progressions) must also be noticed, mostly with a reporting
delay lower than 3 months.
As for the risk-groups, the infection has been most prevalent amongst the heterosex-
ual community, mainly after 1999, which is natural due to the large size of this group. A
large frequency of IDUs is also visible from 1996 to 2003 (Figure 5.25). The cases are
approximately equally distributed by the different reporting delays and diagnosis years.
The major reporting institutions are the hospitals, and most of the reporting delays are
lower than 3 months (Figure 5.26 ).
Considering the regional health administration, it can be seen that RHA North had the
majority of the reported cases. It can also be noticed that the time lag between diagnosis
and reporting is, in most cases, less than 3 months (Figure 5.27).
Considering the reporting delay grouped into only two groups - the 0−3months and> 3
months - the distribution of the number of cases according to sex, age, nationality, disease
stage, HIV risk-group, type of health care institution and regional health administration is
presented in Table 5.1. The results show that the two groups have similar characteristics
with the exception of “Disease Stage” and “HIV Risk Group”. Themajority of the cases in the
faster group are AIDS cases and in the slower group are asymptomatic cases. This may be
due to the urge of treatment for these cases. Concerning the risk group, a slight difference
is observed for the two groups: in the faster group, heterosexuals are the prevalent risk-
group followed by the IDU’s; in the slower group, this pattern is still visible but the difference
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Figure 5.22: Number of HIV-AIDS infections by
year of diagnosis (x-axis), reporting
delay quarter (y-axis) and gender
(right vertical boxes)
Figure 5.23: Number of HIV-AIDS infections by
year of diagnosis (x-axis), reporting
delay quarter (y-axis) and patients
nationality (right vertical boxes)
Figure 5.24: Number of HIV-AIDS infections by
year of diagnosis (x-axis), reporting
delay quarter (y-axis) and disease
status (right vertical boxes).
Figure 5.25: Number of HIV-AIDS infections by
year of diagnosis (x-axis), report-
ing delay quarter (y-axis) and risk
group (right vertical boxes)
Figure 5.26: Number of HIV-AIDS infections by
year of diagnosis (x-axis), report-
ing delay quarter (y-axis) and health
care institution (right vertical boxes)
Figure 5.27: Number of HIV-AIDS infections by
year of diagnosis (x-axis), reporting
delay quarter (y-axis) and regional
administration (right vertical boxes)
is narrower.
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Table 5.1: Overview the two classes of reporting delay per demographic variables
Variable 0-3 >3
mean std mean std
Age at diagnosis 37.74 13.03 36.21 12.93
n % n %
Gender Female 4397 24 4832 26Male 13815 76 13466 74
Patient Nationality
Africa 1786 41 1599 53
Americas 448 2 361 2
Europe 15309 84 15688 86
Low Incidence Countries 30 0 23 0
Nat. Other - Unknown 639 4 627 3
Disease stage
A 7501 41 9777 53
AIDS 9063 50 6712 37
SC 1648 9 1809 10
HIV Risk-group
Heterosexual 8491 47 7683 42
Homo - Bisexual 2778 15 2575 14
IDU 6331 35 7452 41
Other - Undetermined 612 3 588 3
Health Care Institution
Centres for treatment of ad-
dictive behaviours
457 3 296 2
Unspecific Administration 2346 13 2898 16
Hospital 13653 75 13913 76
Primary care 1033 6 716 4
Prisons 555 3 358 2
Military 103 1 80 0
Other - Unknown 65 0 37 0
Regional Health
Alentejo 91 0 109 1
Algarve 28 0 10 0
Centro 2367 13 2222 12
Administration
Lisboa e Vale do Tejo 4103 23 4742 26
Norte 6581 36 6381 35
Other - Unknown 5041 28 4834 26
5.2 Discrete Outcomes
5.2.1 Joint Modelling - Count Regression Models
The presence of this section in the thesis is due to the popularity of the joint modelling and
the fact that the methodology has already been applied to the Portuguese data by others
[203, 204].
Consider the cases cross-classified by the notification and diagnosis dates and focus
only in the most ’visible’ stage of the disease - the AIDS stage. The number of AIDS cases
cross-classified by the notification year and the diagnosis year is presented in Table 5.2.
Some important features of that table are as follows:
1. Cells in the upper region are necessarily empty because of the logical relationship
between the diagnosis and the notification year;
2. Most of the cases are at the main diagonal and at the main rows immediately below
it;
3. The cases at the final columns are partially observed due to the presence of reporting
delay.
As the two dimensions of this table are the year of diagnosis and reporting delay, the
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margins for the diagnosis year give the total incidence over time, but with the most recent
values masked by the reporting delay.
Year of Diagnosis
1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Sum
Ye
ar
of
No
tif
ica
tio
n
1985 0 2 16 18
1986 0 0 11 19 30
1987 0 0 1 9 37 47
1988 0 0 0 2 18 89 109
1989 1 0 1 1 10 25 116 154
1990 0 0 0 3 5 6 46 164 224
1991 0 1 0 1 2 6 8 44 181 243
1992 0 1 0 1 2 4 13 22 71 270 384
1993 0 0 0 0 2 4 2 12 30 90 324 464
1994 0 0 0 4 2 6 6 4 8 32 132 416 610
1995 0 0 0 0 0 0 2 4 11 18 54 156 447 692
1996 0 0 0 0 0 0 0 1 0 4 27 47 238 578 895
1997 0 0 0 0 0 1 2 1 1 2 13 14 41 217 602 894
1998 0 0 0 0 0 0 0 1 0 5 2 9 16 33 178 630 874
1999 0 0 0 0 1 0 3 0 1 2 1 8 12 40 68 204 669 1009
2000 0 0 0 0 0 1 1 2 1 1 5 11 17 53 61 74 266 626 1119
2001 0 0 0 1 2 0 0 0 0 0 0 8 8 14 26 32 34 197 652 974
2002 0 0 0 0 0 0 0 0 0 2 3 8 18 27 24 35 46 60 225 622 1070
2003 0 0 0 0 0 0 0 1 0 1 1 0 1 5 10 16 29 41 33 256 562 956
2004 0 0 0 0 0 0 0 1 1 4 3 6 12 12 12 24 40 36 37 70 228 520 1006
2005 0 0 0 0 0 0 0 0 0 1 2 4 4 8 16 17 26 37 31 35 77 198 524 980
2006 0 0 0 0 0 0 1 1 0 2 2 3 5 0 6 8 16 16 26 26 35 53 165 441 806
2007 0 0 0 0 0 0 0 0 0 1 0 0 4 3 5 11 9 18 10 15 19 32 67 197 434 825
2008 0 0 0 0 0 0 0 0 0 1 0 4 1 3 4 2 9 10 9 15 25 17 26 31 117 425 699
2009 0 0 0 0 1 0 0 2 0 1 1 1 2 3 8 14 17 8 15 11 10 9 16 14 34 118 332 617
2010 0 0 0 0 0 0 0 1 0 1 1 1 3 0 1 2 9 9 9 10 11 18 19 28 20 33 118 376 670
2011 0 0 0 0 0 0 0 1 1 0 0 0 0 2 0 3 1 1 3 2 1 6 14 6 11 13 11 84 226 386
Sum 1 4 29 41 82 142 200 262 306 438 571 696 829 998 1021 1072 1171 1059 1050 1062 968 853 831 717 616 589 461 460 226 16755
Table 5.2: Number of cases per notification and diagnosis year
The number of cases cross-classified by reporting delay and diagnosis year is repre-
sented in Figure 5.29 and the number of cases taking into consideration the reporting delay
and the notification year is presented in Figure 5.28. Both approaches include the marginal
distributions. From these representations, it is clear the long tailed distribution of the report-
ing delay as well as its extreme skewness. The marginal distribution of the notification year
and diagnosis year have already been discussed in sub-section 5.1.1.
Figure 5.28: Number of cases per notification
year and reporting delay with
marginal distributions of reporting
delay and number of cases per
notification year
Figure 5.29: Number of cases per diagnosis year
and reporting delay with marginal
distributions for the reporting delay
and incidence
Again, we focus at AIDS cases due to their lower probability of underreporting. The
above table displays how AIDS cases are occurring in the population over time and how
these cases, occurring at a given time point, subsequently arrive at the central office [176].
The latter process may be evolving over time, for example, if reporting improves or if the
increasing number of cases swamps available facilities [176].
This bivariate process may be formulated as a bivariate count process, which can be
fitted as:
Xij = γ + αDelayi + βDiagnosisj (5.1)
where Xij is the number of cases cross-classified by their delay length i and time of diag-
nosis j, with Delay and Diagnosis divided into time intervals and appropriately considered
as categorical variables.
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Let T0 be the date of the first reported diagnosed case and Tn be the most recent date.
Consider that the time interval [T0, Tn] of diagnosis is divided into equal length intervals, say
[Tj−1, Tj ] with j = 1, . . . , n. Let d0 be the shorter reporting delay observed and dm be the
longest. Consider that the reporting delay interval [d0; dm] is also divided into equal length
intervals, say [d(i−1); di] with i = 1, . . . ,m. Let Xij be the random variable representing
the number of AIDS cases diagnosed in the jth calendar interval [Tj−1, Tj ] whose reporting
delay falls on the interval [di−1, di]. Note that only AIDS cases whose diagnosis date plus
the reporting delay is less than Tn are recorded [203, 204]. Thus, only Xij satisfying 1 ≤
i ≤ mj , where mj = max{1, . . . ,m such that Tj + dmj ≤ Tn} are accessible. Whenever
Tj + dmj = Tn , the variable Xij is only partially observed.
The main statistical purpose in estimating the reporting delay distribution is to draw
inferences about an unknown vector θ of parameters that characterizes the joint distribution
of count random variables whose realizations are right-truncated [121].
The estimation of the reporting delay distribution has been based on Poisson regression
models assuming a stationary reporting delay process and estimation by conditional like-
lihood [203, 204, 199, 208, 121]. However, since Table 5.2 presents many zeros and too
much variation in the magnitude of the numbers, besides the fitting of the classical Poisson
process other models have also been considered: over-dispersed Poisson, Negative Bino-
mial, Zero-Inflated Poisson, Zero-Inflated Negative Binomial, Hurdle Poisson and Hurdle
Negative Binomial. The fit from these models is presented in Table 5.3.
The time intervals consisted of yearly quarters, a maximum delay of 9.5 years was
assumed (the other cases being considered as noise) and the first 39 months of registries
were included (from 1983 until 1986), due to the lack of quality in the data.
Comparing the estimates produced by all models, it can be seen that they do not vary
much. Also, the estimates of the effects attributed to the reporting delay decrease as the
length of the delay increases but the standard deviation is fairly constant until the delays
get larger than 96 months (approximately 8 years). In terms of the effect of the diagnosis,
the estimated effect increases until approximately month 120 (corresponding to the year
1993 when HAART was introduced); thereafter, the estimates slightly oscillated between
2.29 and 3.29 until the trim 288 (corresponding to the year 2007) where it started to slowly
decrease.
Table 5.3: Count regression models using as predictors the delays quarter and diagnosis quarter
Poisson Poisson
overdisper-
sion
Negative
Binomial
Zero-Inflated
Poisson
Zero-Inflated
Negative
Binomial
Hurdle Pois-
son
Hurdel Nega-
tive Binomial
value (sd) value (sd) value (sd) value (sd) value (sd) value (sd) value (sd)
(Intercept) 1.96 (0.28) 1.96 (0.35) 2.00 (0.33) 2.01 (0.35) 1.97 (0.29) 1.96 (0.35) 1.92 (0.42)
Delay (3,6] -1.48 (0.02) -1.48 (0.03) -1.55 (0.06) -1.48 (0.02) -1.54 (0.052) -1.48 (0.02) -1.53 (0.05)
Delay (6,9] -2.18 (0.03) -2.18 (0.04) -2.24 (0.06) -2.17 (0.03) -2.23 (0.06) -2.17 (0.03) -2.21 (0.05)
Delay (9,12] -2.65 (0.04) -2.65 (0.05) -2.74 (0.07) -2.63 (0.04) -2.71 (0.06) -2.64 (0.04) -2.7 (0.06)
Delay (12,15] -2.92 (0.05) -2.92 (0.06) -3.00 (0.07) -2.88 (0.047) -2.96 (0.07) -2.88 (0.047) -2.95 (0.06)
Delay (15,18] -3.26 (0.06) -3.26 (0.07) -3.34 (0.08) -3.21 (0.06) -3.28 (0.07) -3.22 (0.06) -3.27 (0.07)
Delay (18,21] -3.43 (0.06) -3.43 (0.07) -3.53 (0.08) -3.34 (0.06) -3.45 (0.08) -3.35 (0.06) -3.43 (0.08)
Delay (21,24] -3.68 (0.07) -3.68 (0.08) -3.77 (0.09) -3.59 (0.07) -3.70 (0.09) -3.63 (0.08) -3.72 (0.09)
Delay (24,27] -3.75 (0.07) -3.75 (0.09) -3.85 (0.09) -3.66 (0.07) -3.76 (0.09) -3.65 (0.08) -3.73 (0.09)
Delay (27,30] -3.93 (0.08) -3.93 (0.10) -4.02 (0.10) -3.77 (0.09) -3.89 (0.10) -3.73 (0.09) -3.80 (0.10)
Delay (30,33] -3.97 (0.08) -3.97 (0.10) -4.08 (0.10) -3.87 (0.08) -4.00 (0.10) -3.88 (0.10) -3.97 (0.11)
Delay (33,36] -4.04 (0.08) -4.04 (0.10) -4.16 (0.10) -3.89 (0.09) -4.04 (0.10) -3.89 (0.10) -4.00 (0.11)
Delay (36,39] -4.17 (0.09) -4.17 (0.11) -4.30 (0.11) -4.06 (0.09) -4.20 (0.11) -4.07 (0.11) -4.19 (0.12)
Delay (39,42] -4.39 (0.10) -4.39 (0.12) -4.50 (0.11) -4.25 (0.10) -4.39 (0.12) -4.18 (0.12) -4.29 (0.14)
Delay (42,45] -4.24 (0.09) -4.24 (0.12) -4.37 (0.11) -4.14 (0.10) -4.29 (0.11) -4.13 (0.11) -4.23 (0.13)
Delay (45,48] -4.57 (0.11) -4.57 (0.14) -4.70 (0.12) -4.46 (0.11) -4.61 (0.13) -4.34 (0.14) -4.47 (0.16)
Delay (48,51] -4.41 (0.10) -4.41 (0.13) -4.53 (0.12) -4.32 (0.11) -4.44 (0.12) -4.34 (0.13) -4.44 (0.15)
Delay (51,54] -4.64 (0.11) -4.64 (0.14) -4.78 (0.13) -4.49 (0.12) -4.68 (0.13) -4.28 (0.15) -4.43 (0.16)
Delay (54,57] -4.6 (0.11) -4.62 (0.14) -4.77 (0.13) -4.48 (0.12) -4.65 (0.13) -4.20 (0.14) -4.33 (0.16)
Delay (57,60] -4.53 (0.11) -4.5 (0.14) -4.68 (0.13) -4.40 (0.12) -4.58 (0.13) -4.26 (0.14) -4.38 (0.15)
Delay (60,63] -4.8 (0.13) -4.8 (0.16) -4.96 (0.14) -4.72 (0.13) -4.87 (0.14) -4.37 (0.16) -4.51 (0.18)
Delay (63,66] -4.72 (0.12) -4.72 (0.15) -4.85 (0.14) -4.62 (0.13) -4.77 (0.14) -4.37 (0.16) -4.48 (0.18)
Delay (66,69] -4.97 (0.14) -4.97 (0.17) -5.12 (0.15) -4.86 (0.14) -5.03 (0.15) -4.68 (0.20) -4.84 (0.21)
Delay (69,72] -4.80 (0.13) -4.80 (0.16) -4.94 (0.14) -4.66 (0.14) -4.84 (0.14) -4.51 (0.18) -4.66 (0.19)
Delay (72,75] -4.94 (0.14) -4.94 (0.17) -5.10 (0.15) -4.81 (0.15) -4.98 (0.15) -4.44 (0.18) -4.59 (0.20)
Delay (75,78] -5.33 (0.17) -5.33 (0.21) -5.47 (0.18) -5.22 (0.17) -5.37 (0.18) -5.29 (0.32) -5.43 (0.33)
Delay (78,81] -5.33 (0.17) -5.33 (0.21) -5.47 (0.18) -5.23 (0.18) -5.38 (0.18) -5.28 (0.32) -5.44 (0.33)
Delay (81,84] -5.13 (0.16) -5.13 (0.19) -5.28 (0.17) -5.02 (0.16) -5.18 (0.17) -4.82 (0.23) -4.97 (0.25)
Delay (84,87] -5.25 (0.17) -5.25 (0.21) -5.39 (0.18) -5.16 (0.17) -5.30 (0.18) -4.87 (0.26) -5.01 (0.27)
(Table continues...)
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Table 5.3: Count regression models using as predictors the delays quarter and diagnosis quarters
Poisson Poisson
Overdisper-
sion
Negative
Binomial
Zero-Inflated
Poisson
Zero-Inflated
Negative
Binomial
Hurdle Pois-
son
Hurdle Nega-
tive Binomial
value (sd) value (sd) value (sd) value (sd) value (sd) value (sd) value (sd)
Delay (87,90] -5.56 (0.20) -5.56 (0.24) -5.70 (0.21) -5.43 (0.20) -5.60 (0.21) -4.9 (0.31) -5.09 (0.33)
Delay (90,93] -5.27 (0.17) -5.27 (0.21) -5.41 (0.18) -5.11 (0.18) -5.30 (0.19) -4.24 (0.21) -4.39 (0.23)
Delay (93,96] -5.44 (0.19) -5.44 (0.24) -5.59 (0.20) -5.33 (0.19) -5.49 (0.20) -5.24 (0.34) -5.41 (0.35)
Delay (96,99] -5.98 (0.25) -5.98 (0.31) -6.13 (0.26) -5.87 (0.25) -6.04 (0.26) -5.51 (0.48) -5.71 (0.49)
Delay (99,102] -6.02 (0.26) -6.02 (0.32) -6.17 (0.27) -5.91 (0.26) -6.07 (0.27) -5.26 (0.48) -5.44 (0.49)
Delay (102,105] -5.34 (0.19) -5.34 (0.23) -5.50 (0.20) -5.19 (0.19) -5.39 (0.2) -4.30 (0.23) -4.51 (0.25)
Delay (105,108] -6.29 (0.31) -6.29 (0.38) -6.42 (0.31) -6.18 (0.31) -6.33 (0.31) -21.33
(1775.63)
-18.38
(361.69)
Delay (108,111] -5.83 (0.24) -5.83 (0.30) -5.98 (0.25) -5.72 (0.25) -5.89 (0.25) -5.31 (0.43) -5.50 (0.44)
Delay (111,114] -6.34 (0.32) -6.34 (0.39) -6.49 (0.32) -6.22 (0.32) -6.39 (0.32) -6.44 (0.98) -6.71 (0.99)
Diagnosis (39,42] -0.17 (0.41) -0.17 (0.51) -0.13 (0.48) -0.21 (0.51) -0.13 (0.44) -0.03 (0.50) 0.10 (0.60)
Diagnosis (42,45] -0.17 (0.41) -0.17 (0.51) -0.09 (0.48) -0.24 (0.46) -0.11 (0.45) -0.33 (0.54) -0.28 (0.64)
Diagnosis (45,48] 0.84 (0.33) 0.84 (0.41) 1.01 (0.41) 0.77 (0.39) 0.97 (0.37) 0.66 (0.42) 0.74 (0.51)
Diagnosis (48,51] 0 (0.39) 0 (0.49) -0.04 (0.48) 0.18 (0.48) 0.22 (0.53) 0.19 (0.49) 0.21 (0.59)
Diagnosis (51,54] 0.61 (0.34) 0.61 (0.43) 0.59 (0.43) 0.54 (0.40) 0.59 (0.38) 0.58 (0.42) 0.57 (0.52)
Diagnosis (54,57] 1.24 (0.31) 1.24 (0.40) 1.10 (0.40) 1.21 (0.38) 1.11 (0.35) 1.30 (0.39) 1.22 (0.48)
Diagnosis (57,60] 0.99 (0.32) 0.99 (0.40) 1.18 (0.40) 0.92 (0.38) 1.14 (0.36) 0.80 (0.41) 0.89 (0.50)
Diagnosis (60,63] 1.12 (0.32) 1.12 (0.40) 1.11 (0.40) 1.10 (0.39) 1.10 (0.35) 1.10 (0.40) 1.08 (0.49)
Diagnosis (63,66] 0.48 (0.35) 0.48 (0.44) 0.47 (0.44) 0.47 (0.43) 0.48 (0.46) 0.55 (0.43) 0.59 (0.54)
Diagnosis (66,69] 0.96 (0.33) 0.96 (0.41) 0.95 (0.41) 1.05 (0.39) 1.18 (0.40) 1.12 (0.40) 1.28 (0.50)
Diagnosis (69,72] 1.67 (0.30) 1.67 (0.38) 1.75 (0.38) 1.60 (0.37) 1.72 (0.34) 1.66 (0.38) 1.76 (0.47)
Diagnosis (72,75] 1.33 (0.31) 1.33 (0.39) 1.25 (0.40) 1.27 (0.38) 1.25 (0.35) 1.38 (0.39) 1.39 (0.48)
Diagnosis (75,78] 1.20 (0.32) 1.20 (0.40) 1.11 (0.40) 1.22 (0.38) 1.21 (0.38) 1.28 (0.39) 1.26 (0.49)
Diagnosis (78,81] 1.56 (0.31) 1.56 (0.38) 1.51 (0.39) 1.52 (0.38) 1.51 (0.34) 1.62 (0.38) 1.66 (0.47)
Diagnosis (81,84] 1.78 (0.30) 1.78 (0.37) 2.07 (0.37) 1.71 (0.36) 2.02 (0.33) 1.70 (0.37) 1.95 (0.46)
Diagnosis (84,87] 1.46 (0.31) 1.46 (0.38) 1.49 (0.39) 1.40 (0.38) 1.48 (0.34) 1.47 (0.38) 1.55 (0.48)
Diagnosis (87,90] 1.51 (0.31) 1.51 (0.38) 1.45 (0.39) 1.50 (0.37) 1.49 (0.36) 1.61 (0.38) 1.70 (0.47)
Diagnosis (90,93] 1.72 (0.30) 1.72 (0.38) 1.68 (0.38) 1.65 (0.37) 1.67 (0.34) 1.76 (0.37) 1.82 (0.47)
Diagnosis (93,96] 1.9 (0.30) 1.9 (0.37) 2.11 (0.37) 1.83 (0.36) 2.06 (0.33) 1.88 (0.37) 2.09 (0.46)
Diagnosis (96,99] 1.77 (0.30) 1.77 (0.37) 1.68 (0.38) 1.74 (0.37) 1.70 (0.35) 1.85 (0.37) 1.92 (0.46)
Diagnosis (99,102] 1.67 (0.30) 1.67 (0.38) 1.65 (0.38) 1.60 (0.37) 1.64 (0.34) 1.71 (0.38) 1.77 (0.47)
Diagnosis (102,105] 1.89 (0.30) 1.89 (0.37) 1.89 (0.38) 1.92 (0.36) 2.05 (0.34) 1.99 (0.37) 2.15 (0.46)
Diagnosis (105,108] 2.20 (0.29) 2.20 (0.36) 2.43 (0.36) 2.13 (0.36) 2.39 (0.32) 2.16 (0.37) 2.41 (0.45)
Diagnosis (108,111] 2.13 (0.29) 2.13 (0.37) 2.08 (0.37) 2.11 (0.36) 2.14 (0.34) 2.20 (0.37) 2.32 (0.46)
Diagnosis (111,114] 2.15 (0.29) 2.15 (0.36) 2.10 (0.37) 2.15 (0.36) 2.20 (0.34) 2.24 (0.37) 2.36 (0.46)
Diagnosis (114,117] 2.37 (0.29) 2.37 (0.36) 2.60 (0.36) 2.36 (0.36) 2.76 (0.32) 2.43 (0.36) 2.87 (0.45)
Diagnosis (117,120] 2.46 (0.29) 2.46 (0.36) 2.82 (0.36) 2.39 (0.36) 2.77 (0.31) 2.42 (0.36) 2.79 (0.45)
Diagnosis (120,123] 2.29 (0.22) 2.29 (0.36) 2.38 (0.37) 2.28 (0.36) 2.49 (0.33) 2.37 (0.36) 2.63 (0.45)
Diagnosis (123,126] 2.38 (0.29) 2.38 (0.36) 2.26 (0.37) 2.36 (0.36) 2.30 (0.33) 2.44 (0.36) 2.47 (0.45)
Diagnosis (126,129] 2.43 (0.29) 2.43 (0.36) 2.34 (0.37) 2.39 (0.36) 2.33 (0.32) 2.47 (0.36) 2.50 (0.45)
Diagnosis (129,132] 2.74 (0.29) 2.74 (0.36) 2.92 (0.36) 2.68 (0.35) 2.91 (0.32) 2.72 (0.36) 2.91 (0.44)
Diagnosis (132,135] 2.50 (0.29) 2.50 (0.36) 2.34 (0.37) 2.50 (0.36) 2.43 (0.33) 2.57 (0.36) 2.57 (0.45)
Diagnosis (135,138] 2.57 (0.29) 2.57 (0.36) 2.61 (0.36) 2.53 (0.35) 2.62 (0.32) 2.60 (0.36) 2.74 (0.45)
Diagnosis (138,141] 2.73 (0.29) 2.73 (0.36) 2.84 (0.36) 2.68 (0.35) 2.84 (0.32) 2.74 (0.36) 2.93 (0.44)
Diagnosis (141,144] 2.82 (0.29) 2.82 (0.36) 3.15 (0.35) 2.77 (0.35) 3.20 (0.31) 2.82 (0.36) 3.20 (0.44)
Diagnosis (144,147] 2.60 (0.29) 2.60 (0.36) 2.60 (0.36) 2.60 (0.35) 2.75 (0.32) 2.67 (0.36) 2.86 (0.45)
Diagnosis (147,150] 2.81 (0.29) 2.81 (0.36) 2.65 (0.36) 2.78 (0.35) 2.66 (0.32) 2.84 (0.36) 2.78 (0.44)
Diagnosis (150,153] 3.00 (0.28) 3.00 (0.35) 3.06 (0.36) 2.95 (0.35) 3.04 (0.31) 3.00 (0.36) 3.10 (0.44)
Diagnosis (153,156] 3.16 (0.28) 3.16 (0.35) 3.60 (0.35) 3.10 (0.35) 3.60 (0.31) 3.12 (0.36) 3.51 (0.44)
Diagnosis (156,159] 2.70 (0.29) 2.70 (0.36) 2.63 (0.36) 2.69 (0.35) 2.72 (0.32) 2.75 (0.36) 2.83 (0.45)
Diagnosis (159,162] 2.86 (0.28) 2.86 (0.36) 2.80 (0.36) 2.86 (0.35) 2.93 (0.32) 2.90 (0.36) 2.92 (0.44)
Diagnosis (162,165] 3.03 (0.28) 3.03 (0.35) 2.87 (0.36) 3.00 (0.35) 2.92 (0.31) 3.06 (0.36) 3.03 (0.44)
Diagnosis (165,168] 3.08 (0.28) 3.08 (0.35) 3.52 (0.35) 3.01 (0.35) 3.43 (0.31) 3.02 (0.36) 3.33 (0.44)
Diagnosis (168,171] 2.90 (0.28) 2.90 (0.35) 2.96 (0.36) 2.83 (0.35) 2.92 (0.31) 2.88 (0.36) 2.96 (0.44)
Diagnosis (171,174] 2.81 (0.29) 2.81 (0.36) 2.93 (0.36) 2.75 (0.35) 2.90 (0.32) 2.79 (0.36) 2.92 (0.44)
Diagnosis (174,177] 2.94 (0.28) 2.94 (0.35) 3.00 (0.36) 2.90 (0.35) 3.01 (0.32) 2.94 (0.36) 3.05 (0.44)
Diagnosis (177,180] 3.29 (0.28) 3.29 (0.35) 3.60 (0.35) 3.22 (0.35) 3.54 (0.30) 3.24 (0.36) 3.47 (0.44)
Diagnosis (180,183] 2.92 (0.28) 2.92 (0.35) 3.03 (0.36) 2.84 (0.35) 2.99 (0.31) 2.88 (0.36) 2.97 (0.44)
Diagnosis (183,186] 2.81 (0.28) 2.81 (0.36) 2.70 (0.36) 2.75 (0.35) 2.69 (0.31) 2.82 (0.36) 2.78 (0.44)
Diagnosis (186,189] 3.16 (0.28) 3.16 (0.35) 3.17 (0.35) 3.12 (0.35) 3.18 (0.31) 3.16 (0.36) 3.22 (0.44)
Diagnosis (189,192] 3.23 (0.28) 3.22 (0.35) 3.70 (0.35) 3.15 (0.35) 3.63 (0.30) 3.15 (0.36) 3.49 (0.44)
Diagnosis (192,195] 2.90 (0.28) 2.90 (0.35) 2.95 (0.36) 2.86 (0.35) 2.99 (0.31) 2.90 (0.36) 2.97 (0.44)
Diagnosis (195,198] 3.05 (0.28) 3.05 (0.35) 2.99 (0.36) 2.98 (0.35) 2.97 (0.31) 3.02 (0.36) 2.94 (0.44)
Diagnosis (198,201] 2.94 (0.28) 2.94 (0.35) 3.01 (0.36) 2.87 (0.35) 2.98 (0.31) 2.91 (0.36) 2.98 (0.44)
Diagnosis (201,204] 3.26 (0.28) 3.26 (0.35) 3.61 (0.35) 3.19 (0.35) 3.55 (0.31) 3.19 (0.36) 3.41 (0.44)
Diagnosis (204,207] 2.92 (0.28) 2.92 (0.35) 3.00 (0.36) 2.87 (0.35) 2.96 (0.31) 2.89 (0.36) 2.94 (0.44)
Diagnosis (207,210] 2.84 (0.29) 2.84 (0.36) 2.76 (0.36) 2.80 (0.35) 2.77 (0.32) 2.85 (0.36) 2.83 (0.44)
Diagnosis (210,213] 3.11 (0.28) 3.11 (0.35) 2.94 (0.36) 3.06 (0.35) 2.94 (0.31) 3.11 (0.36) 3.0 (0.44)
Diagnosis (213,216] 3.08 (0.28) 3.08 (0.35) 3.46 (0.35) 3.01 (0.35) 3.38 (0.31) 3.00 (0.36) 3.20 (0.44)
Diagnosis (216,219] 2.95 (0.28) 2.95 (0.35) 2.89 (0.36) 2.88 (0.35) 2.88 (0.31) 2.92 (0.36) 2.88 (0.44)
Diagnosis (219,222] 2.84 (0.29) 2.84 (0.36) 2.52 (0.36) 2.84 (0.35) 2.63 (0.32) 2.90 (0.36) 2.72 (0.44)
Diagnosis (222,225] 3.04 (0.28) 3.04 (0.35) 2.90 (0.36) 3.02 (0.35) 2.93 (0.31) 3.07 (0.36) 3.018 (0.44)
Diagnosis (225,228] 3.19 (0.28) 3.19 (0.35) 3.46 (0.35) 3.12 (0.35) 3.40 (0.31) 3.13 (0.36) 3.31 (0.44)
Diagnosis (228,231] 2.89 (0.29) 2.89 (0.35) 2.95 (0.36) 2.82 (0.35) 2.26 (0.31) 2.87 (0.36) 2.95 (0.44)
Diagnosis (231,234] 2.92 (0.28) 2.92 (0.35) 2.89 (0.36) 2.91 (0.35) 3.02 (0.32) 2.96 (0.36) 3.11 (0.44)
Diagnosis (234,237] 2.91 (0.28) 2.91 (0.35) 2.94 (0.36) 2.87 (0.35) 2.99 (0.31) 2.93 (0.36) 3.05 (0.44)
Diagnosis (237,240] 3.11 (0.28) 3.11 (0.35) 3.37 (0.35) 3.04 (0.35) 3.32 (0.31) 3.08 (0.36) 3.34 (0.44)
Diagnosis (240,243] 2.88 (0.28) 2.88 (0.35) 2.82 (0.36) 2.84 (0.35) 2.83 (0.32) 2.89 (0.36) 2.92 (0.44)
Diagnosis (243,246] 2.80 (0.29) 2.80 (0.36) 2.89 (0.36) 2.73 (0.35) 2.87 (0.31) 2.77 (0.36) 2.89 (0.44)
Diagnosis (246,249] 2.88 (0.29) 2.88 (0.35) 2.91 (0.36) 2.82 (0.35) 2.89 (0.31) 2.88 (0.36) 2.97 (0.44)
Diagnosis (249,252] 3.02 (0.28) 3.02 (0.35) 3.30 (0.35) 2.95 (0.35) 3.24 (0.31) 2.98 (0.36) 3.24 (0.44)
Diagnosis (252,255] 2.76 (0.29) 2.76 (0.36) 2.71 (0.36) 2.71 (0.35) 2.70 (0.31) 2.77 (0.36) 2.79 (0.44)
Diagnosis (255,258] 2.52 (0.29) 2.52 (0.36) 2.48 (0.37) 2.51 (0.36) 2.58 (0.32) 2.55 (0.36) 2.60 (0.45)
Diagnosis (258,261] 2.79 (0.29) 2.80 (0.36) 2.74 (0.36) 2.75 (0.35) 2.74 (0.32) 2.1 (0.36) 2.83 (0.44)
Diagnosis (261,264] 3.08 (0.28) 3.08 (0.35) 3.30 (0.35) 3.02 (0.35) 3.25 (0.31) 3.03 (0.36) 3.17 (0.44)
Diagnosis (264,267] 2.66 (0.29) 2.66 (0.36) 2.58 (0.36) 2.60 (0.35) 2.57 (0.32) 2.66 (0.36) 2.63 (0.45)
Diagnosis (267,270] 2.57 (0.29) 2.57 (0.36) 2.50 (0.37) 2.51 (0.35) 2.48 (0.32) 2.55 (0.36) 2.47 (0.45)
Diagnosis (270,273] 2.61 (0.29) 2.61 (0.36) 2.56 (0.37) 2.58 (0.35) 2.62 (0.33) 2.64 (0.36) 2.72 (0.45)
Diagnosis (273,276] 2.90 (0.29) 2.90 (0.36) 3.09 (0.36) 2.83 (0.35) 3.05 (0.31) 2.87(0.36) 3.08 (0.44)
Diagnosis (276,279] 2.48 (0.29) 2.48 (0.36) 2.32 (0.37) 2.50 (0.35) 2.47 (0.33) 2.56 (0.36) 2.57 (0.45)
(Table continues...)
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Table 5.3: Count regression models using as predictors the delays quarter and diagnosis quarters
Poisson Poisson
Overdisper-
sion
Negative
Binomial
Zero-Inflated
Poisson
Zero-Inflated
Negative
Binomial
Hurdle Pois-
son
Hurdle Nega-
tive Binomial
value (sd) value (sd) value (sd) value (sd) value (sd) value (sd) value (sd)
Diagnosis (279,282] 2.63 (0.29) 2.63 (0.36) 2.62 (0.37) 2.59 (0.35) 2.64 (0.33) 2.65 (0.36) 2.73 (0.45)
Diagnosis (282,285] 2.54 (0.29) 2.54 (0.36) 2.54 (0.37) 2.48 (0.35) 2.53 (0.32) 2.52 (0.36) 2.55 (0.45)
Diagnosis (285,288] 2.77 (0.29) 2.76 (0.36) 2.83 (0.36) 2.70 (0.35) 2.81 (0.32) 2.72 (0.36) 2.77 (0.44)
Diagnosis (288,291] 2.51 (0.29) 2.51 (0.36) 2.33 (0.37) 2.52 (0.36) 2.49 (0.33) 2.58 (0.36) 2.58 (0.45)
Diagnosis (291,294] 2.27 (0.29) 2.27 (0.36) 2.03 (0.38) 2.22 (0.36) 2.05 (0.33) 2.29 (0.37) 2.15 (0.45)
Diagnosis (294,297] 2.51 (0.29) 2.51 (0.36) 2.38 (0.37) 2.47 (0.36) 2.39 (0.33) 2.52 (0.36) 2.48 (0.45)
Diagnosis (297,300] 2.76 (0.29) 2.76 (0.36) 2.75 (0.37) 2.69 (0.35) 2.73 (0.32) 2.73 (0.36) 2.72 (0.45)
Diagnosis (300,303] 2.48 (0.29) 2.48 (0.36) 2.23 (0.38) 2.45 (0.36) 2.25 (0.33) 2.50 (0.36) 2.36 (0.45)
Diagnosis (303,306] 2.27 (0.29) 2.27 (0.36) 2.18 (0.38) 2.26 (0.36) 2.29 (0.34) 2.32 (0.37) 2.38 (0.46)
Diagnosis (306,309] 2.30 (0.29) 2.30 (0.36) 2.26 (0.38) 2.24 (0.36) 2.25 (0.33) 2.28 (0.37) 2.28 (0.45)
Diagnosis (309,312] 2.41 (0.29) 2.41 (0.36) 2.30 (0.38) 2.36 (0.36) 2.31 (0.33) 2.42 (0.36) 2.41 (0.45)
Diagnosis (312,315] 2.34 (0.29) 2.34 (0.36) 2.12 (0.39) 2.30 (0.36) 2.15 (0.33) 2.36 (0.36) 2.27 (0.46)
Diagnosis (315,318] 2.22 (0.29) 2.22 (0.37) 1.95 (0.39) 2.24 (0.36) 2.13 (0.35) 2.29 (0.37) 2.23 (0.46)
Diagnosis (318,321] 2.25 (0.29) 2.25 (0.37) 2.14 (0.39) 2.24 (0.36) 2.25 (0.35) 2.29 (0.37) 2.34 (0.46)
Diagnosis (321,324] 2.62 (0.29) 2.61 (0.36) 2.46 (0.39) 2.56 (0.36) 2.48 (0.34) 2.61 (0.36) 2.54 (0.45)
Diagnosis (324,327] 2.46 (0.29) 2.46 (0.36) 2.27 (0.40) 2.41 (0.36) 2.30 (0.34) 2.46 (0.36) 2.36 (0.46)
Diagnosis (327,330] 2.17 (0.30) 2.17 (0.37) 1.82 (0.41) 2.12 (0.36) 1.88 (0.36) 2.17 (0.37) 1.95 (0.47)
Diagnosis (330,333] 2.21 (0.30) 2.21 (0.37) 198 (0.42) 2.16 (0.36) 2.02 (0.36) 2.21 (0.37) 2.09 (0.47)
Diagnosis (333,336] 2.25 (0.30) 2.251 (0.37) 2.03 (0.44) 2.20 (0.36) 2.07 (0.38) 2.25 (0.37) 2.14 (0.48)
Diagnosis (336,339] 2.04 (0.31) 2.04 (0.38) 2.01 (0.5) 2.00 (0.37) 2.04 (0.44) 2.04 (0.38) 2.09 (0.52)
R2 or pseudo R2 0.99 0.97 0.88 0.95 0.89 0.91 0.85
RMSD 3.29 3.29 7.64 4.16 6.61 7.36 7.85
AIC 9768.9 9768.9 9433.5 9819.82 9578.59 10609.55 10432.34
BIC 10603.82 10274.51 11265.19 11029.24 12055.19 11883.24
Number parameters 138 138 139 239 240 239 240
Log L -4746 -4578 -4671 -4549 -5066 -4976
From all measures of goodness-of-fit of the models, the Poisson process represented
the best choice.
Harris described the basic statistical model in [121], and an application to the Por-
tuguese AIDS incidence data reported until 2001 was presented in [203, 204]. This process
may be formulated as a bivariate Poisson process corresponding to a log-linear model with
an independence structure, and can be used as a measure of the stationarity of the process.
Assume that Xij are independent and identically distributed following a Poisson distri-
bution with parameter µij . If Y ∗ =
m∑
i=1
Xij represents the total number of AIDS cases diag-
nosed in [tj−1, tj ] , whether or not they have been reported by the time tn, then {Y ∗} are in-
dependent and identically distributed, following a Poisson distribution with mean
m∑
i=1
µij (θ),
which may be interpreted as the AIDS incidence in the time interval [tj−1, tj ].
For each j = 1, . . . , n , we also have that {Xij , X2j , . . . , Xmj} |Y ∗j has a multinomial
distribution upon Y ∗j trials with probabilities
Π = {Π1j (θ) ,Π2j (θ) , . . . ,Πmj (θ)}. (5.2)
Here
Πij (θ) =
µij
m∑
i=1
µij (θ)
(5.3)
is the probability of an AIDS case being reported with a delay in the time interval [di−1, di],
given that it has been diagnosed in the time interval [tj−1, tj ].
Assuming a separability restriction on µij (θ), the parameter θ can be partitioned as
(α, θ) so that
µij (α, β) = Πij (α)
m∑
i=1
µij (β). (5.4)
As such, the delay probabilities depend only on α and the incidence depends only on β.
For each j = 1, . . . , n, let
Yj =
mj∑
i=1
Xij (5.5)
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be the number of observed AIDS cases that were diagnosed at the time interval [Tj−1, Tj ]
and reported until the end of the observation period. The
{
Yj |Y ∗j
}
are independent and
identically distributed with a Binomial distribution with the probability of a success given by
Ωj (α) =
mj∑
i=1
Πij (α) .
This represents the probability of an AIDS case being reported until Tn, given that it was
diagnosed at the time interval [Tj−1, Tj ].
For j = 1, . . . , n, {(X1j , X2j , . . . , Xmj)|Yj} is multinomial upon Yj trials with probabilities{
Π1j (α)
Ωj (α)
, . . . ,
Πmjj (α)
Ωj (α)
}
. (5.6)
Here, Πij(α)Ωj(α) is the probability that an AIDS case is reported with delay falling in [di−1, di],
given that it is diagnosed in [Tj−1, Tj ] and reported until Tn.
The likelihood function L (θ), given the separability restriction above, can be written as
L (α, β) = Lc (α)Lm (β) (5.7)
with Lc (α) being the conditional likelihood based on the observed data and Lm (β) the
marginal likelihood. As such,
Lc (α) =
n∏
j=1
mj∏
i=1
[
piij (α)
Ωj (α)
]xij
(5.8)
and
Lm (α, β) =
n∏
j=1
[
Ωj (α)
m∑
i=1
µij (β)
]yj
exp
(
−Ωj (α)
m∑
i=1
µij (β)
)
. (5.9)
Brookmeyer and Damiano relied in the likelihood (5.8) to produce the estimates for the
parameters in the reporting delay distribution [203, 204, 212, 199, 208]. They considered
that
{
X1j , X2j , . . . , Xmjj
}
|Yj follows a Multinomial distribution with probabilities given by
pij (αi) =
Πij (αi)
Ωj (αi)
= exp (αi)mj∑
i=1
exp (αi)
(5.10)
which can be easily estimated using a Multinomial-Poisson transformation and standard
regression packages. As mentioned by Amaral, Pereira and Paixão [203, 204], the num-
ber of diagnosed and reported cases in the time calendar [Tj−1, Tj ], j = 1, . . . , n can be
multiplied by the weighting factormj−1∑
i=1
pij (αˆi) +
pmjj
(
ˆαmj
)
2
−1 (5.11)
in order to obtain an estimate of the cases which were diagnosed and reported [204,
208].
A common consideration is letting α1 = β1 = 0, which is equivalent to say that at the
beginning of the epidemic there was only one person [208].
Returning to Table 5.3, a further inspection of the fitted Poisson model was performed.
The relationship between the Poisson mean and variance presents slight problems, repre-
sented on Figure 5.31, and few outliers seem to be affecting the fit of the model - Figure
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Figure 5.30: Half-normal plot of the residuals of
the Poisson model
Figure 5.31: Relationship between mean and
variance
Figure 5.32: Number of observed AIDS cases against the predicted number of AIDS by the Poisson
model
5.30. The observed problems of the relationship between the mean and variance of the
Poisson process seem to be related to the existence of missing cells in Table 5.2 [176]. For
this model, it was obtained a deviance of 4276.5 with 2997 degrees of freedom, indicat-
ing a non-stationary process or quasi-independent model which will be further analysed in
subsection 5.2.2.
However, the comparison of the observed values against the predicted values suggests
the model is useful in capturing the observed patterns. For further evaluating the accuracy
of the model, the holdout method was applied. The Xij data was randomly divided into two
sets: 75% of the data was used to train the model (2351 cases) and 25% used to test it
(784 cases). Within the training set, the maximum value of the log-likelihood function for
the estimations was LL = -4746. Within the test set, it was estimated RMSE = 5.511 and
R2 = 0.899. These results indicate that the Poisson model is able to capture the trend in
the data and fits moderately well. For obtaining the final reporting delay estimate we used
the whole data set; RMSE = 3.291 and R2 = 0.969 were found.
The results from estimating the reporting delay probabilities with equation (5.10) are
presented in Table 5.4 .
These estimates are close to the ones obtained previously for the Portuguese epidemic
in [203, 204].
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Table 5.4: Estimated reporting delay probabilities for each quarter
Reporting delay in quarters Estimated probabilities of reporting delay
0 - 3 0.548
4 - 6 0.125
7 - 9 0.062
10 - 12 0.039
13 - 15 0.030
16 - 18 0.021
19 - 21 0.018
22 - 24 0.014
25 - 27 0.013
28 - 30 0.011
31 - 33 0.010
34 - 36 0.010
The evaluation indicates that approximately 80% of the AIDS cases were reported within
one year after the diagnosis and that the majority of the cases were notified within the first
three months. The accuracy of the procedure can also be indicated by the relative stability
over time of the resulting estimates of the reporting delay observed in Figure 5.21.
Underreporting
Fader and Hardie in 2000 proposed a model for under-reported Poisson counts using nat-
ural conjugate prior distributions and maximum likelihood, described in [213]. The method-
ology proposed that the probability of an AIDS case not being reported can be estimated
by the Beta Binomial / Negative Binomial model developed by [213].
Let Y ∗ be the current (unobserved) number of events and Y be the number of reported
events. We are interested in the following:
• the probability of occurring y∗ AIDS cases, conditional on the fact that y AIDS cases
have been reported:
P (Y ∗ = y∗|Y = y) ; (5.12)
• the distribution of the reporting probability of one case in light of the fact that y AIDS
cases have been reported:
g (p|Y = y) ; (5.13)
• the distribution of the true rate parameter, conditional on y reported AIDS cases:
f (λ|Y = y) . (5.14)
The model assumes that:
(i) The actual (unobserved) number of AIDS cases - Y ∗ - in the unit time interval is
Poisson distributed with rate λ, i.e.,
Y ∗|λ ∼ P (λ) (5.15)
P (Y ∗ = y∗|λ) = λ
y∗ exp(−λ)
y∗! , y
∗ = 0, 1, . . . ;λ > 0 (5.16)
5.2. Discrete Outcomes 121
(ii) An AIDS case is reported with probability p. So, conditional on y∗, the number of
reported AIDS, Y , follows a binomial distribution with probability mass function
Y |Y ∗ = y∗ ∼ B (y∗, p) (5.17)
P (Y = y|y∗, p) =
(
y∗
y
)
py (1− p)y∗−y , y = 0, 1, . . . , y∗; 0 < p < 1, y∗ ∈ Z+ (5.18)
(iii) The probability of an AIDS case being reported (p) is independent from the rate de-
velopment of AIDS (λ)
(iv) λ ∼ Gamma (α, r) (the Gamma function is a conjugate prior of the Poisson family)
f (λ) = α
rλr−1 exp(−λα)
Γ (r) , λ > 0; r, α > 0 (5.19)
and Γ (r) =
∫ ∞
0
tr−1 exp (t) dt (5.20)
(v) p ∼ Beta (a, b)
g (p) = 1
B(a, b)p
a−1 (1− p)b−1 , 0 < p < 1, a, b > 0 (5.21)
a
B (a, b) =
Γ (a+ b)
Γ (a) Γ (b) (5.22)
From assumptions (i) and (iii) it follows that
P (Y ∗ = y∗) = Γ (r + y
∗)
Γ (r) y∗!
(
α
α+ 1
)( 1
α+ 1
)y∗
(5.23)
and assumptions (ii) and (iv) define the Beta-Binomial (BB) model
Y |Y ∗ ∼ BB(α, β) (5.24)
with
P (Y = y|Y ∗) =
(
y∗
y
)
Beta (α+ y, β + y∗ − y)
Beta (α, β)
=
(
y∗
y
)
Γ (α+ y) Γ (β + y∗ − y)
Γ (α+ β + y∗)
Γ (α+ β)
Γ (α) Γ (β) . (5.25)
From assumptions (i) and (ii), Y |λ, p ∼ P (λp) i.e.,
P (Y = y|λ, p) =
∞∑
Y ∗=y
P (Y = y|n, p)P (Y ∗ = y∗|λ)
= (λp)
y exp (−λp)
y! . (5.26)
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Finally, from (i), (iii), (iv) and (v):
P (Y = y) =
∫ ∫
P (Y = y|λ, p) f (λ) g (p) dλdp
= Γ (r + y)Γ (r) y!
(
α
α+ 1
)r ( 1
α+ 1
)y Γ (a+ y)
Γ (a)
Γ (a+ b)
Γ (a+ b+ y) ×
×2F1
(
r + y, b; a+ b+ y; 1
α+ 1
)
= 1(r + y)Beta (r, y + 1)
Beta (a+ y; b)
Beta (a, b)
αr
(α+ 1)r+y
×
×2F1
(
r + y, b; a+ b+ y; 1
α+ 1
)
, y = 0, 1, 2, . . . ; r, α, a, b > 0 (5.27)
where 2F1 (.) is theGauss hypergeometric function defined by 2F1 (a, b; c; z) =
∞∑
n=0
(a)n (b)n
(c)n n!
zn,
with |z| < 1, c ̸= 0,−1,−2, . . .. The symbol (a)n is the Pochhammer’s symbol and can be
calculated using
(a)n =
Γ (a+ n)
Γ (a) (5.28)
This is known as the BB / NBD model with
E (Y ) = ra
α (a+ b)
V ar (Y ) = ra
α (a+ b)
[ 1
α (a+ b+ 1)
(
rb
a+ b + a+ 1
)
+ 1
]
.
It can be shown ([213, 214, 215, 216]) that the expected value of Y ∗ given Y is
E (Y ∗|Y = y) = y + r + y
α+ 1
Beta (a+ y, b+ 1)
Beta (a+ y, b)
2F1
(
r + y + 1, b+ 1; a+ b+ y + 1; 1α+1
)
2F1
(
r + y, b; a+ b+ y; 1α+1
) ,
(5.29)
that the expected value of pi conditional to Y is
E (pi|Y = y) = a+ y
a+ b+ y
2F1
(
r + y, b; a+ b+ y + 1; 1α+1
)
2F1
(
r + y, b; a+ b+ y; 1α+1
) (5.30)
and finally, that the expected value of λ given Y is
E (λ|Y = y) = r + y
α+ 1
2F1
(
r + y + 1, b; a+ b+ y; 1α+1
)
2F1
(
r + y, b; a+ b+ y; 1α+1
) (5.31)
The estimation of a, b, r and α from the BB/NBD model can be obtained by minimizing the
log likelihood function which, in this case, is a complex numerical problem since this function
has several ridges.
To study which combination of initial parameters and which numerical optimization al-
gorithms are able to find the minimum, the function was reparametrized in order to expand
the search space. A combination of initial parameters in the set (r, α, a, b) ∈ [0, 1]× [0, 1]×
[0, 1] × [0, 1] with step = 0.1 was considered; that is, a web of 10 × 10 × 10 × 10 = 10000
starting points was created. The minimum was found by application of the most common
optimization algorithms, namely:
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• the Nelder and Mead algorithm used for unconstrained problems (no lower or upper
specified); it uses only function values, is robust but relatively slow and works reason-
ably well for non-differentiable functions (Figure 5.33a);
• the BFGS or the variable metric method; updates an approximation of the inverse
Hessian using the BFGS update formulas, along with an acceptable point line search
strategy but appears to work best with analytic gradients (Figure 5.33b);
• the L-BFGS method; it is a generalization of the BFGS allowing box constraints, ie,
each variable can be given a lower and/or upper bound (Figure 5.33c);
• the BOBYQA algorithm; it implements an optimization by quadratic approximation for
box constrained problems (Figure 5.33d);
• the NEWUOA algorithm; it implements an optimization by quadratic approximation for
unconstrained minimization (Figure 5.33e);
• the NLM algorithm; it implements a Newton-type algorithm (Figure 5.33f);
• the NLMINB algorithm; it implements unconstrained and box-constrained optimization
using PORT routines (Figure 5.33g);
• the SPG algorithm; it implements a spectral projected gradient method for large-scale
optimization with simple constraints (Figure 5.33h);
• the UCMINF algorithm; used for general-purpose unconstrained non-linear optimiza-
tion (Figure 5.33i).
From the 10000 times the optimization algorithms were started, the algorithm SPG con-
verged more times, that is 1770 (almost 18% of the runs) and the NEWUOA converged the
least times, 540 (5.4%). The algorithms NLMINB, UCMINF and LBFGSB performed close
to the SPG.
In terms of starting values naturally, the Neldermead, NLMINB, SPG, UCMINF, NLM and
LBFGSB algorithms allowed a larger variety of combinations but a pattern of combinations is
common to all algorithms; that is, rmust be in {1; 0.8; 0.6; 0.4; 0.2} and αmust be in the same
subset (here, r and α are the Γ parameters). From the different methods, a maximum value
for the log-likelihood function of LL = −586.601 was found, corresponding to rˆ = 61.86,
αˆ = 0.21, aˆ = 1.20 and bˆ = 0.87. To evaluate the goodness-of-fit of the model, the number
of AIDS cases was divided into intervals of length 25 and the χ2- test was used. The values
χ2 = 9.03 and p = 0.43 were obtained, thus supporting the use of the model (5.34). Using
equation (5.30), the model suggests that the probability of an AIDS case being notified is
higher when a large amount of AIDS cases had already been notified. This relationship
is represented in Figure 5.35. The estimated number of diagnosed AIDS cases adjusted
for reporting delay and underreporting was estimated by equation (5.29). As Figure 5.36
suggests, this distribution is very different from the distribution of AIDS cases diagnosed
and reported to CVDT, not capturing the marked decrease of the AIDS incidence from 1999
onwards. Although the model goodness-of-fit seems to be reasonable, the underreporting
process is not being captured using only marginal data.
5.2.2 Separate Modelling - Accounting for a Non Stationary Process
As the need for medical care is much higher in late-stage infections, the under - diagnosis
is less likely to occur in AIDS cases. We will therefore restrict ourselves only to this stage
in the following analysis.
The reporting delay is defined as the time mediating from HIV - AIDS diagnosis to the
reporting of this event at national level [69].
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Figure 5.33: Optimization Performance
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Figure 5.34: Number of AIDS cases observed against number of AIDS cases estimated by the
BB/NBD model.
Figure 5.35: Expected probability of an AIDS case being notified for a given number of notified AIDS
cases. The estimations were obtained with the BB/NBD model
Figure 5.36: Number of AIDS cases diagnosed and reported to CVDET per year (without adjust-
ment) and number of AIDS cases adjusted for reporting delay and underreporting
The first case diagnosed (and reported) will be represented by 0 and x∗ will denote the
end of the observation period. The time interval [0, x∗] thus represents the observed time
for diagnosis observed.
Let this time interval be divided into 3 months-unit length. The same division is set to
the reporting delay time interval.
The AIDS cases are then cross-classified by the diagnosis and reporting delay quarter.
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Figure 5.37: Percentage of AIDS cases per di-
agnosis and delay quarters. The
shaded region identifies those (re-
cent) years that have to be cor-
rected.
Figure 5.38: Percentage of AIDS cases per quar-
ter of diagnosis and delay quarter
longer than 3 months
We denote by Xij the annual percentage of AIDS cases that were diagnosed in quarter i
and have a reporting delay falling into quarter j. Fixing a reporting delay quarter, one can
observe a delay pattern over time.
We now proceed as follows:
1. identification of homogeneous patterns for the observed delays considering that there
is no bias. The clustering is performed by a longitudinal version of the K-means algo-
rithm. This step identifies the tendencies across the reporting delays, thus reducing
the number of curves of reporting delays to be considered.
2. evaluation of the effects of the reporting delays and date of diagnoses on the evolution
of the epidemic (percent-wise). We use linear regression with estimation performed by
generalized least squares, thus allowing for heteroscedastic errors. We will consider
only cases diagnosed until 2008 due to the reporting delay.
3. Imputation on Xij according to the obtained results.
Due to the lack of understanding of the HIV infection development during its first years, we
will consider only cases diagnosed after June 1986.
Longitudinal K-means Figure 5.37 depicts the reporting delays that are registered in the
national AIDS surveillance system. The delays were grouped into trimesters and the annual
percentage of cases within each diagnosis year is represented.
The most recent year (shaded region) does not seem to be describing the real situation
as several cases have not been notified yet. Most of the cases are reported within 3 months
after diagnosis but some are still being reported with more than one year of delay. For
the sake of clarity, delays longer than 18 months are omitted from figures 5.37 and 5.38.
The longer delays, e.g. more than 6 months, have an almost constant behaviour through
time not exceeding 10% of the cases (figure 5.38). Graphical inspection may suggest a
2-cluster structure since the delay curve (0, 3] is fully separated from the rest. However,
due to epidemiological interest it is important to explore other clustering structures.
Since clustering analysis involves exploratory methods, 2-, 3- and 4-cluster structures,
each of them with 40 randomly chosen starting points, were studied. The longitudinal K-
means algorithm was applied, considering the euclidean distance with the Gower adjust-
ment and implemented via Expectation-Maximization. The optimal number of clusters was
determined with the help of several criteria: Calinsky and Harabatz, Ray and Turi, Davies
and Bouldin, and the Bayesian and Akaike Information Criteria (BIC and AIC, respectively).
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All should ideally agree and be as large as possible except BIC and AIC that should be low
[182].
For the reporting delays, and considering partitions from 2 to 4 clusters, the behaviour
of the quality criteria is represented in figure 5.39. The clustering result for 3 classes is
described in table 5.5.
Figure 5.39: Quality Criteria for longitudinal clustering. 0 - Calinsky and Harabatz; 1 - Calinsky and
Harabatz2; 3 - Calinsky and Harabatz3; 4 -Ray and Turi; 5 -Davies and Bouldin; 6 -
Bayesian Information Criterion (BIC); 7 - BIC with correction for finite sample size; 8-
Akaike Information Criterion (AIC); 9- AIC with correction for finite sample size
Table 5.5: Description of analysed clusters
Number of Clusters Clusters ID
2 C1: (0,3]; C2: >3 months
3 C1: (0,3]; C2: (3,6]; C3: >6 months
4 C1: (0,3]; C2: (3,6]; C3: (6,9]; C4: >9 months
From the analysis of figure 5.39 and table 5.5, we considered a 2-cluster structure.
Generalised least squares Since the number of AIDS cases in the most recent diagnosis
are biased due to the effect of the reporting delay, the latest 4 years were removed from
the analysis.
The general equation of the adjusted time evolution model for the reporting delay curves
is
X̂i = 0.461 + 0.0104i+ (−0.415)C2 + (−0.0103)i ∗ C2 (5.32)
were Xi is the annual percentage of AIDS cases, i is the year of diagnosis and C2 is as
described in Table 5.5 (the reference level is the cluster (0, 3]) .
The adjusted time effect on the AIDS incidence rate has to be described within each
of the identified clusters: in Cluster [0, 3] months (resp. [3 − 18] months ), the model pre-
dicted a yearly increase of 1.04% (p<0.001) (resp. increase of 0.01% (p<0.005). For any
fixed values of the covariates in the model, including time, Cluster [0, 3] have the highest
percentage of cases (Table 5.6). Estimates for the main effects and the interaction effects
are presented in Table 5.7.
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Table 5.6: Estimates from the regression model for the relative AIDS incidence (within the HIV pop-
ulation) cross-classified by year of diagnosis and reporting delay quarter
Variable Estimated Estimated t-value P-value
Coefficient Standard Error
Intercept 0.461 < 0.001 7.82E+08 < 0.001
Year of diagnosis 0.0104 < 0.001 1.09E+08 < 0.001
C2 ([0, 3] is the reference class) -0.415 0.0135 9.47E+02 < 0.001
Year of diagnosis * C2 -0.0103 < 0.001 1.43e+04 < 0.001
The homocedasticity and normality of the residuals were studied by graphical analysis
and these assumptions did not seem to be compromised.
Individual delay curves can be obtained from (5.32) and these models can be used for
estimating the expected percentage of cases for each delay.
Table 5.7: Individual models for the annual AIDS percentage cross-classified by diagnosis year and
reporting delay quarter
Reporting delay Estimated model
(0, 3] Xi = 0.461 + 0.0104i
> 3 Xi = 0.046 + 0.0001i
5.2.3 Non-Parametric Estimates
In order to identify the main factors influencing the reporting delays in the HIV-AIDS cases
within the Portuguese Surveillance System, several data mining models were considered:
multilayer artificial neural networks (MLP), naive Bayesian classifiers (NB), support vector
machines (SVM) and the K-Nearest Neighbour algorithm (KNN).
Data Pre-Processing As most HIV-AIDS cases were seen to be reported within the first 3
months after diagnosis, and the reporting behaviour seemed to be homogeneous from that
onwards (Figure 5.20), reporting delays were discretized into two classes, with a cut-point
at 3 months after diagnosis [22, 204]. This method may some of the administrative inac-
curacies inherent to the continuous reporting delays. Patients nationalities were classified
according to the World Health Organization (WHO) HIV-AIDS Regions. All residents in Por-
tugal have access to health care services provided by the National Health Service (NHS).
It is managed at 5 regional levels through Regional Health Administrators (RHA) that are
accountable to the Ministry of Health: North, Centre, Lisbon and Vale do Tejo , Alentejo
and the Algarve. Each RHA is responsible for the strategic management of its population
health, supervision and control of hospitals, management of primary care/NHS primary care
centres, centres for treatment of addictive behaviours, and implementation of the national
health policy objectives [109]. The Ministry of Health cooperates with the Ministry of Justice
for providing health care services on prisons and with the Ministry of Defence for providing
health care services to the servicemen. Given this structure, the information on the health
providers responsible for the diagnoses and reporting processes was cross-classified by
type of health care institute and regional administration. Prisons and Military Institutions
were considered a single type of health care provider. An additional category (’Admin’) was
created to accommodate observations without a specific health care provider. Supervised
classification was then built upon that 2-class discretization, through feed-forward multi-
layer perceptron, naive networks, support vector machines and the K-nearest neighbour
5.2. Discrete Outcomes 129
algorithm with the following input features: age at diagnosis, gender, patient nationality,
disease stage, HIV risk group, type of health provider, and administrative and financial re-
sponsibility of health care providers. To predict whether a case will ever be reported and to
identify which factors influence that characteristic, we used feed-foward multilayer percep-
tron, naive neural networks, SVMs and the k-nearest neighbour algorithm.
Feed-foward multilayer perceptron
Artificial neural networks are a popular alternative to conventional statistical models [186].
In particular feedfoward multilayer perceptron networks with back-propagation training al-
gorithms are the most widely used. They are effective in the analysis of complex data with
non-linear trends and time-dependent covariates, and even high-order interactions [187].
In this section it was implemented a feed-forward multilayer perceptron with a hidden
layer (with 18 neurons). Sigmoid functions were used as transfer and activations functions.
For training, a back propagation algorithm with 500 training cycles, a learning rate of 0.3, a
momentum of 0.2, and an error of ϵ = 1.0E−5 was used. The constants were finely tuned
according to the data and results.
Naive bayesian classifier
A naive (or simple) Bayesian classifier (NB) is a probabilistic classifier which assumes that
all attributes contribute equally, and independently, to the final decision [173]. It is a com-
putational simple algorithm that can handle a data set with many attributes and thus widely-
used in medical data mining.
Support Vector Machines Learning
Support Vector Machines (SVM) are amongst the most popular and efficient classification
and regression methods currently available. These algorithms apply simple linear methods
in a high-dimensional feature space that is non-linearly related to the input space. Usually,
all attributes are employed and non-overlapping partitions are generated. In this thesis
we used a SVM for classification purposes, with a sigmoid kernel of degree 3, a gamma
parameter equal to the inverse of the sample size, a constant of the regularization term in
the Lagrange formulation equal to one, a tolerance equal to 0.001, an error of ϵ = 0.1 and a
heuristic shrinking. The training set was randomly chosen and contained 80% of the initial
data. The constants were finely tuned according to the data and results.
K - Nearest Neighbour
The k-nearest neighbour algorithm is one of the most popular classification algorithms. The
algorithm performs a case partition in a pre-user-defined number of clusters by comparing a
given test sample with a training sample. Each object is assigned to the class corresponding
to the majority vote from its K nearest neighbours. “Closeness” is defined in terms of a
distance metric. For the given data, the K-means algorithm with 2 clusters was applied,
with a mixed euclidean distance given the nominal and the quantitative nature of the input
features.
A 10-fold cross-validation was used for MLP, NB and KNN validation. A leave-one-out
method was applied to the SVM model.
Table 5.8 describes the performance of the data mining algorithms. The accuracy in
predicting the class membership ranged from 53% (NB) to 63% (MLP) approximately, the
precision ranged from 16% (NB) to 76% (MLP) and finally the recall ranged from 60% (MLP,
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NB and SVM) to 66%(KNN). Excluding the SMV which had a different fitting process, the
fastest algorithm needed 15s (Naive) to produce the results and the slowest approximately
51 min (MLP).
Table 5.8: MLP, KNN, NAIVE and SVM performance
Confusion matrix
Actual: 0-3 Actual: >3 sum (%) Accuracy Precision Recall Time
MLP
Predicted: 0-3 13831 9136 22967 (60%) 62.98% +/- 76% 60% 50min37s
Predicted: >3 4381 9162 13543 (68%) 0.78%
sum (%) 18212 (76%) 18298 (50%)
KNN
Predicted: 0-3 8344 4261 12605 (66%) 61.30% +/- 45% 66% 2 min
Predicted: >3 9868 14037 23905 (59%) 0.88%
sum (%) 18212 (45%) 18298 (77%)
Naive
Predicted: 0-3 2997 1983 4980 (60%) 52.90% +/- 16% 60% 15s
Predicted: >3 15215 16315 31530 (48%) 0.97%
sum (%) 18212 (16%) 18298 (11%)
SVM
Predicted: 0-3 12795 8412 21207 (60%) 62% 70% 60% 2min
Predicted: >3 5417 9886 15303 (65%)
sum 18212 (70%) 18298 (54%)
Analysing the behaviour of these two groups according to the year of diagnosis, it can be
seen that it is mostly constant until the most recent years (in the last years the percentage
of cases is biased due to the reporting delay). Moreover, the two groups seemed to behave
similarly with respect to the patient’s age at the diagnosis, gender, stage of the disease,
transmission risk group, nationality, type of the health care provider that made the diagnosis
and administrative and financial responsible from the health care provider (Table 5.1).
Tables 5.8 show that MLP provided the best results, with a higher classification accuracy
(approximately 63%), precision (approximately 76%) and recall (approximately 60%), but
on the other hand it was considerably slower. It can predict, with reasonable efficiency the
group of reporting delays less than 3 months long. The SVM model provided similar results
and was considerably faster.
While around 60% of the accuracy may be a reasonable result, it can be explained by
characteristics of the input data. In many cases,the quality of the data within the biomed-
ical and healthcare fields is inferior to that found in other fields [173]. In our data set the
main reasons for the poor classification quality are most probably related to stigma around
the disease that leads patients to provide incorrect informations (mainly with respect to the
transmission group), to high demands of the healthcare systems and to the implementation
of the surveillance system, more specifically paper form reports and poor communication
between the stakeholders. In a previous qualitative assessment of the Portuguese Surveil-
lance System, Mauch pointed out that all clinicians reported that they complete the notifica-
tion form after the patient has left the office, sometimes several days or weeks later. This
practice has the potential to contribute to inaccuracies in reporting for some variables, such
as the associated risk group, due to recall errors[93]. Moreover, errors may also arise from
the transcription of the information in the paper report to databases.
5.3 Continuous Outcome - Multilevel Regression
Since almost cases were reported within the reporting delay [0, 3] months, we decided to
model delays in continuous time and using a fully parametric approach. The parametric
survival analysis is an appropriate method because reporting delay can be viewed as a
’time from diagnosis to report’. This approach avoids the need to, somehow arbitrarily,
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classify the delays into discrete categories which considers that no matter whether a person
is diagnosed at the beginning or at the end of a time unit, a same reporting delay proportion
applies [119] . When the time unit is large, such as a quarter, this can yield very imprecise
estimates for recent incidence. Moreover, by fitting a continuous long tail distribution we
are allowing the model to assess the underreporting, since this issue can be considered as
a particular case of reporting delay with infinite length.
Similarly to Noufailly, using a continuous time framework the reporting delay distribu-
tion can span over all values helping rinse a better understanding of the processes gener-
ating the delays [198]. Finally, we decided to avoid the reverse time proportional hazards
regression model in favour of an explicit model for the reporting delay (measured in num-
ber of days), using common distributions in survival analysis parametric models: normal,
log-normal, exponential, Weibull and gamma. This allows a flexible representation of the
reporting delay distribution at moderately long delays and accommodates the observed ex-
tremely long tails, which are a striking feature of these data [198]. Moreover, if the cases
are reported in batches, the multinomial assumption does not capture the patterns and if
the discretized time intervals are large this can yield very imprecise estimates for recent
HIV-AIDS incidence.
Since the data is only right - truncated (there are no censored reporting delay length),
the inferences on covariate effects are mainly driven by the shorter delays, which are much
more numerous than longer delays [198]. This is appropriate for rapid detection of changes
in epidemic patterns.
Moreover, since reporting delay is an administrative process, and considering the orga-
nizational structure of the National Health System and historical changes on the HIV -AIDS
Surveillance System, we considered fitting multilevel regression models with a distribution
consistent with the parametric survival analysis approach.
So, the main aim is to describe the reporting delay distribution gaining a better under-
standing of the reporting process taking into consideration the individual, administrative,
organizational and historical context, and to investigate whether individual and structural
factors influence the reporting delays. Cases diagnosed more recently will be weighted
more heavily than those diagnosed further in the past, reflecting the fact that less of the
recently diagnosed cases have been reported.
For fitting purposes, we follow the strategy from simple to complex models following the
next steps for the normal, log-normal, gamma and Weibull:
1. Fit a simple generalized linear model, without a multilevel structure, for validating the
covariates and the choice of the appropriate distribution. Selection of the best model
is based on the Bayesian Information Criterion (BIC);
2. Fit the null multilevel (containing no covariates) model for validating the multilevel
structure;
3. Fit a multilevel model adding the covariates found in 1.
4. Fit a multilevel model adding higher-level covariates.
5.3.1 The specification of the reporting delay model
In this preliminary step we investigate whether if the reporting delays should be modelled
directly or using a logarithm transformation (AFT) and which distribution should be specified.
This method presents several advantages when compared to the traditional Proportional
Hazards (PH) model, namely:
• it does not require the assumption of proportional hazards;
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• it models directly the effect of covariates on the survival, so the interpretation of the
results is clearer and easier (in terms of effects on the mean survival time) than the
PH model, where we model the effect of covariates on a conditional probability;
• it is simpler to evaluate and it can be extended to more complex situations such as, for
example, interactions between covariates and time, or include non-parametric effects,
of some covariates or covariates with time-dependent parameters [217].
The following covariates were taken into consideration:
• Age of the patient (continuous)
• Notification Year (continuous)
• Nationality classified using WHO system for HIV-AIDS epidemic (European, African -
reference level and American)
• Sex (female as the reference level)
• Disease stage (AIDS and Asymptomatic, being the last the reference level)
• Risk-group (Heteressexual - reference level, IDU and MSM)
• Type of health service (Admin meaning not specific identification of type of service
but its known the region were the report took place, Hospital, Primary Care, Health
services shared with Justice Ministery and with Defence Ministery, Other/Unknown
and Addictive Behaviours - reference level)
• Administration Region (RHA North , LVT, Algarve, Alentejo - reference level and Cen-
tro and the same for IDT’s which, until the end of the data collection period, were
independent from RHA’s)
• Recent incidence of the institution determined by the number of cases diagnosed in
the same quarter as the notified case; the idea here is to use the local incidence as a
proxy for the notifications’ overload.
• Historical epocs (time periods with specific surveillance rules and regulations defined
by special alterations of the surveillance system or introduction of a new treatment or
prevention actions: E2 - from 1992 until 1997 -reference level, E3 - from 1997 until
2005, E4 - from 2005 until 2009 and finally E5 - from 2009 until the present days.)
We considered that the data collected before 1992 had not enough quality for performing
any regression model, so the data were truncated at this time stamp.
Models with the above covariates and errors following the normal, log-normal, Weibull
and Gamma distribution (with log-link for consistency with the other regression models).
The estimates of the coefficients, their standard errors as well as model BIC criterion are pre-
sented on (Table 5.9). All models were fitted using the iteratively reweighted least squares
(IWLS) method.
Comparing the Weibull and the Gamma models, it can be seen that with some point
exceptions, the coefficients are remarkably similar to each other. Even the standard errors
are almost identical. Both have very close coefficient estimates and standard errors to
those from the log-normal distribution. These models are not nested since they assume
different distributions for the response, which makes direct comparison problematic. Note
that purely numerical comparisons such as AIC and BIC (since these criterium uses the
likelihood function which depends of very different distributions) are risky and that some
attention to residual diagnostics, scientific context and interpretation is necessary [168].
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Table 5.9: The estimates and standard error of a full model for the normal, log-normal, Weibull and
gamma distribution
Normal Log-Normal Weibull Gamma
Estimate (Std.
Error)
Estimate (Std.
Error)
Estimate (Std.
Error)
Estimate (Std.
Error)
Intercept -9550 (2025.00) -23.880 (8.50) -39.785 (8.42) -41.880 (7.42)
Age -0.803 (0.16) -0.003 (0.001) -0.004 (0.001) -0.004 (0.001)
Notification Year 4.900 (1.01) 0.014 (0.004) 0.022 (0.004) 0.024 (0.004)
Male -1.693 (4.22) -0.021 (0.018) -0.016 (0.017) -0.016 (0.015)
AIDS -83.010 (3.68) -0.448 (0.015) -0.345 (0.014) - 0.332 (0.013)
America -6.894 (12.32) -0.013 (0.052) -0.016 (0.049) -0.014 ( 0.045)
Europe 9.967 (6.07) 0.059 (0.025) 0.033 (0.024) 0.031 (0.022)
IDU 57.440 (4.59) 0.193 (0.019) 0.222 (0.018) 0.220 (0.017)
MSM -7.950 (5.87) 0.011 (0.025) -0.034 (0.024) -0.038 (0.022)
Admin -0.470 (19) 0.496 (0.080) -0.031 (0.077) -0.062 (0.070)
Hospital 1.322 (18.46) 0.433 (0.077) -0.048 (0.075) -0.074 (0.068)
INST. / SERV. - MD 17.900 (34.93) 0.465 (0.147) -0.046 (0.141) -0.072 (0.128)
INST. / SERV. - MJ -118.100 (21.05) -0.039 (0.088) -0.620 (0.085) -0.646 (0.077)
Other/Unknown 92.440 (46.45) 0.666 (0.195) 0.268 (0.187) 0.239 (0.170)
Primary care -56.050 (20.08) 0.095 (0.084) -0.312 (0.081) -0.332 (0.074)
RHA ALGARVE -211.100 (17.52) -0.856 (0.074) -0.727 (0.071) -0.705 (0.064)
RHA CENTRO -220.30 (16.66) -0.814 (0.070) -0.744 (0.066) -0.726 (0.061)
RHA LVT -135.80 (15.86) -0.521 (0.067) -0.431 (0.064) -0.418 (0.058)
RHA NORTE -196.70 (16.15) -0.750 (0.068) -0.668 (0.065) -0.652 (0.059)
IDT ALENTEJO -356.20 (49.83) -1.031 (0.209) -1.579 (0.201) -1.602 (0.183)
IDT ALGARVE -348.70 (33.88) -1.178 (0.142 ) -1.547 (0.137) -1.541 (0.124)
IDT CENTRO -218.20 (52.02) -0.725 (0.218) -0.816 (0.21) -0.811 (0.191)
IDT LVT -193.80 (31.93) -0.493 (0.134) -0.660 (0.129) -0.661 (0.117)
IDT NORTE -346.30 (40.65) -1.301 (0.171) -1.567 (0.164) -1.554 (0.149)
E3 122.100 (12.01) 0.684 (0.050) 0.915 (0.049) 0.935 (0.044)
E4 94.720 (15.30) 0.593 (0.064) 0.832 (0.063) 0.850 (0.056)
E5 36.550 (17.94) 0.314 (0.075) 0.542 (0.074) 0.563 (0.066)
Recent Incidence 0.429 (0.03) 0.002 (0.000) 0.002 (0.0001) 0.002 (0.000)
AIC 371977.1 82282.67 337156.00 337894.8
BIC 372214.4 82519.99 338132.1
For a better comparing the estimates we consider the plot of the estimates together with
their profile confidence interval, for each regression model (Figures 5.40 until 5.43) with
the exception of the Intercept due to its large coefficient. From these plots, although with
different scales, the estimates provided by the gamma distribution are similar to the ones
given by the normal distribution. From the comparison between the estimated obtained
from normal and the log-normal models, it can be seen that the former yielded narrower
confidence intervals and from the comparison between the log-normal and gamma it can be
seen that some coefficients changed statistical significance, such as ’Primary care’, ’Other
/ unknown’, ’Inst. / Serv. MJ’, ’Inst. / Serv. MD’ , ’Hospital’ and ’Admin’ all from the same
covariate which represents the type of health provider.
The skewness of the confidence intervals obtained from the Weibull model allowed us
to restrict the residuals’ analysis to the normal, log-normal and gamma models. (Figures
5.44, 5.45 and 5.46).
The plots of the residuals against the fitted values show a linear decreasing pattern.
This pattern is often associated with counting variables and when there are lots of observa-
tions with the same values. These hard limits are also responsible for the apparent set of
points lying on a straight line in the scale-location plots. Moreover, there is a suggestion of
a mild association between residuals and fitted values (Figures 5.44, 5.45 and 5.46 ). An-
other important characteristic is that the residuals have approximately the same variance,
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Figure 5.40: The estimates and profile confi-
dence intervals from the normal dis-
tribution
Figure 5.41: The estimates and profile confi-
dence intervals from the log normal
distribution
Figure 5.42: The estimates and profile confi-
dence intervals from the Weibul dis-
tribution
Figure 5.43: The estimates and profile confi-
dence intervals from the gamma
distribution
regardless of the predicted values which is a suggestion of homocedasticity. The normal
quantile-quantile (QQ) plot do not reveal serious problems on the adherence to the normal
distribution (Figures 5.44, 5.45 and 5.46 ).
The collection of the previous findings led to the choice of the log-normal distribution
for the response. The stepwise algorithm based on AIC was then applied as a variable
selection method. The obtained model is presented in Table 5.10.
The variance of Y depends on both the expected values of Y , µy, and the variance of
Z = ln (Y ), σ2Z ; V ar (Y |X) = σ2Y |X =
(
exp
(
σ2z
)− 1)µ2y
Table 5.10: The estimates of the log-normal model
Estimate EXP(Estimate) Std. Error t value Pr(>|t|)
Intercept -333.80 0.000 7.22 -46.22 < 0.001
Age -0.003 0.997 0.00 -4.009 < 0.001
Notification Year 0.17 1.18 0.00 46.961 < 0.001
AIDS -0.45 0.64 0.01 -30.708 < 0.001
America 0.05 1.06 0.05 1.113 0.266
Table continues...
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Table 5.10: The estimates of the log-normal model
Estimate EXP(Estimate) Std. Error t value Pr(>|t|)
Europe 0.08 1.08 0.02 3.293 0.001
IDU 0.20 1.22 0.02 11.394 < 0.001
MSM/Bisexual 0.03 1.03 0.02 1.249 0.212
Admin 0.49 1.64 0.08 6.52 < 0.001
Hospital 0.39 1.47 0.07 5.261 < 0.001
INST. / SERV. - MD 0.30 1.35 0.14 2.149 0.032
INST. / SERV. - MJ 0.00 1.002 0.08 0.029 0.977
Other/Unknown 0.49 1.624 0.19 2.62 0.009
Primary care 0.10 1.109 0.08 1.289 0.198
ARS ALGARVE -0.79 0.455 0.07 -11.261 < 0.001
ARS CENTRO -0.74 0.477 0.07 -11.118 < 0.001
ARS LVT -0.44 0.642 0.06 -7.004 < 0.001
ARS NORTE -0.66 0.516 0.06 -10.253 < 0.001
IDT ALENTEJO -0.99 0.370 0.20 -4.993 < 0.001
IDT ALGARVE -0.99 0.373 0.14 -7.287 < 0.001
IDT CENTRO -0.82 0.438 0.21 -3.972 < 0.001
IDT LVT -0.52 0.596 0.13 -4.058 < 0.001
IDT NORTE -1.21 0.298 0.16 -7.451 < 0.001
E3 -0.79 0.452 0.04 -21.963 < 0.001
E4 -1.96 0.141 0.05 -39.788 < 0.001
E5 -2.85 0.058 0.06 -48.525 < 0.001
Recent Incidence 0.001 1.001 0.00 13.132 < 0.001
The residuals of this model were inspected and the model assumptions did not seem to
be compromised.
From the model and assuming that all other values remain constant, it can expect that
with an increase of year of the patient age, we would expect an decrease of 0.3% of the
reporting delay. An increase of one notification year will produce approximately 18% of
change in the reporting delay and one case increase of the incidence will produce and
change of 0.1% in the reporting delay. An AIDS case is approximately 36% faster than
an asymptomatic case and an American case is almost 6% slower than an African. An
European case is approximately 8% slower than an African case. A IDU case is 20% slower
than a Heterossexual and a MSM / Bisexual is almost 3% slower than a Heterossexual
case. A reported case from an Administrative entity is almost 64% slower than an entity of
type ’Addictive Behaviours’. An Hospital is 47% slower than a type ’Addictive Behaviours’
entity. The shared services between the Defense Ministry and the Health is 34% slower
than type ’Addictive Behaviours’ and the shared services with the Ministry of Justice is only
0.23% slower than type ’Addictive Behaviours’. Other/ Unknown is 62% slower than type
’Addictive Behaviours’. Primary Care is 11% slower than type ’Addictive Behaviours’. The
RHA of Algarve is 54% faster than RHA Alentejo. The RHA LVT is 35% faster than RHA
Alentejo. IDT Alentejo is 63% faster than RHA Alentejo. IDT Algarve is 62% faster that RHA
Alentejo. IDT Centro is 56% faster than RHA Alentejo. IDT LVT is 40% faster than RHA
Alentejo. IDT Norte is 70% faster than RHA Alentejo. The cases reported in E3 were 54%
faster than E2; the cases reported in E4 were 85% faster than in E2; the cases reported in
E5 were 94% faster than E2.
From the model above it can be seen that the institutional variables such as: Type of
services and Region of Health Administration (RHA) have high variability and high standard
deviations suggesting a multilevel structure underlying the model.
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Figure 5.44: Residuals from normal distribution
Figure 5.45: Residuals from log normal distribution
5.3.2 Reporting delay with a Multilevel Structure
In order to determine the best multilevel structure, a full theoretical model was consid-
ered. The first approach was developed based on the contextual framework of this problem.
Namely, individuals (Population) are diagnosed in a health service institution that gets the
case reported (Reporting Entity), which in turn belongs to a certain type of service, such
as Hospital care, primary care, additive behaviours... (Type of Service). These entities are
under a Region of Health Administration, which in turn follows therapeutic, administrative
rules and regulations defined by Scientific Communities and Governments. This framework
is represented on Figure 5.47.
This context can be expressed as the following multilevel structure
Level 1 - Population (i=1,..., 27461)
log(Yijklm) = β0jklm + ϵijklm
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Figure 5.46: Residuals from log gamma distribution
Figure 5.47: Conceptual representation of the nested structure
where Yijklm is the reporting delay measured in days.
Level 2 - Reporting Entity -Group Level (j=1,..., 593)
β0jklm = γ00klm + νjklm
Level 3 - Type of service - Group Level(k=1,..., 100)
γ00klm = θ000lm + υklm
Level 4 - Administrative Responsibility - Group Level (l=1,...,38)
θ000lm = ψ0000m +ϖlm
Level 5 - Historical and Context Epocs - Group Level (m=1,..., 4)
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ψ0000m = ς00000 + φm
where,
ϵijklm ∼ N
(
0, σ2
)
νjklm ∼ N
(
0, σ21
)
υklm ∼ N
(
0, σ22
)
ϖlm ∼ N
(
0, σ23
)
φm ∼ N
(
0, σ24
)
The model was fitted with the restricted maximum likelihood (REML) and the results are
represented on Table 5.11.
Table 5.11: Null Multilevel Model
Groups Variance Std.Dev. Std. Dev. 2.5 % C.I. Limit Std. Dev. 97.5 % C.I. Limit
Random Effects
Level 2 - σ1 0.36 0.6 0.45 0.56
Level 3 - σ2 0.25 0.50 0.30 0.55
Level 4 - σ3 0.002 0.042 0.00 0.32
Level 5 - σ4 0.17 0.41 0.13 0.80
Residual - σ 1.18 1.09 0.93 0.94
Fixed Effects Estimate Std. Error
Intercept 4.68 0.1636
Note that, σ is much higher than the other standard deviations and there is evidence
that σ3 and σ4 are not significant due to the curvilinear form of Figure 5.48.
The profile zeta plot ζ for the fixed - effect parameter (Intercept) term is slightly over-
dispersed relative to the normal distribution. While for σ, σ1 and σ2 have a good normal
approximation while the standard deviations for σ3 and σ4, are skewed. The skewness for σ4
is worse than that for σ3, making the estimate of σ4 less precise than of σ3 , in both absolute
and relative senses (Figure 5.48). For an absolute comparison we compare the widths
of the confidence intervals (σ3 ∈ [0.00; 0.32] and σ4 ∈ [0.13; 0.80] ) for these parameters.
Clearly, the lack of precision of these estimates is a consequence of only having 4 distinct
levels of the Epocs factor.
In general, it is more difficult to estimate a measure of spread, such as the standard
deviation, than to estimate a measure of location, such as a mean, especially when the
number of levels of the factor is small. Six levels are about the minimum number required
for obtaining sensible estimates of standard deviations for simple, scalar random effects
terms [179].
So, we proceed to fit several null nested models in order to validate the minimal multi-
level structure.
Model A - random effect on the Reporting Entity
Level 1 - Population (i=1,..., 27461)
log(Yij) = β0j + ϵij (5.33)
Level 2 - Reporting Entity - Group Level (j = 1,..., 351)
β0j = γ00 + νj (5.34)
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Figure 5.48: Profile zeta plot of the parameters in full null hierarchical model.
where,
ϵij ∼ N
(
0, σ2
)
νj ∼ N
(
0, σ21
)
Model B - random effect by Entity nested within the Type of Service:
Level 1 - Population (i=1,..., 27461)
log(Yijk) = β0jk + ϵijk (5.35)
Level 2 - Reporting Entity - Group Level (j = 1,..., 351)
β0jk = γ00k + νjk (5.36)
Level 3 - Type of Service - Group Level (k = 1,..., 8)
γ00k = θ000 + υk (5.37)
where,
ϵijk ∼ N
(
0, σ2
)
νjk ∼ N
(
0, σ21
)
υk ∼ N
(
0, σ22
)
Model C - random effect by Reporting Entity, nested within the Type of Service
which are nested in Administrative Responsibility Level 1 - Population (i=1,..., 27461)
log(Yijkl) = β0jkl + ϵijkl (5.38)
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Level 2 - Reporting Entity - Group Level (j = 1,..., 354)
β0jkl = γ00kl + νjkl (5.39)
Level 3 - Type of Service - Group Level (k = 1,..., 30)
γ00kl = θ000l + υkl (5.40)
Level 4 - Administrative Responsibility - Group Level (l = 1,..., 10)
θ000l = ψ0000 +ϖl (5.41)
where,
ϵijkl ∼ N
(
0, σ2
)
νjkl ∼ N
(
0, σ21
)
υkl ∼ N
(
0, σ22
)
ϖl ∼ N
(
0, σ23
)
Model D: random effect by Reporting Entity, nested within the Type of Service
which are nested in Administrative Responsibility, nested within Historical Rules and
Regulations
Level 1 - Population (i=1,..., 27461)
log(Yijklm) = β0jklm + ϵijklm
where Yijklm is the reporting delay measured in days.
Level 2 - Reporting Entity -Group Level (j=1,..., 593)
β0jklm = γ00klm + νjklm
Level 3 - Type of service - Group Level(k=1,..., 100)
γ00klm = θ000lm + υklm
Level 4 - Administrative Responsibility - Group Level (l=1,...,38)
θ000lm = ψ0000m +ϖlm
Level 5 - Historical and Context Epocs - Group Level (m=1,..., 4)
ψ0000m = ς00000 + φm
where,
ϵijklm ∼ N
(
0, σ2
)
νjklm ∼ N
(
0, σ21
)
υklm ∼ N
(
0, σ22
)
ϖlm ∼ N
(
0, σ23
)
φm ∼ N
(
0, σ24
)
5.3. Continuous Outcome - Multilevel Regression 141
The interclass correlation associated to the group level Reporting Entity of model A is
approximately equal to 29.67%. Thus, 29.67% of the variance of the reporting delay is at
the Reporting Entity group level. Considering the model B, 20.24% of the variance of the
reporting delay is at the Reporting Entity and 8% is at the Type of Services. For the model
C, 18.37% of the variance of the reporting delay is at the Reporting Entity, 10.50% is at the
Type of services group level and 1.42% is at the Administrative Responsibility group level.
For the model D, 18.15% of the variance is at the Reporting Entity level, 12.89% at the
Type of Services level, 0.09% at the Administrative Responsibility level and 8.66% at the
Historical Rules and Regulations level (Table 5.12). Since these models are intercept - only
models that do not contains no explanatory variables, the residuals variances represent
unexplained error variance.
Table 5.12: Null Models I.C.C.
Model A Model B Model C Model D
σ2 I.C.C. σ2 I.C.C. σ2 I.C.C. σ2 I.C.C.
Reporting Entity 0.537 29.67% 0.359 20.24% 0.336 18.37% 0.357 18.15%
Type of Services 0.142 8.00% 0.192 10.50% 0.253 12.89%
Administrative Responsibility 0.026 1.42% 0.002 0.09%
Historical Rules and Regulations 0.170 8.66%
Residuals 1.273 1.273 1.273 1.183
We found that the model B was the best based on the results from the Likelihood Ratio
test. The tests statistics are presented on Table 5.13. It can be seen that B improve A, but
C does not improve B. So, the multilevel structure represented by model B was select.
Table 5.13: Models Evaluation
Models: Df AIC BIC logLik deviance Chisq Chi Df Pr(>Chisq)
A 3 80188 80213 -40091 80182
A - B 4 77085 77118 -38538 77077 3105.7 1 <0.001
B - C 5 77100 77141 -38545 77090 0.001 1 1.000
C - D 6 75359 75409 -37674 75347 1742.5 1 <0.001
The profile zeta plot for the constant intercept (β0) for themodel B, which it was called the
minimal null model has almost symmetric intervals. The profile zeta plot for σ, σ1 appears
to be a good normal approximation and although the plot σ2 is not a straight line, the bias
is very mild 5.49.
Figure 5.49: Profile zeta plot of the parameters in the minimal multilevel model
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For the next experience we added the covariates according to the minimal set determine
in (5.10) model. It was considered just a random intercept:
Level 1 Model
log(Yijk) = β0jk + β1DataNotificationijk + β2RiskGroupijk +
β3Nationalityijk + β4Stageijk + β5Ageijk +
β6RecentIncidenceijk + ϵijk, with ϵijk ∼ N
(
0, σ2
)
(5.42)
Level 2 Model
β0jk = γ00k + ψ0jk, with ψ0jk ∼ N
(
0, σ21
)
(5.43)
Level 3 Model
γ00k = θ000 + ν00k, with ν00k ∼ N
(
0, σ22
)
. (5.44)
.
We used the restricted likelihood to fit the models and Bayesian approaches and found
that there were no significant changes in the coefficient values. So, only the results obtained
from REML are presented. From the model and assuming that all other values remain
constant, it can expect that with an increase of one year in the notification date it would be
expected an increase of 0.1% of the reporting delay. An increase of one year in patient age
will produce approximately -0.31% of change in the reporting delay and one case increase in
the recent incidence will produce an increase of 0.23% in the reporting delay. An AIDS case
is approximately 31% faster than an asymptomatic case and an American case is almost
7% faster than an African. An European case is approximately 2.1% slower than an African
case. A case from Low incidence country may be 22.5% slower that an African (note: there
are just a hand full of this cases). A IDU case is 16% slower than a Heterossexual and a
MSM / Bisexual is almost 3.6% faster than a Heterossexual case.
Note that the variables Intercept, NotificationDate and Nationality as well as the
category MSM/Bisexual are not statistically significant. The Intra Class Correlation Co-
efficient (ICC) for the Type of Services level is 10% and for the Reporting Entities level is
21% (Table 5.14).
Table 5.14: Model with a random intercept and population level covariates
Estimate Std. Error 95% I.C
Fixed
Intercept 2.714 3.290 -3.740 9.170
Notification date 0.001 0.002 -0.002 0.004
Risk Group IDU 0.150 0.015 0.120 0.180
MSM/Bisexual -0.036 0.019 -0.070 0.001
Nationality America -0.070 0.040 -0.150 0.010
Europe 0.022 0.021 -0.020 0.060
Low Incidence
Countries
0.200 0.160 -0.110 0.520
Stage AIDS -0.310 0.012 -0.330 -0.280
Age -0.003 0.0006 -0.004 -0.002
Recent incidence 0.002 0.0001 0.002 0.003
Random
Level 3
(Between Type of Ser-
vices, 8 levels)
std 0.36
Level 2
(Between Entities, 349
levels)
std 0.5
(Table continues...)
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Table 5.14: Model with a random intercept and population level covariates - continue
Estimate Std. Error 95% I.C
Level 1
(Between individuals) std 0.9
Number of obs: 26461
Analysing the profile zeta plot no significant problem was detected (Figure 5.50).
Figure 5.50: Profile zeta plot of the parameters of the random intercept model.
The prediction intervals for the random effects (Figures 5.51 (each line of the chart
corresponds to a Health Reporting Institution, and since there are 349 levels the names
were omitted for clarity representation) and 5.52) confirm that the conditional distribution
of the random effects for type of services has a lower variability than does the conditional
distribution of the random effects for the Reporting Entity, in the sense that the dots in Figure
5.52 have a lower variability than those in Figure 5.51. (Note the different independent axes
for the two figures.) However, the conditional distribution of the random effects for some
particular Type of services can have a lower variability than the conditional distribution of
the random effects of particular reporting entities. Also, Hospitals seem to take longer to
report a case than the Primary care services.
The final experiment consisted of adding a random slope allowing for the possibility
that, for example, Entities with a higher reporting delay may, on average, be more strongly
affected by recent incidence registered on its services. This model, which incorporates a
random intercept and a random ”slope” for Recent Incidence, can be written as:
Level 1 Model
log(Yijk) = β0jk + β1DataNotificationijk + β2RiskGroupijk +
β3Nationalityijk + β4Stageijk + β5Ageijk +
β6RecentIncidenceijk + ϵijk (5.45)
Level 2 model
β0jk = γ00k + γ1jkRecentIncidence0jk + ψ0jk, with ψ0jk ∼ N
(
0, σ21
)
(5.46)
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Figure 5.51: 95% prediction intervals for the ran-
dom effect Entity
Figure 5.52: 95% prediction intervals for the ran-
dom effect Administration
Level 3 model
γ00k = θ000 + ν00k, with ν00k ∼ N
(
0, σ22
)
(5.47)
and with ϵijk following the a normal distribution.
We now interpret the statistically significant fixed-effects of the model. Assuming that
the values from the remaining covariates are kept constant, it it is expected that: any 1-year
increase in the notification date increases the reporting delay by 0.5%; any 1-year increase
in the patients’ age decreases the reporting delay by 0.3% and an 1-patient increase in
the absolute incidence increases the reporting delay by 4%. Moreover, an AIDS case is
expected to be approximately 25% faster to report than an asymptomatic case. An IDU case
is expected to be 14% slower than a Heterosexual while no significant differences regarding
the expected reporting delay were identified for MSM/Bisexuals and Heterosexuals. (Table
5.15).
Table 5.15: Estimates from the model with a random intercept and a random slope
Estimate Std. Error 95% I.C
Fixed
Intercept -4.8 3.31 -11.29 1.700
Notification date 0.005 0.001 0.001 0.0079
Risk Group IDU 0.14 0.01 0.10 0.17
MSM/Bisexual -0.03 0.02 -0.065 0.008
Nationality Americas -0.06 0.04 -0.14 0.02
Europe 0.02 0.021 -0.02 0.06
Low Incidence Countries 0.28 0.16 -0.02 0.59
Stage AIDS -0.28 0.012 -0.31 -0.26
Age -0.003 0.0005 -0.004 -0.002
Recent incidence 0.039 0.0059 0.026 0.054
Random
Level 3
(Between Type of Services, 8 levels) Intercept std 0.31
Level 2 (Between Entities, 349 levels)
Intercept std 0.38
Recent Incidence std 0.04
Level 1
(Between individuals) std 0.9
Number of obs: 26461
Again, no relevant problems were identified from the profile zeta plot (Figure 5.53).
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Figure 5.53: Profile zeta plot of the parameters from themodel with a random intercept and a random
slope.
In Figure 5.54 each line corresponds to a Reporting Institution. In the left panel are
presented the estimated intercepts and in the right panel the estimates for the coefficient
with respect to Recent Incidence are shown. A large variability is observed by type of
services provided (Figure 5.55).
Figure 5.54: 95% prediction intervals on the ran-
dom effect Entity
Figure 5.55: 95% prediction intervals on the ran-
dom effect Administration
In Table 5.16 it is present the comparison between this two models, which revealed that
there are significantly different. Moreover, given the AIC, BIC values the model with the
random intercept presents as an improvement.
Table 5.16: Multilevel Models comparison
Models: Df AIC BIC logLik deviance Chisq Chi Df Pr(>Chisq)
M1: random in-
tercept
13 72073 72179 -36023 72047
M2: random in-
tercept and ran-
dom slope
15 70768 70890 -35369 70738 1309.3 2 < 0.001
Concluding, the estimates provided by the null model, the model with a random inter-
cept and the last model with a random intercept and a random slope are presented in Table
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5.17. Adding fixed effects to the null model produced an increase on the standard devi-
ations of the random effects - Level ’Type of Services’ and ’ Entities’ and a decrease of
the residual standard deviation. When adding the random slope, all standard deviations
decreased when comparing to the random intercept model. The comparison of the fixed
effect estimates between M1 and M2 models, suggest mild differences between the two
models.
Table 5.17: Full model and with random intercept and random intercept and slop
Model M0: Null M1: random inter-
cept
M2: random inter-
cept and random
slop
Fixed Coeff.(s.e.) Coeff.(s.e.) Coeff.(s.e.)
Intercept 4.67(0.128) 2.714 (3.29) -4.79 (3.3)
Notification date 0.001 (0.002 ) 0.005 (0.001)
Risk Group IDU 0.15(0.015) 0.14 (0.015)
MSM/Bisexual -0.04(0.02) -0.028 (0.019)
Nationality Americas -0.074(0.042) -0.06 (0.04)
Europe 0.022(0.021) 0.02 (0.02)
Low Incidence
Countries
0.203(0.16) 0.28 (0.16)
Stage AIDS -0.31(0.01) -0.29 ( 0.013)
Age -0.0031(0.0006) -0.003 (0.0006)
Recent incidence 0.002(0.0001) 0.039 (0.006)
Random
Level 3 (Between Type of Services, 8 levels) std std std
0.31 0.36 0.31
Level 2 (Between Entities, 349 levels) std std std
Intercept 0.49 0.50 0.38
Recent Incidence 0.04
Level 1 (Between individuals) std std std
0.98 0.94 0.91
AIC 77085 72073 70768
BIC 77118 72179 70890
logLik -38538 -36023 -35369
Deviance 77077 72047 70738
5.4 Summary
Since the beginning of the epidemic, the majority of the reported cases were from asymp-
tomatic cases closely followed by the AIDS patients. Following the observed pattern in
the European countries, most of the diagnosed cases were men. The heterosexual risk-
group was the most common risk-group category. In Portugal, the first case known was
diagnosed in 1983 and the first notification was just in 1985. Late diagnosis, that is AIDS,
was the most reported stage at the early beginning of the epidemic and of the surveillance
system. Around the year 2000 asymptomatic cases were reported more frequently being
followed closely by the AIDS cases . The same pattern was observed when this character-
istic is represented by the notification year. In the whole epidemic history, males were most
frequently observed. IDU ’ s were the most frequent diagnosed and reported risk - group
until around the year 2002 and then it started to decrease giving place to the heterosexual
risk - group. Throughout the years there were several fluctuations on the number of cases
per year of notification and RHAs, being Lisbon and the Tagus, and the North the regions
with the majority of the cases. It is important to notice a large contribute of cases coming
from a non identified source.
Throughout the notification years, the curve of number of notified cases per Region of
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Health Administration demonstrated a large variation and with a large number of spikes.
The majority of the contributions arose from the RHA LVT and from the RHA North, the two
RHA’s serving the two major Portuguese cities. From the perspective of the diagnosis year,
the epidemic curves were smoother and naturally, the main contributions arose from the
same regions.
The observed number of diagnosed HIV-AIDS cases (at all stages) in Portugal, from
1983 to 2011, exhibited an increasing trend between 1983 and the year 2000, four years af-
ter the introduction of HAART. Since then, the numbers of diagnosed cases have been
steadily decreasing. When the notification became mandatory a slight growth was ob-
served.
Considering the reporting delay classified in two groups (0, 3] months and > 3 months,
the descriptive behaviours seemed to be similar with respect to the patient’s age at the
diagnosis, gender, stage of the disease, transmission risk group, nationality, type of the
health care provider that made the diagnosis and administrative and financial responsible
from the health care provider.
The reporting delay was firstly studied using the classical approach, developed for large
epidemics, more specifically from the CDC data: considering the division into quarters and
cross - classifying the quarters of the diagnosis date and considering only AIDS cases.
The probability of these cases getting reported is higher than in other stages due to the
severe symptoms and the urge of treatment. The model for the reporting delays, based on
Poisson counts, estimated that the majority of AIDS cases are reported with 3 months after
the diagnosis. And this result was consistent with previous statistical publications using
the Portuguese HIV - AIDS data found in [203, 204] and by Mauch when performing the
global evaluation of the surveillance system [121]. The assumption of Poisson distribution,
although a classical approach, is not unwarranted because HIV - AIDS is a contagious
disease and the development of the disease is long and variable and thus recent number
of AIDSmay be positively correlated with past numbers [69]. Moreover, the model indicated
the existence of a slight non-stationary process.
Analysing the longitudinal trajectories of the different quarters of reporting delay (each
trajectory is the relative incidence of cases in a particular class of reporting delay), it was
found that the trajectory of the quarter (0, 3] months is completely separated from the other
trajectories, that can be grouped together. Along the diagnosis year, the trajectories within
(0, 3] months always counted with the major percentage of cases. It was observed some
fluctuations that ranged from 25% until 75%. Delays longer than 9 months had very close
trajectories. These delays had less than 10% of the cases each. So, for modelling, and
considering the epidemiological and surveillance relevance, the partitions (0, 3]months and
more than 3 months seem to be a good classification for the set of all trajectories.
From the longitudinal model we could conclude that the delay curves have small fluctu-
ations over time. Individuals delay curves can be used to estimate the corresponding delay
distribution.
Surveillance systems rely on processes using pre-specified disease case definitions and
employ manual data collection, human decision making, and manual data entry. The anal-
ysis of incidence and prevalence should thus include the analysis of the historical events
that may affect the way systems collect the data.
Considering the reporting delay divided into quarters, a 2-class division arises naturally
from the previous analysis, with a cut-off at the 3-month delay. According to this classifica-
tion, several supervised learning techniques were applied.
Applying data mining in order to build a classification model based on the variable de-
scribed above, it was applied the Naive Bayes classifier, the K- nearest neighbour algorithm,
multilayer perceptrons and support vector machines. The results showed that multilayer
perceptrons provided the best results, with a higher classification accuracy (approximately
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63%), precision (approximately 76%) and recall (approximately 60%), on the other hand
it is considerably slower. It can predict, with reasonable efficiency the group of reporting
delays less than 3 months long considering the inputs. The support vector machines model
had similar results and was considerable faster.
Since the majority of cases were reported in the reporting delay group [0, 3] months
and some fluctuations of the percentage of this pattern were observed, it was decided to
model the delays in continuous time and to use a fully parametric approach. This approach
avoids the need to, somehow arbitrarily, classify the delays into discrete categories. When
the time unit is large, such as a quarter, this can yield very imprecise estimates for the
recent incidence. Moreover, by fitting a continuous long tail distribution we are allowing
the model to assess the underreporting, since this issue can be considered as a particular
case of reporting delay with infinite length. Finally, it was decided to avoid the reverse
time proportional hazards regression model in favour of an explicit model for the reporting
delay (measured in number of days), using commonly distributions from survival analysis
parametric models: normal, log-normal, exponential, Weibull and gamma. This allows a
flexible representation of the reporting delay distribution at moderately long delays and
accommodates the observed extremely long tails, which are a striking feature of these data
[198]. Moreover, if the cases are reported in batches, the multinomial assumption does
not capture the pattern and if the discretized time intervals are large this can yield very
imprecise estimates for recent HIV-AIDS incidence. Finally, since data is right - truncated
(there are no censored reporting delay lengths), the inferences on covariate effects are
mainly driven by the shorter delays, which are much more numerous than the longer delays
[198]. This is appropriate for rapid detections of changes in epidemic patterns. Within this
approach, it was also considered that patients are nested in health care facilities, which are
grouped according to its type (hospital, primary care services,...), which in turn are grouped
in administrative regions and government by historical policies. After pruning the level of
random effects, the final model considered the individuals nested within reporting entities
nested into types of services. The final model included fixed-effects from the notification
date, the risk group, the nationality, the stage, Age and recent incidence. The distribution
of the response was chosen to be the log-normal. From the model and assuming that the
values from the remaining covariates are kept constant, it is expected that: any 1-year
increase in the notification date increases the reporting delay by 0.5%; any 1-year increase
in the patients’ age decreases the reporting delay by 0.3% and an 1-patient increase in
the absolute incidence increases the reporting delay by 4%. Moreover, an AIDS case is
expected to be approximately 25% faster to report than an asymptomatic case. An IDU case
is expected to be 14% slower than a Heterosexual while no significant differences regarding
the expected reporting delay were identified for MSM/Bisexuals and Heterosexuals.
Finally a note for the BB/NBD model, which is a Bayesian approach with the purpose
of capturing the unobserved heterogeneity in reporting AIDS cases. The model was also
applied and it was more likely to report an AIDS case when a large number of cases has
already been notified. Although the model goodness of fit seems to be reasonable, its
estimates do not captured the decreasing pattern that the disease has been showing. One
explanation may rely on the fact this is a stop Poisson process without information on the
time of diagnosis and treatment effect.
Chapter 6
Conclusions
In God we trust, all others must bring data.
William Edwards Deming (1900-1993)
This chapter summarizes the contributions and limitations of this thesis, and points out
future related work. In order to have timely and accurate representation of the state of the
epidemic, the surveillance system must collect data efficiently and effectively. Moreover, it
must apply a systematic collection of methods in order to have data with the highest quality
possible. This thesis covered some of the essential components of the statistical process
flow for modelling and analysing reporting delays for infectious diseases such as HIV-AIDS.
This included evaluating and improving data quality, and retrieving knowledge about the
reporting delay process in the Portuguese HIV-AIDS surveillance system.
6.1 Synthesis and Main Contributions
The main contributions of this work are concentrated in three distinct areas: concise and
detailed description of all the processes leading to the evaluation of infectious diseases
incidence numbers; data pre-processing and data quality improvement methods for surveil-
lance data; and definition and implementation of reporting delay modelling methods.
Firstly, the process resulting in the reported incidence numbers was described in a holis-
tic approach. For that purpose, the biology of the virus and its transmission model and the
factors influencing HIV - related and / or behaviour - change were described. Focus was
given to the processes, which directly or indirectly influence the number of cases observed
and reported. These factors can be organized into nested levels: individual, interpersonal
/ network, institutional / health system and finally structural. The European epidemic was
also assessed and the surveillance systems were described in terms of collecting data pro-
cesses, main stakeholders, and issues rising in each step.
A unified approach for the definition of data quality was described uniting the common
issues described in computer science literature and the state-of-the-art of the officials’ sta-
tistical business processes. A systematic process for performing statistical data pre - pro-
cessing was proposed, composed by two different components: one for detecting issues
and the other for improving data quality with appropriate methods for surveillance data. The
methodology was applied to the Portuguese HIV-AIDS Surveillance System.
The classical joint modelling with Poisson counts considering reporting delay and diag-
nosis date divided into quarters (which were developed in a context of large epidemics)
do not fully capture the reporting process of the Portuguese system. These results are
consistent with a previous publication using the Portuguese data set but the assumption of
Poisson distribution is not unwarranted because HIV - AIDS is a contagious disease and
thus recent number of AIDS may be positively correlated with past numbers. Moreover, this
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model indicated some non-stationary characteristics of the reporting delay process. When,
analysing the reporting delays as a function of the the diagnosis year, two well-separated
patterns were identified. In addition, some fluctuations indicated variability in the structure
underneath.
Other researchers have also found increases in reporting delay over time that can be
attributed largely to changes over time in the distributions of the covariates, or to tempo-
rary periods of slower reporting in specific geographical areas that are typically followed by
‘catch-up’ periods of faster reporting.
For the identification of themain factors influencing the reporting delays in the HIV - AIDS
cases within the Portuguese Surveillance System, data - mining methods were applied.
The reporting delay was divided into quarters and in a 2-class division with a cut-off at the
3-months delay. According to this classification, several supervised learning techniques
were applied and the best performance was obtained by MLP and SVMs. These methods
had approximately an accuracy of 60% which is a reasonable result in the biomedical field,
and more specifically in the area of reporting delay prediction, and can be explained by the
input data characteristics.
Since most of the cases were reported in the reporting delay [0, 3] months and some
fluctuations of the percentage of this pattern were observed, it was decided to model delays
in continuous time and to use a fully parametric approach allowing a more flexible approach.
The right - truncated characteristic was accommodated naturally in the sense that it was
allowed that the inferences on covariate effects were mainly driven by the shorter delays
which are appropriate when the goal is to rapidly detect changes in epidemic patterns. The
model was improved by adding the context considering the patient nationality, age, risk
group, the notification date and recent incidence observed in each institution. It was taken
into consideration that patients are nested within health care facilities, which in turn are
grouped according to their type (hospital, primary care services,...), which are grouped in
administrative regions and governed by historical policies. A maximum model with different
theoretical distributions for the (conditional) response and different nested contexts was
fitted and, afterwards, this complex model was pruned.
The under-report issue was addressed in two different ways: with a Bayesian approach
and with no covariate effects and integrated with the continuous multilevel model as a par-
ticular case of reporting delay with infinite length.
All the multilevel models presented in the thesis were also fitted using Bayesian ap-
proaches, with very similar results to the ones here exposed. A simple probabilistic record
linkage between the Portuguese HIV-AIDS data set and with the Portuguese tuberculosis
data set was also performed but the data available on both data sets did not enable an in
depth analysis.
6.2 Limitations
The main limitation of this work is related with the data specific characteristics and the data
collection method. It is widely recognized that the quality of the data within the biomedical
and healthcare fields is inferior to that found in other fields. In our data set the main reasons
for the poor classification quality are most probably related to stigma around the disease
that leads patients to provide incorrect information (mainly in the transmission group), to
high demands of the healthcare systems and to implementation of the surveillance system,
more specifically paper form reports and poor communication between the stakeholders.
In a previous qualitative assessment of the Portuguese Surveillance System, Mauch in
[93] pointed out that all clinicians reported that they complete the notification form after the
patient has left the office, sometimes several days or weeks later. This practice has the po-
tential to contribute to inaccuracies in reporting for some variables, such as the associated
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risk group, due to recall errors. Moreover, errors may also arise from the transcription of
the information from the paper report to computer databases.
6.3 Recommendations for Future Work
Inspired by the work made in this thesis, a number of interesting fields of investigation were
open. In the following paragraphs, several recommendations for future work are suggested:
• Creation of a longitudinal missing data imputation method that can capture the data
missing mechanism and accommodate changes in the surveillance system.
• Extension of the BB/NBD model in order to capture the data heterogeneity and that
may work properly, in a more stable and reliable manner.
• Comparison of the methodologies expressed in this thesis with others and with the
ones defined for epidemics of other countries, taking into consideration that the data
collection methods and culture are the main differentiating keys.
• Fit the multilevel models with other distributions such as Tweedie distributions which
have a higher point mass at zero.
• Extend the multilevel model by adding a degree of (un)confidence to each variable,
independently of the type in which it they are measured.
• Extend the approach allowing ensembling methods.
• Apply the methods developed for data pre-processing and report delay modelling for
other infectious diseases surveillance data such as Tuberculosis.
All these perspectives for future work could lead to a better understanding andmodelling
of the data. However, the statistical data preprocessing and reporting delay estimation
methods, proposed in this thesis are a concise first step, in the improvement of infectious
diseases surveillance systems, towards the creation of more effective epidemics control
procedures.
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Appendix A
HIV-AIDS European Case Definition
Since 1982, many definitions have been used for national and international reporting. In
2012, European Parliament and the Council established case definitions for AIDS and
HIV on Commission Decision of 27/09/2012 to the Community network under Decision No
2119/98/EC .
• Clinical Criteria (AIDS)
Any person who has any of the clinical conditions as defined in the European AIDS
case definition for:
– Adults and adolescents ≥15 years
– Children < 15 years of age Laboratory Criteria (HIV)
– Adults, adolescents and children aged ≥18 months At least one of the following
three:
– Positive result of a HIV screening antibody test or a combined screening test
(HIV antibody and HIV p24 antigen) confirmed by a more specific antibody test
(e.g. Western blot)
– Positive result of 2 EIA antibody test confirmed by a positive result of a further
EIA test
– Positive results on two separate specimens from at least one of the following
three:
– Detection of HIV nucleic acid (HIV-RNA, HIV-DNA)
– Demonstration of HIV by HIV p24 antigen test, including neutralisation assay
– Isolation of HIV
– Children aged < 18 months Positive results on two separate specimens (exclud-
ing cord blood) from at least one of the following three:
– Isolation of HIV
– Detection of HIV nucleic acid (HIV-RNA, HIV-DNA)
– Demonstration of HIV by HIV p24 antigen test, including neutralisation assay in
a child ≥ 1 month of age
Epidemiological Criteria: NA
Case Classification
A. Possible case: NA
B. Probable case: NA
C. Confirmed case:
• HIV infection: Any person meeting the laboratory criteria for HIV infection
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• AIDS: Any person meeting the clinical criteria for AIDS and the laboratory criteria for
HIV infection
ECDC case definition for adults and adolescents differs from the CDC’s revised defini-
tion by not including the CD4 cell counts as an AIDS-defining criterion [218].
HIV disease staging and classification systems are critical tools for tracking and moni-
toring the epidemic. Two major classification systems currently are in use: the CDC Classi-
fication System and the WHO Clinical Staging and Disease Classification System [99, 100].
Both systems use the large spectrum of specific HIV - related clinical manifestations.
While WHO system (revised in 2007) can be used readily in resource-constrained settings,
CDC classification system (revised in 1993) assesses the severity of HIV by adding to the
clinical manifestations the CD4 cell count. For CDC the definition of AIDS includes all HIV
- infected individuals with CD4 counts of < 200cells/µL as well as those with certain HIV -
related conditions and symptoms. Although the fine points of the classification system rarely
are used in the routine clinical management of HIV infected patients, a working knowledge
of the staging criteria is useful in patient care. In addition, the CDC system is used in clinical
and epidemiology research. [99, 100].
Appendix B
European AIDS case definition
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Surveillance in Children -Revision 1995
EUROPEAN CENTRE FOR THE EPIDEMIOLOGICAL MONITORING OF AIDS
CENTRE EUROPEEN POUR LA SURVEILLANCE EPIDEMIOLOGIQUE DU SIDA
WHO-EC Collaborating Centre on AIDS -Centre Collaborateur OMS-CE sur le SIDA
94410 Saint-Maurice, France
[2]* * * *
* *
* *
***
European Case Definition for AIDS Survelll.ance
in Children*
Revision 1995
Definition europeenne pour la surveillance des cas
de SIDA chez I'enfant*
Revision de 1995
The following revised European case definition for surveillance of
acquired immunodeficieny syndrome (AIDS) in children is based
on the 1987 revision of CDC/WHO case definition for AIDS (1.2)
and incorporates modifications consistent with the CDC 1994
revised classification system for human immunodeficiency virus
(HIV) infection in children.(J) This European defmition was
prepared by the European Centre for the Epidemiological
Monitoring of Ams, Saint-Maurice, France following a decision
taken by national representatives for Ams surveillance in Europe
and paediatric HIV/AIDS experts at a meeting held in Saint-
Maurice on 12-13 January 1995. The main modifications concern
changes in the diagnosis of HIV infection (Annex 1) and in the
definitions of HIV encephalopathy and mv wasting syndrome
(Annex 2).
La nouvelle definition europeenne pour la surveillance des cas de
syndrome d'immunodeficience acquise (SIDA) chez l'enfant est basee sur
la definition CDCJOMS du SIDA modifiee en 1987(1.2) et tient compte de
la revision de 1994du systeme de classification du CDC de l'infection par
le virus de l'immunodeficience humaine (VIH).c3) Cette nouvelle
definition europeenne a ete preparee par le Centre Europeen pour la
Surveillance Epidemiologique du SillA, Saint-Maurice, France, a la suite
de la decision prise par les representants nationaux de la surveillance du
SillA en Europe et par des specialistes de l'infection a VIR et du SillA
chez l'enfant, lors d'une reunion qui a eu lieu a Saint-Maurice 1es 12 et
13 janvier 1995. Les principales modifications concement le diagnostic
de l'infection a VIH(Annexe 1) et les definitions de l'encephalopathie due
au VIR et du syndrome cachectique dft au VIR (Annexe 2).
For surveillance purposes, a case
an illness characterized by one or
diseases, depending on the statu
infection, as shown below.
Dans un but de surveillance, un cas de smA chez l'enfant* est defini par
une ou plusieurs des pathologies indicatrices suivantes, en fonction de la
connaissance du statut serologique vis-A-vis du Vlli.
I. Without Laboratory Evidence for HIV Infection
If laboratory tests for HIV were not perfonl1ed or gave
inconclusive results (Annex 1) and the patient had no other
cause of immunodeficiency listed in Section I.A below, then
any disease listed in Section I.B indicates AIDS if it was
diagnosed by a defInitive method (Annex 2).
I. En I'absence de preuve biologique de I'infectlon a VIH
Si les examens de laboratoire pour le VIR n ' ont pas ete faits ou si leur
resultat est indetennine (Annexe I) et si l'enfant n'a pas une des
causes d'immunodeficience enumerees ci-dessous dans le paragraphe
I.A, chacune des pathologies enumerees dans le paragraphe I.B
permet de porter le diagnostic de SIDA dans la mesure oIl le
diagnostic de certitude de la pathologie a ete etabli (Annexe 2).
A. Causes d'immunodeficience qui emp@Chent de porter le
diagnostic de smA lors du diagnostic d'une des pathologies
enumerees en I.B
1. corticotherapie par voie generale, a dose elevee ou au long
coms, ou autre traitement immunosuppressem ou cytotoxique
daDS les trois mois precedaDt le diagnostic de la pathologie
2. chacune des maladies suivaDtes diagnostiquees dans les trois
mois suivaDt le diagnostic de la pathologie : maladie de
Hodgkin, lymphome non hodgkinien (autre que le lymphome
cerebral primitif), leucemie lymphoide, myelome multiple,
autre cancer du systeme lymphoreticulaire ou du tissu
histiocytaire, lymphadenopathie aDgio-immunoblastique
3. syndrome d'immunodeficience congenitale, ou immuno-
deficience acquise non evocatrice de l'infection a VIH telle
que l'immunodeficience par hypogarnmaglobulinemie
4. exposition a des doses aDormales de radiations
A. Causes of immunodeficiency that disqualify diseases as
indicators of AIDS in the absence of laboratory evidence
for mv infection
1. high-dose or long-tenn systemic corticosteroid therapy
or other immuno-suppressive/cytotoxic therapy .s3
months before the onset of the indicator disease
2. any of the following diseases diagnosed ~3 months after
diagnosis of the indicator disease: Hodgkin's disease,
non-Hodgkin's lymphoma (other than primary brain
lymphoma), lymphocytic leukaernia, multiple myeloma,
any other cancer of Iymphoreticular or histiocytic tissue,
or angioimmunoblastic lymphadenopathy
3. a genetic (congenital) immunodeficiency syndrome or
an acquired immunodeficiency state atypical of my
infection, such as one involving hypogarnmaglobulin-
aernia
4. exposure to abnormal levels of radiation
* Less than 13 years of age (Belarus. France and United Kingdom:
less than 15 years)
* Ages de mains de 13 ans (Belarus. France et Rayaume-Uni : mains de
15 ans)
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of AIDS in a child* is defined as
more of the following .'indicator"
s of laboratory evidence of HIV
B. Indicator diseases diagnosed definitively (Annex 2)
I. candidiasis of the oesophagus. trachea. bronchi. or lunJ~s
2. cryptococcosis, extrapulmonary
3. cryptosporidiosis with diarrhoea persisting > 1 month
4. cytomegalovirus disease of an organ other than liver.
spleen. or lymph nodes in a child > I month of age
5. herpes simplex virus infection causing a mucOCutaneous
ulcer that persists longer than 1 month; or bronchitis.
pneumonitis. or oesophagitis for any duration affecting
a child > 1 month of age
6. Kaposi's sarcoma
7. lymphoma of the brain (primary)
8. lymphoid interstitial pneumonia or pulmonary lymphoid
hyperplasia (LIP/PLH complex)
9. Mycobacterium avium complex or M. kansasii diseasf~,
disseminated (at a site other than or in addition to lung!i.
skin, or cervical or hilar lymph nodes)
10. Pneumocystis carinii pneumonia
11. progressive multifocalleukoencephalopathy
12. toxoplasmosis of the brain affecting a child > 1 month of
age
B. Pathologies indicatrices diagnostiquees avec certitude
(Annexe 2)
1. candidose de l'resophage, de la tra
~ ee, des bronches, ou des
poumons
2. cryptococcose extra-pulmonaire
3. cryptosporidiose avec diarrhee p istant depuis plus d'un
mois
4. infection a cytomegalovirus attei~ant au moins un organe
autre que le foie, la rate ou les gan*lions, chez un enfant age
de plus de 1 mois i
5. infection a virus herpes simplex en~nant un ulcere cutaneo-
muqueux persistant plus d'un moi$, ou infection herpetique
bronchique, pulmonaire ou oesophagienne quelle que soil sa
duree, chez un enfant age de plus de 1 mois
6. sarcome de Kaposi I
7. Iymphome cerebral (primitit)
8. pneumonie interstitielle Iymphoide <1u hyperplasie pulmonaire
lymphoide (complexe PllJHPL) !
9. infection due au complexe Mycobbcteriwn aviwn ou a M.
kansasii disseminee (atteignant au ~oins un organe autre que
les poumons,la peau au les ganglidns cervicaux ou hilaires)
10. pneumonie a Pneumocystis carinii
11. leucoencephalapathie multifocale ptogressive
12. toxoplasmose cerebrale chez un enflmt age de plus de 1 mais
II. With Laboratory Evidence for HIV Infection
Regardless of the presence ofother causes ofimmunodeficienCJ/
(I.A), in the presence of laboratory evidence for mY infection
(Annex 1 -paragraph A), any disease listed above (I.B) or belo~1
(II.A or II.B) indicates a diagnosis of AIDS.
II. En cas de preuve bio'ogique de "Infection a V'H
Si l'infection a VIR a ete diagnostiquee de fa~on fonnelle par le
laboratoire (Annexe 1 -paragraphe A), toutes les pathologies
enumerees ci-dessus (paragraphe I.B) 00 ci-dessous (paragraphes ll.A
et ll.B) pennettent de porter le diagnostic de,smA, queUes que soient
les autres causes d'immunodeficienc~ (enumerees dans le
paragraphe l.A). I
A. Indicator diseases diagnosed definitively (Annex 2)
1. serious bacterial infections. multiple or recUlTent (i.e"
any combination of at least two culture-confinnedl
infections within a 2-year period). of the following:
types: septicaemia. pneumonia. meningitis, bone or joint
infection. or abscess of an internal organ or body cavity
(excluding otitis media. superficial skin or mucosal
abscesses. and indwelling catheter-related infections)
2. coccidioidomycosis. disseminated (at a site other than or
in addition to lungs or cervical or hilar lymph nodes)
3. ffiV encephalopathy
4. histoplasmosis. disseminated (at a site other than or in
addition to lungs or cervical or hilar lymph nodes)
5. isosporiasis with diarrhoea persisting >1 month
6. lymphoma. small. noncleaved cell (Burkitt's). or
immunoblastic or large cell lymphoma of B-cell or
unknown immunologic phenotype
7. any mycobacterial disease caused by mycobacteria other
than Mycobacterium tuberculosis, disseminated (at a
site other than or in addition to lungs. skin. or cervical
or hilar nodes)
8. Mycobacterium tuberculosis. disseminated or
extrapulmonary
9. Salmonella (nontyphoid) septicaemia. recurrent
10. ffiV wasting syndrome (emaciation. "slim disease")
A. Pathologies indicatrices diagnostiquees avec certitude
(Annexe 2)
I. infections bacteriennes graves, multiples ou recidivantes (au
moins deux infections confinnees par culture dans one periode
de 2 ans), sous une des fonnes suivantes: septicemie, infection
pulmonaire, meningite, infection osseuse ou articulaire, abces
visceral ou d'une cavite naturelle (a I'exception des otites
moyennes, des abces superficiels cu~es ou muqueux, et des
infections sur catheter)
2. coccidioidomycose disseminee (atteignant au moins on organe
autre que les poumons ou les ganglions cervicaux ou hilaires)
3. encephalopathie due au VIR
4. histoplasmose disseminee (atteignant au moins un organe
autre que les poumons ou les ganglions cervicaux ou hilaires)
5. isosporidiose avec diarrhee persistant depuis plus d'un mois
6. Iymphome a petites cellules non clivees (type Burkitt),
Iymphome immonoblastique, ou Iymphome a grandes cellules
de type B, ou autre Iymphome de p~otype immonologique
inconnu
7. infection a mycobacteries autre$ que Mycobacterium
tuberculosis, disseminee (atteignant au moins on organe autre
que le poumon,la peau ou les gangliQl1s cervicaux ou hi1aires)
8. infection a Mycobacterium tuberculotis, disseminee ou extra-
pu1monaire I
9. septicemie recidivante a Salmonella lautre que S. typhi
10. syndrome cachectique dfl au VIR
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B. Indicator diseases diagnosed presumptively (by a method
other than those in Annex 2)
Note: Given the seriousness of diseases indicative of AIDS,
it is generally important to diagnose them definitively
(Annex 2), especially when therapy that would be used may
have serious side effects or when definitive diagnosis is
needed for eligibility for antiretroviral therapy. Nonetheless,
in some situations, a patient's condition will not permit the
performance of definitive tests. In other situations, accepted
clinical practice may be to diagnose presumptively based on
the presence of characteristic clinical and laboratory
abnormalities. Guidelines for presumptive diagnoses are
given in Annex 3.
I. candidiasis of the oesophagus
2. cytomegalovirus retinitis with loss of vision
3. Kaposi's sarcoma
4. lymphoid interstitial pneumonia or pulmonary lymphoid
hyperplasia (LIP/PLH complex)
5. mycobacterial disease (acid-fast bacilli with species not
identified by culture), disseminated (involving at least
one site other than or in addition to lungs, skin, or
cervical or hilar lymph nodes)
6. Pneumocystis carinii pneumonia
7. toxoplasmosis of the brain affecting a child > I month of
age
B. Pathologies indicatrices dont le diagnostic est presomptif
(diagnostic par une methode autre que celles enumerees dans
l'Annexe2)
Note: Etant donne la gravite des pathologies indicatrices de
SIDA, il est important qu'elles soient diagnostiquees avec
certitude (Annexe 2), en particulier lorsque les traitements
preconises peuvent entrainer des effets secondaires graves ou
lorsque la confimlation du diagnostic est necessaire pour
l'instauration d'un traitement antiretroviral. Cependant,l'etat du
maIade ne pemlet pas toujours d'effectuer les examens requis pour
le diagnostic de certitude. Dans certains cas, un diagnostic de
presomption peut etre porte sur la presence de caracteristiques
cliniques et d'anomalies biologiques. Les critCres pour le
diagnostic de presomption sont donnes dans l'Annexe 3.
1. candidose oesophagienne
2. retinite a cytomegalovirus avec atteinte de la vision
3. sarcome de Kaposi
4. pneumonie interstitielle lymphoide 00 hyperplasie pulmonaire
lymphoide (complexe PlIlHPL)
5. infection a mycobacreries (bacilles acido-alcoolo-resistants
non identifies par la culture), disseminee (atteignant au moins
un organe autre que les poumons, la peau ou les ganglions
cervicaux ou hilaires )
6. pneumonie a Pneumocystis carinii
7. toxoplasmose cerebrale chez un enfant age de plus de 1 mois
"" En cas de preuve biologique de non Infection par le VIH
En cas de resultats d'examens de laboratoire negatifs pour le VIH
(negativite du test ELISA, ainsi que de tous les autres tests de
detection du VIH s'ils ont ete faits), le diagnostic de smA est porte,
dans un but de surveillance, si :
A. toutes les autres causes d'immunodeficience enumerees dans le
paragraphe I.A ont ete exclues
et .1
8. l'eilfant a :
I. une pneumonie a Pneumocystis carinii diagnostiquee avec
certitude (Annexe 2)
au
2. a) une des autres pathologies enumerees dans le paragraphe
1.8, diagnostiquee avec certitude (Annexe 2)
et
b) une immunodeficience diagnostiquee en utilisant les
nonnes de lymphocytes CD4+ specifiques par age (voir la
revision de 1994 du systeme de classification de l'infection
VIR chez l'enfant de moins de 13 ans(3) 
III. With Laboratory Evidence against HIV Infection
With laboratory test results negative for mv infection (a non-
reactive my antibody enzyme immunoassay [ElA] without a
reactive or positive result on any other mv detection test, if
done) a diagnosis of AIDS for surveillance purposes is ruled out
unless:
A. all the other causes of immunodeficiency listed above in
Section I.A are excluded and
B. the child has had either:
I. Pneumocystis carinii pneumonia diagnosed by a
defInitive method (Annex 2)
or
2. a) any of the other diseases indicative of AIDS listed
above in Section I.B diagnosed by d defmitive
method (Annex 2)
and
b) evidence of immunodeficiency using appropriate
age-specific CD4+ lymphocyte standards (see 1994
revised classification system for human
immunodeficiency virus infection in children less
than 13 years of age (3) 
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Annex 1. Diagnosis of human immunodeficiency virl~S
(HIV} infection in children
Annexe 1. Diagnostic de I'infection par le virus de
I'immunodeficience humaine (VIH) chez I'enfant
A. mv infected child
I. A child <18 months of age who is known to be mv
seropositive or born to an HIV- infected mother
and either
-has positive results on two separate determinations
(excluding cord blood) from one or more of the
following mv detection tests:
-mv culture,
-mv polymerase chain reaction,
-mv antigen (p24),
or
-meets criteria for acquired immunodeficiency syndrome
(AIDS) diagnosis according to the present AIDS
surveillance case definition.
A. Enfant infecte par le VIR
1. Enfant age de moins de 18 mois, dont la serologie vis-8--vis du
VIR est positive ou qui est ne d'une mere infectee par le VIR,
et
.qui a deux resultats positifs de detection du VIR lors de deux
prelevements differents (excluant les prelevements du sang du
cordon) pour au moins 1 'un des examens suivants :
-culture virale VIR,
-PCR VIR,
-antigenemie VIR p24,
ou
-qui verifie les criteres de diagnostic du smA selon la presente
definition du smA.
2. A child ?:18 months of age born to an HIV-infected mother
or any child infected by blood, blood products, or other
mode of transmission (e.g. sexual contact) who either
-is HIV -antibody positive by repeatedly reactive enzyme
immunoassay (EIA) and by a confirmatory antibody test
or
-meets any of the criteria in paragraph 1. above.
2. Enfant age d'au moins 18 mois, qui est ne d'une mere infectee
par le VIR ou qui a ere infecte par transfusion ou par injection de
derives sanguins ou par tout autre mode connu de transmission du
VIR (par voie sexuelle par exemp1e), et
-qui a une serologie VIR positive par des tests ELISA repetees
et par un test de confirmation
ou
-qui verifie les criteres mentionnes dans le paragraphe 1 ci-
dessus.
B. Perinatally-exposed -Infection status indeterminate
A child who does not meet the criteria above who either
-is mY seropositive by EIA and by a conflnnatory
antibody test and is <18 months of age at the time of test
or
-has unknown antibody status, but was born to a mother
known to be infected with mY .
B. Exposition perinatale -Infection par le vm non determinee
Enfant qui ne verifie pas les crireres cites plus haut et :
.qui a une serologie VIII positive par un test ELISA et par un
test de conflm1ation et qui est age de moins de 18 mois lors du
test;
ou
.qui a un statut serologique inconnu, mais qui est ne d'une
mere infectee par le VIII.
c. Perinatally-exposed -Seroreverter
A child who is born to an mv-infected mother and who
-has been documented as mv -antibody negative (i.e. two
or more negative EIA tests performed at 6-18 months of
age or one negative EIA test after 18 months of age)
and
-has had no other laboratory evidence of infection (has
not had two positive viral detection tests, if performed)
and
-has not had an AIDS indicator disease
c. Exposition perinatale -Enfant non infecte par le VIH
Enfant qui est ne d tune mere infectee par le VIR et :
-qui a une serologie VIR negative (au moins deux tests negatifs
par ELISA entre ltage de 6 et de 18 moist ou un test negatif
parELISA apres I'age de 18 mois);
et
-qui nta pas dtautre preuve biologique dtinfection par le VIH
(n'a pas eu deux tests positifs de detection du virus stils ont
ete faits);
et
-qui n t a pas eu de pathologies indicatrices du smA
Note: Passively acquired maternal HIV antibodies may be present
in the child until 18 months of age. This may hamper the
serological diagnosis of H1V infection in children vertically
exposed to HIV infection.
Note : Les anticoIps anti-VIH maternels (transmis a l'enfant a travers la
barriere placentaire ) peuvent persister chez l' enfant jusqu ' a l' age de 18
mois. La seule detection des anticoIps anti-VIR chez un enfant age de
moins de 18 mois qui a ere expose verticalement (mere-enfant) au VIR ne
permet donc pas de porter le diagnostic d'infection a VIR chez cet enfant.
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Annex 2. Definitive Diagnostic Methods for Di~;eases
Indicative of AIDS in Children
Annexe 2. Methodes de diagnostic de certitudes des
pathologies indicatrices de SIDA chez I'enfant
Disease Definitive Diagnostic Method Pathologie Methode de diagnostic de certitude
microscopy (histology or cytology) microscopie (histologie ou cytologie)cryptosporidiosis
isosporiasis
Kaposi's sarcoma
lymphoma
lymphoid interstitial
pneumonia
Pneumocystis carinii
pneumonia
progressive multifocal
leukoencephalopathy
toxoplasmosis of the
brain
cryptosporidiose
isosporidiose
leucoencephalopathie
multifocale progressive
lymphome
pneumonie interstitielle
lymphoide
pneumonie a
Pneumocystis carinii
sarcome de Kaposi
toxoplasmose cerebrale
candidiasis either by gross inspection by
endoscopy or autopsy or by
microscopy (histology or cytology)
on a specimen obtained directly -
not from a culture-from the tissues
affected (including scrapings from
the mucosal surface)
candidose examen macroscopique par endoscopie
ou autopsie, ou examenmicroscopique
(histologie ou cytologie) direct (et non
sur une culture) d'un prelevement de
tissu infecte (y compris prelevement
des muqueuses)
coccidioidomycosis
cryptococcosis
cytomegalovirus
herpes simplex virus
histoplasmosis
microscopy (histology or cytology),
culture or detection of antigen in a
specimen obtained directly from
the tissues affected or a fluid from
those tissues
microscopie (histologie ou cytologie),
culture ou detection d'antigene sur un
prelevement obtenu directement du
tissu infecte ou sur un liquide qui en
est issu
coccidioldomycose
cryptococcose
histoplasmose
infection a cytomegalo-
virus
infection a virus herpes
simplex
culture culturetuberculosis
other mycobacteriosis
salmonellosis
other bacterial infection
tuberculose
autre mycobacteriose
salmonellose
autre infection bacterienne
my encephalopathy encephalopathie due au
VIR
au moins I'un des signes evolutifs
suivants, constate sur une periode d'au
moins deux mois, en l'absence de
maladie autte que l'infection a VIH qui
poUITait expliquer ces signes :
-retard ou perte des acquisitions
psychomotrices ou intellectuelles,
evalues par des echelles de
developpement ou des tests
neuropsychologiques adaptes
-ralentissement de la croissance
cerebrale ou microcephalie acquise
prouves par la mesure du perimetre
cranien, ou atrophie corticale
prouvee par scanner ou IRM
(plusieurs examens d'imagerie
medicale sont necessaires pour les
enfants ages de moins de 2 ans)
-deficit moteur symetrique acquis, se
manifestant par au moins deux des
signes suivants : paresie, reflexes
pathologiques, ataxie ou troubles de
la marche
at least one of the following
progressive findings present fOr at
least 2 months in the absence of a
concwrent illness other than my
infection that could explain the
findings:
.failure to attain or loss of
developmental milestones or loss
of intellectual ability, verified by
standard developmental scale or
neuropsychological tests
-impaired brain growth or
acquired microcephaly derl1on-
strated by head circumference
measurements or brain atrophy
demonstrated by computerized
tomography or magnetic
resonance imaging (serial
imaging is required for children
<2 years of age)
-acquired symmetric motor deficit
manifested by two or more of the
following: paresis, pathologic
reflexes, ataxia, or gait
disturbance
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Diseases Indicative of AIDS in Children
(continued)
Annexe 2. Methodes de diagnostic de certitudes des
pathologies indicatrices de SIDA chez I'enfant
(suite)
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~Annex 3. Suggested Guidelines for PresLlmptive
Diagnosis of Diseases Indicative of AIIDS
Annexe 3. Diagnostic presomptif
indicatrices de SIDA
des pathologies
Disease Presumptive Criteria Pathologie
candidose oesophagienne
Criteres diagnostiques
candidiasis of
oesophagus
-douleur retrosternale a la deglutition
d'apparition recente,
-recent onset of retrosternal pain
on swallowing
and
-oral candidiasis diagnosed by
the gross appearance of white
patches or plaques on an
erythematous base or by the
microscopic appearancl~ of
fungal mycelial filaments in an
uncultured specimen scraped
from the oral mucosa
et
-candidose buccale diagnastiquee
macroscapiquement (plaques
blanches sur une base
erythemateuse) au microscapique-
ment (filaments myceliens a
l'examen direct -et non sur une
culture -d'un prelevement de la
muqueuse buccale)
cytomegalovirus
retinitis
a characteristic appearance on
serial ophthalmosc:opic
examinations (e.g. discrete patches
of retinal whitening with djstinct
borders, spreading in a centrifugal
manner, following blood vessels,
progressing over several months,
frequently associated with retinal
vasculitis, haemorrhage and
necrosis); resolution of active
disease leaves retinal scarring and
atrophy with retinal pi!,'Inent
epithelial mottling
retinite a cytomegalovirus aspect caracteristique sur les examens
repetes du fond d'ceil (taches
retiniennes blanch§.tres, a bords nets,
s'etendant de maniere centrifuge en
suivant les vaisseaux sanguins,
evoluant sur plusieurs mois,
accompagnees frequemment de
vascularite retinienne avec hemorragies
et necrose) ; sequelles retiniennes a
type de cicatrices et d'atrophie avec
taches epitheliales pigmentees
mycobacteriosis microscopy of a specimen from
stool or nonnally sterile body fluids
or tissue from a site other than
lungs, skin, or cervical or hilar
lymph nodes, showing acid-fast
bacilli of a species not identified by
culture
infection a mycobacteries mise en evidence, a l'examen
microscopique d'un prelevement de
senes, de liquides corporels
normalement steriles ou de tissus
provenant d'un organe autre que les
poumons, la peau ou les ganglions
cervicaux 00 hilaires, de bacilles acido-
alcoolo-resistants non identifies par la
culture
Kaposi's sarcoma a characteristic gross appeararlce of
an erythematous or violaceuous
plaque-like lesion on skin or
mucous membrane (presumptive
diagnosis of Kaposi's sarcoma
should not be made by clinicians
who have seen few cases of it)
sarcome de Kaposi plaques erythemateuses ou violacees
caracteristiques a l'examen macro-
sCOPique de la peau ou des muqueuses
(un diagnostic presomptif de sarcome
de Kaposi ne doit pas etre parte par des
cliniciens qui n'ont vu que peu de cas)
lymphoid interstitial
pneumonia
bilateral reticulonodular interstitial
pulmonary infiltrates present on
chest X-ray for ?2 months with no
pathogen identified and no res]~onse
to antibiotic treatment
pneumonie interstitielle
lympholde
infiltrats pulmonaires interstitielst
reticulo-nodulaires et bilaterauxt a la
radiographie pulmonairet depuis plus
de 2 moist en ltabsence de germes
identifies et en l'absence de reponse au
traitement antibiotique
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Annex 3. Suggested Guidelines for Presumptive
Diagnosis of Diseases Indicative of AIDS
(continued)
Annexe 3. Diagnostic presomptif
indicatrices de SIDA (suite)
des pathologies
Pneumocystis carinii
pneumonia
-dyspnee d'effort ou toux non
productive d'apparition recente
(dans Ies trois mois precedents)
pneumonie a
Pneumocystis carinii
et
-infiltrats interstitiels diffus
bilateraux a la radiagraphie
pulmanaire, au aspect de
pneumopathie diffuse bilaterale a la
scintigraphie au gallium
et
.gaz du sang arteriels avec une Pa02
< 70 rnm Hg, une faible capacite de
diffusion ( < 80% des valeurs
prevues), ou une augmentation du
gradient alvOOlo-capillaire en O2
et
-absence
bacterienne
de pneumopathie
-a history of dyspnoea on
exertion or nonproductive cough
of recent onset (within the past
3 months)
and
-chest X-ray evidence of diffuse
bilateral interstitial infiltrates or
gallium scan evidence of diffuse
bilateral pulmonary disease
and
-arterial blood gas analysis
showing an arterial pO2 of
<7Ornm Hg or a low respiratory
diffusing capacity «80% of
predicted values) or an increase
in the alveolar-arterial oxygen
tension gradient
and
.no evidence of a bacterial
pneumonia
toxoplasmosis of the
brain
toxoplasmose cerebrale -anomalies neurologiques focalisees
d'apparition recente evoquant une
lesion intra-cerebrale, ou troubles
de la conscience
et
.mise en evidence, par scanner au
par IRM, d'une lesion entrainant un
effet de masse au prenant le produit
de cantraste
et
-serologie de la toxoplasmose
positive ou reponse au traitement de
la toxoplasmose
-recent onset of a focal
neurologic abnormality
consistent with intracranial
disease or a reduced level of
consciousness
and
-evidence by brain imaging
(computed tomography or
nuclear magnetic resonance) of
a lesion having a mass effect or
the radiographic appearance of
which is enhanced by injection
of contrast mediwn
and
-serum antibody to
toxoplasmosis or successful
response to therapy for
toxoplasmosis
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Appendix C
Codes of AIDS Indicator Disease
1 = Bacterial infections, multiple or recurrent in a child under 13 years of age
2 = Candidiasis of bronchi, trachea, or lungs
3 = Candidiasis, oesophageal
4 = Coccidioidomycosis, disseminated or extrapulmonary
5 = Cryptococcosis, extrapulmonary
6 = Cryptosporidiosis, intestinal with diarrhoea (>1 months duration)
7 = Cytomegalovirus disease (other than liver, spleen, or nodes) in a patient over one
month of age
8 = Cytomegalovirus retinitis (with loss of vision)
9 = Herpes simplex: chronic ulcer(s) (>1 months duration); or bronchitis, pneumonitis, or
oesophagitis in a patient over one month of age
10 = Histoplasmosis, disseminated or extrapulmonary
11 = Isosporiasis, intestinal with diarrhoea (>1 months duration)
12 = Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary
13 = Mycobacterium tuberculosis, pulmonary in an adult or an adolescent (aged 13 years
or over)*
14 = Mycobacterium tuberculosis, extrapulmonary
15 = Mycobacterium, other species or unidentified species, disseminated or extrapul-
monary
16 = Pneumocystis carinii pneumonia
17 = Pneumonia, recurrent in an adult or an adolescent (aged 13 years or over)*
18 = Progressive multifocal leukoencephalopathy
19 = Salmonella (non typhoid) septicaemia, recurrent
20 = Toxoplasmosis of brain in a patient over one month of age
21 = Cervical cancer, invasive in an adult or an adolescent (aged 13 years or over)*
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22 = Encephalopathy, HIV-related
23 = Kaposi s sarcoma
24 = Lymphoid interstitial pneumonia in a child under 13 years of age
25 = Lymphoma, Burkitt s (or equivalent term)
26 = Lymphoma, immunoblastic (or equivalent term)
27 = Lymphoma, primary, of brain
28 = Wasting syndrome due to HIV
30 = Opportunistic infection(s), not specified
31= Lymphoma(s), not specified
Appendix D
Portuguese Regulation
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ANEXO II
Insígnias doutorais
Barrete
Capelo
(Frente)
(Costas)
ANEXO III
Brasão de armas
Bandeira
ANEXO IV
Emblema
ANEXO V
Selo branco
ANEXO VI
Ex-líbris
MINISTÉRIO DA SAÚDE
Portaria n.o 258/2005
de 16 de Março
Em Portugal, a tabela de doenças de declaração
obrigatória está ordenada de acordo com o código da
10.a Revisão da Classificação Internacional de Doen-
ças, conforme a deliberação n.o 131/97, de 27 de Julho,
e constante da Portaria n.o 1071/98, de 31 de Dezem-
bro.
Considerando que a monitorização e a projecção no
curto emédio prazos da infecção por VIH é fundamental
para a sua prevenção e controlo, o que apenas se torna
exequível com o conhecimento do padrão epidemioló-
gico da infecção do VIH em Portugal:
Manda o Governo, pelo Ministro da Saúde, o
seguinte:
1.o A infecção pelo VIH passa a integrar a lista de
doenças de declaração obrigatória, sendo por este meio
alterada a tabela anexa à Portaria n.o 1071/98, de 31
de Dezembro.
2.o A declaração é obrigatória aquando do diagnóstico
em qualquer estádio da infecção por VIH de portador
assintomático (PA), complexo relacionado com a sida
(CRS-LGP) e sida, e sempre que se verifique mudança
de estadiamento ou óbito.
3.o É aprovado o modelo de folha de notificação
relativa à vigilância epidemiológica da infecção por
VIH, anexo a esta portaria e dela fazendo parte
integrante.
4.o É revogada a Portaria n.o 103/2005, de 25 de
Janeiro.
5.o A presente portaria produz efeitos desde a data
da sua assinatura.
OMinistro da Saúde, Luís Filipe da Conceição Pereira,
em 1 de Fevereiro de 2005.
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Despacho Normativo n.o 17/2005
O regime de codificação das embalagens dos medi-
camentos encontra-se consagrado no Despacho Norma-
tivo n.o 1/2003, de 15 de Janeiro, alterado pelo Despacho
Normativo n.o 4/2004, de 16 de Janeiro, publicado na
sequência da entrada em vigor do Decreto-Lei
n.o 270/2002, de 2 de Dezembro, que cria o sistema
de preços de referência para os medicamentos com-
participados pelo Estado, e pelo Despacho Normativo
n.o 34/2004, de 25 de Junho, publicado no Diário da
República, 1.a série-B, n.o 170, de 21 de Julho de 2004,
na sequência da entrada em vigor do Decreto-Lei
n.o 81/2004, de 10 de Abril, que introduziu o artigo
5.o-A ao Decreto-Lei n.o 101/94, de 19 de Abril.
O Despacho Normativo n.o 4/2004 prevê no seu n.o 3
que serão aprovadas por despacho as especificações téc-
nicas da codificação de medicamentos, mediante pro-
posta do INFARMED.
A solução técnica a que se chegou passa pela sim-
plificação dos dados impressos nas embalagens, o
aumento da universalidade do sistema e a capacidade
de aquisição automática de dados fixos e variáveis dos
medicamentos.
O sistema de códigos de barras ora adoptado é o
seguinte:
O actual Código de Barras 39, correspondente ao
número de registo da apresentação do medi-
camento;
Um Código de Barras 39 complementar, alfanu-
mérico, que, em conjunto com o anterior, per-
mite o acesso a uma base de dados que contém,
entre outros elementos, o lote, a validade e os
preços.
Aproveita-se ainda a oportunidade para introduzir
algumas modificações consideradas adequadas, nomea-
damente a possibilidade de recolha de dados para
suporte informático de elementos das especialidades
farmacêuticas.
Appendix E
Portuguese Notification Form
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Appendix F
Literature Review
Over almost 40 years, researcher have been interested with obtaining valid estimates of
recent incidence of reportable diseases which are, inevitable, subject to delays. Accurate
and timely estimates are necessary for research evidence guiding Public Health decision-
makers. A Literature Review summary table of key publications in reporting delay and the
incidence of HIV-AIDS is given in F.1 .
Table F.1: Reporting Delays and HIV-AIDS Incidence - Modelling Approaches
Publication Approach, Objectives and Estimation Tech-
nique
Application Strengths [+] and Limitations [-]
Nonparametric Analy-
sis of Truncated Sur-
vival Data, with Appli-
cation to AIDS, 1988,
Biometrika, [201]
Regression models based on reverse time
hazards. Developed methods for estimat-
ing and comparing the identifiable aspects
of the distribution for several groups.
Non- parametric estimations based on con-
ditional log-likelihood.
Reported to CDC
infection and in-
duction times from
persons infected
by contaminated
blood transfusions
and developed
AIDS. Data was
aggregated by
grouping dates
of infection ans
AIDS into 3-month
intervals.
[+] Nonparametric methods can estimate the induction distribution
based on a identifiable portion. Can be generalized to allow a cate-
gorization of cases by the type of opportunistic illness. Can be used
for comparing groups and stratified data. Can be used to estimate
the cumulative distribution of time of infection.
[-] No direct use of the nonparametric cumulative distribution for pre-
dict the future. Although it can be generalized to proportional haz-
ards regression, it is difficult due to the complex dependence be-
tween the identifiable portion of the cumulative distribution on the
model parameters and baseline hazard functions.
A Process of Events
with Notification
Delay and the Fore-
casting of AIDS,
1989, Philosophical
Transactions of Royal
Society [219]
Analysis and prediction of a point process
in the presence of delay in the notification
of the occurrence of an event. A paramet-
ric approach is taken to study the process
and to predict future properties of the sys-
tem. Application to AIDS data. Used sev-
eral distributions for the reporting delay and
presented one (weighted sum of two first or-
der gamma distributions).
Conditional log-likelihood
Case bases AIDS
cases in the United
Kingdom. Use an
exponential model
for the incidence
function.
[+] Process formulated in continuous time
[-] Epidemic is not described adequately by simple exponential
growth. Since the number of cases are inflated by the long tail re-
porting delay distribution, delay lag were arbitrarily truncated in 3
years long.
Reporting delays
and the Incidence of
AIDS, 1990, Journal
of the American Sta-
tistical Association
[121]
AssumeYtu as independent and with Pois-
son distribution. Describe the joint prob-
ability function and assume the likelihood
function can be written as a product of the
conditional likelihood and the marginal. De-
scribe methods for estimating both the prob-
ability distribution of reporting delays and
the actual incidence of AIDS. Are described
categorical, mixed categorical / continuous
-time models for reporting delay. Cate-
gorical and continuous-time model for inci-
dence of AIDS. Estimates Incidence of HIV
based on back calculation.
Maximum Likelihood
Reported AIDS
cases to the CDC.
Aggregated cases
of AIDS stratified
by region. Estimate
incidence of HIV
among non-drug-
using homosexual
men based on
backcalculation.
[+] Describes themodels for reporting delay and incidence under the
assumption of Poisson distribution. The corresponding likelihood
and the decomposition between conditional and marginal likelihood.
Can accommodate both truncated and censored data. Estimates of
HIV incidence consistent with serological data.
[-] Imposes constraints on the distributions that may be satisfied only
by some type of regression models. The counts of cross-classified
HIV - AIDS cases are very unlikely to be independent Poisson. If
the cases are reported in batches the independent multinomial as-
sumption does not capture the pattern. Restrictiveness of assump-
tion that incidence and reporting delay models share no common
parameters. Do not reflect uncertainty in the HIV incubation density
which is assumed to be stationary.
Statistical modelling
of the AIDS Epidemic
for forecasting Health
Care Needs, 1990,
Biometrics [202]
Extend the method of back-calculation to al-
low for a multistage model.
Fitting regression models based on reverse
time hazard. Quasi-likelihood estimates
through iteratively reweighted least squares
under weakly parametric models.
AIDS Epidemic in
the United States
with CD4 cells
count.
[+] Short term projections are given of both AIDS incidence and the
numbers of HIV-infected incorporating CD4 cells count. Consider
individuals stratified by stage of disease. Evaluate the impact of
therapeutics.
[-] Uncertainty in the hazard functions of disease progression, in
the parametric model for the infection rate, in the AIDS incidence
data, in the efficacy of treatment, and in the proportions of the HIV-
infected individuals receiving treatment. Backcalculation methods
assume a progressive disease model. Data most be transformed.
(Table continues...)
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Table F.1: Reporting Delays and HIV-AIDS Incidence - Modelling Approaches
Publication Approach, Objectives and Estimation Tech-
nique
Application Strengths [+] and Limitations [-]
A simple correction
of AIDS Surveillance
Data for Report-
ing Delays, 1990,
Journal of Acquired
Immune Deficiency
Syndromes [208]
A simple noniterative method based on
Poisson model counts.
Maximum likelihood estimations.
CDC cross-
classified surveil-
lance data.
[+] Easily implemented
[-] Assume reporting delay is stationary.
Regression Models
for Right Truncated
Data With Appli-
cations to AIDS
Incubation Times
and Reporting Lags,
1991, Statistica
Sinica [122]
Fitting regression models based on a re-
verse time hazard function to obtain non-
parametric estimates of AIDS latency dis-
tribution. The reverse time hazards are
expressed for both discrete and continu-
ous times. Discuss regression models and
related semi-parametric methods for right
truncated data. Develop tests concerning
the independence of time and truncation
time.
Full log-likelihood in the discrete case or the
partial in the continuous case.
AIDS cases re-
ported to the CDC,
with diagnoses
data and report-
ing date. AIDS
cases on risk group
“Blood transfu-
sion” since the
date of infection is
known and age of
patients.
[+] The reverse time hazards are expressed for both discrete and
continuous times. The models allow the easy comparison of trun-
cated distributions for different populations. May be used to assess
the quasi-stationarity of lag distributions which arise in connection
with pair of events. The models provide flexible and realistic repre-
sentations of covariate effects for truncated data. [-] Can be applied
only to the proportional hazards model and accommodate only right
truncated data. Assume that the reporting delay is stationary.
The use of AIDS
surveillance data for
short term predic-
tions of AIDS cases
in Madrid, Spain,
1991, European Jour-
nal of Epidemiology
[220]
Join estimation of incidence function and
distribution of reporting delays. Preliminary
attempt to predict the numbers of AIDS
cases in the Community of Madrid up to
1992. Uses surveillance data to determine
trends and predict the likely future patterns
of diagnoses. A parametric approach is
taken to study the process and to predict
future properties of the system.
Conditional likelihood
Surveillance data
of Community of
Madrid, with dates
of diagnosis, report,
alive and deaths
due to AIDS.
[+] Gives approximate confidence limits for the number of new diag-
noses. The parametric form here should capture the broad shape,
and is acceptable to produce estimates. A starting point for plan-
ning.
[-] Just an application. No new methods are described. The con-
fidence limits are skewed since underreporting was not included.
Prediction depend completely on the choice of the incidence func-
tion.
Regression Anal-
ysis of Censored
and truncated Data:
Estimating Reporting-
Delay Distributions
and AIDS Incidence
from Surveillance
Data, 1994, Inter-
national Biometrics
Society [8]
Truncation is a time of missing data. Dis-
cuss fitting regression models to data that
can be truncated and even censored in ar-
bitrary intervals.
Expectation-Maximization as a data aug-
mentation and account truncation.
CDC surveillance
data grouped
based on quarterly
intervals and strat-
ified by regions.
Apply two high
risk-groups: men
who have sex with
men and male
intravenous drug
users.
[+] Allows to model the time trends of the reporting delay sepa-
rately for each of the regions. Proved string interaction between
the chronologic time trends and geographic regions. Permits fitting
a variety of models, including those for categorical data analysis ,
to arbitrarily censored and truncated data using standard software
packages.
[-] Analysis conditional on the cases with delays less than 6 years.
Small number of parameters model.
Backcalculation of
HIV Infection Rates,
1993, Statistical
Science [209]
Reviews of the backcalculation technique,
focusing on the key assumptions of the
method, including the necessary informa-
tion regarding incubation, reporting delay,
and models for the infection curve. A sum-
mary is given of the extent to which the ap-
propriate external information is available
and whether checks of the relevant assump-
tions are possible through use of data on
AIDS incidence from surveillance systems.
New features of the approach include incor-
poration of seasonal variation in diagnosis
rates, smooth nonparametric estimation of
both the HIV infection curve and nonstation-
ary aspects of the incubation period and re-
porting delay distributions, and an analysis
of residuals from backcalculation fits. A like-
lihood approach to backcalculation.
AIDS incidence
data in the United
States with diagno-
sis and reporting
dates, trans-
mission group,
incubation time.
[+] New features of the approach include incorporation of seasonal
variation in diagnosis rates, smooth nonparametriec estimation of
both the HIV infection curve and nonstationary aspects of the incu-
bation period and reporting delay distributions, and an analysis of
residuals from backcalculation fits. Unexplained lack of fit is exam-
ined and discussed.
[-] Uncertainty associated with backcalculation estimates caused by
misspecified assumptions and inaccurate external estimates of key
components of the technique. Such uncertainty limits the useful-
ness of backcalculation and highlights the need for complementary
approaches. Use of cohorts data which may not be representative
of the more general population.
Adjustments for re-
porting delays and
the prediction of
occurred but not re-
ported events, 1994,
Canadian Journal of
Statistics [207]
Estimate the number of events that have oc-
curred but not yet been reported. Allow ran-
dom temporal fluctuations in reporting de-
lays, and consequently, confidence or pre-
diction limits.
AIDS case from
Canada
[+] The objective of this paper was to present methods of adjust-
ment for reporting delays when delay probabilities vary somewhat
over time, but not in a systematic fashion.
[-] Need the investigator to choose the degree of smoothing. Dis-
crete time framework.
A neural network for
survival data, 1995,
Statistics in Medicine
[197]
Modelling censored survival data using the
input-output relationship associated with a
Feed - Forward neural network as the basis
for a non-linear proportional hazard model
for censored survival data.
Maximum likelihood.
Survival data of
men with prostatic
carcinoma who
entered a four-
group clinical trial
comparing the
effect of several
concentrations of
diethylstilbestrol.
Data on twelve co-
variates, beside the
treatment group,
were available, in
addition to survival
time and survival
status.
[+] Introduce a broad applicability of the neural networks approach
to survival data and any generalized linear models. Emphasis given
to predictive power rather than inference about model parameters
since the latter are generally difficult to interpret. It allows the topol-
ogy of a single hidden layer feed-forward network to be used for
representing the relationship between the hazard function and co-
variates. Back.propagation can be used for training censored sur-
vival data.
[-] Comparisons of neural network models to other models in a va-
riety of applications is necessary to evaluate the utility of this ap-
proach. The confidence interval must be constructed via bootstrap,
which is computationally intensive. There are not available methods
for computation of asymptotic variance for the statistics due to the
functional dependences of the predicted outcomes on the survivals
throughout the estimated parameters. A boostrap technique is nec-
essary to obtain a more precise estimate of predictive accuracy for
each model. Careful attention to computational issues is necessary
due to the possible non unimodal likelihood function.
(Table continues...)
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Table F.1: Reporting Delays and HIV-AIDS Incidence - Modelling Approaches
Publication Approach, Objectives and Estimation Tech-
nique
Application Strengths [+] and Limitations [-]
Using surveillance
data to monitor trends
in the AIDS epidemic,
1998, Statistics in
Medicine [120]
Describes adjustments that accounts for de-
lays in reporting AIDS cases, the lack of
HIV-exposure information for some cases,
and future diagnoses of AIDS-defining op-
portunistic illnesses among persons re-
ported with AIDS under severe immunosup-
pression criteria of the 1993 AIDS surveil-
lance case definition. Partition of the cases
being analysed into clusters that are small
enough for within-cluster reporting delays
to be fairly homogeneous but large enough
to yield precise estimates of their report-
ing delay distributions. First select the vari-
ables throughout binary response regres-
sion models and then the reporting delay
is estimated separately for each group of
cases defined by the cross-classification of
levels identified during the first stage, and
groups with similar estimated delay distribu-
tions are combined
Conditional maximum likelihood.
CDC AIDS cases
with diagnosis and
reporting date,
AIDS defining
illness,State of res-
idency at the time
of AIDS diagnosis;
risk group; race /
ethnicity; indicators
of whether the
population state of
residence at diag-
nosis exceeds one
million and whether
AIDS diagnosis
and death occur
during the same
month
[+] Deterministic evaluation of the model by a CDC expect. Report-
ing delay stratified by variables. Determine a key determinant of the
length of reporting delay that is the location and type of health care
facility. Determine that the time variation of reporting delay is due to
time variation of reporting behaviour of the reporting health-facility
(’catch-up’ periods). Takes the context of the reporting facility into
consideration. Allow variations in AIDS incidence trends by mode
of exposure to HIV, sex, race/ethnicity and geographic region which
are in qualitative agreement with reported variations in HIV preva-
lence rates and changes in HIV prevalence over time.
[-] Analysis of a short period of time. Reporting delay does not vary
over six-year period within groups for which separate estimates are
made. A maximum of four years of delay is assumed. Uncertainty
in the exposure distributions. Underreporting was not covered.
Applications of mul-
tiple imputation in
medical studies: from
AIDS to United States
National Health and
Nutrition Examination
Survey (NHANES)
, 1999, Statistical
Methods in Medical
Research [116]
This paper reviews three applications of Ru-
bin’s method that are directly relevant for
medical studies: estimating the reporting
delay in acquired immune deficiency syn-
drome (AIDS) surveillance systems for the
purpose of estimating survival time after
AIDS diagnosis; missing data and noncom-
pliance in randomized experiments, where
a school choice experiment is used as an
illustration; and handling nonresponse in
United States National Health and Nutrition
Examination Surveys . The emphasis of our
review is on the building of imputation mod-
els (i.e. the first step), which is the most
fundamental aspect of the method.
CDC surveillance
data with diagnosis
and reporting dates
[+] Its flexibility in separately handling the incomplete-data problems
and the substantive analysis. In the context of dealing with nonre-
sponse in public-use data files, it is a method without serious compe-
tition in terms of both generality and validity because of the unavoid-
able separation of the creators and the users of the database and
because of the information and resource constraints on the average
users for sensibly handling the nonresponse. When used for other
purposes, it is an effective addition to a statistician’s toolkit because
of the conceptual and implementation simplicity offered by the sep-
aration of the tasks of handling incomplete data and analysing com-
plete data.
[-] If the imputation model is seriously flawed in terms of capturing
the missing-data mechanism, then so will be any analysis based on
such imputations. Less efficient than joint modelling of the missing-
data mechanism and the substantive analysis, in terms of both sta-
tistical efficiency (e.g. avoiding the reliance on a finite number of
imputations) and computational efficiency (e.g. avoiding simulation
via the use of the EM algorithm).
Joint Analysis of HIV
and AIDS Surveil-
lance Data in Back
- Calculation, 2000,
Statistics in Medicine
[210]
Generalization of back-calculation method
of HIV cases based on AIDS surveillance
data by incorporating information gained by
linkage with an HIV surveillance system,
containing data on the first positive HIV test.
It allows a flexible HIV testing rate model,
which incorporates dependence on both cal-
endar time and since infection. Use a flex-
ible approach to smoothing, based on gen-
eralized additive models. Em algorithmwith
generalized additive model smoothing.
Data of AIDS and
HIV surveillance
systems from
Veneto, Itlay
[+] Generalization of backcalcualtion for inclusion of first HIV test
data on AIDS-free individuals as well as those with AIDS. Estimates
based on combination of data are more precise that based only on
AIDS. The improvement in efficiency of HIV incidence estimates is
consistent with results of other publications. Allows the assessment
of trends in the testing rates of HIV positive individuals.
[-] Estimates dependent on assumptions of incubation distribution.
Needs to be extended for inclusion of CD4 cells count.
Data and projections
of HIV and AIDS in
Portugal, 2000, Jour-
nal of Applied Statis-
tics [203]
Backcalculation method of back-calculation
for obtaining forecasts of the portuguese
surveillance system accounting for report-
ing delay and . The method used to es-
timate the reporting delay distribution is
based on Poisson regression and involves
cross-classifying each reported case by cal-
endar time of diagnosis and reporting de-
lay. The adjusted AIDS incidence data are
then used to obtain short-term projections
and lower bounds on the size of the AIDS
epidemic. The estimation procedure ‘back-
calculates’ from AIDS incidence data us-
ing the incubation period distribution to ob-
tain estimates of the numbers previously in-
fected. The expectation-maximization algo-
rithm is used to obtain maximum-likelihood
estimates when the density of infection
times is parametrized as a step function.
Portuguese Surveil-
lance data with di-
agnosis and report-
ing delay dates and
risk groups.
[+] The methodology is applied to AIDS incidence data in Portugal
for four different transmission categories: injecting drug users, sex-
ual transmission (homosexual/bisexual and heterosexual contact)
and other, mainly haemophilia and blood transfusion related. the
method does not require knowledge of the total number of seropos-
itives in the population. The projections indicate that the AIDS epi-
demic constitutes a major public health problem in Portugal.
[-] It produces a lower bound, since it only estimates the cumulative
number of individuals that will eventually develop AIDS from those
already infected with HIV1. The method requires accurate data on
the incidence of the disease over time, as well as information on the
incubation period distribution. Uncertainty in the the incubation pe-
riod distribution. Assumptions that activities (such as underreport-
ing) are the same for all transmission categories or constant over
time. Parametric hazard models for incubation or clinical latency
period distribution with Weibull distribution.
Data and Projections
of HIV / AIDS Cases
in Portugal: An Un-
stoppable Epidemic?,
2005, Journal of Ap-
plied Statistics [204]
Back-calculation for estimating the size of
Portuguese HIV epidemic. The EM algo-
rithm was applied to obtain maximum like-
lihood estimates of the HIV incidence. The
density of infection times was parametrized
as a step function.
AIDS incidence in
Portugal for four
different transmis-
sion categories
(injecting drug
users, heterosex-
ual, homo/bisexual
and other) to obtain
short-term projec-
tions (2002–2005)
and an estimate
of the minimum
size of the epi-
demic. Reporting
delay distribution
estimated based
on a conditional
likelihood .
[+] Projections consistent with the observed trend of the epidemic.
[-] Recent discussions suggest that the backcalculation is gradu-
ally becoming less appropriate for reliable incidence and prevalence
estimates, as it does not take into account the effect of treatment.
Lower bound of the epidemic defined. Incubation period distribution
is not precisely known, there is inaccuracy in the observed disease
incidence over time, the assumptions made relative to the under-
reporting percentage and treatment effect is not been taken into
consideration.
(Table continues...)
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Table F.1: Reporting Delays and HIV-AIDS Incidence - Modelling Approaches
Publication Approach, Objectives and Estimation Tech-
nique
Application Strengths [+] and Limitations [-]
Modelling Reporting
Delays and Reporting
Corrections in Cancer
Registry Data, 2005,
Journal of the Ameri-
can Statistical Associ-
ation [205]
The primary objective is to predict the even-
tual net count, ideally after an infinite de-
lay, based on the data collected up until
the current reporting year. A secondary
interest is in the reporting delays and cor-
rections themselves, for data quality con-
trol purposes. We would like to know, for
example, the average reporting delay, the
percentage of diagnosed cancers reported
within 2 years, the percentage of reporting
errors in the data, and whether these mea-
sures have improved or worsened in recent
years. Divide the SEER population into sub-
populations based on registry and the usual
subgroups used for reporting, that is, one
for each combination of levels of the fol-
lowing variables: registries, year of diag-
nosis (17 years), gender, race, and 5-year
age groups then assumed Poisso n counts.
Conditional Maximum Likelihood.
SEER cancer data
Set from US
[+] Explicitly jointly model the reporting corrections, model the delay
distribution with very general models, combining aspects of previ-
ous nonparametric-like models with more parametric models and
allow random reporting-year effects in the model.
[-] All of the reporting models assume that the reporting process is
relatively stable . The modified AIC model selection criterion per-
formed well in simulations, but the authors noted that some care
must be used when fitting nonstationary models, because there is a
risk of confounding diagnosis year, reporting year, and delay time ef-
fects, which could have a significant effect on prediction of eventual
counts and might not be detected by the AIC. It was e introduced a
random reporting-year effects version of the reporting model that
fit our data much better than did the nonrandom model, but still
exhibited some lack of fit. For simplicity, it was assumed that the
random effects were normally distributed and independent; alterna-
tively, one could allow the random effects to be correlated or use
nonparametric methods to estimate the distribution of effects. This
model allows correlation within reporting year and it would be useful
to also allow correlation with diagnosis year.
Modelling reporting
delays for outbreak
detection in infectious
disease data, 2015,
Journal of the Royal
Statistical Society
[198]
Themain aim is to describe the reporting de-
lay hazard, with the aim of gaining a better
understanding of the reporting process, and
to investigate whether temporal factors, no-
tably calendar time, season and recent in-
cidence, influence reporting delays. Use a
continuous time spline-based model for the
hazard of the delay distribution, along with
an associated proportional hazards model.
The delay distributions are found to have ex-
tremely long tails, the hazard at longer de-
lays being roughly constant, suggestive of
a memoryless process.
Public Health
England Lab-
Base surveillance
database with
12 Infectious
diseases: Acine-
tobacter baumanii,
Campylobacter
jejuni, Chlamydia
sp, Giardia lam-
blia, Norovirus ,
Salmonella abony,
Salmonella braen-
derup , Salmonella
brandenburg,
Salmonella
enteritidis ,
Salmonella infantis,
Salmonella sen-
ftenberg, Salonella
typhimurium, Fac-
tors: calendar time,
season and recent
incidence .
[+] The modelling framework that we have used is based on a semi-
parametric regression model for the hazard. This allow to visualize
the hazard in continuous time, and to study the effect of covariates
in a natural fashion, with a simple relative hazard interpretation. De-
scribe and characterize the delay distribution in its entirety, including
long delays, which are often dropped from the analysis of surveil-
lance data.
[-] The major disadvantage of the approach is that it is more cum-
bersome than the generalized linear model method. Estimates of
the hazard at long delays are sensitive to irregularities in the data,
notably those resulting from discontinuities in reporting.
Two artificial neu-
ral networks for
modelling discrete
survival time of cen-
sored data, 2015,
Journal Advances in
Artificial Intelligence
[186]
Present a comprehensive comparison of
two different approaches of utilizing Artifi-
cial Neural Networks (ANN) in modelling
smooth conditional hazard probability func-
tion. Use ANN in survival time modelling of
skin cancer.
Male and Female
melanoma cancer
from Surveillance,
Epidemiology, and
end results pro-
gram (SEER) data
.
[+] Applying ANN is more applicable and efficient, especially when
the data does not satisfy Cox PH assumptions. ANN does not re-
quire any assumptions that need to be justified, and it is more pre-
cise in fitting nonlinear models.
[-] More investigation and statistical data analysis are required to
better understand the causes of the differences between young
males and females and to plan new strategies to fight the major
pernicious form of skin cancer.
Models for surveil-
lance data under-
reporting delay:
applications to US
veteran first-time
suicide attempters,
2015, Journal of
Applied Statistics
[163]
Allow separate models for the incidence
and reporting delay in a distribution-free
fashion, but with joint inference for both
modelling components, based on functional
response models. Discuss inference about
projections of future disease incidence to
help identify significant shifts in temporal
trends modelled based on the observed
data.
Simulated and
real data from US
veteran first-time
suicide attempters
surveillance sys-
tem.
[+] Allows modelling disease incidence and reporting delay sepa-
rately to allow for accommodation of a subsample of data for mod-
elling the reporting delay; Use of the Functional Response Models
to frame the two modelling components (disease incidence and re-
porting delay) within the context of a single model; Use of a set
of weighted generalized Estimating Equations adapted to the Func-
tional Response Models to provide consistent parameter estimates
and valid inference and presented new methods for projecting dis-
ease incidence. Simulated data provided good performance, even
for relatively small sample sizes.
[-] For modelling incidence assumption on distributions are needed
Appendix G
French Notification Form
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Caractéristiques sociodémographiques
Sérologie VIH actuelle
Statut clinique et immunologique au moment du diagnostic d’infection à VIH
Circonstances probables de la contamination
Surveillance virologique*
VHC, VHB et IST (syphilis, gonococcie, chlamydiose, LGV)
Observations       
Partenaire sexuel à l’origine probable de la contamination*
Cette fiche de déclaration obligatoire doit être adressée au médecin de l’ARS sous pli portant la mention « secret médical ».
* Voir au verso de la fiche                                                                  
Ac anti-VHC au moment du diagnostic VIH :   positif          négatif          inconnu
Ag HBs au moment du diagnostic VIH :   positif          négatif          inconnu
IST au moment du diagnostic VIH ou dans les 12 mois précédents :
  oui, la(es)quelle(s) :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .   non        inconnu
Stade clinique :  primo-infection symptomatique*                               asymptomatique                               symptomatique non sida                               inconnu
  sida*, préciser :    - pathologie(s) inaugurale(s) de sida :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
   - date de diagnostic du sida :   
   -  traitements antirétroviraux pré-sida ≥3 mois :    oui        non        inconnu  
(au cours des deux dernières années) 
Nombre de CD4 :  /mm3       Date :   Charge virale :  copies/ml       Date : 
(mesure la plus proche possible du diagnostic d’infection à VIH)    (mesure la plus proche possible du diagnostic d’infection à VIH)
Préciser s’il s’agit d’un partenaire :
  homosexuel/bisexuel
  usager de drogues injectables
  originaire d’Afrique subsaharienne
  originaire des Caraïbes/Guyane
   appartenant à une autre population exposée au VIH 
Préciser :    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
   n’appartenant pas à une autre population exposée au VIH 
Préciser :    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
  aucune information disponible sur le partenaire
Date du prélèvement de la sérologie positive :   
Motif(s) de réalisation de la sérologie actuelle* (plusieurs choix possibles) :
  risque d’exposition au VIH datant de moins de 6 mois
  risque d’exposition au VIH datant de 6 mois ou plus
  symptômes/signes cliniques liés au VIH
  infection sexuellement transmissible
  contrôle d’une séropositivité connue
  confirmation d’un TROD positif
  confirmation d’un autotest positif
  grossesse
  dépistage sans notion d’exposition au VIH
  autre, préciser :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
Initiative de la sérologie actuelle* :     proposée par le médecin 
 demandée par la personne
Mode(s) probable(s) de contamination :
   rapports  homo sexuels*, préciser s’il s’agit d’un homme ayant aussi des 
rapports hétérosexuels :  oui         non         inconnu
  rapports hétérosexuels
  usage de drogues injectables
  autre, préciser :    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
  inconnu 
La date de contamination peut-elle être estimée :  oui   non
   Si oui, préciser à quelle date ou période :   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  
   et comment (prise de risque unique, test antérieur...) :  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Lieu probable de contamination :     France        autre pays  inconnu
Après avoir été informée, la personne refuse les tests de la surveillance 
virologique :   (ne cocher cette case qu’en cas de refus de la personne)
ARS de :
 
 
Fiche clinicien : infection à VIH chez l’adulte (15 ans et plus)
Maladie à déclaration obligatoire (Art. L3113-1, R3113-1, R3113-2,  R3113-3, R3113-5,  D3113-7 du Code de la santé publique).
Critères de notification : toute sérologie VIH confirmée positive chez un sujet de 15 ans et plus .
Information individuelle des personnes : droit d’accès et de rectification (loi du 6 janvier 1978 
modifiée) pendant 12 mois, par l’intermédiaire du médecin déclarant, auprès de l’Institut de veille 
sanitaire .
Code d’anonymat* :             Année de naissance :  
Sexe* :   H           F           transgenre H vers F           transgenre F vers H                                    
Pays de domicile* :    France, préciser le département :                autre pays  
Lieu de naissance :  France métropolitaine  Guadeloupe, Martinique, Guyane, Saint-Martin, Saint-Barthélemy    France d’outre-mer autre 
    autre pays, préciser :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Année d’arrivée en France : 
Nationalité :      française      étrangère, préciser :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Profession (exercée ou non)* :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . En activité professionnelle :       oui           non (formation, chômage, retraite, etc .)
Statut vital  :   vivant    décédé, préciser la date du décès :            inconnu
  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Nom :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Tél. : 
Courriel :   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Cadre d’exercice :
       Hôpital ou clinique (nom) :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
          Chef de service et spécialité :   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
       Médecine libérale, préciser la spécialité :    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
       Autre, préciser :   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Adresse :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Code postal :    Ville :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
Date de notification :  
(si oui, merci 
de compléter 
néanmoins cette déclaration)
Confirmée positive* :      oui          non          inconnu
   Si oui, date de la première confirmée positive :  
Recours à une PrEP :     oui          non          inconnu
Négative :   oui          non          inconnu 
 Si oui, date de la dernière négative :             
Clinicien déclarantBiologiste à l’origine du diagnostic VIH
Nom :  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . Tél. : 
Courriel :   .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .
Nom et adresse du laboratoire (ou cachet) :
  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 
Date de notification :  
Sérologies VIH antérieures et recours à une PrEP*
(y compris 
tests rapides*)
(quelle que soit la période) 
12221*xx
50959#xx
V
e
rs
io
n
 2
0
1
5
Ce formulaire téléchargeable n’est à utiliser que si vous ne parvenez pas 
à déclarer en ligne sur : www.e-do.fr
1 - Critères de notification de l’infection à VIH chez l’adulte (15 ans et plus)
Doit être déclaré tout diagnostic d’infection à VIH (sérologie VIH confirmée positive) chez une personne de 15 ans et plus. 
2 - Mode de remplissage du formulaire par le clinicien
Caractéristiques sociodémographiques
- Le code d’anonymat est calculé directement dans l’application de déclaration en ligne (www .e-do .fr) . À défaut, il peut 
être calculé au moyen du logiciel d’anonymisation fourni par l’InVS sur demande, à partir du prénom, de l’initiale du nom, 
de la date de naissance et du sexe de la personne . Ce code, indispensable à l’enregistrement du cas, permet de repérer 
les doubles déclarations .
- Concernant le sexe, le terme « transgenre » désigne toute personne dont l’identité de genre, l’expression ou le 
comportement sont en inadéquation avec son sexe biologique .
- Le pays de domicile correspond au lieu où vit habituellement la personne et non à une adresse temporaire liée à une 
prise en charge médicale ou autre .
- La profession ou la catégorie socioprofessionnelle (ex : cadre, profession intermédiaire, employé…) doit être précisée, 
que la personne soit en activité ou non . Si la personne n’est plus en activité, indiquer la dernière profession exercée . « Sans 
profession » concerne seulement les personnes n’ayant jamais exercé de profession .
Sérologie VIH actuelle : Les variables « Motif(s) de réalisation de la sérologie actuelle » et « Initiative de la sérologie 
actuelle » ont pour objectifs de décrire les circonstances de réalisation d’une sérologie VIH, dans le cadre des évolutions 
de la stratégie de dépistage .
Sérologies VIH antérieures et recours à une prophylaxie pré-exposition au VIH (PrEP)
- L’information sur l’existence de sérologies antérieures négatives et la date de la dernière négative est très importante, 
car indispensable à l’estimation de l’incidence du VIH (nombre annuel de nouvelles contaminations) . Les tests rapides 
négatifs (TROD ou autotests) sont également à mentionner dans cette rubrique.
- La notion d’une sérologie antérieure confirmée positive est demandée, car la séropositivité peut être déjà connue sans 
jamais avoir été déclarée. Ne pas tenir compte des TROD ou autotests positifs, non confirmés par une sérologie classique. 
Statut clinique et immunologique au moment du diagnostic d’infection à VIH
- La primo-infection symptomatique correspond à une période de réplication virale intense, au cours de laquelle la 
personne peut présenter des manifestations cliniques débutant 2 à 6 semaines après sa contamination (syndrome pseudo-
grippal, pharyngite, éruption cutanée, adénopathies superficielles…).  
- Si la personne est au stade sida au moment de la découverte de séropositivité, il est possible d’indiquer sur ce formulaire 
la(les) pathologie(s) inaugurale(s) de sida, la date de diagnostic du sida et la notion de traitements antirétroviraux . Dans ce 
cas, il est inutile de remplir un formulaire de déclaration de sida .
Circonstances probables de la contamination : Concernant les hommes contaminés par rapports homosexuels, 
l’intérêt de préciser s’ils ont aussi des rapports hétérosexuels est de caractériser la population bisexuelle découvrant sa 
séropositivité VIH et d’appréhender le risque de diffusion de l’infection à la population hétérosexuelle .
Partenaire sexuel à l’origine probable de la contamination
-  Le libellé « partenaire originaire des Caraïbes/Guyane » inclut notamment la Guadeloupe et la Martinique .
- Les « autres populations exposées au VIH » incluent notamment les partenaires originaires d’une autre zone 
géographique à forte prévalence (Asie, Europe de l’Est…) et les partenaires prostitué(e)s .
Surveillance virologique : Il s’agit de tests complémentaires effectués par le Centre national de référence (CNR) du 
VIH sur le premier prélèvement réalisé pour le diagnostic, notamment du test d’infection récente qui permet de calculer 
l’incidence du VIH . Il vous incombe d’informer la personne séropositive sur cette surveillance virologique, et sur le fait 
qu’elle peut s’y opposer. Cochez l’item correspondant seulement en cas de refus.
Coordonnées du clinicien déclarant et du biologiste : Il vous est demandé d’indiquer vos coordonnées, ainsi que 
celles du biologiste à l’origine du diagnostic VIH, afin de permettre à l’InVS, pendant une période de 12 mois, de valider 
éventuellement certaines informations (code d’anonymat invalide, information manquante, feuillet médical non reçu…) .
3 - Envoi du formulaire
Ce formulaire de déclaration obligatoire doit être adressé au médecin de l’ARS de votre lieu d’exercice, sous pli portant la 
mention « secret médical ». L’ARS transmettra ensuite les déclarations de sa région à l’InVS pour saisie et analyse des 
données .
Il vous est demandé de conserver un double de cette déclaration pendant 12 mois, pour permettre une validation éventuelle 
par le médecin de l’InVS .
Les notices d’information, destinées aux personnes dont vous déclarez l’infection VIH, sont disponibles sur le site web de 
l’InVS : www .invs .sante .fr
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Pieczątka podmiotu wykonującego działalność leczniczą: ZLK-4 
Zgłoszenie podejrzenia lub 
rozpoznania zakażenia HIV/ 
zachorowania na AIDS/            
zgonu osoby zakażonej HIV/ chorej 
na AIDS* 
Adresat: 
Państwowy Powiatowy/Graniczny* 
Inspektor Sanitarny  
 
w .............................................................. 
 
Resortowy kod identyfikacyjny podmiotu1)   
Część I. Numer księgi rejestrowej     
 
            
 
Część II. TERYT siedziby   
 
       
 
Część III. Podmiot tworzący2) 
 
  
 
Część IV. Specjalność komórki organizacyjnej          
    
 
Uwagi:  
1) Wypełnić zgodnie z rozporządzeniem Ministra Zdrowia z dnia 17 maja 2012 r. w 
sprawie systemu resortowych kodów identyfikacyjnych oraz szczegółowego sposobu 
ich nadawania (Dz. U. poz. 594). 
2)  Wypełnić w przypadku podmiotu leczniczego niebędącego przedsiębiorcą. 
*Niepotrzebne skreślić. 
I . ROZPOZNANIE/PODEJRZENIE* 
 
1. Kod ICD-10                      2. Określenie słowne                                                                                        3. Data (dd/mm/rrrr)  
   –                             /   /     
 
 
4. Informacje dotyczące rozpoznania 
 
A. Nowo wykryte zakażenie ludzkim wirusem niedoboru odporności (HIV) 
 
Badanie potwierdzające:  
 
 
numer badania ………………………………………. data badania : …………………………………………………………………………………………. 
 
metoda: 
 
    western-blot         badanie wirusologiczne 
 
    badanie molekularne                   
 
    
              inna (wpisać jaka) ……………………………………………………………. 
 
….   
      
 
Jednostka zlecająca badanie:  …………………………………………………………….. …………………... tel. …………………………………………. 
 
 
Laboratorium potwierdzające: ………………………………………………………………………………. …. tel. …………………………………………. 
 
 
Stan kliniczny przy rozpoznaniu HIV: 
 ARS          zakażenie bezobjawowe 
 
 objawy choroby HIV, nie-AIDS    AIDS 
  
 
B. Rozpoznanie AIDS 
 
Choroby wskazujące na AIDS rozpoznane metodą definitywną:                 Choroby wskazujące na AIDS rozpoznane metodą prawdopodobną: 
1. …..…………………………………………………………………                1. ……………………………………………………………………………… 
 
2. ……………………………………………………………………...                2. ……………………………………………………………………………… 
 
3. ……………………………………………………………………...                3. ……………………………………………………………………………… 
 
 
4. ………………………………………………………………………               4. ……………………………………………………………………………… 
 
5. Zgon osoby zakażonej HIV/chorej na AIDS* -  przyczyna podejrzenia lub rozpoznania zgonu  
 
Kod ICD-10                         Określenie słowne                                                                                             Data (dd/mm/rrrr)  
   –                             /   /     
  
* Niepotrzebne skreślić. 
II.  DANE CHOREGO*  
1. Nazwisko  
                              
2. Imię                                                                                                 3. Data urodzenia (dd/mm/rrrr)      4. Nr PESEL** 
                       /   /                 
5. Inny krajowy nr identyfikacyjny**                        6. Płeć (M, K)   7. Wiek*** 
                                
 
Adres miejsca zamieszkania: 
8. Kod pocztowy                       9. Miejscowość  
  -                              
10. Ulica                                                                                                                                                 11. Nr domu      12. Nr lokalu 
                     
 
* Jeżeli pacjent zastrzeże  dane osobowe, należy wpisać:  zamiast nazwiska  i  imienia -  w  poz. 1  i  2 inicjały imienia i nazwiska lub hasło, zamiast daty 
urodzenia -  w poz. 7 wiek, zamiast adresu -  w poz. 9  nazwę powiatu właściwego ze względu na miejsce zamieszkania.  Pacjent nie może zastrzec danych o 
płci. 
** Wypełnić w przypadku, gdy osobie nie nadano numeru PESEL, wpisując  serię i  numer paszportu  albo  numer  identyfikacyjny  innego dokumentu, na 
podstawie którego jest możliwe ustalenie  danych  osobowych.  
*** Nie wypełniać w przypadku wpisania daty urodzenia. 
 
                                        
III. DANE EPIDEMIOLOGICZNE 
 
Badanie w kierunku HIV: 
 
 
data ostatniego ujemnego badania: ……………………………….. …   data pierwszego dodatniego badania: ………………………………………… 
 
 
AIDS: data rozpoznania pierwszego epizodu: ………………………………………………………………………………………………………………… 
 
Liczba komórek CD4 w odstępie 3 miesięcy od rozpoznania HIV/AIDS: …………………………………………………………………………………... 
 
Leczenie ARV przed rozpoznaniem AIDS/zgonem: 
    TAK         NIE 
 
  Nie wiadomo 
  
Przynależność do grup szczególnie narażonych: 
  IDU   MSM,WSW  CSW 
 
  Pracownicy ochrony zdrowia/personel medyczny      
 
Drogi nabycia zakażenia: 
 
    kontakt homoseksualny         kontakt heteroseksualny 
 
   kontakt seksualny, brak dokładnych danych 
  
    wstrzyknięcie narkotyku        wertykalna 
 
   transfuzja krwi/preparatów krwiopochodnych 
  
    jatrogenna         inna (jaka?) ………………………………………………………………………………… 
 
…………………... 
 
 
Inne choroby przenoszone drogą płciową: …………………………………………………………………………………………………………………….. 
 
IV. DANE ZGŁASZAJĄCEGO LEKARZA/FELCZERA/KIEROWNIKA SZPITALA 
 
 
 
1. Pieczątka imienna .................................................... 2. Telefon kontaktowy: ............................................ 3. Podpis ........................................... 
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PATIENT DATA COLLECTION 
Patient Entry  
Upon patient entry into the Stichting HIV Monitoring database, the following information is collected: 
Items collected upon initial enrolment for HIV-infected adults 
Demographic data Date of birth, gender, first and second nationality, country of birth, height, location of 
testing and health care body that referred pt to specialist 
History of HIV 
infection 
 
Date of the last negative HIV-1 and HIV-2 test 
Date of the first positive HIV-1 and HIV-2 test 
Was the patient diagnosed with a primary HIV infection? (yes, no, most likely) 
 Primary HIV infection based on: recent 
negative test, indeterminant  western-
/immunoblot, patient knows moment of risk 
behaviour, symptoms reported < 6 months, 
other, unknown. 
Symptoms reported < 6 months: 
Lymphadenopathy, flu like symptoms, 
fatigue, malaise, headache, fever, night 
sweats, photophobia, mouth ulcers, 
pharyngitis, neck stiffness, anorexia, nausea, 
vomiting, weight loss (>2,5 kg), diarrhoea, 
genital ulcers, anal ulcers, arthralgia / joint 
pain, myalgia / muscle pain, rash, confusion, 
gingivitis, unkown. 
HIV transmission 
 
The most likely transmission route:  
homosexual 
heterosexual 
injecting drug use (IDU) 
blood and blood products 
during pregnancy/partum 
via breastfeeding 
other and unknown 
For sexual transmission, the most likely 
transmission route is entered: either a steady 
sexual partner or multiple sexual contacts 
Country where the patient became infected 
Congenital Has the patient haemophilia?   
Intoxication Data on smoking, alcohol consumption and drug intake 
 
Additional data for HIV-infected children 
Demographic data Nationality and country of birth of patient’s parents 
Family data HIV status of patient’s mother, father, brothers and sisters 
Perinatal data Pregnancy duration, way of birth, weight at birth, Apgar scores, congenital defects, perinatal 
exposure to antiretroviral (ARV) therapy and co-medication, antenatal complications 
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Additional data for HIV-infected pregnant women 
Demographic data Nationality and country of birth of patient’s parents 
Patient’s ethnicity (‘Asian’, ‘Caucasian’, ‘Black’, ‘other’, or ‘unknown) 
Screening Was the patient found to be HIV-positive at the national pregnancy screening? 
 
Visits to 
Gynaecologist  
Visit date, Blood pressure 
Obstetric data 
 
Nationality and country of birth biological 
father of child 
Expected birth date 
Number of pregnancies (>37 weeks, 
between;  33-36 weeks, 28-32 weeks,  
16-27 weeks) 
Number of spontaneous abortions (<16 
weeks) 
Number of  Apla 
Number of EUG 
Pregnancy risk 
Smoking during pregnancy 
Alcohol use during pregnancy 
Drugs use during pregnancy 
Delivery data Has there been a delivery/abortion? 
Date of delivery/abortion 
Sex of the baby 
Duration of pregnancy 
Child number 
Prophylactic antibiotics? 
Intra-uterine infection 
Duration of dilation 
Duration of ruptured membranes 
 of expulsion 
Mode of delivery 
Caesarean section? 
Fetal scalp electrode 
Episiotomy or rupture 
Birth weight of the baby 
Apgar scores after 1 minute/5 minutes 
Duration of stay in the incubator 
Perinatal mortality 
Breast-feeding? 
Complications 
during pregnancy 
 
Complications during and/or after birth? 
Blood loss during the first half of 
pregnancy? 
Blood loss during second half of 
pregnancy? 
Intercurrent infection? 
Version (attempt) with breech 
presentation?  
Pre-eclampsia? 
Intra-uterine retardation of growth 
(sonography<p5%)?  
PPROM (preterm premature rupture of outer 
membranes) at how many weeks? 
Abdominal trauma at how many weeks? 
 
Extra lab results HIV1_DNA 
HIV2_DNA 
CMV_RNA 
EBV_RNA 
Anti-VCA-IGG 
Anti-VCA-IGM 
Anti-EA_IGG 
Anti_EA_IGM 
Anti_EBNA_IGG 
T_Gondii_IGG 
T_Gondii_IGM 
Anti_VZV_IGG 
Anti_VZV_IGM 
Total protein urine (g/L) 
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After patient enrolment, clinical data are collected every time the patient is seen by his or her treating 
physician. These data contain the following information:  
Items collected at every follow-up visit for HIV-infected adults 
Clinical examination Weight, blood pressure 
CDC events 
Start and stop date and the 
status of event at current 
visit (ongoing: yes or no). 
HIV-related events as classified by CDC. Definition of diagnosis (possible, 
presumptive or definitive) are recorded by standard protocol 
Adverse events  
Start and stop date and the 
status of event at current 
visit (ongoing: yes or no). 
Every event that results in a change of antiretroviral treatment is collected. In 
addition, the following events are always recorded: 
Peripheral neuropathy 
Myopathy 
Lactate acidosis 
Hepatic fibrosis / cirrhosis 
Osteopenia / Osteoporosis 
Hepatic steatosis 
Hepatic encephalopathy 
Oesophagus varices 
Bleeding from the oesophagus varices 
Hepatorenal syndrome 
Liver transplantation 
Pancreatitis 
Nephrolithiasis 
Renal insufficiency and failure 
Kidney dialysis 
Kidney transplantation 
Lipodistrophy, fat loss in extremities 
Lipodistrophy, central fat accumulation 
Rash 
Abacavir hypersensitivity 
Sexual dysfunction (loss of  libido, 
erectile dysfunction) 
Congestive heart failure (cardiac 
decompensation 
Non-AIDS malignancies 
Anal dysplasie 
Diabetes mellitus 
Myocardial infarction 
Hypertension 
Arrhythmia 
Cardiomyopathy 
Stroke 
Coronary artery by-pass grafting 
Coronary angioplasty / stenting 
Carotid endarterectomy 
Pregnancy 
Hospital admission 
Liver cirrhosis 
Liver fibrosis  
Neurosyfilis 
Pneumonia 
Myopathy 
Castle Mann disease 
Salmonella sepsis 
Herpes Zoster 
Angina pectoris 
Fractures pathological, specify 
Fractures traumatic, specify 
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Antiretroviral therapy, 
(including hepatitis B 
treatment 
hepatitis C treatment) 
 
Start units, route of 
admission, reason for stop 
and the status of 
medication at current visit 
(ongoing: yes or no t and 
stop date, dosage and) 
 
 
 
 
 
 
 
 
 
 
Standard stop reasons are as follows: 
 
Virological failure 
Immunological failure 
Patient’s decision 
Toxicity 
New CDC-B and or CDC-C events 
Interaction with co-medication  
Simplification of the regimen  
Related to blood concentration of ARV 
Structured treatment interruption 
Newly available medication 
As a precaution 
Viral load undetectable  
Palliative / terminal  
Died 
 
 
Pregnancy wish 
Pregnancy 
End of pregnancy 
Compliance problems 
Other, specify 
Unknown 
Doses increase 
Start hepatitis treatment 
Hepatitis; completed treatment 
Hepatitis; no RVR (rapid viral response) 
Hepatitis; no EVR (early viral response) 
Hepatitis; no response (not specify) 
Protocol 
Viral load undetectable/ viral load 
decrease 
  
 
 
 
Co-medication 
Start and stop date and the 
medication status at current 
visit (ongoing: yes or no) 
CDC events, prophylaxis 
CDC events, treatment 
Anti-epileptic agents 
Anti-coagulant agents 
Platelet aggregation inhibitors 
Anti-hypertensive agents 
Anti-arrhythmic agents 
Lipid lowering agents 
Anti-diabetic agents 
Insulin and its derivatives 
Anabolic steroids and appetite stimulants 
Medication that interacts with 
antiretroviral therapy 
Miscellaneous: megestrol acetate, 
dranabinol and methadone 
Chemotherapy 
 
Lab results 
 
 
 
 
 
HIV virology: RNA 
Value (copies/ml), laboratory, sample date, VL assay type, sample material, cut-off 
and undetectable: yes or no 
Immunology: T-cell count 
Value, units, laboratory and sample date for the following determinates: CD4 count, 
CD8 count, CD4 percentage, CD8 percentage, CD4/CD8 ratio 
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Chemistry 
Value, units, laboratory and sample date for the following determinates: 
Glucose >N*                                      Triglycerides always collected                                                                                                                     
Amylase >250 mmol/l                       Cholesterol always collected 
ALAT/SGPT>3 x N*                            Cholesterol HDL always collected 
ASAT/SGOT>3 x N*                            Albumin always collected 
Alkaline phosphatase >3 x N*           Bilirubin always collected 
Gamma GT >3 x N*                            Phosphate always collected 
Lactate>N*                                         LDH always collected 
Creatinine always collected               PTT always collected 
* N is normal value; can vary for different laboratories 
Haematology 
Value, units, laboratory and sample date for the following determinates: 
Haemoglobin <5.5 mmol/l 
Leukocytes  <2.0 10e9/l 
Thrombocytes always collected 
Other viral infections 
Value (positive or negative), laboratory, sample date for the following determinates: 
HBsAg, HBsAb, HBcAb, HBeAg, HBeAb, HBV-DNA (quantitative and qualitative 
values), 
HCV-Ab, HCV-RNA (quantitative and qualitative values), CMV-IgG, CMV-IgM 
Sexually transmitted diseases 
Value, units, laboratory and sample date for the following determinates: 
Chlamydia  
Condylomata accuminata 
Gonorrhoea 
Human Papilloma virus 
Syphilis 
Herpes HSV 1,2 
HTLV 
 ART drug concentrations  
Plasma concentration,  laboratory, sample data, time after drug intake, dosage and 
units of the medication 
Patient’s participation in 
clinical trials 
 
Trial name, start and stop date, informed consent. 
 
Additional data; Liver diagnostic (HIV patient and HIV patient with and hepatitis) 
Fibro scan Results; date, which hospital fibro scan was done, how many measurement were 
done, how many successful measurements were done,  Inter Quartile Range IQR, 
Median score ‘stiffness’, metavir range / metavir score (F0-F4), success range (%) 
Liver pathology  Results; date, hepatocellular carcinoma, cirrhoses or fibroses, hepatic steatosis, HAI 
index,  
Ishak score, knodell score, metavir range / metavir score (F0-F4) 
Radiology Results: date, what radiology diagnostic was done: echo, CT or MRI,  
height/length/size spleen.  focal lesions, portal flow/hypertension, cirrhoses or 
fibroses, hepatic steatosis, hepatocellular carcinoma, splenomegaly, ascitis, collateral 
vessels 
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Additional data for HIV and Hepatitis (HBV or HCV)  –infected adults  
Vaccinations HAV 1, HAV 2, HBV 1, HBV 2, HBV 3 
HCC treatment Start date, stop date, type of treatment 
Viral response  Results: date, early viral response, rapid viral response, Sustained viral response. 
Mutations and genotype Results: date, (host cell) HBV genotype / mutations, (host cell) HCV 
genotype/mutations. 
Extra Lab results  HBV-DNA, HCV-Ab, HCV-AG/AS, HDAg, HAV_Total, HAV_IGG, HAV_IGM  
 
Additional data for HIV-infected children 
Clinical examination Skull circumference, puberty stage 
CDC events 
Start and stop date and 
the status of event at 
current visit (ongoing: yes 
or no). 
HIV-related events as classified by CDC. Definitions of diagnosis (possible, 
presumptive or definitive) are recorded by standard protocol. In addition to CDC-B 
and –C events, CDC-A events are also collected. 
Adverse events  
 
Pathologic and traumatic fractures, abnormalities of psychological development, 
abnormalities of locomotion development, abnormalities of puberty development 
Additional treatment 
Start and stop date, status 
at current visit 
Psychologist, pedagogue, psychiatrist, speech therapist, physiotherapist, rehabilitation 
worker, social worker 
Care and education  Care by: Mother, father, parents, family, foster family, care institute, other and 
unknown 
Education: Nursery school, playgroup, primary school, secondary school, other and 
unknown 
Vaccinations date  DKTP1, DKTP2, DKTP3, DKTP4, HIB1, HIB2, HIB3, HIB4, BMR, BCG, PNCV, influenza, 
meningitis C, pneumovax, other 
Lab results HIV virology: DNA 
Value (positive or negative), laboratory, sample date for the following determinates: 
HIV-1 DNA, HIV-2 DNA, HIV-1 antibodies, HIV-2 antibodies 
Chemistry: 
The following determinates are always collected: 
Glucose, Amylase, ALAT/SGPT,ASAT/SGOT, Alkaline phosphatase, Gamma GT, 
Lactate, Triglycerides, Cholesterol, Cholesterol, HBA1c 
Haematology: 
The following determinates are always collected: 
Haemoglobin, Leukocytes, Thrombocytes, MCV 
Other viral infections 
Value (positive or negative), laboratory, sample date for the following determinates: 
In addition to Hepatitis and CMV, Toxoplasmosis and Varicella Zoster Virus are 
collected. 
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Record	
type
Record	
type	
version
Variable Full	name Description Type Coded	value	list Required Repeatable Allow	NA Allow	UNK
Default	(if	not	
reported)
Date:	Allowed	
formats
Number:	Min	
value
Number:	Max	
value
AIDS 3 RecordId RecordId Unique	identifier	for	each	record	within	and	across	the	
national	surveillance	system	–	MS	selected	and	
generated
TEXT True	(Error) No No No
AIDS 3 RecordType RecordType Structure	and	format	of	the	data	(case	based	reporting	
and	aggregate	reporting).
CV 'AIDS' True	(Error) No No No
AIDS 3 RecordTypeVersion RecordTypeVersio
n
There	may	be	more	than	one	version	of	a	recordType.	
This	element	indicates	which	version	the	sender	uses	
when	generating	the	message.	Required	when	no	
metadata	set	is	provided	at	upload.
NUM No No No No
AIDS 3 Subject Subject Disease	to	report CV [Subjects	for	AIDS]:	AIDS	=	AIDS True	(Error) No No No
AIDS 3 Status Status Status	of	reporting	NEW/UPDATE	or	DELETE	
(inactivate).	Default	if	left	out:	NEW/UPDATE.	If	set	to	
DELETE,	the	record	with	the	given	recordId	will	be	
deleted	from	the	TESSy	database	(or	better	stated,	
invalidated.	If	set	to	NEW/UPDATE	or	left	empty,	the	
record	is	newly	entered	into	the	database.
CV [Statuses]:	DELETE	=	Delete	a	previously	
reported	record.	NEW/UPDATE	=	Report	a	
new	or	update	a	previously	reported	record	
(default).
No No No No
AIDS 3 DataSource DataSource The	data	source	(surveillance	system)	that	the	record	
originates	from.
CV [Data	sources]	(see	the	coded	values	list) True	(Error) No No No
AIDS 3 ReportingCountry ReportingCountry The	country	reporting	the	record. CV [Countries]	(see	the	coded	values	list) True	(Error) No No No
AIDS 3 DateUsedForStatisti
cs
DateUsedForStatis
tics
The	reference	date	used	for	standard	reports	that	is	
compared	to	the	reporting	period.	The	date	used	for	
statistics	can	be	any	date	that	the	reporting	country	
finds	applicable,	e.g.	date	of	notification,	date	of	
diagnosis	or	any	other	date.
DATE True	(Error) No No No yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd
AIDS 3 Age Age Exact	age	at	diagnosis	of	AIDS.	Age	as	a	crude	number	is	
preferred	-	calculated	from	date	of	diagnosis
NUM True	
(Warning)
No No Yes UNK 0 120
AIDS 3 AgeClass Age	class For	AIDS	case	based	reporting,	the	exact	age	is	
preferred	but	aggregate	age	classes	are	allowed.	
Previous	coding	as	‘unknown/paediatric’	and	
‘unknown/adult’	is	not	allowed.	The	previously	used	age	
grouping	is	provided	in	the	list	of	age	groups.
CV AgeClass2	(see	the	coded	values	list) True	
(Remark)
No No Yes UNK
AIDSIndicatorDisease:
1	=	Bacterial	infections,	multiple	or	
recurrent	in	a	child	under	13	years	of	age
10	=	Histoplasmosis,	disseminated	or	
extrapulmonary
11	=	Isosporiasis,	intestinal	with	diarrhoea	
(>1	months	duration)
12	=	Mycobacterium	avium	complex	or	M.	
kansasii,	disseminated	or	extrapulmonary
13	=	Mycobacterium	tuberculosis,	
pulmonary	in	an	adult	or	an	adolescent	
(aged	13	years	or	over)*
14	=	Mycobacterium	tuberculosis,	
extrapulmonary
15	=	Mycobacterium,	other	species	or	
unidentified	species,	disseminated	or	
extrapulmonary
16	=	Pneumocystis	carinii	pneumonia
3AIDS YesTrue	(Error)CVNote	that	this	is	a	repetable	field	and	can	be	repeated	
to	submit	mutlipel	diagnoses.
AIDS	indicator	
disease	at	the	
time	of	AIDS	
diagnosis
AIDSIndicatorDiseas
e
NoNo
17	=	Pneumonia,	recurrent	in	an	adult	or	an	
adolescent	(aged	13	years	or	over)*
18	=	Progressive	multifocal	
leukoencephalopathy
19	=	Salmonella	(non	typhoid)	septicaemia,	
recurrent
2	=	Candidiasis	of	bronchi,	trachea,	or	lungs
20	=	Toxoplasmosis	of	brain	in	a	patient	over	
one	month	of	age
21	=	Cervical	cancer,	invasive	in	an	adult	or	
an	adolescent	(aged	13	years	or	over)*
22	=	Encephalopathy,	HIV-related
23	=	Kaposi	s	sarcoma
24	=	Lymphoid	interstitial	pneumonia	in	a	
child	under	13	years	of	age
25	=	Lymphoma,	Burkitt	s	(or	equivalent	
term)
26	=	Lymphoma,	immunoblastic	(or	
equivalent	term)
27	=	Lymphoma,	primary,	of	brain
28	=	Wasting	syndrome	due	to	HIV
3	=	Candidiasis,	oesophageal
30	=	Opportunistic	infection(s),	not	specified
31	=	Lymphoma(s),	not	specified
4	=	Coccidioidomycosis,	disseminated	or	
extrapulmonary
5	=	Cryptococcosis,	extrapulmonary
6	=	Cryptosporidiosis,	intestinal	with	
diarrhoea	(>1	months	duration)
7	=	Cytomegalovirus	disease	(other	than	
liver,	spleen,	or	nodes)	in	a	patient	over	one	
month	of	age
8	=	Cytomegalovirus	retinitis	(with	loss	of	
vision)
9	=	Herpes	simplex:	chronic	ulcer(s)	(>1	
months	duration);	or	bronchitis,	
pneumonitis,	or	oesophagitis	in	a	patient	
over	one	month	of	age
AIDS 3 ARTTreatment Any	kind	of	
antiretroviral	
treatment	at	any	
time	prior	to	AIDS
This	variable	indicates	if	the	patient	receives	any	kind	of	
antiretroviral	treatment	at	any	time	prior	to	AIDS	
diagnosis.	There	is	no	minimum	duration	and	no	
restriction	on	timing.
CV YesNoUnk:	N=N0;	Unk	=	Unknown;	Y	=	Yes True	
(Warning)
No No Yes UNK
CaseClassification:
CONF	=	Confirmed
POSS	=	Possible
PROB	=	Probable
Unk	=	Unknown
YesNoNAUnk:
N	=	No
NA	=	Not	applicable
Unk	=	Unknown
Y	=	Yes
Country_Incl_HistCountries
3AIDS YesTrue	(Error)CVNote	that	this	is	a	repetable	field	and	can	be	repeated	
to	submit	mutlipel	diagnoses.
AIDS	indicator	
disease	at	the	
time	of	AIDS	
diagnosis
AIDSIndicatorDiseas
e
NoNo
3AIDS NoTrue	
(Warning)
CVFor	AIDS,	only	‘Confirmed’	cases	CONF	are	reportable	at	
European	level.
Case	ClassificationClassification UNKYesNo
CVFor	AIDS,	only	cases	meeting	the	clinical	criteria	should	
be	reported	to	the	European	level.
Clinical	Criteria	
Met
ClinicalCriteria3AIDS
3AIDS
UNKYesYesNoTrue	
(Warning)
NoFALSECVThis	is	the	prefered	variable.	If	it	is	not	available,	then	
submit	CountryOfNationality,	and	if	this	is	not	available,	
then	RegionOfOrigin.
Country	of	birth	of	
patient
CountryOfBirth UNKYesNo
(see	the	coded	values	list)
AIDS 3 CountryOfNationali
ty
Country	of	
nationality	of	
patient
CountryOfBirth	is	the	prefered	variable.	If	it	is	not	
available,	then	submit	CountryOfNationality,	and	if	this	
is	not	available,	then	RegionOfOrigin.	Please	still	submit	
CountryOfNationality,	if	possible.
CV Country	(see	the	coded	values	list) FALSE No No Yes
AIDS 3 DateOfDeath Date	of	death Date	of	death	because	of	HIV/AIDS DATE FALSE No Yes Yes UNK yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-mm-dd,	
UNK,	NA
AIDS 3 DateOfDiagnosis Date	of	Diagnosis Date	should	be	provided	as	exact	date	or	incomplete	
date.	The	exact	date	is	preferred	and	should	be	
provided	if	available;	incomplete	dates	(e.g.	quarter,	
month,	year)	are	allowed	as	well.
DATE True	(Error) No No No yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd
AIDS 3 DateOfHIVDiagnosis Date	of	first	
positive	HIV	test
Date	of	first	positive	HIV	test DATE FALSE No No Yes UNK yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-mm-dd,	
UNK
AIDS 3 DateOfNotification Date	of	
Notification
The	exact	date	is	preferred	and	should	be	provided	if	
available;	incomplete	dates	(e.g.	quarter,	month,	year)	
are	allowed	as	well.
DATE FALSE No No Yes UNK yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd,	
UNK
AIDS 3 DateOfOnset Date	of	Onset	of	
Disease
For	AIDS,	this	should	be	coded	as	Unk	‘Unknown’	except	
for	acute	primo-infection	or	proven	seroconversion	by	
laboratory	confirmation.
DATE FALSE No No Yes UNK yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-mm-dd,	
UNK
AIDS 3 DateOfReportDeath Date	of	death	
report	to	national	
HIV/AIDS	
surveillance
The	exact	date	is	preferred	to	obtain	more	accurate	
information	and	to	allow	better	comparison	and	
grouping.
DATE FALSE No Yes Yes UNK yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-mm-dd,	
UNK,	NA
YesNoNAUnk:
N	=	No
NA	=	Not	applicable
Unk	=	Unknown
Y	=	Yes
Sex:
F	=	Female
M	=	Male
O	=	Other	(e.g.,	transsexual)
Unk	=	Unknown
HIVType:
HIV1	=	HIV1	only
HIV12	=	HIV1	and	HIV2	(co-infection)
HIV2	=	HIV2	only
Unk	=	Unknown
LabResults:
CONF	=	Confirmed
NA	=	Not	Applicable
PROB	=	Probable
UNK	=	Unknown
Outcome2:
A	=	Alive
D	=	Died
UNK	=	Unknown
NUTS
3AIDS NoFALSECVThis	is	the	prefered	variable.	If	it	is	not	available,	then	
submit	CountryOfNationality,	and	if	this	is	not	available,	
then	RegionOfOrigin.
Country	of	birth	of	
patient
CountryOfBirth UNKYesNo
3AIDS NoFALSECVFor	AIDS,	this	is	not	applicable	and	should	be	coded	as	
‘Not	Applicable’	NA.
Epidemiological	
Link	Criteria	Met
EpiLinked UNKYesYes
CVTranssexual	should	be	coded	as	O	-	OtherGenderGender3AIDS
3AIDS
UNKYesNoNoTrue	
(Warning)
NoTrue	(Error)CVDescribes	the	type	of	HIV	infectionDescribes	the	type	
of	HIV	infection
HIVType YesNo
CVFollowing	EU	case	definition	2008,	only	laboratory	
confirmed	cases	are	reported.	Historical	data	as	well	as	
cases	reported	using	another	case	definition	decribed	in	
Data	source	may	have	value	NA.
Laboratory	resultLaboratoryResult3AIDS
3AIDS
UNKYesYesNoFALSE
NoFALSECVInformation	on	whether	the	case	is	alive	or	deceased.	
The	death	should	be	due	to	the	reported	disease.
Outcome	of	caseOutcome UNKYesNo
CVPlace	of	the	first	notification	of	the	case	to	a	regional	
authority.	Select	the	most	detailed	NUTS	level	possible.
Place	of	
notification
PlaceOfNotification3AIDS YesNoNoFALSE
(see	the	coded	values	list)
NUTS
(see	the	coded	values	list)
RegionOfOrigin:
ABROAD	=	Abroad	but	sub	continent	
unknown
AUSTNZ	=	Australia	and	New	Zealand
CAR	=	Caribbean
CENTEUR	=	Central	Europe
EASTASIAPAC	=	East	Asia	and	Pacific
EASTEUR	=	East	Europe
EUROPE	=	If	a	case	can	not	be	reported	in	
West,	central	or	Eastern	Europe,	he/she	
should	be	reported	in	Europe	(sub-continent	
unknown).
LATAM	=	Latin	America
NORTHAFRMIDEAST	=	North	Africa	and	
Middle	East
NORTHAM	=	North	America
REPCOUNTRY	=	Same	as	country	of	report
SOUTHASIA	=	South	and	South	East	Asia
SUBAFR	=	Sub	Sahara	Africa
Unk	=	Unknown
WESTEUR	=		West	Europe
Transmission:
HAEMO	=	haemophiliac	patient
HETERO	=	heterosexual	contact
IDU	=	ever	injected	drugs
MSM	=	MSM/homo	or	bisexual	male
MTCT	=	mother-to-child-transmisison
NOSO	=	Nosocomial
TRANSFU	=	transfusion	recipient
Unk	=	Unknown	or	undetermined
TransmissionHetero:
NA	=	not	applicable
ORIGINHP	=	Originating	from	a	country	with	
generalized	epidemic
SEXBI	=	Sex	with	a	bisexual	male
SEXHAEMO	=	Sex	with	a	haemophiliac
SEXHIVPOS	=	Sex	with	a	person	known	to	be	
infected	and	not	know	to	belong	to	any	of	
categories	above
SEXHP	=	Sex	with	a	person	originating	or	
living	in	a	country	with	a	generalized	
epidemic
SEXIDU	=	Sex	with	a	injecting	drug	user
SEXUNK	=	Strongly	believed	to	have	been	
infected	through	heterosexual	contact,	
information	on	risk	factor	and	partner	not	
available
TransmissionMTCT:
MOTHHET	=	Infected	through	heterosexual	
contact	and	not	known	to	belong	to	
category	above
CVPlace	of	the	first	notification	of	the	case	to	a	regional	
authority.	Select	the	most	detailed	NUTS	level	possible.
Place	of	
notification
PlaceOfNotification3AIDS
3AIDS
YesNoNoFALSE
NoFALSECVPlace	of	residence	of	patient	at	the	time	of	disease	
onset.	Select	the	most	detailed	NUTS	level	possible.
Place	of	residencePlaceOfResidence YesNo
CVRegion		of	origin,	where	from	patient	is	originating.	If	
country	of	birth	is	reported,	it	should	correspond	to	the	
region.	CountryOfBirth	is	the	prefered	variable.	If	it	is	
not	available,	then	submit	CountryOfNationality,	and	if	
this	is	not	available,	then	RegionOfOrigin.	Please	still	
submit	RegionOfOrigin,	if	possible.
Region	of	origin	of	
patient
RegionOfOrigin3AIDS
3AIDS
UNKYesNoNoTrue	
(Warning)
NoTrue	
(Warning)
CVNosocomial	infection	includes	patients	infected	in	
health	care	settings.	Case	of	occupational	exposure	
should	be	classified	as	UNK	‘Unknown	or	
undetermined’.	Cases	which	are	not	fully	documented	
should	be	coded	as	Unk.
Describes	the	
most	probable	
route	of	
Transmission
Transmission UNKYesNo
CVThis	allows	to	specify	the	heterosexual	route	of	
transmission	and	this	should	be	provided	if	
Transmission=	HETERO	(variable	21);	in	other	cases	the	
variable	is	coded	as	default	NA	‘not	applicable’.	
Heterosexual	contact	refers	to	a	person	for	who	risk	
factors	for	HIV	infection	other	than	heterosexual	
contact	have	not	been	identified	and	who	either	
originates	from	a	country	with	generalized	epidemic	
(HIV	prevalence	in	pregnant	women>1%,	see	list	of	
countries	in	the	Annex	3)	or	has	had	sex	with:	bisexual	
male,	IDU,	haemophiliac	-	recipient,	a	person	from	a	
country	with	generalized	epidemic,	a	person	known	to	
be	HIV	positive	and	not	known	to	belong	to	one	of	the	
above	mentioned	or	is	strongly	believed	to	have	been	
infected	through	sexual	transmission,	information	on	
risk	factors	and	HIV	status	of	partner(s)	not	available.
Specifies	the	
heterosexual	
route	of	
transmission
TransmissionHetero3AIDS
3AIDS
NoYesNoFALSE
NoFALSECVThis	allows	to	specify	the	transmission	categories	for	
mother	to	child	cases	and	this	should	be	provided	if	
Transmission=MTCT	(variable	21);	in	other	cases	the	
variable	is	coded	as	default	NA	‘not	applicable’.
TransmissionMTCTTransmissionMTCT YesYes
MOTHHP	=	Originating	from	a	country	with	
generalized	epidemic
MOTHIDU	=	Injecting	drug	use
MOTHTRANSFU	=		Transfusion	recipient
NA	=	not	applicable
Unk	=	Other/undetermined
HIV 4 RecordId RecordId Unique	identifier	for	each	record	within	and	across	the	
national	surveillance	system	–	MS	selected	and	
generated
TEXT True	(Error) No No No
HIV 4 RecordType RecordType Structure	and	format	of	the	data	(case	based	reporting	
and	aggregate	reporting).
CV 'HIV' True	(Error) No No No
HIV 4 RecordTypeVersion RecordTypeVersio
n
There	may	be	more	than	one	version	of	a	recordType.	
This	element	indicates	which	version	the	sender	uses	
when	generating	the	message.	Required	when	no	
metadata	set	is	provided	at	upload.
NUM No No No No
[Subjects	for	HIV]:
HIV	=	HIV	infection
[Statuses]:
DELETE	=	Delete	a	previously	reported	
record.
NEW/UPDATE	=	Report	a	new	or	update	a	
previously	reported	record	(default).
[Data	sources]
(see	the	coded	values	list)
[Countries]
(see	the	coded	values	list)
HIV 4 DateUsedForStatisti
cs
DateUsedForStatis
tics
The	reference	date	used	for	standard	reports	that	is	
compared	to	the	reporting	period.	The	date	used	for	
statistics	can	be	any	date	that	the	reporting	country	
finds	applicable,	e.g.	date	of	notification,	date	of	
diagnosis	or	any	other	date.
DATE True	(Error) No No No yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd
HIV 4 Age Age Exact	age	at	diagnosis	of	HIV.	Age	as	a	crude	number	is	
preferred	-	calculated	from	date	of	diagnosis
NUM True	
(Warning)
No No Yes UNK 0 120
HIV 4 CD4Cells CD4	count	at	the	
time	of	HIV	
diagnosis
CD4	count	at	the	time	of	HIV	diagnosis NUM FALSE No Yes Yes 0 6000
CaseClassification:
CONF	=	Confirmed
POSS	=	Possible
PROB	=	Probable
Unk	=	Unknown
YesNoNAUnk:
N	=	No
NA	=	Not	applicable
Unk	=	Unknown
Y	=	Yes
Country_Incl_HistCountries
(see	the	coded	values	list)
Country
(see	the	coded	values	list)
HIV 4 DateOfAIDSDiagnos
is
Date	of	AIDS	
diagnosis
For	HIV	cases	initially	reported	at	a	pre-AIDS	stage,	the	
date	of	AIDS	diagnosis	is	'follow-up'	information,	which	
necessitates	updating	of	the	record.	The	exact	date	is	
preferred	to	obtain	more	accurate	information	and	to	
allow	better	comparison	and	grouping.	Incomplete	
dates	(quarter,	month,	year)	are	allowed	as	well.
DATE FALSE No Yes Yes yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-mm-dd,	
UNK,	NA
3AIDS NoFALSECVThis	allows	to	specify	the	transmission	categories	for	
mother	to	child	cases	and	this	should	be	provided	if	
Transmission=MTCT	(variable	21);	in	other	cases	the	
variable	is	coded	as	default	NA	‘not	applicable’.
TransmissionMTCTTransmissionMTCT YesYes
CVDisease	to	reportSubjectSubject4HIV
4HIV
NoNoNoTrue	(Error)
NoNoCVStatus	of	reporting	NEW/UPDATE	or	DELETE	
(inactivate).	Default	if	left	out:	NEW/UPDATE.	If	set	to	
DELETE,	the	record	with	the	given	recordId	will	be	
deleted	from	the	TESSy	database	(or	better	stated,	
invalidated.	If	set	to	NEW/UPDATE	or	left	empty,	the	
StatusStatus NoNo
CVThe	data	source	(surveillance	system)	that	the	record	
originates	from.
DataSourceDataSource4HIV
4HIV
NoNoNoTrue	(Error)
NoTrue	(Error)CVThe	country	reporting	the	record.ReportingCountryReportingCountry NoNo
CVFor	HIV,	only	‘Confirmed’	cases	CONF	are	reportable	at	
European	level.	In	case	when	MTCT	cases	<18	month	
are	not	confirmed,	they	should	be	reported	as	probable	
“PROB”.
Case	ClassificationClassification4HIV
4HIV
UNKYesNoNoTrue	
(Warning)
NoFALSECVFor	HIV,	NA	is	the	expected	value.Clinical	Criteria	
Met
ClinicalCriteria UNKYesYes
CVThis	is	the	prefered	variable.	If	it	is	not	available,	then	
submit	CountryOfNationality,	and	if	this	is	not	available,	
then	RegionOfOrigin.
Country	of	birth	of	
patient
CountryOfBirth4HIV
4HIV
YesNoNoFALSE
NoFALSECVCountryOfBirth	is	the	prefered	variable.	If	it	is	not	
available,	then	submit	CountryOfNationality,	and	if	this	
is	not	available,	then	RegionOfOrigin.	Please	still	submit	
Country	of	
nationality	of	
patient
CountryOfNationali
ty
YesNo
HIV 4 DateOfDeath Date	of	death Date	of	death	because	of	HIV/AIDS DATE FALSE No Yes Yes UNK yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-mm-dd,	
UNK,	NA
HIV 4 DateOfDiagnosis Date	of	Diagnosis Date	should	be	provided	as	exact	date	or	incomplete	
date.	The	exact	date	is	preferred	and	should	be	
provided	if	available;	incomplete	dates	(e.g.	quarter,	
month,	year)	are	allowed	as	well.
DATE True	(Error) No No No yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd
HIV 4 DateOfNotification Date	of	
Notification
Date	when	the	case	report	is	first	reported	or	notified	
to	public	health	authorities.
DATE FALSE No No Yes UNK yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd,	
UNK
HIV 4 DateOfOnset Date	of	Onset	of	
Disease
Date	of	onset	of	disease.	Not	applicable	in	
asymptomatic	cases.	If	not	applicable,	please	use	'Unk'
DATE FALSE No No Yes UNK yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-mm-dd,	
UNK
YesNoNAUnk:
N	=	No
NA	=	Not	applicable
Unk	=	Unknown
Y	=	Yes
Sex:
F	=	Female
M	=	Male
O	=	Other	(e.g.,	transsexual)
Unk	=	Unknown
HIVStatus:
NEG	=	Negative
PREVPOS	=	previous	HIV	positive
Unk	=	Unknown
HIVType:
HIV1	=	HIV1	only
HIV12	=	HIV1	and	HIV2	(co-infection)
HIV2	=	HIV2	only
Unk	=	Unknown
LabResults:
CONF	=	Confirmed
NA	=	Not	Applicable
PROB	=	Probable
UNK	=	Unknown
Outcome2:
A	=	Alive
D	=	Died
UNK	=	Unknown
NUTS
(see	the	coded	values	list)
NUTS
(see	the	coded	values	list)
Country_Incl_HistCountries
(see	the	coded	values	list)
CVFor	HIV,	this	shoudl	be	coded	as	NA.Epidemiological	
Link	Criteria	Met
EpiLinked4HIV
4HIV
UNKYesYesNoFALSE
NoTrue	
(Warning)
CVTranssexual	should	be	coded	as	O	-	OtherGenderGender UNKYesNo
CVThis	variable	provides	information	on	previous	positive	
test	results,	prior	to	the	first	time	of	reporting.	This	
variable	allows	cases	"newly	diagnosed"	to	be	
distinguished	from	case	who	had	positive	HIV	test	in	the	
past	but	are	reported	for	the	first	time	in	the	country.
HIV	status;	
previous	positive	
test
HIVStatus4HIV
4HIV
UNKYesNoNoFALSE
NoTrue	(Error)CVDescribes	the	type	of	HIV	infectionDescribes	the	type	
of	HIV	infection
HIVType YesNo
CVFor	HIV,	CONF	is	the	expected	coding.Laboratory	resultLaboratoryResult4HIV
4HIV
UNKYesYesNoFALSE
NoFALSECVInformation	on	whether	the	case	is	alive	or	deceased.	
The	death	should	be	due	to	the	reported	disease.
Outcome	of	caseOutcome UNKYesNo
CVPlace	of	the	first	notification	of	the	case	to	a	regional	
authority.	Select	the	most	detailed	NUTS	level	possible.
Place	of	
notification
PlaceOfNotification4HIV
4HIV
YesNoNoFALSE
NoFALSECVPlace	of	residence	of	patient	at	the	time	of	disease	
onset.	Select	the	most	detailed	NUTS	level	possible.
Place	of	residencePlaceOfResidence YesNo
CVIf	Imported=Yes:	One	entry	for	each	country	visited	
during	the	incubation	period	of	the	disease	should	be	
provided.	The	entry	could	be	UNK	even	if	the	case	is	
known	to	be	imported.
Probable	Country	
Of	Infection
ProbableCountryOfI
nfection
4HIV YesNoNoFALSE
RegionOfOrigin:
ABROAD	=	Abroad	but	sub	continent	
unknown
AUSTNZ	=	Australia	and	New	Zealand
CAR	=	Caribbean
CENTEUR	=	Central	Europe
EASTASIAPAC	=	East	Asia	and	Pacific
EASTEUR	=	East	Europe
EUROPE	=	If	a	case	can	not	be	reported	in	
West,	central	or	Eastern	Europe,	he/she	
should	be	reported	in	Europe	(sub-continent	
unknown).
LATAM	=	Latin	America
NORTHAFRMIDEAST	=	North	Africa	and	
Middle	East
NORTHAM	=	North	America
REPCOUNTRY	=	Same	as	country	of	report
SOUTHASIA	=	South	and	South	East	Asia
SUBAFR	=	Sub	Sahara	Africa
Unk	=	Unknown
WESTEUR	=		West	Europe
Stage:
ACUTE	=	Acute	HIV	infection
AIDS	=	AIDS
ASYMP	=	Asymptomatic
NONAIDS	=	Non-AIDS,	not	further	specified
SYMPNONAIDS	=	Symptomatic	non-AIDS
UNK	=	Unknown
Transmission:
HAEMO	=	haemophiliac	patient
HETERO	=	heterosexual	contact
IDU	=	ever	injected	drugs
MSM	=	MSM/homo	or	bisexual	male
MTCT	=	mother-to-child-transmisison
NOSO	=	Nosocomial
TRANSFU	=	transfusion	recipient
Unk	=	Unknown	or	undetermined
TransmissionHetero:
NA	=	not	applicable
ORIGINHP	=	Originating	from	a	country	with	
generalized	epidemic
SEXBI	=	Sex	with	a	bisexual	male
SEXHAEMO	=	Sex	with	a	haemophiliac
SEXHIVPOS	=	Sex	with	a	person	known	to	be	
infected	and	not	know	to	belong	to	any	of	
categories	above
SEXHP	=	Sex	with	a	person	originating	or	
living	in	a	country	with	a	generalized	
epidemic
SEXIDU	=	Sex	with	a	injecting	drug	user
SEXUNK	=	Strongly	believed	to	have	been	
infected	through	heterosexual	contact,	
information	on	risk	factor	and	partner	not	
available
4HIV NoTrue	
(Warning)
CVRegion		of	origin,	where	from	patient	is	originating.	If	
country	of	birth	is	reported,	it	should	correspond	to	the	
region.	CountryOfBirth	is	the	prefered	variable.	If	it	is	
not	available,	then	submit	CountryOfNationality,	and	if	
this	is	not	available,	then	RegionOfOrigin.	Please	still	
submit	RegionOfOrigin,	if	possible.
Region	of	origin	of	
patient
RegionOfOrigin UNKYesNo
CVThis	variable	specifies	the	clinical	stage	at	the	time	of	
HIV	diagnosis.	In	case	of	acute	infection	(Stage=ACUTE)	
the	DateOfOnset	should	be	provided.	•	In	countries	
with	both	laboratory	and	clinician	reports,	the	latter	
may	be	delayed	and	the	clinical	stage	may	evolve	in	the	
meantime.	In	such	cases,	the	clinical	stage	should	be	
that	one	provided	by	the	clinician.
Clinical	stage	at	
the	time	of	HIV	
diagnosis
Stage4HIV
4HIV
UNKYesNoNoFALSE
NoTrue	
(Warning)
CVNosocomial	infection	includes	patients	infected	in	
health	care	settings.	Case	of	occupational	exposure	
should	be	classified	as	UNK	‘Unknown	or	
undetermined’.	Cases	which	are	not	fully	documented	
should	be	coded	as	UNK.
Describes	the	
most	probable	
route	of	
Transmission
Transmission UNKYesNo
CVThis	allows	to	specify	the	heterosexual	route	of	
transmission	and	this	should	be	provided	if	
Transmission=HETERO	(variable	21);	in	other	cases	the	
variable	is	coded	as	default	NA	‘not	applicable’.	
Heterosexual	contact	refers	to	a	person	for	who	risk	
factors	for	HIV	infection	other	than	heterosexual	
contact	have	not	been	identified	and	who	either	
originates	from	a	country	with	generalized	epidemic	
(HIV	prevalence	in	pregnant	women>1%)	or	has	had	sex	
with:	bisexual	male,	IDU,	haemophiliac	-	recipient,	a	
person	from	a	country	with	generalized	epidemic,	a	
person	known	to	be	HIV	positive	and	not	known	to	
belong	to	one	of	the	above	mentioned	or	is	strongly	
believed	to	have	been	infected	through	sexual	
transmission,	information	on	risk	factors	and	HIV	status	
of	partner(s)	not	available.		The	sub-variable	
heterosexual	transmission	includes	not	only	information	
on	the	reported.
Specifies	the	
heterosexual	
route	of	
transmission
TransmissionHetero4HIV NoYesNoFALSE
TransmissionMTCT:
MOTHHET	=	Infected	through	heterosexual	
contact	and	not	known	to	belong	to	
category	above
MOTHHP	=	Originating	from	a	country	with	
generalized	epidemic
MOTHIDU	=	Injecting	drug	use
MOTHTRANSFU	=		Transfusion	recipient
NA	=	not	applicable
Unk	=	Other/undetermined
HIVAIDS 1 RecordId RecordId Unique	identifier	for	each	record	within	and	across	the	
national	surveillance	system	–	MS	selected	and	
generated
TEXT True	(Error) No No No
HIVAIDS 1 RecordType RecordType Structure	and	format	of	the	data	(case	based	reporting	
and	aggregate	reporting).
CV 'HIVAIDS' True	(Error) No No No
HIVAIDS 1 RecordTypeVersion RecordTypeVersio
n
There	may	be	more	than	one	version	of	a	recordType.	
This	element	indicates	which	version	the	sender	uses	
when	generating	the	message.	Required	when	no	
metadata	set	is	provided	at	upload.
NUM No No No No
[Subjects	for	HIVAIDS]:
HIVAIDS	=	HIV	diagnoses	case-based,	
including	AIDS
[Statuses]:
DELETE	=	Delete	a	previously	reported	
record.
NEW/UPDATE	=	Report	a	new	or	update	a	
previously	reported	record	(default).
[Data	sources]
(see	the	coded	values	list)
[Countries]
(see	the	coded	values	list)
HIVAIDS 1 DateUsedForStatisti
cs
DateUsedForStatis
tics
The	reference	date	used	for	standard	reports	that	is	
compared	to	the	reporting	period.	The	date	used	for	
statistics	can	be	any	date	that	the	reporting	country	
finds	applicable,	e.g.	date	of	notification,	date	of	
diagnosis	or	any	other	date.
DATE True	(Error) No No No yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd
AcuteInfectionHIV:
EV24ANT	=	Evidence	from	p24	antigen
EVWBLOT	=	Evidence	from	Western	Blot
NA	=	Not	applicable	(not	acute	infection)
NEGTEST	=		Last	negative	test	within	6	
months	of	HIV	diagnosis
SEROILL	=	Seroconversion	illness
UNK	=	Unknown
HIVAIDS 1 Age Age Exact	age	at	diagnosis	of	HIV.	Age	as	a	crude	number	is	
preferred.	If	not	available,	age	can	be	calculated	by	the	
MS	from	the	date	of	birth	and	date	of	diagnosis.
NUM True	
(Warning)
No No Yes 0 120
AIDSIndicatorDisease:
1	=	Bacterial	infections,	multiple	or	
recurrent	in	a	child	under	13	years	of	age
10	=	Histoplasmosis,	disseminated	or	
extrapulmonary
4HIV NoFALSECVThis	allows	to	specify	the	transmission	categories	for	
mother	to	child	cases	and	this	should	be	provided	if	
Transmission=MTCT	(variable	21);	in	other	cases	the	
variable	is	coded	as	default	NA	‘not	applicable’.
TransmissionMTCTTransmissionMTCT YesYes
CVDisease	to	reportSubjectSubject1HIVAIDS
1HIVAIDS
NoNoNoTrue	(Error)
NoNoCVStatus	of	reporting	NEW/UPDATE	or	DELETE	
(inactivate).	Default	if	left	out:	NEW/UPDATE.	If	set	to	
DELETE,	the	record	with	the	given	recordId	will	be	
deleted	from	the	TESSy	database	(or	better	stated,	
invalidated.	If	set	to	NEW/UPDATE	or	left	empty,	the	
record	is	newly	entered	into	the	database.
StatusStatus NoNo
CVThe	data	source	(surveillance	system)	that	the	record	
originates	from.
DataSourceDataSource1HIVAIDS
1HIVAIDS
NoNoNoTrue	(Error)
NoTrue	(Error)CVThe	country	reporting	the	record.ReportingCountryReportingCountry NoNo
CVAn	infection	can	be	considered	to	be	recent	if	a	patient	
demonstrates	with	seroconversion	illness,	has	a	
negative	HIV	test	within	6	months	of	diagnosis	or	has	
evidence	from	p24	antigen	or	Western	Blot	assays.	This	
is	a	repeatable	field	and	up	to	4	options	can	be	entered.	
You	should	replace	empty	fields	with	N/A.
Evidence	of	recent	
infection,	aside	
from	the	recent	
infection	assay	
result
AcuteInfection1HIVAIDS
1HIVAIDS
YesYesYesFALSE
YesFALSECVAIDS	indicator	disease	at	the	time	of	AIDS	diagnosis	
occurring	within	two	consecutive	months	from	the	date	
of	AIDS	diagnosis.	This	is	a	repeatable	field	for	up	to	4	
diagnoses.	You	should	replace	empty	fields	with	N/A.
AIDS	indicator	
disease	at	the	
time	of	AIDS	
diagnosis
AIDSIndicatorDiseas
e
NoNo
11	=	Isosporiasis,	intestinal	with	diarrhoea	
(>1	months	duration)
12	=	Mycobacterium	avium	complex	or	M.	
kansasii,	disseminated	or	extrapulmonary
13	=	Mycobacterium	tuberculosis,	
pulmonary	in	an	adult	or	an	adolescent	
(aged	13	years	or	over)*
14	=	Mycobacterium	tuberculosis,	
extrapulmonary
15	=	Mycobacterium,	other	species	or	
unidentified	species,	disseminated	or	
extrapulmonary
16	=	Pneumocystis	carinii	pneumonia
17	=	Pneumonia,	recurrent	in	an	adult	or	an	
adolescent	(aged	13	years	or	over)*
18	=	Progressive	multifocal	
leukoencephalopathy
19	=	Salmonella	(non	typhoid)	septicaemia,	
recurrent
2	=	Candidiasis	of	bronchi,	trachea,	or	lungs
20	=	Toxoplasmosis	of	brain	in	a	patient	over	
one	month	of	age
21	=	Cervical	cancer,	invasive	in	an	adult	or	
an	adolescent	(aged	13	years	or	over)*
22	=	Encephalopathy,	HIV-related
23	=	Kaposi	s	sarcoma
24	=	Lymphoid	interstitial	pneumonia	in	a	
child	under	13	years	of	age
25	=	Lymphoma,	Burkitt	s	(or	equivalent	
term)
26	=	Lymphoma,	immunoblastic	(or	
equivalent	term)
27	=	Lymphoma,	primary,	of	brain
28	=	Wasting	syndrome	due	to	HIV
3	=	Candidiasis,	oesophageal
30	=	Opportunistic	infection(s),	not	specified
31	=	Lymphoma(s),	not	specified
4	=	Coccidioidomycosis,	disseminated	or	
extrapulmonary
5	=	Cryptococcosis,	extrapulmonary
6	=	Cryptosporidiosis,	intestinal	with	
diarrhoea	(>1	months	duration)
7	=	Cytomegalovirus	disease	(other	than	
liver,	spleen,	or	nodes)	in	a	patient	over	one	
month	of	age
8	=	Cytomegalovirus	retinitis	(with	loss	of	
vision)
9	=	Herpes	simplex:	chronic	ulcer(s)	(>1	
months	duration);	or	bronchitis,	
pneumonitis,	or	oesophagitis	in	a	patient	
over	one	month	of	age
YesNoUnk:
N	=	No
Unk	=	Unknown
Y	=	Yes
1HIVAIDS YesFALSECVAIDS	indicator	disease	at	the	time	of	AIDS	diagnosis	
occurring	within	two	consecutive	months	from	the	date	
of	AIDS	diagnosis.	This	is	a	repeatable	field	for	up	to	4	
diagnoses.	You	should	replace	empty	fields	with	N/A.
AIDS	indicator	
disease	at	the	
time	of	AIDS	
diagnosis
AIDSIndicatorDiseas
e
NoNo
CVWas	the	patient	receiving	antiretroviral	therapy	(ART)	at	
the	date	last	seen	for	care?		If	yes,	last	attendance	date	
should	be	reported.
Antiretroviral	
therapy
ART1HIVAIDS YesNoNoFALSE
HIVAIDS 1 CD4Latest Last	known	CD4	
count
Last	known	CD4	count.	This	variable	is	for	historical	
updates	on	CD4	provided	over	time.	Enter	the	numeric	
value	of	the	CD4	(0-6000)	or	unknown	(UNK).
NUM FALSE No No Yes 0 6000
HIVAIDS 1 CD4LatestDate Date	of	last	CD4	
count	assessment
The	exact	date	is	preferred	and	should	be	provided	if	
available;	incomplete	dates	(e.g.	week,	quarter,	month,	
year)	are	allowed	if	exact	date	is	not	available.	If	
CD4Latest	is	not	available,	enter	NA	for	date.
DATE FALSE No Yes Yes yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd,	
UNK,	NA
Country_Incl_HistCountries
(see	the	coded	values	list)
HIVAIDS 1 DateOfAIDSDiagnos
is
Date	of	AIDS	
diagnosis
Date	of	AIDS	diagnosis.The	exact	date	is	preferred	and	
should	be	provided	if	available;	incomplete	dates	(e.g.	
week,	quarter,	month,	year)	are	allowed	if	exact	date	is	
not	available.
DATE FALSE No Yes Yes yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd,	
HIVAIDS 1 DateOfDeath Date	of	death Date	of	death	due	to	any	cause.	The	exact	date	is	
preferred	to	obtain	more	accurate	information	and	to	
allow	better	comparison	and	grouping.	Incomplete	
dates	(quarter,	month,	year)	are	permissible.	All	cases	
that	are	still	alive	or	where	the	outcome	(i.e.,	whether	
the	case	is	alive	or	dead)	is	unknown	are	to	be	coded	as	
‘NA’.
DATE True	
(Warning)
No Yes Yes NA yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd,	
UNK,	NA
HIVAIDS 1 DateOfDiagnosis Date	of	Diagnosis The	date	of	first	HIV	diagnosis;	clinical	or	laboratory	
diagnosis.	Date	should	be	provided	as	exact	date	or	
incomplete	date.	The	exact	date	is	preferred	and	should	
be	provided	if	available;	incomplete	dates	(e.g.	quarter,	
month,	year)	are	allowed	if	exact	date	is	not	available.
DATE True	(Error) No No No yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd
HIVAIDS 1 DateOfNotification Date	of	
Notification
This	is	the	date	on	which	the	HIV	case	was	notified	for	
the	first	time	to	the	reporting	country.The	exact	date	is	
preferred	and	should	be	provided	if	available;	
incomplete	dates	(e.g.	quarter,	month,	year)	are	
allowed	if	exact	date	is	not	available.
DATE True	
(Warning)
No No Yes yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd,	
UNK
DeathCause:
A	=	Alive
DAIDS	=	Death	due	to	AIDS
DNOAIDS	=	Non	AIDS-related	death
DUNK	=	Died	of	unknown	cause
UNK	=	Unknown
HIVAIDS 1 FirstCD4Count CD4	cell	count	at	
time	of	diagnosis
The	variable	specifies	the	CD4	cells	count	at	the	time	of	
HIV	diagnosis.	Enter	the	numeric	value	of	the	CD4	(0-
6000)	or	unknown	(UNK).
NUM True	
(Warning)
No No Yes 0 6000
HIVAIDS 1 FirstCD4Date Date	of	first	CD4	
cell	count	at	time	
of	diagnosis
The	exact	date	is	preferred	and	should	be	provided	if	
available;	incomplete	dates	(e.g.	week,	quarter,	month,	
year)	are	allowed	if	exact	date	is	not	available.	If	
FirstCD4Count	is	not	available,	enter	NA	for	date.
DATE True	
(Warning)
No Yes Yes yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd,	
UNK,	NA
Sex:
F	=	Female
M	=	Male
O	=	Other	(e.g.,	transsexual)
Unk	=	Unknown
HIVStatus:
NEG	=	Negative
1HIVAIDS NoTrue	
(Warning)
CVDefines	the	country	of	birth	at	country	level,	the	ISO	list	
of	countries	is	provided.	CountryofBirth	is	the	preferred	
variable.	If	Unknown	code	as	UNK.
Country	of	birth	of	
patient
CountryOfBirth YesNo
CVInformation	on	whether	the	case	is	alive	or	deceased	
(due	to	AIDS-related	and	non-AIDS	related	causes).
Outcome	of	caseDeathCause1HIVAIDS
1HIVAIDS
YesNoNoTrue	
(Warning)
NoTrue	
(Warning)
CVTranssexual	should	be	coded	as	O	-	OtherGenderGender YesNo
CVThis	variable	provides	information	on	previous	positive	
test	results,	prior	to	the	first	time	of	reporting.	This	
variable	allows	cases	"newly	diagnosed"	to	be	
distinguished	from	case	who	had	positive	HIV	test	in	the	
past	but	are	reported	for	the	first	time	in	the	country.
HIV	status;	
previous	positive	
test
HIVStatus1HIVAIDS YesNoNoFALSE
PREVPOS	=	previous	HIV	positive
Unk	=	Unknown
HIVType:
HIV1	=	HIV1	only
HIV12	=	HIV1	and	HIV2	(co-infection)
HIV2	=	HIV2	only
Unk	=	Unknown
HIVAIDS 1 LastAttendanceDat
e
Date	the	patient	
was	last	seen	for	
HIV-related	care	
(can	be	a	date	
prior	to	the
The	exact	date	is	preferred	and	should	be	provided	if	
available;	incomplete	dates	(e.g.	week,	quarter,	month,	
year)	are	allowed	if	exact	date	is	not	available.
DATE FALSE No No Yes yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd,	
UNK
Country_Incl_HistCountries
(see	the	coded	values	list)
RegionOfOrigin:
ABROAD	=	Abroad	but	sub	continent	
unknown
AUSTNZ	=	Australia	and	New	Zealand
CAR	=	Caribbean
CENTEUR	=	Central	Europe
EASTASIAPAC	=	East	Asia	and	Pacific
EASTEUR	=	East	Europe
EUROPE	=	If	a	case	can	not	be	reported	in	
West,	central	or	Eastern	Europe,	he/she	
should	be	reported	in	Europe	(sub-continent	
unknown).
LATAM	=	Latin	America
NORTHAFRMIDEAST	=	North	Africa	and	
Middle	East
NORTHAM	=	North	America
REPCOUNTRY	=	Same	as	country	of	report
SOUTHASIA	=	South	and	South	East	Asia
SUBAFR	=	Sub	Sahara	Africa
Unk	=	Unknown
WESTEUR	=		West	Europe
Transmission:
HAEMO	=	haemophiliac	patient
HETERO	=	heterosexual	contact
IDU	=	ever	injected	drugs
MSM	=	MSM/homo	or	bisexual	male
MTCT	=	mother-to-child-transmisison
NOSO	=	Nosocomial
TRANSFU	=	transfusion	recipient
Unk	=	Unknown	or	undetermined
TransmissionPartnerHIV:
PHAEMO	=	Partner	haemophiliac
PHETEPI	=	Partner	heterosexual	from	
generalised	epidemic	country
PHETNEPI	=	Partner	heterosexual	from	non-
generalised	epidemic	country
PIBLOOD	=	Partner	infected	through	blood	
products
PIDU	=	Partner	injecting	drug	user
PINOSO	=	Partner	infected	nosocomially
CVThis	variable	provides	information	on	previous	positive	
test	results,	prior	to	the	first	time	of	reporting.	This	
variable	allows	cases	"newly	diagnosed"	to	be	
distinguished	from	case	who	had	positive	HIV	test	in	the	
past	but	are	reported	for	the	first	time	in	the	country.
HIV	status;	
previous	positive	
test
HIVStatus1HIVAIDS
1HIVAIDS
YesNoNoFALSE
NoTrue	(Error)CVDescribes	the	type	of	HIV	infectionDescribes	the	type	
of	HIV	infection
HIVType YesNo
CVCountry	or	countries	where	infection	of	the	patient	is	
likely	to	have	occurred.
Probable	country	
of	infection
ProbableCountryOfI
nfection
1HIVAIDS
1HIVAIDS
YesNoYesFALSE
NoFALSECVRegion	from	which	the	case	originates.	If	the	case	is	
from	the	reporting	country,	it	should	be	coded	as	
REPCOUNTRY.	CountryOfBirth	is	the	prefered	variable.	
If	this	is	not	available,	then	submit	RegionOfOrigin.	If	
both	are	submitted,	CountryOfBirth	should	match	
RegionOfOrigin.
Region	of	origin	of	
patient
RegionOfOrigin YesNo
CVMost	probable	route	of	HIV	transmission	classified	as:	
sex	between	men;	heterosexual	contact;	ever	injected	
drugs;	mother-to-child	transmission;	transfusion	
recipient;	nosocomial.	Nosocomial	infection	includes	
patients	infected	in	health	care	settings.	Case	of	
occupational	exposure	should	be	classified	as	exposure	
unknown	or	undetermined.	Cases	which	are	not	fully	
documented	should	also	be	coded	as	unknown.
Describes	the	
most	probable	
route	of	
Transmission
Transmission1HIVAIDS
1HIVAIDS
YesNoNoTrue	
(Warning)
NoFALSECVDescribes	the	most	probable	route	of	HIV	transmission	
of	the	partner.	A	list	of	countries	with	generalised	HIV	
epidemics	can	be	found	in	the	reporting	protocol.
Describes	the	
most	probable	
route	of	HIV	
transmission	of	
the	partner
TransmissionPartne
r
YesNo
PIVER	=	Partner	infected	through	mother-to-
child	transmission
PMSM	=	Partner	MSM
UNK	=	Partner	undetermined	or	unknown
HIVAIDS 1 VLLatest Last	known	viral	
load
Last	known	viral	load.	Enter	the	numeric	value.	If	the	
test	provides	no	numeric	value	and	is	simply	"low"	or	
"undetectable"	code	as	0.If	the	VL	is	greater	than	
999999	mm3,	code	as	999999.		If	the	latest	viral	load	is	
unknown	code	as	UNK.
NUM FALSE No No Yes
HIVAIDS 1 VLLatestDate Date	of	last	known	
viral	load	
assessment	(date	
of	blood	test	
where	available)
The	exact	date	is	preferred	and	should	be	provided	if	
available;	incomplete	dates	(e.g.	week,	quarter,	month,	
year)	are	allowed	if	exact	date	is	not	available.	If	
VLLatest	is	not	available,	enter	NA	for	date.
DATE FALSE No Yes Yes yyyy,	yyyy-Qq,	
yyyy-mm,	
yyyy-Www,	
yyyy-mm-dd,	
UNK,	NA
HIVAIDS 1 YearOfArrival Year	patient	
arrived	in	the	
reporting	country
Year	patient	arrived	in	the	reporting	country. DATE FALSE No Yes Yes yyyy,	UNK,	NA
1HIVAIDS NoFALSECVDescribes	the	most	probable	route	of	HIV	transmission	
of	the	partner.	A	list	of	countries	with	generalised	HIV	
epidemics	can	be	found	in	the	reporting	protocol.
Describes	the	
most	probable	
route	of	HIV	
transmission	of	
the	partner
TransmissionPartne
r
YesNo
